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Abstract 
Introduction 
Haemophilia is an inherited bleeding disorder caused by a deficiency in one of the 
coagulation or blood clotting factors in the blood. When injured someone with 
haemophilia does not bleed more intensely than a person without haemophilia, but they 
tend to bleed for a much longer time. For people affected by severe haemophilia, the 
deficiency in coagulation factor can cause spontaneous internal bleeding in joints and 
muscles, as well as intracranial bleeding, and bleeding in soft tissues (e.g. nosebleeds or 
bleeding gums). The most common form is Haemophilia A which is caused by a 
deficiency in factor VIII. Haemophilia B is caused by a deficiency of factor IX and tends to 
be less severe than haemophilia A.  
Haemophilia is treated by replacing the deficient coagulation factor in the blood through 
intravenous injections of factor concentrate. Treatment can be on-demand, where 
medication is used to treat a bleeding episode; or preventative, where factor replacement 
treatment is used to increase the concentration of coagulation factor in the blood to 
prevent bleeding. Most young people with severe haemophilia in the UK follow a 
preventative treatment regimen (prophylactic treatment or prophylaxis). Patients with 
severe haemophilia A usually take 3 or 4 injections per week on alternate days, whereas 
patients with severe haemophilia B usually take 2 or 3 injections per week.  
There is good evidence that prophylaxis reduces bleeds and joint damage, whilst also 
improving quality of life. Therefore it is imperative for future health and functioning that 
young people with haemophilia (YPH) follow the prophylactic regimen they agreed with 
their haemophilia team. However, reported adherence levels among YPH vary widely   
(17 - 93%).  Additionally, drivers of (non)adherence among YPH specifically have not 
been evidenced.  
 
Aims 
The overall aim of the research described in this thesis was to gain a better 
understanding of the extent to which YPH adhere to their prophylactic treatment, and 
better understand what drives their (non-)adherence. 
The aims of the quantitative questionnaire study were to measure levels of adherence 
among YPH, and to assess whether psychosocial factors that have been shown to be 
associated with adherence among young people with other chronic illnesses, such as 
self-efficacy and social support, are also associated with adherence among YPH. 
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Based on previous research on adherence and social cognitive models of illness, it was 
hypothesised that: 
- there would be differences between adolescents and young adults in relation to 
psychosocial correlates of adherence. 
- higher perceptions of pain and impact of pain would be associated with better 
adherence (De Moerloose, Urbancik, Van Den Berg, & Richards, 2008; Treil, 
Rice, & Leissinger, 2007). 
- higher perceptions of chronicity, consequences and treatment control would be 
predictive of higher adherence (Chilcot et al., 2010; Horne & Weinman, 2002).  
- greater perception of necessity of prophylaxis would be predictive of higher 
adherence whereas concerns about prophylaxis would not be predictive (de 
Thurah, Nørgaard, Harder, & Stengaard-Pedersen, 2010; Horne et al., 2013; 
Horne & Weinman, 1999; Llewellyn, Miners, Lee, Harrington, & Weinman, 2003; 
Wileman et al., 2014).  
- greater negative mood would be associated with lower adherence scores (Cox & 
Hunt, 2015; Helgeson, Siminerio, Escobar, & Becker, 2009; Snell, Fernandes, 
Bujoreanu, & Garcia, 2014). 
In addition, based on evidence that lower adherence results in worse disease outcomes 
(Berntorp, 2009; M. J. Manco-Johnson et al., 2007), it was anticipated that non-
adherence to prophylaxis would be associated with higher numbers of bleeds and 
hospital visits.  
The aims of the qualitative interview studies with YPH, parents of YPH, and haemophilia 
healthcare professionals were to examine perceptions and experiences in relation to 
prophylaxis and how they make sense of these experiences. It was anticipated that this 
would provide evidence to gain a better understanding of the complexities surrounding 
prophylaxis and of the barriers and facilitators to adherence among YPH. 
 
Methods 
Questionnaire study 
90 patients (aged 12-25, diagnosed with severe haemophilia, and on a prophylactic 
regimen) were recruited from 13 haemophilia centres across England and Wales. One 
further participant was recruited through the Haemophilia Society. Participants were 
invited to complete a questionnaire (on paper or online) which included questions in 
relation to: self-reported adherence (VERITAS-Pro; N. Duncan, Kronenberger, Roberson, 
& Shapiro, 2010), illness perceptions (Brief Illness Perceptions Questionnaire; Broadbent, 
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Petrie, Main, & Weinman, 2006), beliefs about medicines (Beliefs about Medicines 
Questionnaire; Horne, Weinman, & Hankins, 1999), mood (The Positive Affect and 
Negative Affect Schedule; Watson, Clark, & Tellegen, 1988) ); social support, self-
efficacy, and outcome expectations. Clinical information in relation to the number of 
bleeds and hospital visits each participant had during the previous 6 months were 
collected from their medical notes. 
Qualitative interview studies 
Participants for the first study were YPH who follow a prophylactic treatment regimen.  
Participants for the second study were parents of YPH who follow a prophylactic regimen, 
and participants for the third study were haemophilia healthcare professionals (HP). 
Interview participants were recruited from five haemophilia centres across England and 
Wales. To protect confidentiality parents of YPH who took part in the interview study with 
YPH were excluded from taking part. .The interviews were transcribed verbatim and 
analysed using Interpretative Phenomenological Analysis (IPA). 
 
Results 
The quantitative findings of this study suggest that overall adherence among young 
people with haemophilia (YPH) is generally good.  The qualitative findings confirm this, 
and suggest the support provided by haemophilia centres is likely to contribute to these 
high levels of adherence. The good relationship and regular contact between the clinical 
team and their patients appears to enable healthcare professionals to identify and 
address potential issues (such as non-adherence) early.  
The quantitative study found that non-adherence was more likely to be due to forgetting 
than skipping. It is likely that young peoples’ busy lifestyles are partially responsible for 
this. However, findings from the qualitative studies also indicate that patients may find it 
easier to admit to forgetting than skipping. This may be because they are more likely to 
be ‘told off’ if they admit to intentionally skipping injections, whereas they get a more 
understanding response when they admit to sometimes forgetting injections.  
Interestingly, comparison of clinical outcomes (number of bleeds and hospital visits) 
indicated that adherent participants had more bleeds and hospital visits during the 
previous six months in comparison to non-adherent participants. Comparison of age 
groups indicated that there were no significant differences in adherence scores between 
adolescents and young adults. In relation to psychosocial predictors of adherence, the 
findings suggest that better social support, greater belief in the necessity and efficacy of 
prophylaxis, fewer concerns about this treatment and more negative feelings (such as 
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fear, anxiety or anger) about haemophilia are the most important factors associated with 
better adherence among young people with haemophilia. 
The findings of the three qualitative interview studies suggest that YPH may experience a 
tension between their desire to live a ‘normal’ life on the one hand and managing their 
haemophilia successfully on the other. This is because prophylaxis is a demanding 
treatment, but also because self-management revolves around ‘managing risk’ to prevent 
bleeding episodes, which can interfere with YPH lifestyles. Both parents and YPH felt it is 
ok to miss occasional injections. However they agreed that the gaps between injections 
should not be too long and that treatment should always be taken in preparation of 
physical activity.  
As a result of the increasingly flexible and personalised approach to prophylaxis in the UK 
it is much more challenging to define and assess adherence. It also appears that some 
patients ‘get away’ with non-adherence without suffering bleeds.  In reality this means 
that HP often focus their efforts on those patients who are struggling (e.g. who are 
presenting with bleeds), or those who have clearly become disengaged (e.g. not 
attending clinical appointments, not responding to letters or telephone messages, not 
completing treatment logs, etc.). 
The main barriers to adherence suggested by YPH and parents were broadly in line and 
included: lifestyle (fitting treatment in with other priorities such as school or work); being 
out of normal routine (e.g. on holiday); treatment being time-consuming and unpleasant; 
not wanting to be ‘different’; issues around venous access; and psychological issues 
(such as anxiety and stress). HP added some additional barriers including: difficulty in 
engaging YPH during adolescence; absence of symptoms may reduce motivation to take 
prophylaxis; lack of knowledge about haemophilia and prophylaxis; and challenging 
family dynamics (e.g. lack of parental support; chaotic lifestyle, etc.). 
The key finding from all three interview studies is that support from the haemophilia 
centre is an important facilitator to adherence. It appears that the current approach that 
haemophilia centres follow is helping patients to keep on track with their treatment and 
self-management more generally.  
 
Conclusion 
This programme of research is the first large nationwide study to examine adherence to 
prophylaxis among YPH specifically. It is also the first to utilise a mixed methodology, 
combining rigorous quantitative assessment of adherence with in-depth qualitative 
analysis of the complexities around adherence among YPH. Based on the findings of this 
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programme of research a new framework for understanding adherence among YPH is 
put forward. This framework proposes that, due to the increasingly flexible approach to 
prophylaxis in the UK, adherence should be considered in combination with the key 
clinical outcome (bleeds) and health-related quality of life (QoL). By considering an 
individual patient’s adherence, QoL, and bleeding together one can truly understand what 
is driving outcomes for this patient. This will in turn allow clinicians to understand which 
patients are in most need of help, and in what way they are most likely to achieve 
improvements for individual patients.   
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Chapter 1: Introduction to Haemophilia 
 
1.1 What is Haemophilia? 
Haemophilia is an inherited bleeding disorder caused by a deficiency in one of the coagulation 
factors in the blood. The normal blood clotting process involves as many as 20 different plasma 
proteins, known as coagulation or blood clotting factors (Lee, Berntorp, & Hoots, 2005). These 
factors interact with other chemicals in the body to form fibrin, which is necessary to maintain a scab 
and stop the bleeding. Someone with haemophilia does not bleed more intensely than a person 
without haemophilia, but they tend to bleed for a much longer time.  This is because after a blood 
vessel is injured in someone with haemophilia, the amount of fibrin that is formed is insufficient to 
main a robust clot. 
The most common form is Haemophilia A which is caused by a deficiency in factor VIII. Haemophilia 
B (also known as Christmas disease) is caused by a deficiency of factor IX and tends to be less 
severe than haemophilia A (Online Mendelian Inheritance in Man®, 2014). Haemophilia occurs 
mostly in males and females were historically considered asymptomatic carriers. However, more 
recently there is a move to recognise females with symptoms as having mild haemophilia.  It is very 
rare for women to have severe or even moderate haemophilia, unless there is an additional genetic 
abnormality (e.g. Turner’s syndrome). Bleeding disorders among females may cause special 
challenges because of the bleeding associated with menstruation and childbirth. 
Factor XI deficiency (also known as Haemophilia C in some parts of the world) is a rare inherited 
bleeding disorder. It affects men and women as its inheritance is autosomal (not x-linked as 
haemophilia A and B), and is most common among people of Ashkenazi Jewish descent. 
Haemophilia C differs from haemophilia A and B in that the majority of cases are mild and that 
bleeding in joints and muscles is very rare (Seligsohn & Bolton-Maggs, 2010).  
Acquired haemophilia is a rare condition that is not caused by inherited gene mutations, but instead 
results from autoantibodies that attack and disable coagulation factor VIII. In some cases the 
production of these antibodies is related to pregnancy, autoimmune diseases such as rheumatoid 
arthritis, cancer, or as a reaction to certain medications. However, in approximately half of cases the 
reason for the antibody production is never found (Delgado, Jimenez-Yuste, Hernandez-Navarro, & 
Villar, 2003).  
Haemophilia A affects 1 in 5,000 to 1 in 10,000 male live births, which is five times more common 
than haemophilia B (Online Mendelian Inheritance in Man®, 2014). There are just under 10,000 
people in the UK who have been diagnosed with haemophilia, of which approximately 5,900 with 
Haemophilia A and 1,200 with Haemophilia B (UKHCDO Annual Report, 2014). The remainder 
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have been diagnosed with factor XI deficiency or acquired haemophilia. Despite relatively few 
patients, haemophilia healthcare represents a significant cost to the NHS. Total estimated lifetime 
costs for one patient following a prophylactic (preventative) treatment regimen for severe 
haemophilia are £5.98million for haemophilia A, and £2.47million for haemophilia B (Miners, 2009). 
 
1.2 Symptoms 
Haemophilia A and B are classified as mild, moderate or severe (table 1.1). This classification 
predicts patients’ bleeding risk and outcome, and guides clinicians towards the best treatment 
strategy. Patients’ tendency to bleed is correlated with the concentration of the deficient factor in the 
blood, which is measured through a blood test. 
 
Table 1.1: Classification of haemophilia A and B (Bolton-Maggs & Pasi, 2003) 
Concentration of 
factor measured 
through blood test 
Classification 
Patients in UK, N (%)* 
Symptoms 
Haemophilia A Haemophilia B 
< 1% of normal Severe 2002 (35%) 410 (34%) 
Spontaneous joint 
and muscle bleeding; 
excessive bleeding 
after injuries, 
accidents and 
surgery. 
1 – 5% of normal Moderate 512 (9%) 249 (21%) 
Bleeding into joints 
and muscles after 
minor injuries; 
excessive bleeding 
after surgery or 
dental extractions. 
5 – 40% of normal Mild 3172 (56%) 546 (45%) 
Spontaneous 
bleeding does not 
occur; bleeding after 
surgery, dental 
extractions and 
accidents. 
*UKHCDO Annual report (Bleeding disorder statistics for April 2013 to March 2014) 
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For people affected by severe haemophilia, the deficiency in coagulation factor can cause 
spontaneous internal bleeds in joints and muscles, as well as nosebleeds and bleeding gums. In 
severe cases even minor injuries can result in blood loss lasting days or weeks, which in some 
cases never heal completely. Intracranial bleeding is another important, albeit less common, 
complication which can be life threatening or permanently debilitating. People affected by moderate 
haemophilia can also experience spontaneous bleeds, although most of their bleeds tend to be due 
to (minor) injuries, surgery or dental extractions. In mild cases spontaneous bleeding does not 
occur, but treatment is usually required to stop severe bleeding following accidents, surgery or 
dental extractions. 
Haemophilia symptoms manifest along a spectrum between mild and severe bleeding, and vary 
between patients identified as having the same numerical levels of clotting factor deficiency. This is 
why in clinical practice there is often a focus on an individual patient’s tendency to bleed, referred to 
as bleeding phenotype, rather than what would be expected based on their classification. 
Internal bleeds usually begin with a tingling feeling and mild pain in the affected area. If a bleed is 
not treated, it can lead to severe pain, stiffness and the site of the bleed becoming hot, swollen and 
tender. The most common muscle bleeds occur in the upper and forearm, groin area (psoas muscle 
which runs down the back of the abdomen hidden from view), calf and thigh. The most commonly 
affected joints are the knee, ankle and elbow. Recurring bleeding into a joint can damage it, lead to 
formation of a ‘target joint’ (a joint with recurring bleeding) and ultimately lead to Haemophilic 
arthropathy (a chronic form of arthritis). This can be very painful and cause disability. It is estimated 
that approximately 50% of people with haemophilia will develop arthropathy (Madhok,York, & 
Sturrock, 1991), which often requires joint repair or joint replacement surgery. 
Young boys with severe haemophilia are likely to experience bleeds from a very early age, most 
commonly as they start to learn to crawl and walk. The majority of patients will experience a 
significant bleed in the first 2 years of life. If severe haemophilia is untreated from early childhood, a 
patient is likely to be significantly disabled by the end of their first decade (if they are still alive). 
Joint damage is more common in older adults with severe haemophilia because preventative 
treatment (prophylaxis) was not available to them when they were young (a description of treatment 
options will be outlined below). Thanks to modern treatments children growing up with haemophilia 
today may be less likely to develop severe joint damage in future.  
Complications of haemophilia are much more common among patients with moderate or severe 
haemophilia. These can be caused directly by the condition itself (such as arthropathy as a result of 
repeated bleeding in a joint), through its treatment (such as Hepatitis C and HIV infections acquired 
through contaminated blood), or through inhibitors, which are immune system reactions to treatment 
(K. Fischer, Valentino, Ljung, & Blanchette, 2008). In the past men with haemophilia were likely to 
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die in their youth. However, thanks to advances in diagnosis and development of effective and safe 
recombinant (non-plasma derived) treatment, affected individuals can now enjoy a normal life 
expectancy.  
 
1.3 Aetiology of Haemophilia 
Both Haemophilia A and B are X-linked recessive conditions, which means that they are usually 
passed down through the x chromosome. Females can inherit the defective gene from either their 
mother or father. It is very rare for a female to inherit haemophilia, as she would need to be the 
daughter of a mother who is a carrier and a father with haemophilia.  
A male with haemophilia will always pass the affected gene to his daughters (making them a so-
called ‘obligate carrier’), whereas his sons will not inherit the gene. All children of a female who is a 
carrier of the gene have a 1 in 2 chance to be affected, meaning that daughters have a 50% chance 
to be a carrier, and sons have a 50% chance to be affected by haemophilia.  However, not in all 
cases of haemophilia there is a preceding family history, approximately a third of all cases of 
haemophilia are caused by spontaneous genetic mutations (Bowen, 2002).  
 
1.4 Diagnosis of Haemophilia 
Severe haemophilia is often diagnosed during the first year of life. This can be shortly after birth, 
particularly if there is marked bruising or a haematoma (a collection of blood) caused by the 
delivery. But usually diagnosis happens once babies start crawling or walking, when small bumps or 
falls can cause heavy bruising. Milder forms of haemophilia are often not diagnosed until a person 
experiences abnormal blood loss following an operation, accident or dental extraction. As the 
bleeding patterns and problems caused by haemophilia A and B are the same, only a blood test can 
confirm which type of the disorder a person has.  This blood test is crucial, as the treatment for 
haemophilia A and B are completely different. 
Daughters of female carriers (who therefore have a 50% chance to be a carrier too), can chose to 
be tested before they reach child bearing age to check if they carry the gene. As daughters of males 
with haemophilia always inherit the gene this test is not usually carried out for them, as the test 
would essentially be a paternity test. However, in many cases clinicians would simply check their 
levels of clotting factor through a blood test (particularly if they experience any symptoms). Recent 
developments in prenatal testing now allow female carriers to have their children tested before they 
are born. Thanks to new methods it is now possible to test foetal DNA from peripheral blood of the 
mother (making more invasive testing such as Chorionic Villus Sampling, which takes a sample 
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from the placenta, unnecessary). Prenatal diagnosis is possible from as early as 10 weeks into 
pregnancy (R. C. Ljung, 1996; Peyvandi, 2005).  
 
1.5 Treatment 
Haemophilia is treated by replacing the deficient coagulation factor in the blood through intravenous 
injection of factor concentrate. Treatment for haemophilia A contains Factor VIII, whereas treatment 
for haemophilia B contains Factor IX. Factor concentrate treatment can be either on-demand, where 
medication is used to treat a bleeding episode; or preventative, where medication is used to 
increase the concentration of coagulation factor in the blood to prevent bleeding. This preventative 
treatment is often referred to as prophylactic treatment or prophylaxis (Manco-Johnson, et al., 
2007).  
Up to the mid-1980s treatment was made from human blood (plasma-derived), which put patients at 
significant risk of infection with blood-borne viruses such as hepatitis C and HIV.  Many of the 
patients who were infected with HIV died as a result. The risk of contaminated blood products was 
significantly reduced by the introduction of recombinant products (factor concentrates that are 
manufactured using genetically engineered cells that carry a human factor gene, which are treated 
to inactivate or remove blood-borne viruses). The latest recombinant products use no human or 
animal-derived proteins in the manufacturing process at all, virtually eliminating the risk of 
transmission of infection. Recombinant products are concentrated into a powder form that is mixed 
with sterile water before it is injected. Factor concentrates are measured in units, with one unit being 
the equivalent of the amount of factor activity found in 1 cc or 1 ml of fresh plasma. Factor treatment 
is delivered in glass vials with labels indicating the number of units per vial. Treatment comes in 
different vial sizes, but patients may need to mix more than one vial to add up to the approximate 
number of units they require.  Administering treatment can be time consuming as it involves several 
steps including: preparation (clearing and cleaning a space to do the injection); making up treatment 
(mixing the sterile water and powder together to make up the dose and get the treatment into the 
syringe ready for injection); preparing the skin (often with an antiseptic wipe); injecting the treatment 
into the vein; taking out the needle and applying pressure on the puncture wound to stop the 
bleeding; disposing of the needle and other materials; logging the treatment on the treatment log 
(Haemtrack). 
In some parts of the developing world on-demand treatment with Fresh Frozen Plasma (FFP) is still 
the only option for people with haemophilia. In addition to the risk of viral contamination, there are 
other considerable problems associated with the use of FFP in the treatment of haemophilia leading 
to much worse prognosis for patients unable to access modern treatment. Most notably, because 
the factor in FFP is much less concentrated, large volumes of plasma must be transfused. This in 
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turn can lead to a complication called circulatory overload which is associated with increased in-
hospital mortality and longer lengths of stay in hospital and intensive care (Murphy et al., 2013). 
 
1.5.1 On-demand treatment 
When a bleeding episode occurs people with haemophilia usually require immediate factor 
replacement treatment to stop the bleeding. This treatment is referred to as on-demand treatment, 
and should be administered as quickly as possible after the bleeding has started to prevent long-
term damage. Bleeding usually stops when enough coagulation factor reaches the bleeding site. 
Many patients with severe haemophilia follow a regular prophylactic treatment regimen, described in 
the next section, to prevent bleeds. The majority of patients with mild and moderate haemophilia 
only use on-demand treatment if and when a bleed occurs. 
Initially patients (or their parents if they are young) are encouraged to telephone the haemophilia 
centre whenever they are experiencing a serious bleed, so that the clinical team can advise on how 
to treat it. Over time parents and then the individual boy/young man become confident about how to 
treat their bleeds at home early, without the need to contact their haemophilia team or attend the 
hospital. The majority of patients in the UK record their prophylaxis, bleeding episodes and on-
demand treatment through an online portal, Haemtrack. This allows the haemophilia team to review 
how patients are doing without needing to contact them, and highlights potential issues that may 
need attention from the haemophilia team (e.g. recurring bleeding, non-adherence, etc.).  
Haemtrack can also be a useful conversation starter during check-up appointments, as it allows 
patients and the haemophilia team to jointly review  what has happened since the last check-up 
appointment in terms of treatment and bleeding episodes.   
The required dose to treat a bleed is calculated based on a number of factors including the severity 
of the bleed; body weight; the patient’s bleeding phenotype (their individual tendency to bleed); the 
baseline level of factor in the patient’s blood; and the estimated level of factor to be achieved to stop 
the bleeding. Severe bleeds usually require several injections over a number of days. Those who 
follow a prophylactic treatment regimen may take on-demand treatment in addition to their regular 
prophylactic injections. Many clinicians recommend that after patients have administered their on-
demand treatment, they apply RICE (Rest, Ice, Compression and Elevation) to the affected area. 
This helps to reduce swelling and tissue damage, and is an important supplement to the factor 
therapy.  
For people with haemophilia, dental extractions and surgery have to be planned in advance. It is 
vital that the haemophilia team is involved from the start to ensure that the patient receives 
additional treatment to protect them from bleeding complications.  In cases of mild haemophilia or 
very small procedures people may be given Tranexamic acid alone (a medicine that is used in 
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treating and preventing bleeding problems and usually comes in tablet form), or Desmopressin (also 
known as DDAVP, a synthetic hormone which stimulates the release of endogenous factor VIII and 
is usually given by injection). For people with more severe forms of haemophilia and for more 
invasive procedures, additional factor treatment is usually required to provide protection during and 
after the procedure. This is sometimes referred to as short-term prophylaxis. Many haemophilia 
centres in the UK are situated in or are affiliated to large hospitals; this is to ensure that the 
haemophilia teams are on-hand to deal with potential complications that may arise during or after 
surgery. 
 
1.5.2 Prophylactic treatment 
Most young people with severe haemophilia in the UK follow a preventative treatment regimen 
(prophylactic treatment or prophylaxis). The purpose of prophylaxis is to increase the concentration 
of coagulation factor in the patient’s blood to a level which protects them from spontaneous bleeding 
episodes in joints and muscles (often brought on by activities), bleeding in response to minor 
trauma (bumps and scratches), and intracranial bleeding. This is achieved by raising the baseline 
concentration of residual coagulation factor in the blood to levels similar to those of people with mild 
or moderate  
haemophilia, recognising that as the baseline levels of clotting factor rise, spontaneous and/or 
serious bleeding episodes become less common (Ahlberg, 1965; R. Ljung, 2009). Patients with 
severe haemophilia A in the UK usually take 3 or 4 injections per week on alternate days, whereas 
patients with severe haemophilia B usually take 2 or 3 injections per week. 
Prophylactic treatment has revolutionised haemophilia treatment, particularly for people with severe 
haemophilia. There is good evidence that it reduces joint bleeds and resulting joint damage (K. 
Fischer, 2002; M. J. Manco-Johnson et al., 2007) as well as intracranial bleeds (R. Ljung, 2009; 
Witmer et al., 2011), whilst also improving quality of life (Richards et al., 2010).  According to a joint 
statement made by the World Health Organisation (WHO) and the World Federation for 
Haemophilia (WFH), initiating prophylaxis at an early age is the optimal form of treatment for people 
with severe haemophilia (Coppola, Di Capua, & De Simone, 2008).  
In the UK, prophylaxis is often initiated shortly after diagnosis of severe haemophilia, either before 
or at the time of the first joint bleed (so called primary prophylaxis). Regular prophylaxis may require 
the insertion of a permanent indwelling intravenous catheter (e.g. Port-a-cath) to enable infusions.  
Parents are trained by the haemophilia team to give the injections to their child at home, however in 
some cases a nurse may visit the family at home to help with the treatment, or treatment may be 
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administered by a nurse in the hospital. This tends to only be during the first few weeks or months 
of training a family to get competent and confident with home treatment.  
There are many different potential issues surrounding initiating prophylaxis for young children (such 
as difficulty in finding babies’ or infants’ veins because they are so small or their arm is "chubby", 
parents and/or children may have  or develop needle phobia, or parents’ lifestyle or personal 
circumstances may not be  ideal for administration of regular intravenous treatment, etc.). These 
difficulties in turn can have a detrimental effect on treatment adherence. 
Children are usually encouraged to help with the treatment from a young age (e.g. to mix up the 
treatment ready for the injection, clean the skin, etc.), and are then slowly trained to gradually take 
over the responsibility for their injections. Haemophilia teams generally aim for their patients to do 
their own injections by the time they start senior school.  However, the age at which patients 
become responsible for their own treatment varies widely, with some children able to do the 
injection independently from a young age, whereas others prefer someone else (usually a parent) to 
do their injections for as long as possible. In some cases a port-a-cath or an external catheter 
(called a Hickman line or Broviac) can be surgically inserted into a vein, making it easier to give 
regular factor treatment or draw blood for tests. The use of such catheters can be complicated by 
infection and blockage and they have to be used with great care.  
In previous decades prophylactic regimens often required patients to do their injections in the 
morning on set days each week. Most patients were directed to do their injections on Monday, 
Wednesday and Friday morning, which left them unprotected on Sundays and did not take their 
individual activities into account. In recent years regimens have become more flexible and tailored 
to individuals, and it appears that many clinicians now encourage patients to adjust their treatment 
according to their lifestyle and planned activities. This means that patients should take their 
treatment on days they are planning to be active and on some occasions top up with an additional 
injection if they feel their usual regimen will not afford them enough protection. Equally, if they are 
planning to be inactive on a day they usually take their treatment, it may be more sensible to bring 
the treatment forward or back.  However, it is important to highlight that it is not clear from the 
literature how widespread this more flexible approach is in paediatric and adult practice. 
Usually patients are encouraged to continue taking prophylaxis into adulthood, and in many cases 
for the rest of their lives.  However in some cases it may be possible to change to an on-demand 
regimen, as some people with severe haemophilia are able to live the lifestyle they want without the 
need for prophylaxis. However, these patients are usually encouraged to attend regular check-ups 
in the hospital, and to consider switching back to prophylaxis if they start to experience bleeding 
problems.  
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There is currently no consensus on how prophylaxis should be managed for patients with severe 
haemophilia once they reach adolescence and young adulthood. However, results from one study 
suggest that a significant proportion of patients with severe haemophilia may not require intensive 
prophylaxis for the rest of their lives. In their study of a cohort of 218 patients registered at 19 
haemophilia centres across Europe, Richards et al. (2007) found that approximately half had 
successfully reduced or stopped prophylaxis when they reached adolescence, and that only 28% of 
the patients who had stopped had to reintroduce prophylaxis due to an increase in bleeding. 
However, further studies are currently being undertaken across Europe to gather more evidence to 
inform future practice. 
 
1.5.3 Inhibitors 
In some cases the body responds to factor replacement treatment by producing antibodies that 
inhibit or interfere with the function of the treatment and make it much harder to prevent and treat 
bleeds. These antibodies are known as inhibitors and occur in approximately 30-35 percent of 
people with severe haemophilia A,  and are much less common in severe Haemophilia B (K. Fischer 
et al., 2008). 
When a patient develops inhibitors, more intensive or alternative treatment may be required to 
control bleeds and try and eliminate inhibitors. Most inhibitors are temporary and often appear 
during the first year of treatment. People with moderate to severe inhibitors are often prescribed a 
treatment called immune tolerance therapy (ITT), which aims to manipulate the immune system and 
involves a course of daily injections of recombinant factor treatment that last between 6 and 24 
months. If the treatment is successful the immune system will start to recognise the blood clotting 
factors as "self" and stop producing inhibitors. ITT is estimated to be successful in approximately 
80% of cases (Hay, 2012)  . 
In the event of a bleed people with inhibitors have to use a medication called a bypass agent, which 
is a separate product that can be used to stop bleeding by ‘bypassing’ the inhibitor. Those patients 
for whom ITT doesn't work may need to use bypass agents for the rest of their lives. Bypass agents 
can be used as prophylaxis, but are not as effective at preventing bleeds as prophylaxis with factor 
concentrate. For these patients it will therefore be less likely that their haemophilia will be well 
controlled, and they are therefore more likely to suffer joint damage. People who develop inhibitors 
face a higher mortality rate, and the cost of their treatment rises significantly. Although much 
progress has been made in the treatment of inhibitors, they remain a significant problem in the 
management of haemophilia today.  
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1.5.4 Multidisciplinary haemophilia care 
In the UK haemophilia care is provided by NHS haemophilia centres and haemophilia 
comprehensive care centres (CCC). Haemophilia centres are usually smaller and not able to 
provide a complete range of specialist treatment. CCC are usually larger (looking after patients from 
a wider geographic area) and have the resources to cope with more complex treatment issues as 
well as routine care. There are currently 22 CCC and 64 haemophilia centres in the UK (UKHCDO 
annual report, 2014).  
Many patients with severe haemophilia receive their care from CCC where they are usually looked 
after by a multidisciplinary team that in addition to doctors and nurses may include physiotherapists, 
psychologists, play specialists, and social workers. In these teams nurses in particular take a 
prominent role in liaising with patients and looking after their treatment. Similarly physiotherapists 
have a key role in assessment, rehabilitation and education of patients and their families. 
 
1.6 Self-management 
People with haemophilia are encouraged to take an active role in monitoring and managing their 
condition from childhood. Responsibility for managing their condition increases gradually with age 
and maturity, with most patients becoming fully self-sufficient by late adolescence. For people with a 
severe bleeding phenotype (most people with severe haemophilia and some with moderate 
haemophilia) this includes many self-management behaviours, of which the most important are 
shown in table 1.2. 
Patients who are on prophylaxis (most patients with severe haemophilia, and patients with 
moderate haemophilia with a severe bleeding phenotype) are encouraged to attend routine check-
up appointments every 3 to 4 months during childhood, and then every 6 months as an adult. 
Patients with mild or moderate haemophilia who are not on prophylaxis generally only attend one 
annual check-up appointment.  
All people with haemophilia, even those who are not on prophylaxis, need to consider the risks 
associated with their condition, particularly in relation to medical procedures and emergencies. 
Haemophilia centres (or CCC) encourage all patients to contact the centre in the case of medical 
emergencies or in preparation of planned medical procedures. 
 
  
11 
 
Table 1.2: Haemophilia self-management behaviours for people with a severe bleeding phenotype 
Day-to-day management: 
 Manage stock of factor treatment and associated materials (such as needles). Most people with severe 
haemophilia in the UK receive regular home deliveries of treatment. 
 Take treatment, this includes working out dose and frequency based on planned activities. 
 Complete treatment log to record time and dose of treatment. Many patients now use Haemtrack, an online 
treatment log which includes smart phone functionality. 
 Monitor and treat bleeds, including liaising with the haemophilia centre, and attending hospital if required. 
 Ensure treatment is available at school/college/university or work, and carry emergency treatment when 
away from home. 
 
Contact with haemophilia centre: 
 Book and attend check-up appointments. 
 Attend physiotherapy and occupational therapy appointments. 
 Contact the haemophilia centre when a bleeding episode occurs to receive advice and guidance on how to 
treat it, and attend the hospital for assessment and treatment if required. 
 Inform the haemophilia centre of any planned medical procedures or dental work. 
 
Lifestyle considerations: 
 Avoid medications that can interfere with coagulation (such as aspirin and NSAIDs). 
 Avoid activities and sports that increase risk of bleeding. 
 Wear medical alert bracelet and/or carry medical alert card. 
 Ensure there is always someone around who knows what to do in an emergency. 
 Take out additional travel insurance for trips abroad and avoid countries where adequate emergency 
treatment is not available. 
 
 
 
1.7 Prognosis 
Life expectancy varies with the severity of haemophilia and availability of adequate treatment. 
Before effective treatment became available in the 1960s the average life expectancy for someone 
with haemophilia in the UK was 11 years (Jones, 1991). By the 1980s life expectancy for those 
receiving appropriate treatment increased to 50-60 years, and today someone who receives optimal 
treatment can expect a life expectancy that is very similar of those who are not affected by 
haemophilia (Rodriguez-Merchan, 2010). 
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Before the advent of recombinant factor concentrates patients were at significant risk of infection 
with HIV and Hepatitis C through contaminated treatment. A study published in 1998 (AIDS Group 
of the United Kingdom Haemophilia Centre Directors) reported that HIV antibodies were found in 
41% of people with haemophilia A and 6% of those with haemophilia B. These percentages 
increased to 59% and 11% respectively for those affected by severe haemophilia.  Many men with 
haemophilia alive today who received treatment in the 1970s and 1980s are infected with both 
Hepatitis C and HIV, resulting in a much worse prognosis (Wilde, 2004).  
An important advance in the search for better treatment and a cure for haemophilia is gene therapy. 
In summary, this involves the transfer of a normal copy of a gene to an individual who has a 
mutation in that gene (Ponder, 2006). Gene therapy research trials are ongoing in both animals and 
humans, and studies have been published showing the first durable gene therapy in severe 
haemophilia B (Nathwani et al., 2014; Nathwani et al., 2011). Gene therapy trials for haemophilia A 
are lagging behind a little but the first human trials are currently underway in the UK.  It is 
anticipated that gene therapy may eventually help people with haemophilia to produce their own 
coagulation factor, reducing or even removing their need to inject factor treatment on a regular 
basis.  
 
1.8 Impact of Haemophilia 
1.8.1 Impact on patient 
Young people with haemophilia (YPH), even those with severe bleeding phenotypes, are usually 
able to live a relatively normal life.  Studies in the US, Netherlands, and Australia found that 
haemophilia A did not appear to impact academic achievements (Drake et al., 2010; Plug et al., 
2008; Talaulikar, Shadbolt, McDonald, & Pidcock, 2006), although some studies suggest that 
people with severe haemophilia may participate less in full-time work (Plug et al., 2008; Talaulikar et 
al., 2006), and that discrimination at school and work still exists (J. Barlow, Stapley, Ellard, & 
Gilchrist, 2007; J. H. Barlow, Stapley, & Ellard, 2007). In addition to the demanding treatment 
regimen and general practicalities of managing a chronic health condition, there are some specific 
issues for people living with haemophilia. 
 
Exercise 
People with haemophilia are generally encouraged to be active and exercise, as it can help develop 
strong bones and muscles and therefore protect against damage caused by bleeds (Von 
Mackensen, 2007). However, they are advised to avoid contact sports such as rugby and boxing 
and other activities that increase the risk of bleeding. Haemophilia teams in the UK tend to work 
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closely with patients and their parents to assess individual circumstances and consider a wide 
range of criteria before advising patients on the sports and activities that are safe and best suited for 
them. These criteria include personal bleeding history, the associated risk level and contact level of 
the sport, and the benefits it may bring (such as muscle strengthening and stretching). Many 
haemophilia centres employ specialist haemophilia physiotherapists, who work with patients on 
existing injuries and suggest strategies they can employ to prevent future injuries. 
 
Medication  
Certain medications, including widely available painkillers and cold remedies (such as aspirin and 
ibuprofen), can interfere with blood clotting. Parents of children with haemophilia are taught to be 
very cautious with medication, and to always check with the haemophilia centre if they are unsure. 
Many haemophilia nurses and doctors remind their patients of the dangers of some medications 
regularly.   
As haemophilia is a fairly rare disorder, some doctors and nurses who work in different specialties 
are unaware of the risks of inappropriate treatment, which can sometimes lead to life-threatening 
complications (J. H. Barlow et al., 2007; Talaulikar et al., 2006). To avoid such complications, 
patients are encouraged to always contact the haemophilia centre about any non-haemophilia 
related medical issues they are seeking treatment for. During routine check-ups many clinicians will 
also ask patients if they have any medical treatments planned to ensure that involvement from the 
haematology team is arranged if needed. People with haemophilia are also encouraged to have a 
medical alert card/bracelet on them at all times to ensure that in the case of an emergency medical 
assistance is sought.  
 
Psychosocial impact 
Physical or functional limitations caused by haemophilia can make young people feel shy, insecure 
or embarrassed. Visible joint damage, needle marks and decreased muscle tone can result in 
young people developing poor body image. For some this may mean that they do not want to 
expose the affected area to others (avoiding activities such as swimming and wearing clothes that 
cover them at all times), while for others it may lead to psychological issues that can manifest 
themselves in many ways including low self-esteem and anxiety. These psychological issues are 
likely to influence social interaction, quality of life, and can have a detrimental impact on treatment 
adherence. 
The current literature suggests that even today people with haemophilia may experience stigma or 
judgement, including discrimination at work or school (J. H. Barlow et al., 2007; Cassis, Querol, 
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Forsyth, & Iorio, 2012). Some CCC employ a specialist social worker or psychologist to support 
patients with the psychological, social and practical challenges of living with haemophilia. Other 
centres refer patients to external support services.  
 
1.8.2 Impact on family 
 Over the decades it has been documented that there is a social impact of living with haemophilia 
(Beeton, Neal, Watson, & Lee, 2007; Boon & Roberts, 1970; Cassis et al., 2012). This is not just the 
case for the patient themselves, but also for their families and wider social environment. In particular 
carrier mothers may be affected, as in addition to the day-to-day worry about their child they may 
feel guilty about passing the condition onto him. Some studies suggest that mothers are more likely 
to suffer from anxiety and depression that is related to their child’s haemophilia than fathers (Bottos, 
Zanon, Sartori, & Girolami, 2007; Saviolo-Negrin et al., 1999).   
In most cases parents are responsible for the management of haemophilia during childhood; they 
have to learn to recognise the onset of bleeds and administer the intravenous treatment; decide 
which activities their child can take part in (and manage the difficulties associated with stopping their 
child from participating in activities they enjoy); and decide who to inform of their child’s 
haemophilia. Finding a balance between safeguarding a son with haemophilia without over 
protecting him is often reported as a specific issue (Beeton et al., 2007).  It is likely that the way in 
which parents respond to living with a child with haemophilia, and manage the condition during his 
childhood, may form the foundation for the child’s behaviour and perceptions in relation to their 
condition into adulthood (Canclini et al., 2003).  
Treatment and healthcare provisions have improved significantly in recent decades, leading to a 
much better situation for people with haemophilia and their families. However, having a child with 
haemophilia can still impact on family life and family dynamics (Wiedebusch, Pollmann, Siegmund, 
& Muthny, 2008). Unaffected siblings may find it difficult to understand why they need to be more 
careful around their brother because of his haemophilia, especially following a bleed. Situations in 
which a family activity has to be cancelled because of a bleeding episode affects siblings as well as 
the boy with haemophilia. And of course there are the many hospital visits, special arrangements to 
accommodate the child with haemophilia, and other issues that are likely to take parents’ time and 
attention away from their other children, who may or may not have haemophilia as well.  Managing 
these situations and balancing the needs of affected and unaffected children is likely to cause 
additional stress for parents.  
The challenges associated with raising a child with haemophilia may even influence couples’ 
reproductive choices. After having a child with haemophilia some parents decide not to have any 
subsequent children or opt for prenatal diagnosis with the option to terminate the pregnancy, 
15 
 
whereas others may use pre-implantation genetic diagnosis or non-invasive sex determination to 
ensure they have a female child (Kadir, Economides, Braithwaite, Goldman, & Lee, 1997; Knol, 
Voskuilen, Holterman, Kluin‐Nelemans, & Meijer, 2011). Pre-implantation genetic diagnosis is a very 
expensive procedure with a relatively low success rate; resulting in pregnancy for approximately 
17% of women (Nicolle, Talks, & Hanley, 2004).  Natural conception followed by antenatal diagnosis 
increases the chance of successful pregnancy, and is far more cost-effective. However, it is 
associated with a potentially high psychological costs (in case of termination of an affected 
pregnancy) and considerable ethical implications. 
In the UK and many other European countries, families who are (potentially) affected by bleeding 
disorders have access to genetic counselling. In the UK this is usually provided by a haemophilia 
centre. The aim of this counselling is to provide carriers and their partners with sufficient information 
to consider implications for themselves and potential children, and support them through the 
subsequent decision making process. Genetic counselling should ideally take place before 
conception, to allow couples to consider and plan their options without any time pressure (Chi & 
Kadir, 2009; Lee et al., 1998). 
 
1.9 Haemophilia treatment in the context of this research 
The availability of safe and routine prophylaxis has revolutionised haemophilia treatment in this 
country, in particular for those with severe haemophilia. Quality of Life, life-expectancy and long-
term outcomes have improved immensely, and allow most people with haemophilia to live a full and 
productive life. However, patients’ adherence to their prophylactic treatment regimen has a 
considerable influence on its efficacy. Adherence in this context is the extent to which a patient 
follows the treatment regimen they agreed with their haemophilia team. Non-adherence (i.e. not 
keeping to the agreed frequency and/or dosing and/or timing of prophylactic injections) increases 
the risk of spontaneous bleeds (Hacker, Geraghty, & Manco‐Johnson, 2001), which increases 
treatment costs (Panicker, Warrier, Thomas, & Lusher, 2003), and may result in joint damage 
leading to poorer physical and emotional wellbeing (Marilyn J Manco-Johnson et al., 2007; Treil et 
al., 2007). In addition to the immediate costs associated with treating bleeds (on-demand treatment, 
potential hospitalisation, clinic visits, etc.), they may also lead to increased future care-costs due to 
disability. Because of the very high costs, the cost-benefit for prophylaxis correlates strongly with 
treatment adherence (M. J. Manco-Johnson et al., 2007; Thornburg & Pipe, 2006). Even low levels 
of non-adherence can result in significant medical problems and permanent disability (Treil et al., 
2007). 
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Levels of adherence to prophylaxis reported in the existing literature vary widely  from 80-87% in a 
study conducted across 6 European countries (De Moerloose et al., 2008) to 44% in a single centre 
UK study (Llewellyn et al., 2003), and reasons for non-adherence among YPH are not evidenced. In 
addition, reported adherence levels among adolescents and young adults are predominately based 
on estimations made by healthcare professionals and/or parents rather than young people 
themselves (Geraghty et al., 2006; Hacker et al., 2001).  
Despite the wide variation in reported levels of adherence, many of the North American and 
European studies suggest that patients may need additional support to help them keep to their 
treatment regimen during adolescence (Geraghty; Dunkley, Harrington, Lindvall, Maahs & Sek, 
2006; Breakey, Blanchette, & Bolton-Maggs, 2010), as they go through the transition from paediatric 
to adult care and are expected to become responsible for their own treatment. The literature 
suggests that adherence is unlikely to improve into young adulthood, and may indeed reduce 
further, particularly if transition was problematic or unsuccessful (Breakey, Blanchette, & Bolton-
Maggs, 2010; Geraghty et al., 2006). For this reason, this programme of research will aim to assess 
the levels of adherence to prophylactic treatment among YPH who are aged 12-25, and explore 
their reasons for (non-)adherence. 
This will be done using a mixed methods approach involving quantitative and qualitative studies. 
The quantitative part of this research aims to assess levels of adherence and psychosocial factors 
that have been shown to be associated with treatment adherence among young people with other 
chronic health conditions (such as diabetes).  The qualitative studies aim to examine personal 
experiences YPH have in relation to prophylactic treatment, and how they make sense of these 
experiences.   The qualitative work will also include the perspectives of parents and healthcare 
professionals. Before going on to describe these studies, an introduction is provided for theories 
and empirical evidence on adherence in order to (a) highlight its importance in maintaining optimum 
health and (b) identify factors (from theory or research) that may influence adherence in order to 
provide a starting point for the research that follows. Below follows a short description of each of the 
following chapters. 
 
Chapter 2: Introduction to treatment adherence and theoretical models of adherence.  
Chapter 3: Review of literature in relation to adherence among young people with chronic health 
conditions, with a focus on haemophilia. This chapter concludes with a rationale for the methods 
used and a summary or these methods. 
Chapter 4: Cross-sectional analysis of adherence to prophylaxis and psychosocial factors of 
adherence among young people with haemophilia.   
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Chapter 5: Approach and methodology for three qualitative interview studies. 
Chapter 6: Interpretative Phenomenological Analysis of patients’ accounts of prophylaxis and their 
adherence to this treatment. 
Chapter 7: Interpretative Phenomenological Analysis of parents’ accounts of prophylaxis and their 
sons’ adherence to this treatment. 
Chapter 8: Interpretative Phenomenological Analysis of haemophilia healthcare professionals’ 
accounts of adherence to prophylactic treatment. 
Chapter 9: Discussion of qualitative interview studies. 
Chapter 10: General discussion. 
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Chapter 2: Introduction to treatment adherence 
An extensive literature now exists in relation to treatment adherence, particularly for chronic health 
conditions. In the last two decades a number of comprehensive reviews have been published (M. 
DiMatteo, 1994; M. R. DiMatteo, 2004; R. Haynes, McDonald, Garg, & Montague, 2003; R. B. 
Haynes, Ackloo, Sahota, McDonald, & Yao, 2008; Kripalani, Yao, & Haynes, 2007; Osterberg & 
Blaschke, 2005; Vermeire, Hearnshaw, Van Royen, & Denekens, 2001), including a report by the 
World Health Organisation (Sabaté, 2003). 
However, studies investigating adherence have based their research on various theories or models 
of health behaviour and adherence. Therefore this chapter will start with a brief definition of 
adherence, followed by an overview of theoretical models that have been used to try and explain 
(non)adherence to treatment for chronic health conditions. 
 
2.1 Definition of adherence 
The existing literature often uses the terms ‘adherence’ and ‘compliance’ interchangeably. However 
it is important to differentiate between these two terms, as compliance implies that patients should 
keep to their prescribed treatment regimen, whereas adherence implies that patients have a choice 
to follow the treatment regimen that they have agreed with their doctor. Adherence in this context is 
defined as the extent to which a patient’s behaviour matches agreed recommendations from the 
prescriber (Horne, 2006; G. J. Treharne, Lyons, Hale, Douglas, & Kitas, 2006).  
Current prophylaxis regimen for haemophilia are often individualised, with a clear focus on 
concordance between healthcare professional (HP) and patient. Concordance in this context means 
that treatment decisions are agreed jointly between the haemophilia team and patient (and 
parent/caregiver where appropriate). Concordance is subsequently considered an important tool to 
improve patient engagement and adherence, rather than an outcome in itself (Horne, 2006). 
Therefore, this programme of research will use the term ‘adherence’ throughout.  
The existing literature suggests that treatment adherence is multidimensional and determined by a 
number of interacting factors. Different theories and research studies emphasize different 
dimensions, but most agree that the key factors involved in adherence relate to patient 
characteristics (e.g. demographics, self-efficacy, attitudes and perceptions, cognitive factors, socio-
economic status); clinical characteristics (e.g. complexity of regimen, severity of symptoms, level of 
disability and co-morbidities); social environment (availability of social support, family dynamics, 
school or work environment); and the health care provider (e.g. relationship between patient and 
doctor, resources available to support patients, practicalities around medication collection/delivery). 
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Research in other chronic conditions has made a useful distinction between intentional non-
adherence and unintentional non-adherence (M. J. Johnson, 2002; Lehane & McCarthy, 2007). 
Unintentional non-adherence (forgetting) can usually be addressed with simple interventions, such 
reminders on a calendar or diary, telephone or text message reminders (Pop-Eleches et al., 2011) 
or visual prompts (putting medication in a highly visible place such as the kitchen counter). 
However, intentional non-adherence (skipping) is often driven by complex psychological processes 
and is therefore more challenging to address. Research in haemophilia has thus far not made this 
distinction, nor has it investigated the complex psychological processes that are likely to underlie 
non-adherence to prophylaxis.  
 
2.2 Theoretical models of adherence 
Various theoretical models and frameworks for explaining variations in health-related behaviour 
have been used to try and explain and predict treatment adherence, including Social Cognition 
Models (SCM), such as the health belief model, Stage Models and Self-Regulatory Theory.   
 
2.2.1 Social Cognition Models 
Social Cognition Models (SCM) propose that peoples’ beliefs and attitudes, which are derived 
socially, influence their interpretation of information and experiences and are a key determinant in 
behaviour (Conner & Norman, 2005). These models share the common core assumption that 
people carry out a cost-benefit analysis, weighing up their beliefs about the necessity of medications 
against their concerns about the potential adverse effects of taking them.   
 
2.2.1.1 Health Belief Model 
One of the most influential SCM to attempt to explain health behaviour is the health belief model 
(HBM, Rosenstock, 1966). The model was initially applied to explain preventative health 
behaviours, but was later developed further and applied to other health behaviours including 
treatment adherence (Becker & Maiman, 1975).  
The HBM has been described as an ‘expectancy-value’ decision-making model as it is based on the 
assumption that individuals adopt health behaviours only after evaluating and comparing the 
perceived health threats and perceived cost-benefits of all alternatives (Christensen, 2004; Janis, 
1984). Revised versions of the model include the additional components health motivation (Becker, 
Haefner & Maiman, 1977b) and cues to action (Mattson, 1999).  
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In the context of treatment adherence HBM suggests that before making the rational decision to 
take their treatment an individual is likely to assess the health threat by evaluating their perceived 
susceptibility (e.g. of experiencing side effects from medication or developing symptoms due to not 
taking their treatment) and perceived severity (e.g. severity of those side effects or symptoms), 
followed by weighing up the benefits (e.g. reduction in symptoms as a result of taking medication) 
against the perceived barriers (e.g. the time it would cost to take the medication). Internal cues to 
action (e.g. experiencing a symptom) or external cues (e.g. being encouraged to adhere to their 
treatment by a doctor) are suggested to play an important role in maintaining or improving treatment 
adherence.  
The HBM has been used to investigate medication adherence across a number of chronic illnesses 
including  diabetes (Alogna, 1980; Brownlee-Duffeck et al., 1987); hypertension (Nelson, Stason, 
Neutra, Solomon, & McArdle, 1978); and renal disease (Cummings, Becker, Kirscht, & Levin, 1982; 
Hartman & Becker, 1978). These studies have typically found that adherence was predicted by 
various combinations of components of the HBM, rather than the precise interaction of all dimension 
specified by the model (Home, Weinman, Myers, & Midence, 1998). This mixed pattern of findings 
may be explained by limitations of the HBM. One limitation is its failure to include an intention stage 
between beliefs and behaviour, and that it does not include social factors such as subjective norm 
(Sheeran & Abraham, 1996). Another limitation is that the HBM does not specify the beliefs that 
underlie broad constructs such as perceived benefits and barriers (Horne, 1997; Horne & Weinman, 
1994). In the context of adherence to treatment for chronic illness, a key limitation of the HBM is that 
it implies that health-behaviours arise from a single rational decision that is based on a one-off cost-
benefit analysis. The model does not present a framework that explains maintenance of adherence 
to long-term treatment regimens, or specific illness perceptions involved in chronic illness (Horne, 
1997; Leventhal, Diefenbach, & Leventhal, 1992; Sheeran & Abraham, 1996). 
 
2.2.1.2 Beliefs about Medicines  
The Beliefs about Medicines Questionnaire (BMQ, Horne et al., 1999) is an extension to the HBM 
which directly addresses the cost-benefit analysis of perceived benefits and barriers of taking 
medication.  It aims to quantify patients’ personal beliefs about the necessity of their prescribed 
medication and their concerns about taking it, and to assess associations between these beliefs and 
adherence. The cost-benefit analysis in which individuals weigh up their beliefs about their 
treatment can be quantified using the BMQ (necessity total score minus concerns total score), this is 
sometimes referred to as the necessity-concern framework or differential (Emilsson et al., 2011; 
Menckeberg et al., 2008; Tibaldi et al., 2009).   
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Horne (1999) used the BMQ to investigate adherence in a sample of asthmatic, cardiac, renal, and 
oncology patients, and found that specific medication beliefs explained 15-20% of the variance in 
adherence. Studies in rheumatoid arthritis suggest that perceptions in relation to the necessity of 
medication are most important (Thurah, Nørgaard, Harder, & Stengaard-Pedersen, 2010; G. 
Treharne, Lyons, & Kitas, 2004), whereas studies in osteoporosis suggest that it is concerns about 
medication that play a more important role (Desai, Sonone, & Bhasme, 2005). In a study of  65 UK 
males with haemophilia (aged 12 years or older) Llewellyn et al. (2003) found that patients who had 
a greater perception of treatment necessity  were significantly more likely to adhere to their 
treatment and that concerns about treatment were not significantly associated with adherence. It is 
not surprising that beliefs differ between different illness groups, as the characteristics of both 
illness and treatment can vary greatly.  In some adherence research, the BMQ has been used to 
extend the Self-Regulation Model (see below) to provide a more comprehensive view of patients’ 
perceptions in relation to their health condition as well as their treatment. (Horne & Weinman, 2002; 
Rees, Leong, Crowston, & Lamoureux, 2010; Ross, Walker, & MacLeod, 2004). 
 
2.2.1.3 Theory of Reasoned Action and Theory of Planned Behaviour  
The Theory of Reasoned Action (TRA, Ajzen & Fishbein, 1980) is a more general theory of human 
behaviour, which is based on the assumption that behavioural intentions are strong predictors of 
behaviour change and that these intentions are influenced by an individual’s attitudes towards the 
behaviour and their perceived subjective norms.  From the TRA perspective, attitudes include the 
expected consequences of the behaviour and the importance of those consequences. Perceived 
subjective norms refer to what an individual believes others expect or want them to do in relation to 
a particular behaviour.  This component distinguishes the TRA from the HBM and other expectancy-
based models of health-related behaviour. In the context of adherence, the TRA predicts that 
someone is most likely to form an intention to adopt a particular behaviour (e.g. keep to their 
treatment regimen) when the expected consequences are relatively beneficial (e.g. reduction in 
symptoms as a result of taking treatment), the expected consequences are important (e.g. the 
reduction in symptomology is valued), and the behaviour is in line with subjective norms (e.g. 
significant others would prefer the individual to take their treatment). The intention to adhere to 
treatment leads to the behaviour (i.e. adhering to treatment). 
The Theory of Planned Behaviour (TPB, Ajzen, 1988) is an extension of the TRA, which builds on 
Bandura’s (1977) work on self-efficacy and control.  In addition to the attitudinal components and 
subjective norm of the earlier model, the TPB considers an individual’s perceived degree of 
volitional control over the behaviour.  This is influenced by the individual’s belief that they have 
access to the resources and skills needed to carry out the behaviour successfully.  
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In the model an individual’s intention to perform the behaviour is the single most predictive factor of 
behaviour (Ajzen, 1991).  Behavioural intention is influenced by three factors: an individual’s 
attitudes (beliefs about the behaviour and perceived consequences), their perceptions in relation to 
subjective norm (individual assesses if significant others think they should adopt the behaviour or 
not), and their perceived behavioural control (self-efficacy). Perceived behavioural control may also 
predict behaviour directly as it is unlikely that an individual will adopt a behaviour if they feel they 
are not capable of carrying it out, even if their intention is high. 
A number of studies have used the theory of planned behaviour to explain preventive health 
behaviours such as exercise and smoking cessation (Abraham, Sheeran & Johnston 1998; 
Armitage & Conner, 2001), but studies that have explicitly evaluated it in relation to adherence to 
treatment for chronic illness are much less common. However, there is broad support for the 
assertion that behavioural intentions are influenced by attitudes and subjective norms, although the 
strength of the relationship between intentions and behaviour varies across studies and between 
behaviours (Connor & Sparks 1996).  Experimental evidence suggests that changing intentions has 
little effect on changing behaviour (Chatzisarantis & Hagger, 2005), and that interventions based on 
the TPB can sometimes be effective at changing behaviour without changing any of the 
components of the model (Sniehotta, 2009). 
Studies using SCM to explore adherence in chronic illness have produced a mixed pattern of 
findings. For instance, in studies utilizing the HBM, adherence was typically predicted by various 
combinations of components of the model, rather than the precise interaction of all dimensions 
specified by the model (Home et al., 1998). Findings of studies that utilized theories of reasoned 
action and planned behaviour support the suggestion that behavioural intentions are influenced by 
attitudes and subjective norms. Although the strength of the association between intentions and 
behaviour varies between studies and behaviours (Conner & Sparks, 1996), a meta-analysis by 
Webb and Sheeran (2006) showed that medium-to-large change in intention is likely to lead to a 
small-to-medium change in behaviour. 
 
2.2.2 Stages of Health Behaviour 
One key criticism of SCMs is that they do not address the dynamic nature of cognitions and 
behaviour, which are likely to change over time and interact in different ways depending on the 
situation. It has been suggested that health behaviour may proceed in stages, and that the 
importance of different cognitions fluctuates depending on the stage. Weinstein (1988) suggests 
that interventions to promote health behaviour are likely to be more effective if they are targeted at 
the particular cognitions which characterise the stage that the individual has reached in their 
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consideration or implementation of the behaviour. Several stage models of health behaviour have 
been proposed in which health behaviours occur as the result of several stages of cognition.  
The Transtheoretical Model, or Stages of Change Model (TM, Prochaska & DiClemente, 1994; 
Prochaska, DiClemente, & Norcross, 1992) proposes that adoption and maintenance of a health 
behaviour occurs in five progressive stages of change (Pre-contemplation, Contemplation, 
Preparation, Action and Maintenance). In instances where the behaviour change is aimed at 
stopping problematic behaviour (such as smoking) a sixth stage, Termination, may occur when the 
goal has been reached (e.g. smoking cessation). It is likely that an individual may follow a cyclical 
route through the first five stages, which may be characterised by many brief or partially successful 
attempts before behaviour change is established. In general successful progression depends on a 
positive decisional balance (perceived advantages of the behaviour need to outweigh the 
negatives), self-efficacy and strategies that can help to make and maintain the behaviour change 
(referred to as processes of change). The TM has been successfully applied to a variety of 
situations, including smoking cessation (Carlo C. DiClemente et al., 1991); diet and weight control 
(Curry et al., 1992); stress management  (Evers et al., 2006); adherence to antihypertensive 
medication (S. S. Johnson, Driskell, Johnson, Prochaska, et al., 2006) and lipid-lowering drugs (S. 
S. Johnson, Driskell, Johnson, Dyment, et al., 2006); and exercise (Marcus et al., 1992).     
One of the key criticisms of stage models (and indeed SCM) is that they do not fully address how 
motivation to continue a health behaviour is maintained. There is an implicit assumption that the 
main cognitive barrier to maintenance is low self-efficacy. Therefore, if an individual is confident that 
their medication works, believe that they are capable of adhering to their treatment regimen, and are 
motivated to do so, the model assumes that they will continue to take their treatment.   
Another criticism of the TM is that it is a pseudo-stage model, where each different stage reflects a 
different level of intention rather than being qualitatively different from the other stages (Conner et 
al., 2002; Sutton, 2001). In their critique of the model Littell and Girvin (2002) suggest that although 
it may present some potentially helpful ways of considering how people grow and change, its 
explanations of people and processes are not especially true or generalizable. They propose that 
the search for a generic underlying structure of behaviour change does not consider that successful 
change processes may vary depending on the complexity and features of the intended behaviour 
change, external facilitators and barriers, cultural context, and potential other issues an individual 
may be experiencing.  Little experimental evidence exists to support the effectiveness of 
interventions aimed at behaviour change based on the  Transtheoretical  model, and its empirical 
support has been questioned by findings of several systematic reviews (e.g. Cahill, Lancaster, & 
Green, 2010; Littell & Girvin, 2002; Riemsma et al., 2003; Whitelaw, Baldwin, Bunton, & Flynn, 
2000).  
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2.2.3 Self-Regulation Model 
Leventhal and colleagues (1993) suggest that once self-efficacy and outcome efficacy is in place, 
continued behaviour depends on continued motivation. In an attempt to explain the dynamic 
interaction between cognitions, motivation and behaviour, Leventhal and colleagues (Leventhal, 
Meyer, & Nerenz, 1980) developed the Self-Regulatory Theory as a framework for understanding 
illness behaviour. This is often referred to as Leventhal’s Self-Regulatory Model (SRM). The SRM 
views the patient as an active problem solver, whose health-related behaviour is an attempt to close 
the perceived gap between current health status and a future health goal. Patients respond to 
illness in a dynamic way based on their interpretation and evaluation of the illness. In this context 
adherence is considered one of a number of behaviours the patient adopts to cope with their illness 
(based on and influenced by their perceptions) 
According to the SRM, a patient will select coping strategies based on their interpretation and 
evaluation of their illness. These coping behaviours are then appraised and the effectiveness of 
these strategies is fed back into the patient’s model of the illness, and used to shape future coping 
responses (Leventhal, Nerenz, & Purse, 1984; Meyer, Leventhal, & Gutmann, 1985).  The model 
proposes that these three stages of processing (interpretation of the illness; coping with the illness 
and associated symptoms; and appraisal of the coping strategies used) occur in parallel at a 
cognitive and emotional level, and that a mediational relationship exists between illness 
representations, coping strategies and illness outcome, whereby coping mediates the relationship 
between illness representations and illness outcome (Carlisle, John, Fife‐Schaw, & Lloyd, 2005). 
According to the SRM, people form common-sense models of their illness which are organised 
around five broad dimensions (Table 3). Therefore the SRM is sometimes referred to as the 
Common-Sense Model of self-regulation. 
 
Table 2.1: Illness Representations of the Self-Regulatory Model  
Illness representation Definition 
Identity The illness label or diagnosis and the associated symptoms 
Consequences The expected effects that the illness may have on the patient’s life 
Timeline The expected duration of the illness (acute or chronic) 
Control/cure 
Perceptions of the extent to which the illness can be controlled or cured 
through treatment or behaviour  
Cause The factors that the patient believed caused the illness 
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Later versions of the model include additional dimensions which represent perceptions in relation to 
illness coherence (patients’ understanding of their illness); the cyclical nature of illness (symptoms 
may be acute, cyclical or chronic), and emotional responses (Moss-Morris, Weinman, Petrie, Horne, 
Cameron, & Buick, 2002). 
These dimensions provide a framework which enables patients to make sense of their illness and 
symptoms, assess their health risk, and direct action and coping. Each dimension represents one 
aspect of the illness and together they provide the individual's coherent view of their condition 
(Weinman, Petrie, Moss-Morris, Horne, 1996). It is likely  
that illness representations are influenced by cultural context (Landrine & Klonoff, 1992) and by 
other factors such as subjective norm and past experience (Leventhal et al., 1992). 
Ongoing research has shown that patient behaviour is influenced by illness representations, and 
that illness representations form a useful basis for self-regulatory interventions in acute and chronic 
illnesses (Petrie, Broadbent, & Meechan, 2003). Hagger & Orbell (2003) conducted a meta-analysis 
of the intercorrelations between the components of the SRM and found significant relationships 
between some of the illness representations and certain categories of coping strategies, and also 
between certain illness representations and illness outcomes. However, they reported that the role 
of outcome appraisals had remained untested in the literature. This may be because positive 
appraisal of coping may be a coping strategy in itself, whereas maladaptive coping may cause 
negative appraisal (Carlisle et al., 2005). 
A number of studies have investigated illness perceptions in relation to adherence to treatment in 
chronic illness, with variable results. Llewellyn, Miners, Lee, Harrington & Weinman (2003) 
measured adherence to prophylactic treatment among people with severe haemophilia and found 
that only illness identity (symptomatology) and necessity of medications (measured by the BMQ) 
significantly predicted non-adherence. Horne & Weinman (2002) found that for asthma patients 
symptomatology played a key role in adherence to prophylactic treatment. In this study patients who 
were symptom-free were less likely to take their preventer medication compared to those who 
perceived their illness to be chronic and have potentially serious consequences.  In other studies 
Chilcot, Wellsted & Farrington (2010) found among patients with end-stage renal disease that a 
perception of consequences as being less serious predicted non-adherence to fluid restrictions.  
Ross, Walker & MacCleod (2004)  found that less personal control and lower emotional reaction 
predicted non-adherence to hypertension medication. In other studies, illness identity, which is 
based upon symptoms, has been shown to be important in the regulation of the response to illness.    
However, it is important to consider that aetiology, experience and treatment of different chronic 
health conditions are quite disparate, which may lead to the development of different illness 
representations. For example, people with severe haemophilia are generally diagnosed at a very 
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young age, and tend to be involved with (or responsible for) regular preventative treatment from a 
young age. People with end-stage renal disease on the other hand will generally be older at onset 
and less aware of how to manage treatment until they develop some experience.  
Horne (2003) suggests that a symbiotic relationship exists between the SRM or common-sense 
model of self-regulation and the necessity-concern framework (as assessed by the Beliefs about 
Medicines Questionnaire) in explaining variations in treatment uptake and adherence. He proposes 
that treatment perceptions and the necessity-concerns framework can be used to extend the 
explanatory power of the CSM in relation to treatment adherence (Horne, 1997; Horne & Weinman, 
2002), and equally the CSM can contribute to the understanding of the process by which treatment 
perceptions influence adherence.   
The review of studies that have used the SRM to examine treatment adherence shows the majority 
of these studies were cross-sectional studies, and as a result were unable to look at the changes 
that are likely to occur as individuals with chronic illness progress from diagnosis to self-
management. 
 
2.2.4 Efficacy beliefs 
In relation to adherence, beliefs about self-efficacy (e.g. I am confident that I am able to take my 
treatment) and outcome efficacy (e.g. taking my treatment will reduce my symptoms) can play an 
important role.  Self-efficacy beliefs are influenced by an individual’s assessment of their own 
behaviour, the behaviour of others and feedback they receive about their own behaviour from 
significant others (Albert Bandura, 1997).  Perceived self-efficacy has been shown to be associated 
with adherence to health-related behaviours such as smoking cessation (Carlo C DiClemente, 
Prochaska, & Gibertini, 1985) and exercise programmes (Kaplan, Atkins, & Reinsch, 1984), and has 
been proven to be an effective basis for interventions aimed at improving self-management and 
clinical outcomes in a number of chronic health conditions such as arthritis, lung disease and heart 
disease (K. Lorig et al., 1986; Kate Lorig & Holman, 1993; K. R. Lorig, Mazonson, & Holman, 1993; 
K. R. Lorig et al., 1999). Self-efficacy has also been shown to be related with diabetes self-
management and glycaemic control in adolescents with type I diabetes, (Griva, Myers, & Newman, 
2000; Grossman, Brink, & Hauser, 1987; Ott, Greening, Palardy, Holderby, & DeBell, 2000). 
Although positive self-efficacy can encourage adherence on its own, it has been shown to have a 
stronger influence when combined with positive outcome expectations in adults (Williams & Bond, 
2002) and adolescents with type I diabetes (Iannotti et al., 2006) . These findings support Bandura’s 
(1997) original suggestion that individuals are most likely to adopt a health behaviour if they 
perceive themselves to be capable of doing so, and if they expect this behaviour to have mainly 
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positive consequences (more positive outcome expectations and fewer negative outcome 
expectations). 
According to Bandura (1994; 1997) efficacy beliefs are developed and influenced by four main 
sources. Firstly, personal successes (or mastery experiences) can build an individual’s belief in their 
efficacy, particularly if they have had to overcome some obstacles in order to achieve success. On 
the other hand failures or easy successes can undermine perceived self-efficacy. Secondly, 
vicarious experiences through social models can also influence efficacy beliefs (positively or 
negatively), with models who are perceived to be the most similar to an individual having the biggest 
influence. Thirdly, social persuasion can encourage people to try harder and persist for longer in 
trying to succeed, which in turn can promote skills development and a sense of self-efficacy. 
However it can also persuade people that they lack capabilities, which in turn can undermine 
motivation and self-efficacy, and lead to avoidance of challenging activities. Fourthly, an individual’s 
state of mind and their physical and emotional responses to challenges (such as stress or physically 
demanding activities) also influences their efficacy beliefs.  
The inclusion of efficacy beliefs in SCMs such as the TPB has improved their ability to predict 
preventative health behaviours, including medication adherence (Barnhoorn & Adriaanse, 1992; 
Schwarzer & Fuchs, 1996). Beliefs about self-efficacy and outcome efficacy (outcome expectations) 
may be influenced by previous experience and other cognitions. 
 
2.2.5 Social Support 
In addition to the above models, there is also evidence to support the association between 
adherence and social support (DiMatteo, 2004; Owen, Friesen, Roberts, & Flux, 1985). DiMatteo 
(2004) suggested that support and help from friends and family promotes adherence by providing a 
buffer for illness-related stress, encouraging optimism and self-esteem, reducing anxiety and 
depression and giving practical assistance. In his 2004 meta-analysis DiMatteo found that practical 
support with treatment was most strongly associated with adherence, although adherence was also 
found to be related to emotional support, family cohesiveness and conflict, marital status, and living 
arrangements. In research with adolescents with type I diabetes (Annette M. La Greca et al., 1995; 
Annette M La Greca & Bearman, 2002) support from family and friends were both found to be 
significantly associated with better adherence and/or self-management. 
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2.2.6 Summary of theories of adherence 
The existing literature in relation to adherence to long-term therapies for chronic illness suggest that 
it is multidimensional and determined by a number of interacting factors including patient 
characteristics; clinical characteristics; social environment;  and the health care provider. Studies 
using SCM to explore adherence in chronic illness have produced some evidence to support 
sections of models and frameworks such as the HBM and TPB, however there is no evidence to 
support the precise interaction of all dimensions specified by these models. Illness representations, 
beliefs about medicines, self-efficacy and perceived availability and quality of social support have 
been shown to be important correlates of treatment adherence and self-management in chronic 
health conditions, and together they may provide a more rounded explanation of adherence to long-
term therapies such as prophylaxis. The research described in this thesis will therefore combine 
these correlates into a framework for understanding adherence to prophylaxis among YPH. The 
next chapter will provide an overview of the literature in relation to treatment adherence among 
adolescents and young adults with chronic health conditions, with a focus on haemophilia. 
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Chapter 3: Adherence among adolescents and young adults 
with chronic health conditions, with a focus on haemophilia 
The aim of this chapter is to give a comprehensive overview of the literature surrounding treatment 
adherence among young people who are affected by chronic health conditions, with a particular 
focus on adolescents and young adults with haemophilia. The chapter will guide the reader towards 
an understanding of the specific issues that influence adherence to prophylactic treatment among 
young people with haemophilia (YPH). 
 
3.1 Levels of adherence among young people affected by chronic health conditions 
Adherence is an important factor in the efficacy of all medical treatments, in fact adherent patients 
are almost three times more likely to have a good outcome in comparison to non-adherent patients 
(Robin DiMatteo, Giordani, Lepper, & Croghan, 2002). Levels of adherence reported among 
adolescents with chronic illnesses such as diabetes, juvenile rheumatoid arthritis (JVA) and asthma 
vary widely, from 10% to almost 90% (Alvin, Rey, & Frappier, 1995; Michaud, Frappier, & Pless, 
1991; P. Michaud, J. Suris, & R. Viner, 2004; Rapoff & Barnard, 1991).  
For instance, non-adherence rates among adolescents have been reported to be approximately 
28% for medication for epilepsy (Asadi-Pooya, 2005); 25% to insulin injections for diabetes (S. B. 
Johnson et al., 1992; Weissberg-Benchell et al., 1995); 29% for blood glucose monitoring and 81% 
for diet recommendations in diabetes (S. B. Johnson et al., 1992); between 17% and 90% for 
inhaled medication in asthma (Bender et al., 2000; Coutts, Gibson, & Paton, 1992; Lemanek, 1990); 
and 45% for oral medication in juvenile rheumatoid arthritis (JRA, Litt & Cuskey, 1981).  
 
3.2 Measurement of adherence 
Measurement of adherence is challenging, and may vary depending on the self-management 
behaviour that is being assessed. For instance, it is likely that adherence to a diet or exercise 
regimen will be assessed differently from adherence to taking medication or attending clinic 
appointments. The way in which good adherence is defined also influences how adherence may be 
assessed. For instance, for some treatments good adherence may be indicated by a certain level of 
the medication in the bloodstream, whereas for other treatments the level of adherence may be 
determined by the number of times that treatment is taken. The most common ways to assess 
adherence are described below.  
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3.2.1 Self-report data 
One commonly use method to assess adherence in research is to ask patients to indicate their own 
adherence using a questionnaire or diary.  There are many validated questionnaires to assess 
adherence to specific treatments or self-management behaviours, such as the VERITAS-Pro 
(Duncan, Kronenberger, Roberson & Shapiro, 2010) which assesses adherence to prophylactic 
treatment for haemophilia. Many adherence self-report questionnaires are validated against 
treatment logs to check how well they assess adherence. However, a key challenge is that some 
patient may not report their adherence accurately or truthfully. This may be because they do not 
want to admit to sub-optimal adherence or do not remember the exact timing and/or dose of their 
last treatment. 
 
3.2.2 Treatment logs 
Many patients with chronic illnesses are invited (or required) to complete a treatment log every time 
they take their treatment. Patients who follow a prophylactic treatment regimen for their haemophilia 
are required to log all the treatments they take (including any additional treatments taken to treat 
bleeds) on Haemtrack. This is an online treatment log with smartphone functionality that can be 
accessed by the haemophilia team, enabling them to monitor adherence of individual patients 
remotely. As with self-report questionnaires and diaries, this method relies on patients completing 
the information accurately and timely.   
 
3.2.3 Pharmacy data 
Adherence to medication that is dispensed by a pharmacist may be assessed by checking repeat 
prescriptions, looking at how much medication a patient has received from the pharmacy and if this 
would be enough to keep to their agreed treatment regimen. If a patient is not ordering (or receiving) 
sufficient medication from the pharmacy, it is likely that their adherence is suboptimal.  This method 
is often just an estimate, as it only shows how much treatment a patient has received and not how 
much treatment they have actually taken. For instance, it is possible that a patient has received 
enough treatment from the pharmacy, but does not actually take it. 
 
3.2.4 Blood tests 
Some medications can be detected in the blood using a blood test, where the level of medication in 
a patient’s blood stream gives a good indication of how well they adhere to their treatment (e.g. 
Methotrexate, a medication used by patients with rheumatoid arthritis). In other conditions a blood 
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test can give an indication of how well someone is managing their condition (e.g. a HbA1c blood 
test indicates how well blood glucose levels are controlled in someone with diabetes). However, this 
method requires a patient to come to the hospital or surgery to have a blood test and relies on the 
healthcare provider having enough resource to take the blood test and analyse it.  
 
3.2.5 Electronic monitoring 
For medication that is taken through an oral capsule or pill, it is possible to assess adherence by 
recording the date and time that the cap of the pill bottle is opened. This method only gives an 
indication, as of course it is possible that a patient simply opens and closes the pill bottle without 
taking their treatment. 
Due to the limitations associated with these different ways to assess adherence it can be useful to 
combine several methods. For instance, one may use data from treatment logs to validate self-
report questionnaire data, or combine pharmacy data or electronic monitoring with treatment logs. 
Although combining data from several sources is likely to increase the cost of research, it is also 
likely to improve data quality and validity of the research. 
 
3.3 Levels of adherence to prophylactic treatment among young people with haemophilia  
Due to the rarity of haemophilia research samples tend to be small and few studies have been 
published. A recent systematic review on the determinants of adherence to prophylaxis in 
haemophilia (Schrijvers, Uitslager, Schuurmans, & Fischer, 2013) identified just five articles in 
relation to barriers and motivators of adherence to prophylactic treatment in haemophilia, which 
were all published in the period of 2001-2008. After critical appraisal using the STROBE statement 
(von Elm et al., 2008) and criteria for quality of evidence developed by the Dutch Cochrane Centre 
(Offringa, Assendelft, & Scholten, 2008), two of these five studies were considered as the best 
evidence available. The first study (De Moerloose et al., 2008) was a survey of adherence in six 
European countries, and the second study (Llewellyn et al., 2003) was a UK single-centre survey 
study. The three other studies (du Treil, Rice, & Leissinger, 2007; Geraghty et al., 2006; Hacker et 
al., 2001) were excluded from the review because of small sample sizes, concerns about selection 
bias, use of unvalidated questionnaires, and not measuring adherence (instead asking healthcare 
professionals or parents to estimate adherence). The review authors (Schrijvers et al., 2013) 
suggest that the motivators of adherence are: experience of symptoms, a positive belief of necessity 
of treatment and a good relationship with the healthcare provider. Important barriers identified by 
the review are: infrequent or absence of symptoms and increasing age.  
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Levels of adherence reported in the current vary widely. Although the two studies included in the 
above review broadly agreed in relation to the drivers of adherence, they reported very different 
levels of adherence. In their survey of adherence in six European countries (De Moerloose et al., 
2008) found that adherence to prophylaxis across their entire sample (patients of all ages over 2) 
was 93% and overall adherence (to prophylaxis and on-demand treatment) among adolescents 
(aged 12-19) was 98%. A key limitation of this study is that, although the total sample was large 
(N=180), data was collected in six countries which each contributed just 30 participants. Practice 
patterns across these countries are, in some cases significantly, different. Therefore the overall 
findings of this study do not provide insight into local circumstances in each of the six countries, 
whereas the local samples of 30 participants in each country are not sufficiently large enough to 
evidence local levels of adherence and drivers of adherence. 
In their UK single-centre survey study (Llewellyn et al., 2003) found that 34% of patients (patients of 
all ages over 11) were fully adherent to frequency of prophylactic injections, and 44% of patients 
were fully adherent to the recommended dose of their prophylactic injections. A key limitation of this 
study is the small sample (N=65), which included patients who follow a prophylactic treatment 
regimen as well as people following an on-demand regimen, and consisted of participants aged 12 
years and older. Due to the significant differences in haemophilia treatment (and resulting issues 
such as HIV infection as a result of contaminated blood) during the previous decades, haemophilia-
related experiences of older people in the sample would have been completely different from 
younger participants. As the findings are based on the average scores of the total sample, they may 
not be particularly helpful to understand either older patients with significant haemophilia-related 
issues or younger patients who have very few health issues. 
The levels reported by the 3 studies that were excluded from the review also vary considerably. In 
their single-centre study in the US du Treil et al. (2007) found that only 17% of participants on 
prophylaxis had high adherence (defined as 67-100% of treatments taken as prescribed), whereas 
45% of patients on on-demand treatment had high adherence. Hacker et al. (2001) suggested that 
58.8% of responders (mostly mothers of patients aged 18 or younger) in their single-centre study in 
the US reported excellent adherence to prophylaxis (giving 75-100% of prescribed injections). 
Geraghty et al. (2006) sent The Haemophilia A Practice Patterns Survey (PPS 2003) to 274 
haemophilia centres worldwide and received responses from haemophilia nurses in 19 countries. 
Nurses estimated that adherence to prophylaxis would be highest among the 0-12 age group, with 
59% of patients achieving an adherence rate over 90%. Nurses estimated that the percentage of 
patients achieving this high rate of adherence among the other age groups would be considerably 
lower (13% of 13-18 year olds, 6% of 19-28 year olds, and 17% of patients aged 29 and older). 
Findings from a multi-centre study across Denmark, Norway and Sweden, (Lindvall et al., 2006) 
indicate that 41% of their 108 respondents (aged between 13 and 25 years old) had not always kept 
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to their prescribed treatment regimen, but because this study did not specifically investigate 
adherence it was not clear if these were longer periods of non-adherence or one-off situations.  
The large variation in reported adherence levels may be explained by the fact that the practice 
patterns across the different countries in which the studies were carried out are significantly 
different. A survey of haemophilia care in 19 European countries (O'Mahony, Noone, Giangrande, & 
Prihodova, 2011) found enormous variation in relation to the availability of factor concentrates, per 
capita usage of factor treatment, brands of factor concentrates prescribed, and availability of home 
treatment (and home delivery of treatment). Treatment protocols also appear to differ significantly 
between different countries. For instance, in Sweden prophylactic regimen are based on the high-
dose Malmö protocol, with injections of 25-40 International Units (IU) per kg of bodyweight, whereas 
Dutch regimen are based on the intermediate-dose Utrecht protocol, with injections of 15-30 IU/kg. 
Another reason may be the different measures that were used to assess adherence (self-report, 
estimations by clinical staff and/or parents, pharmacological data, and treatment logs) but also 
different definitions of adherence. Despite the variation in reported adherence levels, many of the 
North American and European studies agree that additional support may be needed to help patients 
keep to their treatment regimen during transition from childhood into adulthood (Breakey et al., 
2010; Geraghty et al., 2006). This is because most of these studies found that adherence levels 
reduce during this period, and that adolescent patients are more challenging to engage with 
treatment. 
 
3.4 Factors associated with adherence to long-term treatment among adolescents and 
young adult with chronic health conditions 
A substantial evidence base now exists in relation to factors that are associated with 
(non)adherence among young people affected by a chronic illness (Bosley, Fosbury, & Cochrane, 
1995; Fielding & Duff, 1999; Fotheringham & Sawyer, 1995; Krasnegor, Epstein, Johnson, Yaffe, & 
Epstein, 2013; H. A. KyngÄs, Kroll, & Duffy, 2000; Ivan Barry Pless et al., 1994; Rogers, Miller, 
Murphy, Tanney, & Fortune, 2001; D. L. Roter et al., 1998; Vermeire et al., 2001).  However findings 
are inconsistent, which is not surprising considering the fact that each situation and each treatment 
differs, and that it is therefore challenging to identify one or more factors which can reliably explain 
or predict adherence in the majority of patients and situations.  
However, the literature recognises that there are specific factors that may be associated with 
adherence, and indeed may explain or predict (non)adherence among chronically ill young people. 
These factors can be grouped according to the following themes:  developmental issues; medical 
and demographic factors; cognitive-emotional and motivational factors; family and peer support;, 
and the quality of the interaction between the patient and healthcare provider (H. A. KyngÄs et al., 
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2000). These will be addressed in turn below, both in terms of adherence to chronic conditions in 
general as well as, where it exists, evidence that is relevant to adherence to prophylaxis in 
haemophilia. 
 
3.4.1 Developmental issues 
Adolescent development can be divided into three stages: early, middle and late adolescence. Each 
of these stages is characterised by rapid biological, social and psychological changes, which are 
highly inter-related.  Chronic illness can potentially influence these developmental processes, and 
equally physiological change and psychosocial adjustments can have an impact on the disease. 
The developmental changes that characterise (and are unique to) adolescence result in specific 
disease patterns, unusual symptom presentations, and unique challenges in relation to disease 
management and communication between HP, parents, and patients. As a result of the growing 
body of research in this area, these issues are increasingly recognised by health professionals 
(Jessop & Stein, 1994; Newacheck & Halfon, 1998; Newacheck & Taylor, 1992), and indeed young 
people themselves (Beresford & Sloper, 2003).  
Individuals’ perceptions and beliefs in relation to medication and health in more general are often 
formed during adolescence (P. A. Michaud, J. C. Suris, & R. Viner, 2004). HP working with young 
people who are affected by chronic illness are therefore not only managing the current situation, but 
also laying a foundation for disease (self-) management in later life.  
Rates of adherence among adolescents and young adults are not necessarily always lower than 
among adults (Dunbar-Jacob, Burke, & Puczynski, 1995), however young people with chronic 
illness face specific challenges that are related to biological, psychological and social development. 
Adolescence is characterised by rapid changes in physical appearance and increased comparisons 
of physical attributes with peers. This may heighten awareness of potential physical and social side 
effects of treatment and may lead to young patients questioning the necessity and benefits of their 
treatment (H. A. KyngÄs et al., 2000).  
Identity, self-image, and ego-development can be affected by chronic illness, particularly when 
illness is more severe (Hauser, Jacobson, Noam, & Powers, 1983; Jacobson et al., 1997; Silver, 
Bauman, Coupey, Doctors, & Boeck, 1990). This may explain why young people with chronic illness 
are more likely to have a negative body image, or higher body dissatisfaction (Choquet, Du 
Pasquier Fediaevsky, & Manfredi, 1997; Manworren, 1996), particularly in cases where orthopaedic 
or neuromuscular defects result in disability.  
In order to achieve independence from parental influence, it is common for adolescents to spend 
more time with peers, and to adopt new norms and values (Anderson, Ho, Brackett, Finkelstein, & 
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Laffel, 1997; Suris, Michaud, & Viner, 2004). Adolescents with a chronic illness may value the 
liberating social interaction and acceptance of friends more than their, sometimes restrictive, 
treatment regimen (Keller & Nicolls, 1990; Seiffge-Krenke, 1990). Woodgate (1998a, 1998b) 
suggests that adolescents may experience more restriction, pain and additional worries because of 
chronic illness.  There is also evidence that adolescents who suffer from invisible conditions (such 
as epilepsy and haemophilia) may find it more difficult to accept and discuss their condition (Ivan B 
Pless & Roghmann, 1971), and some may avoid disclosing their condition altogether. This can 
place them in difficult situations such as having to find alternative reasons for not participating in 
peer activities, or placing others in a difficult position when they experience unexpected medical 
situations. 
There is some evidence to suggest that adolescents and young adults affected by chronic illness 
arrange and attend fewer medical appointments in comparison to other age groups (Marcell, Klein, 
Fischer, Allan, & Kokotailo, 2002; Settertobulte & Kolip, 1997).The demands of managing a chronic 
illness and the restrictions on lifestyle inherent in many conditions increase dependence on the 
family and carers at a time when this usually decreases (Eiser & Berrenberg, 1995). Supportive 
relationships with peers may help young people to break away from their parents or caregivers, and 
engage in their individuation process. This process can be encouraged by the healthcare team by 
providing opportunities for young patients to interact with each other, such as peer support groups 
or social outings. 
Treatment adherence requires personal organisation, cognitive ability, and a belief that treatment is 
necessary and beneficial (Sabaté, 2003; Vermeire et al., 2001). In their review KyngÄs and 
colleagues ( 2000) suggest that during adolescence abstract thinking is often not fully developed 
yet, which can manifest itself as an inability to understand future consequences of today’s 
behaviour; young people thinking of themselves as invincible or bullet proof; and relatively poor 
ability to plan and prepare for difficult situations. They argue that as a result of these cognitive 
issues, the prevention of long term complications of illness may be a poor motivator for treatment 
adherence, which may explain poor adherence levels among adolescents with chronic illnesses. 
 
Empirical findings of developmental issues that affect adherence to prophylactic treatment among 
young people with haemophilia  
Transition from childhood into adulthood has implications for treatment and healthcare provision for 
most YPH in the UK. Transition from paediatric to adult care, and the way in which most patients 
gradually take responsibility for their own treatment can be seen as a developmental process. P 
Petrini and Seuser (2009) suggest that adherence to prophylaxis is likely to reduce during 
adolescence because the pressures involved with learning self-management often coincide with the 
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simultaneous physical, psychological, social and sexual developmental changes that characterise 
adolescence (e.g. achieving independence from parents and building new relationships and social 
networks). Several studies have found that adherence to prophylaxis was very high among children 
and significantly worse among adolescents (Kathelijn Fischer et al., 2007; Geraghty et al., 2006), 
however these studies did not provide clear evidence for the suggested reasons for non-adherence 
among adolescents. 
The marks and scars left by regular intravenous injections may impact on young people’s body 
image and confidence. Particularly during the development phase when they start to take control of 
their changing (maturing) body, comparison to peers who do not have haemophilia may highlight 
differences and decrease body confidence (Lee et al., 2005; Seuser, 2009). 
Although physical activity is an important part of self-management for YPH, restrictions in relation to 
which physical activities they can take part in at school may highlight that they are different, which in 
turn may also affect their confidence (Groen, Takken, Van Der Net, Helders, & Fischer, 2011; Lee et 
al., 2005; Petrini & Seuser, 2009).  
 
3.4.2 Medical and demographic factors 
Chronic illnesses and their symptomatology may affect adherence themselves, as patients may 
keep to their treatment regimen simply because they know that non-adherence will have serious 
consequences. 
Disease-related factors are thought to play an important role in treatment adherence. Lower 
adherence has been found to be associated with longer disease duration, earlier age of onset, later 
referral to a specialist, fewer clinical visits, and shorter disease duration among adolescents with 
Juvenile Rheumatoid Arthritis (Litt & Cuskey, 1981), and absence of daily symptoms among 
adolescents with asthma (Dekker, Dieleman, Kaptein, & Mulder, 1993).  
Medication side effects have also been shown to affect adherence among adolescents with chronic 
illnesses (Catz, Kelly, Bogart, Benotsch, & McAuliffe, 2000; Nevins, 2002; Price, 1996; Rogers et 
al., 2001). The nature and complexity of treatment is also an important determinant of adherence. 
For instance, adherence to the demanding physical exercise regimen recommended for JRA 
appears to be significantly lower than adherence to medication in the same patient group (Hayford 
& Ross, 1988). Among young people with type I diabetes adherence to diet recommendation and 
blood glucose monitoring has been found to be significantly higher than adherence to insulin 
injections (S. B. Johnson et al., 1992; Weissberg-Benchell et al., 1995). 
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Empirical findings of medical and demographic factors that affect adherence to prophylactic 
treatment among young people with haemophilia  
The regular intravenous injections make prophylaxis a demanding treatment regimen.  Studies have 
suggested that the time consuming nature of the treatment and issues in relation to the actual 
injection (such as venous access) are important barriers to adherence (Geraghty et al., 2006; 
Hacker et al., 2001). In the UK many patients are encouraged to take their treatment in the morning, 
so that it provides them with cover during the day. Having to fit a time-consuming treatment into the 
morning routine can be challenging as young people have to get ready to leave the house early to 
go to school or work. 
The prophylactic injections require technical skills and confidence, which make it a more challenging 
than taking a tablet or using an inhaler.  The current literature suggests that patient education plays 
an important role in ensuring that patients have adequate knowledge and skills before they take 
over full responsibility for their prophylactic treatment (J. Barlow et al., 2007; K. Fischer et al., 2008). 
In their multi-centre Scandinavian study Lindvall et al. (2006) found that the average age at which 
patients took responsibility for the management and treatment of their haemophilia was 14.1 years. 
Comparable data are not available YPH in the UK.  
As many YPH in the UK started prophylaxis at an early age they may not have experienced many 
(or any) serious bleeds, and are therefore unfamiliar with the resulting joint damage. They do not 
know what life would be like without prophylaxis, and therefore may not appreciate the importance 
of adhering to their treatment (Hacker et al., 2001). However, the findings from a UK single-centre 
qualitative study (K. Khair, Gibson, & Meerabeau, 2012) suggest that adherence tends to be good 
among boys with haemophilia because they generally recognise that prophylaxis offers them 
protection from bleeding. In addition, older (and sportier) boys who took part in this interview study 
understood the need for tailored prophylaxis around risky activities such as sport or events away 
from home. Khair and colleagues suggest that adherence often improves when treatment frequency 
increases to daily, as the injections become part of the daily routine.  
 
3.4.3 Cognitive-emotional and motivational factors 
Adolescents are most likely to adhere to their treatment if they believe it will be effective (H. A. 
KyngÄs et al., 2000). Studies in different chronic illnesses (Carbone, Zebrack, Plegue, Joshi, & 
Shellhaas, 2013; Koster, Philbert, Winters, & Bouvy, 2015) have found that understanding and 
knowledge about illness and treatment are important for adherence, and that understanding is likely 
to follow a developmental progression (Berry, Hayford, Ross, Pachman, & Lavigne, 1993). 
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The Department of Health National Framework for Children (2003)   suggests that children have a 
right to be involved in treatment decisions, and that communication must be tailored to children’s 
level of understanding and developmental stage. Tailoring information based on the constantly 
evolving and changing developmental factors during childhood and adolescence can be challenging 
for HP, and as a result in some cases information is still directed to parents rather than young 
patients themselves (Tates & Meeuwesen, 2001; van Dulmen, 1998).  
Decreased emotional well-being, low self-esteem and social dependence are more common among 
young people with chronic illnesses in comparison to healthy peers (Bosley et al., 1995; Chigier, 
1992; CHRISTIE, 1990; Eiser, 1990). These in turn may have a negative impact on adherence. Litt 
et al (1982) found that adolescents with JRA who were adherent also had greater self-esteem and 
felt more autonomous in comparison to those with lower adherence. 
 
Empirical findings of Cognitive-emotional and motivational factors that affect adherence to 
prophylactic treatment among young people with haemophilia  
As mentioned above, one important factor that may reduce adherence among YPH is their (lack of) 
experience of bleeding and the resulting joint damage, as adherence is often driven by the 
motivation to reduce or prevent symptomatology (Geraghty et al., 2006). In the absence of this 
motivation it may be challenging to convince young people to keep to their treatment regimen, 
particularly as prophylaxis is demanding and time-consuming.  
The findings from a large Dutch study (Triemstra et al., 1998) suggest that psychological 
characteristics (anxiety, depression, anger, and optimism) are strong predictors of adaptation to 
haemophilia, well-being and level of disability.  
The current literature also suggests that poor knowledge and disease understanding may have a 
detrimental influence on adherence during adolescence and young adulthood (Kate Khair, 2013; 
Lindvall et al., 2006). Lindvall et al. (2010) suggest that haemophilia teams should regularly discuss 
topics such as type and severity of haemophilia, treatment issues (including adherence), genetic 
inheritance knowledge and bleed management with patients, as this would lead to a better 
understanding of the risks of complications, benefits of treatment and importance of self-care. In 
addition, current more flexible approaches to prophylaxis treatment regimens engage patient in 
treatment decision making, leading to greater concordance (Khair et al, 2013). The combination of 
better understanding of treatment and involvement in clinical decision-making helps patients to plan 
treatment around their normal day-to-day activities, which in turn is likely to improve treatment 
uptake (Khair et al, 2012). 
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3.4.4 Social support (peer and family support) 
An individual’s social situation influences the way in which they experience their illness, and 
manage their health (Burroughs, Pontious, & Santiago, 1993). Family and peers are important 
sources of support for young people in managing their chronic health condition.  Family support 
often consists of practical and tangible help with disease and treatment management, whereas peer 
support often centres around social interaction and emotional support. Research in young people 
with diabetes and JRA has found that positive family climate, parental supervision, family cohesion 
and open relationships within the family are associated with good adherence, whereas poor 
relationships, conflicts, and behavioural problems within the family seem to be related to poor 
adherence (Chaney & Peterson, 1989; Degotardi, Revenson, & Ilowite, 1999; H. Kyngäs, Hentinen, 
& Barlow, 1998; Weissberg-Benchell et al., 1995). 
Many young people who are affected by chronic illness feel different from their peers, which can 
lead to them feeling socially restricted. Some research suggests that this in turn can affect 
adherence (H. Kyngäs et al., 1998; Seiffge-Krenke, 1990). Emotional peer support can help them 
feel more accepted (H. A. KyngÄs et al., 2000), but friends can also help them keep to their 
treatment (e.g. by reminding them when to take their medication or encouraging them to look after 
themselves). 
However, friends and social contacts can also exert a negative influence on adherence. Not wanting 
to be different, or miss out on activities with friends, can make it challenging for young people to 
follow their treatment regimen as recommended (H. Kyngäs et al., 1998). 
 
Empirical findings of the association between social support and adherence to prophylactic 
treatment among young people with haemophilia  
In their review article Petrini and Seuser (2009) suggest that the most important factor that 
influences compliance is support from parents, peers and caregivers. They emphasize that social 
support encourages young people to look after their haemophilia and is crucial to help patients 
through challenging periods.  Lindvall et al. (2006) suggest that frequent contact and visits to the 
haemophilia centre can foster familiarity between the doctors and nurses and the patient and their 
family, which in turn facilitates open communication can help the haemophilia team to tailor their 
approach to the individual patient. 
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3.4.5 Quality of the interaction between the patient and healthcare provider 
The quality of the interaction between patient and doctor has been shown to affect adherence in 
various chronic illnesses (Bartlett et al., 1984; M Robin DiMatteo & DiNicola, 1982; D. Roter & Hall, 
2006). A good relationship between the patient and health care provider can improve adherence (M 
Robin DiMatteo & DiNicola, 1982; Karlsson, Holmes, & Lang, 1988; H. Kyngäs et al., 1998; Thorne, 
1990), whereas conflicts between patients and healthcare providers are likely to be associated with 
poor adherence (Karlsson et al., 1988).  
Adolescents and young adults who are encouraged to actively participate in treatment decisions 
may be more committed to the resulting treatment regimen, and as a result show higher levels of 
adherence (Berry et al., 1993). 
 
Empirical findings of patient-healthcare provider relationship and adherence to prophylactic 
treatment among young people with haemophilia  
As described above, members of the haemophilia team can play an important role in informing and 
educating patients about their haemophilia and treatment, which in turn can improve adherence and 
self-management (Kate Khair, 2013; Lindvall, Colstrup, Loogna, Wollter, & Gronhaug, 2010; Lindvall 
et al., 2006). However, no studies were found that directly examined the role that the relationship 
between patient and HP plays in adherence to prophylaxis.  
 
3.5 Conclusion of literature review and justification for this programme of research 
A haemophilia research steering committee with members representing haemophilia healthcare 
providers, members of the Haemophilia Society and patients highlighted that adherence to 
prophylaxis among young people in the UK is a key concern that is shared by these stakeholders. 
The committee agreed that there is a lack of knowledge about the drivers of (non-)adherence 
among YPH, and that research in this area should be prioritised. The existing adherence in 
haemophilia literature is very small with only a handful of publications in the world, and it offers very 
little evidence in relation to levels of adherence among YPH. Other limitations of the current 
literature are that most of the studies were conducted outside of the UK in countries where 
haemophilia healthcare is organised in a different way, and that studies do not provide sufficient 
evidence for the suggested barriers and facilitators to adherence. Additionally, the increasing 
flexibility and personalisation of prophylactic regimen in this country, which are likely to influence 
adherence, have thus far not received much attention in the literature. 
 With this in mind, and considering how the particular research questions of this study may best be 
addressed, it was decided to adopt a mixed methodology approach. This approach has the 
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advantage of combining objective and rigorous assessment of quantifiable phenomena (such as 
treatment adherence) and in-depth and detailed study of phenomena that are not easily quantifiable 
(such as patients’ experiences in relation to prophylactic treatment and the way they make meaning 
of those experiences).  It is anticipated that the qualitative and quantitative findings will complement 
each other, and allow the researcher to present a comprehensive study of adherence to 
prophylactic treatment among YPH in the UK, and the strengths and weaknesses in current 
healthcare provisions for this patient group.   
 
3.6 Rationale for a mixed methods approach 
The way in which individuals make sense of their health-related issues is central to many of the 
health psychology models described in the previous chapter. Combining quantitative instruments 
such as the Beliefs about Medicines Questionnaire (Horne et al., 1999) and Brief Illness 
Perceptions Questionnaire (Broadbent et al., 2006), with qualitative interviews based on 
Interpretative Phenomenological Analysis (IPA, Jonathan A Smith, 2010), may contribute towards 
an understanding of the way in which patients make sense of their health-related experiences, and 
the way this may influence their health-related behaviour (Hanson, Creswell, Clark, Petska, & 
Creswell, 2005; Tashakkori & Teddlie, 1998; Teddlie & Tashakkori, 2009). In the context of this 
programme of research it is anticipated that the combination of detailed qualitative analysis of young 
peoples’ experiences in relation to prophylaxis and the way in which they make meaning of these 
experiences, and quantitative analysis of their treatment-related perceptions, beliefs and behaviour, 
could lead to an enhanced understanding of adherence to prophylaxis in this patient group, barriers 
and facilitators to their adherence, and psychosocial factors that may be associated with their self-
management.  
 
3.7 Rationale for Interpretative Phenomenological Analysis (IPA) 
The aim of the qualitative element of this study was to examine personal experiences of YPH, 
parents of YPH, and haemophilia HP in relation to prophylactic treatment, and how they make 
sense of these experiences.  IPA was the chosen approach because it has an idiographic focus, 
which combines psychological, interpretative and idiographic components. It aims to offer insights 
into how a given person, in a given context, makes sense of a given phenomenon (Jonathan A 
Smith, 2010). Therefore its focus is on ‘exploring experience in its own terms’, without reducing it 
down to ‘predefined or overly abstract categories’ (Jonathan A Smith, 2010). IPA employs a ”double 
hermeneutic‟ in which the researcher tries to make sense of the participant trying to make sense of 
their experiences (Smith and colleagues, 2003; 2009) . IPA studies usually employ a fairly 
homogenous sample, drawing on the accounts of a small number of people who have certain 
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experiences in common (Reid, Flowers, & Larkin, 2005). Data were collected through face-to-face 
semi-structured interviews which were audio-recorded. The researcher tried to use as few prompts 
as possible, to encourage participants to tell their story in their own words, and in their own time. 
The interviews were transcribed verbatim and then analysed using IPA (Jonathan A. Smith, 2003; J. 
A. Smith, & Osborn, M. , 2008). A detailed description of the IPA methodology used will be 
described in chapter five. 
 
3.8 Rationale for Quantitative questionnaire 
The aim of the quantitative element of this study was to assess levels of adherence among YPH, 
and psychosocial factors that the current adherence literature suggests may be important correlates 
or even predictors of adherence. The study employed a questionnaire that mainly consisted of 
widely used validated scales which are grounded in health psychology theory.  Using these scales 
will allow the researcher to test current adherence theory, and compare the findings with other 
research studies. Variables for which no appropriate validated scales were available were assessed 
using newly constructed scales which were based on existing scales from research in other chronic 
health conditions (such as diabetes). Several open questions were included to offer participants the 
opportunity to describe their experiences in their own words. A detailed description of the 
quantitative methodology will be described in chapter 5.  
 
3.9 Recruitment 
Haemophilia centres 
Severe haemophilia is rare with approximately 5,900 people with Haemophilia A, and 1,200 with 
Haemophilia B in the UK. Following discussions facilitated by the Haemophilia Research Steering 
Committee, and based on initial estimates of the number of young people who are affected by 
severe haemophilia in the UK (provided by members of the committee), it was decided that we 
would aim to recruit approximately 100 questionnaire participants and 20 interview participants from 
across the 3 large haemophilia centres in London (the Royal Free Hospital, Guy’s and St Thomas’ 
Hospital, and the Royal London Hospital).   
However, a more accurate (and considerably lower) estimate provided by the UK Haemophilia 
Centres Doctors’ Organisation (UKHCDO) database highlighted that there were only 473 people in 
England and Wales who met the inclusion criteria for the studies (diagnosed with severe 
haemophilia, aged 12-25, and following a prophylactic treatment regimen). Additionally, after 
several months the Royal Free Hospital decided they were unable to take further part in the study. It 
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was therefore decided to try and recruit participants in all large haemophilia centres across England 
and Wales, making this a nationwide programme of research. 
The research received external peer reviewed funding from the Bayer Haemophilia Awards 
Programme (Caregiver Award awarded to the author), making it eligible for adoption onto the 
National Institute of Health Research (NIHR) Clinical Research Network (CRN) Portfolio. The 
research was discussed at a national NIHR CRN Non-Malignant Haematology Specialty Group 
meeting, and was prioritised for support throughout the network of haemophilia centres across 
England and Wales. Thanks to this support the study was given access to local networks of 
dedicated skilled research staff (including research nurses and allied health professionals), who 
were able to help with identifying eligible patients, arranging consent to participate in the study, and 
data collection.  Many of the centres that agreed to take part in this study were enthusiastic, and 
keen to take part.  However, the prioritisation by the specialty group helped enormously, as it 
highlighted the importance of the research. Haemophilia centres were invited (and encouraged) to 
take part in the study personally by the Chair of the specialty group Professor Collins, and 
remunerated by the NIHR CRN Portfolio for each participant they recruited into the study. 
 
Participants 
The 13 centres that agreed to take part in the questionnaire study look after approximately 150 of 
the 473 eligible patients in England and Wales. As many of these 150 patients as possible were 
approached face-to-face while they attended an outpatient appointment in the haemophilia centre. 
After they were given the opportunity to read the information sheet and ask questions about the 
study, 108 of the 125 patients who were invited to take part in the questionnaire study agreed to 
participate, although 18 did not return the questionnaire or later withdrew. An additional 47 
members of the Haemophilia Society were invited to complete the questionnaire online, which 
resulted in one additional response. Analysis was thus performed on 91 participants, which is 
approximately 19% of the total population, making this is a substantial sample.  
Five of the haemophilia centres involved with the questionnaire study also agreed to take part in the 
interview studies. In these centres potential participants were given information about both the 
questionnaire and interview study in advance of their routine check-up appointment at the 
haemophilia centre, and it was explained that they could take part in either the questionnaire or the 
interview study. During their appointment they had the opportunity to ask any questions about the 
studies, before being invited to consent to either one of the studies.  Participants who agreed to take 
part in the questionnaire study were invited to complete the consent form and questionnaire 
immediately after their appointment, before leaving the haemophilia centre.  Some participants took 
the questionnaire home and posted it back to the haemophilia centre once they had completed it. 
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Participants who agreed to be interviewed were invited to complete the consent form and asked to 
provide contact details so that the researcher could contact them at a later time to arrange the 
interview time and location.  
 
3.10 Summary of methods used 
In order to provide a complete and comprehensive evaluation of adherence to prophylaxis among 
YPH, a number of studies were carried out. Firstly, levels of adherence and psychosocial predictors 
of adherence were assessed in a large multicentre cross-sectional questionnaire study. In order to 
better understand the drivers of (non-)adherence, qualitative interview studies were conducted with 
patients, parents and haemophilia HP. Interpretative Phenomenological Analysis of the interview 
data, with a specific focus on personal experiences and perceptions in relation to prophylaxis, 
identified key themes in relation to adherence to prophylaxis among YPH, including barriers and 
facilitators to adherence. 
  
45 
 
Chapter 4: Cross-sectional analysis of adherence to 
prophylaxis and psychosocial factors of adherence among 
young people with haemophilia   
4.1 Introduction 
Chapter one discussed the significant burden of self-management on young people with 
haemophilia (YPH) and their families. Patients are required to attend outpatient appointments, keep 
to a demanding treatment regimen, avoid activities that increase the risk of bleeding, and manage 
bleeds if and when they occur. There is strong evidence that early and sustained prophylactic 
treatment with factor replacement therapy reduces joint bleeds and resulting arthropathy (K. 
Fischer, 2002; M. J. Manco-Johnson et al., 2007) whilst also improving quality of life (Richards et 
al., 2010).  However, the benefits of prophylaxis can be difficult to perceive for patients aged 25 and 
younger as many do not know what life would have been like without prophylaxis, whereas they 
often perceive the treatment burden as high (Hacker et al., 2001).     
Patients’ adherence to prophylaxis has a considerable influence on its efficacy. Non-adherence 
increases the risk of spontaneous bleeds (Hacker et al., 2001), which increase treatment costs 
(Panicker et al., 2003), and may result in joint damage leading to poorer physical and emotional 
wellbeing (Marilyn J Manco-Johnson et al., 2007; Treil et al., 2007). In addition to the immediate 
costs associated with treating bleeds (e.g. on-demand treatment), they may also lead to increased 
future care-costs due to disability. Levels of adherence to prophylaxis reported in the existing 
literature vary widely (De Moerloose et al., 2008; Treil et al., 2007), and reasons for non-adherence 
are not evidenced. In addition, reported adherence levels among adolescents and young adults are 
predominately based on estimations made by healthcare professionals (HP) and parents, rather 
than young people themselves (Geraghty et al., 2006; Hacker et al., 2001).  For these reasons this 
study will focus on adherence to prophylaxis among YPH. 
Chapter two discussed that non-adherence can be intentional, where a deliberate decision is made 
not to take treatment or unintentional which is usually due to forgetting. It is likely that there are 
different causes and effects of these different types of adherence, but they have not been reliably 
separated in the literature. Although a thorough review by Clifford, Barber & Horne (2008) 
demonstrated the importance of differentiating between the two, few researchers have consistently 
and reliably measured and reported the differences in their research, particularly in haemophilia. 
Therefore, this study will use the VERITAS-Pro, a validated measure of self-reported adherence to 
prophylaxis, which assesses the different dimensions of adherence through separate subscales. 
Chapter two also discussed the social cognition models that have been shown to be important 
correlates of treatment adherence and self-management in chronic health conditions. It is 
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anticipated that, in combination with self-reported adherence and clinical information in relation to 
bleeding episodes and hospital visits, these models may provide a more rounded explanation of 
adherence to prophylaxis among YPH. 
 
4.2 Aims and hypotheses 
The first aim of this study is to assess self-reported levels of adherence to prophylaxis using the 
VERITAS-Pro questionnaire (Validated Hemophilia Regimen Treatment Adherence Scale—
Prophylaxis; Duncan, Kronenberger, Roberson & Shapiro, 2010).  
The second aim is to provide evidence of the psychosocial factors of adherence to prophylaxis 
based on a large sample of young haemophilia patients, which is currently lacking in the literature. 
This will be done by assessing the key psychosocial factors that have been shown to be associated 
with adherence among young people with various chronic illnesses as described in the literature 
review (illness perceptions, self-efficacy, beliefs about medicines, outcome expectations, mood and 
social support). In addition, clinical data in relation to bleeds and hospital visits will be collected to 
establish the effects of non-adherence on these clinical outcomes.  
Based on previous research on adherence and social cognitive models of illness, it is hypothesised 
that there will be differences between adolescents and young adults in relation to psychosocial 
correlates of adherence:  
1) Unintentional non-adherence is anticipated to be higher among young adults because they tend 
to have less parental involvement and help with their treatment, and are more likely to 
experience life events that may interfere with adherence (e.g. leaving home, university life, first 
job, starting a family, etc.).  
2) Intentional non-adherence is anticipated to be higher among adolescents because of rapid 
biological, psychological and social changes that characterise this developmental stage (e.g. 
difficulty in understanding future repercussions of today’s actions, asserting independence from 
parents, etc.). 
3) Factors of the social cognition models are anticipated to differ between adolescents and young 
adults because of differing experiences of managing haemophilia (e.g. differences in parental 
influence and relationships with doctors/nurses, and fewer long-term issues associated with 
recurring bleeding). 
There has been a large amount of previous research on the effects that social cognitive models of 
illness have on adherence on which the following hypotheses are based for the entire sample:  
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4) Pain; higher perceptions of pain and impact of pain will be associated with better adherence 
(De Moerloose et al., 2008; Treil et al., 2007). 
5) Illness perceptions; higher perceptions of chronicity, consequences and treatment control will 
be predictive of higher adherence (Chilcot et al., 2010; Horne & Weinman, 2002).  
6) Beliefs about medications; higher perceptions of necessity of prophylaxis will be predictive of 
higher adherence whereas concerns about prophylaxis will not be predictive (de Thurah et al., 
2010; Horne et al., 2013; Horne & Weinman, 1999; Llewellyn et al., 2003; Wileman et al., 
2014).  
7) Mood: patients with greater negative mood are anticipated to have lower adherence scores 
((Cox & Hunt, 2015; Helgeson et al., 2009; Snell et al., 2014). 
Based on evidence that lower adherence results in worse disease outcomes (Berntorp, 2009; M. J. 
Manco-Johnson et al., 2007) the following hypothesis was generated:  
8) Non-adherence to prophylaxis will be related to higher numbers of bleeds and hospital visits.  
 
4.3 Methodology  
4.3.1 Participants  
In total, 473 people in England and Wales met the inclusion criteria for this study (diagnosed with 
severe haemophilia, aged 12-25, and following a prophylactic treatment regimen).  The 13 centres 
that agreed to take part in this study look after approximately 150 of these patients. The recruitment 
target was to invite as many of these 150 patients as possible. Eligible patients were approached 
face-to-face while they attended an outpatient appointment in the haemophilia centre. Of the 125 
patients who were invited 108 agreed to participate, although 18 did not return the questionnaire or 
later withdrew. An additional 47 members of the Haemophilia Society were invited to complete the 
questionnaire online, which resulted in one additional response. Analysis was thus performed on 91 
participants, which at approximately 19% of the total population is a substantial sample.  
Figure 4.1 shows the recruitment process. The mean age was 18.83 (SD=5.00). Demographic and 
clinical details for the whole sample are shown in Table 4.2 on page 62. 
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*National Haemophilia Database: 30 – 09 – 2012 
**UKHCDO annual report 2010 
***Haemophilia Society Annual report 2014 
 
Figure 4.1: Recruitment flow-chart questionnaire study 
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4.3.2 Materials and procedure  
All consecutive patients aged 12 to 25 years old (inclusive) diagnosed with severe haemophilia and 
currently on prophylaxis in 13 hospitals across England and Wales were invited to participate. In 
order to recruit patients in the specific age groups, dedicated clinics were targeted for recruitment 
and postal and email invites were also sent to eligible members of the Haemophilia Society. Written 
consent (and parental consent where relevant) was obtained before patients completed the 
questionnaires by themselves in the clinic or at home.  The majority of questionnaires were 
completed on paper (n = 80), with the remainder being completed online (n = 11). A number of 
clinical variables were collected from the notes of patients who consented to the study including; 
number of hospital visits during the last 6 months, number of spontaneous bleeds and traumatic 
bleeds (caused by trauma or injury to the body) during the last 6 months. All data were confidential 
and assigned an anonymous participant identification number. The data were subject to double data 
entry to ensure there were no errors. The study was approved by the Yorkshire & The Humber - 
South Yorkshire NRES Committee (13/YH/0143) and all data handling conformed to Good Clinical 
Practice Guidelines (McGraw, George, Shearn, Hall, & Haws, 2010). 
The full questionnaire is shown in Appendix 4.1 and described in more detail below. The questions 
were reviewed by a panel of patients, haemophilia doctors and nurses and a health psychologist 
who specialises in haemophilia. The questionnaire was then piloted with five patients to ensure 
validity. The final questionnaire consisted of questions assessing self-reported adherence 
(VERITAS-Pro), Haemophilia-related pain and impact of this pain, Illness Perceptions (Brief IPQ; 
Broadbent et al., 2006), Beliefs about Medications (BMQ; Horne et al., 1999), Self-efficacy and 
outcome expectations, Positive Affect and Negative Affect (Watson et al., 1988), and Social 
support.  
 
Validated Hemophilia Regimen Treatment Adherence Scale-Prophylaxis (VERITAS-Pro)  
The VERITAS-Pro (N. Duncan et al., 2010) is a validated measure of self-reported adherence to 
prophylactic treatment among people with haemophilia. The 24-item scale consists of six sub-scales 
which examine the extent to which participants take their injections at the recommended time (time), 
use the recommended dose (dose), plan ahead to ensure they have enough factor treatment and 
supplies (plan), remember to take their injections (remember), skip injections (skip) and 
communicate with the haemophilia centre appropriately (communicate). All questions are scored on 
a 5 point Likert scale with lower scores demonstrating better adherence.  
As the scale was developed and validated in the US, it was necessary to rewrite some of the 
questions to make them appropriate for patients in the UK. For example the word ‘infusions’ was 
changed to ‘injections’. The rewritten scale was reviewed and tested by a panel of patients, 
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haemophilia doctors and nurses and a health psychologist who specialises in haemophilia. The 
members of the panel agreed that the dosing subscale, which aims to gauge whether patients keep 
to the recommended dosing, was not relevant for patients in the UK. This is because many patients 
in the UK are encouraged to tailor the dosing around their physical activity level, increasing the dose 
or frequency of treatment to provide cover for activities. This means that patients who do not keep 
to an agreed treatment schedule are not necessarily non-adherent. In addition, the VERITAS-Pro 
was developed in the US where funding for haemophilia care, and in particular prophylaxis, is often 
limited. The scale was based on previous US studies which suggest that concerns in relation to 
cost/affordability of prophylaxis are important barriers to adherence.  This situation is not relevant in 
the UK where patients receive prophylaxis for free through the National Health Service. Appendix 
4.2 highlights the changes that were made to the VERITAS-Pro scale. 
Scores on each VERITAS-Pro subscale can range from 4 to 20, with higher scores indicating poorer 
adherence. Adherence sum scores for this study can therefore range from 20 to 100. The original 
validation studies (N. Duncan et al., 2010; N. Duncan, Shapiro, Ye, Epstein, & Luo, 2012) put 
forward a cut-off on the VERITAS-Pro total score as a threshold for non-adherence.  Adherence 
was dichotomised into an adherent and non-adherent group using this 52-point cut-off for some of 
the analysis to enable comparison with other studies and between adherers and non-adherers. It 
also allowed the researcher to ascertain the proportion of participants with scores above the cut-off 
indicating they are non-adherent.  However, this study relies primarily on the VERITAS-Pro scores 
as continuous because (i) this allows for testing of associations between level of adherence and 
outcomes rather than a coarse adherence/non-adherence dichotomy, (ii), this makes it possible to 
examine different types of non-adherence (i.e. forgetting and skipping), and (iii) the cut-off score has 
not yet been validated or applied in a patient population.  
 
Clinical information. 
The number of bleeds a patient experiences, and the frequency of their hospital visits, can be an 
indication of how well they manage their condition. Therefore the number of hospital visits and 
bleeds during the last 6 months was collated from medical notes for each patient. Bleed data was 
split into bleeds that were caused by accidents or injuries (traumatic bleeds) and breakthrough 
bleeds (spontaneous bleeds). 
 
Self-Regulatory Model, Brief Illness perceptions Questionnaire 
The Brief Illness Perception Questionnaire (Broadbent et al., 2006) was designed to provide a 
quicker way to assess the cognitive and emotional representations of illness that are included in the 
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Illness Perception Questionnaire-Revised (Moss-Morris et al., 2002).  It is a 9-item questionnaire 
which uses a single-item scale approach to assess perceptions on a 0-10 response scale. The Brief 
IPQ comprises 6 items on cognitive representations of illness perception: consequences (of the 
condition), timeline (is the condition acute or chronic), personal control (patients’ ability to influence 
symptoms), treatment control (extent to which treatment reduces symptoms), coherence 
(understanding of the illness), and identity (extent to which patients experience symptoms). There 
are 2 items on emotional representation: concern (about the condition) and emotional responses 
(extent to which the condition affects the patients feelings). The last item is on the perceived cause 
of illness; in which respondents list the most important causal factors in their illness.  
 
Beliefs about Medicines Questionnaire  
The Beliefs about Medicines Questionnaire (BMQ, Horne & Weinman, 1999) consists of two 
sections; beliefs about medicines in general (BMQ General) and beliefs about the specific 
medication prescribed for a given condition (BMQ Specific). For the purpose of this study only the 
BMQ Specific was included, which consists of two subscales; Concerns and Necessity.  The 
Concerns subscale includes five questions referring to concerns patients might have about taking 
prophylaxis. The Necessity subscale includes five questions related to patients’ perceptions about 
the necessary to take prophylaxis in order to stay well. In all cases, questions were scored on a 5 
point Likert scale with higher scores on the Concerns subscale indicating more concerns and higher 
scores on the Necessity subscale indicating stronger beliefs in the necessity of prophylaxis.  
 
Self-efficacy 
In accordance with Bandura’s (1997) situation-specific behaviour-based model, two self-efficacy 
scales were used. The first scale assessed self-efficacy in relation to haemophilia self-management 
and the second looked at self-efficacy in relation to prophylactic treatment specifically.  As no 
appropriate existing scales were found, new scales were devised using Bandura’s guide for 
constructing self-efficacy scales (Bandura, 2006). The content of the scales was informed by 
previous research looking at self-efficacy, outcome expectations and adherence among young 
people with type I diabetes (Chlebowy & Garvin, 2006; Iannotti et al., 2006). In addition a pilot study 
was undertaken with the aim to identify key haemophilia self-management behaviours and 
difficulties that young people experience in relation to their treatment. This information was then 
used to generate items in relation to self-efficacy and outcome expectations. Participants for the 
pilot (10 adolescents and 10 young adults with severe haemophilia) were recruited through the 
haemophilia society. They completed multiple choice and open questions via an online 
questionnaire. 
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These new scales were then reviewed by the panel and piloted with five patients.  
The haemophilia-related self-efficacy scale consisted of three subscales: Communication (3 items 
assessing confidence in communicating about haemophilia); Taking prophylaxis (7 items assessing 
confidence in relation to all actions that are involved in taking prophylaxis); and Your health (2 items 
assessing confidence in managing health in general and preventing/dealing with haemophilia-
related issues). Each item was scored on a 0-10 response scale. 
To assess prophylaxis-related self-efficacy participants were invited to rate how confident they were 
that they could take their prophylaxis in 10 situations that were identified as challenging by the pilot 
study (e.g. when I am tired, when I’m busy, when I am away from home/on holiday, etc.).  Each item 
was scored on a 0-10 response scale. 
 
Outcomes expectations 
The Outcome expectations scale was devised using the same literature and pilot data as the self-
efficacy scales. Each of the 10 items was a potential answer to the question: ‘If I always did 
everything I am supposed to do to manage my haemophilia, it would.....‘. Patients were invited to 
rate how much they agreed with each answer using a 0-10 response scale.  Five of the answers 
represented positive outcome expectations (e.g. keep me healthy), and 5 represented negative 
outcome expectations (e.g. be too time consuming).  
 
Social support 
Based on research with young people diagnosed with type I diabetes (Bearman & La Greca, 2002; 
Iannotti et al., 2006; Annette M. La Greca et al., 1995; Skinner, John, & Hampson, 2000) and 
previous research in haemophilia (P. Petrini, 2007; P Petrini & Seuser, 2009), a number of potential 
sources of social support in relation to prophylaxis were identified. After careful review and 
discussion, the panel agreed the most important ways in which YPH may be supported in relation to 
their prophylactic treatment. This resulted in an 8-item scale which assesses support in relation to 
being reminded to take treatment; others appreciating how hard it is to take prophylaxis; being told 
off for missing injections; being praised for taking treatment; receiving help with bleeds; having 
someone that listens to concerns and worries; receiving encouragement; and someone showing 
understanding. The design of the questionnaire is based on the widely used The Diabetes Family 
Behavior Checklist (Schafer, McCaul, & Glasgow, 1986). Participants were invited to rate how often 
they receive support in each of the above categories using a 0 to 5- scale (never, less than twice a 
month, twice a month, once a week, several times a week, at least once a day). They were then 
asked to indicate how satisfied they are with this support using a -1 to 3 scale (Unhelpful or NOT 
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supportive, neutral, A little helpful or supportive, Helpful/ supportive, Very supportive).  The overall 
social support score is obtained by multiplying the frequency score by the satisfaction score. 
 
Positive and Negative Affect Schedule (PANAS) 
The Positive and Negative Affect schedule (PANAS; Watson et al., 1988) is a valid and reliable self-
report measure of both negative and positive mood states. This scale was selected over other 
widely used scales, such as the PHQ-9, after extensive discussions with the steering committee. 
Members of the committee felt it was important to assess both positive and negative affect, and in 
particular clinicians felt that it would be inappropriate to use a scale that includes sensitive questions 
(e.g. about suicide ideation). The PANAS consists of two 10-item mood scales asking participants to 
rate specific feelings and emotions associated with positive affect (e.g., enthusiasm) and negative 
affect (e.g., afraid) experienced during a given time. Participants were invited to rate the extent to 
which they experienced each emotion during the current week. Individuals responded to each item 
on the following scale: (1) very slightly or not at all, (2) a little, (3) moderately, (4) quite a bit, and (5) 
very much.  
In summary, all measures included in this research were psychometrically valid and selected on the 
basis of prior use in research about adherence among young people with chronic illness. And they 
were all reviewed and amended by a panel and the steering committee (which included young 
people with haemophilia, members of the haemophilia society, specialist nurses, haematologists 
and academics) to ensure relevance and appropriateness. 
 
4.3.3 Statistical analyses  
Sum scores for each adherence subscale (as continuous measures) and psychosocial factors were 
generated for each patient. Tests of normality were undertaken. In addition to univariate analyses, 
Pearson’s correlation was used to assess bivariate associations between adherence, clinical 
outcomes and psychosocial factors. To establish the predictive ability of the psychosocial factors to 
explain variation in adherence scores, linear multiple regression analyses were carried out. 
Sensitivity analysis confirmed that the regression models were not unduly affected by 
multicollinearity, bias or outliers.  All significance testing used an α level of 0.05. 
To test potential differences between adherent and non-adherent patients, the sample was 
dichotomised into two groups (adherent and non-adherent) using the 51-point cut-off on the 
VERITAS-Pro total score put forward as the threshold for non-adherence in the original validation 
study (N. Duncan et al., 2010).  
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Differences in clinical outcomes and psychosocial factors between adolescents and young adults 
and the two adherence groups were tested using independent t-tests. Bootstrapping was performed 
to reduce the impact of bias. Differences between categorical variables were tested using אַ2. 
Analyses reported in the main section of this thesis were carried out using listwise deletion for 
systematically missing data and means imputation for randomly missing data.  In addition analyses 
were also carried out using means imputation for all missing data, which are shown in the 
appendices ( www.missingdata.org.uk). 
 
4.4 Results 
4.4.1 Statistical power 
Power analyses were undertaken using GPower, version 3.1.9.2 (Faul, Erdfelder, Lang, & Buchner, 
2007). The findings of power calculations for analyses testing the difference of means (t-test) are 
presented in appendix 4.4.a.   
The hypotheses that this study aimed to test were mostly 1-tailed, indicating that a certain outcome 
(such as skipping) or determinant of adherence (such as greater belief in the necessity of 
prophylaxis) would be greater in one group of participants compared to another group (e.g. 
adolescents versus young adults). The outcome of the power calculations indicate that based on an 
effect size between 10% and 15% the t-tests that were carried out had a statistical power around 
80%. As a result we can assume that the sample size was sufficient to test 1-tailed hypotheses with 
reasonable confidence.  
The power calculations for linear multiple regression analyses are presented in appendix 4.4b, and 
indicate that based on an effect size of approximately 20% the sample size was sufficient to achieve 
a statistical power of at least 80%. 
 
4.4.2 Data screening 
Missing data was at an acceptable level for most questionnaires (ranging from 0 – 5%). However, 
there were larger numbers of missing responses for some of the adherence questions (ranging from 
2 to 17%), questions investigating satisfaction about social support (10 to 16%) and the concerns 
about prophylaxis subscale of the BMQ (3 to 12%).  
Closer inspection indicated that a significant proportion of the missing responses to VERITAS-Pro 
adherence questions were due to patients answering ‘not applicable’. This appeared to be 
particularly the case for questions that assume that patients take treatment according to a pre-
agreed schedule that does not allow for flexibility (e.g. I do injections according to the schedule that 
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was given to me by my doctor or nurse).  This reflects the fact that the VERITAS-Pro was 
constructed and validated in the US, and perhaps does not reflect the more flexible and 
personalised way in which many YPH in the UK manage their haemophilia treatment.  
The scoring instructions provided by the authors of the VERITAS-Pro include the following guidance 
on how to treat missing data:  
If a subscale is missing one item, you may extrapolate a value for that item using the 
average of the other three items on the subscale.  
a. Any subscale missing more than one answer is considered invalid and cannot 
be scored.  
b. Any total scale missing more than two answers is considered invalid and 
cannot be scored.  
After implementing this guidance any remaining missing data was addressed by applying listwise 
deletion for the analyses of VERITAS-Pro data. 
In relation to the social support questions the reason for the missing responses was likely to be that 
patients were not sure how to answer the questions due to the potentially confusing lay-out of the 
questionnaire. Patients were asked to indicate how often they received a particular type of social 
support, as well as the extent to which they were satisfied with this support.  On reflection it may 
have been better to separate the frequency and satisfaction into separate sections. 
Further investigation of the original copies of the completed questionnaires showed that at one of 
the study centres the questionnaires were printed incorrectly, which meant that the last two 
questions of the concerns subscale of the BMQ were missing. Apart from the data issues described 
above, most of the data were shown to be randomly missing. It was therefore possible to replace 
the majority of missing values with a suitable substitute (the mean value).  However, the VERITAS-
Pro data were analysed with list-wise deletion (as directed by the authors of the scale).  
Boxplots for the frequency distribution of the VERITAS-pro subscales and adherence sum scores 
are presented in appendix 4.3. The boxplots indicate that the Timing, Planning and Skipping 
subscales are likely to be positively skewed an each contain outliers. Further data screening 
revealed that several of the variables measured by the questionnaire, including the adherence 
subscales mentioned above, were skewed and contained outliers. So as not to violate the 
assumption of normality which is necessary for many of the statistical analyses that were carried 
out, positively skewed variables were log transformed. For negatively skewed data square 
transformations were performed. Log transformation of Social support (frequency*satisfaction) and 
Spontaneous bleeds did not improve skew, therefore original values were used in their non-
parametric analyses. 
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Further inspection of the raw data did not show any obvious inaccuracies, indicating that outliers 
were unlikely to be due to gross errors or mistakes. Therefore, the skews in the data suggest that 
the majority of patients adhere to their treatment with only a small group regularly forgetting or 
skipping injections. For all of the scales that were positively skewed a low score indicates a positive 
outcome (few concerns, few negative outcome expectations few negative feelings, and better 
adherence), whereas for the scales that were negatively skewed higher scores indicate a positive 
outcome (positive outcome expectations, positive feelings, high self-efficacy and a positive belief in 
the necessity of prophylaxis).  The adherence Communicating subscale was the only exception with 
a negative skew (indicating low adherence). However, it could be argued that several items included 
in this scale may not be appropriate for patients in the UK who follow a more flexible treatment 
regimen.  For instance, one of the questions asks patients if they make decisions about their 
treatment themselves, without calling the Haemophilia Centre. In the original scale this behaviour 
would be classed as non-adherent.  
However, many UK patients are now encouraged to tailor their treatment around their activities on a 
week-by-week basis, and are not expected to call the centre for each adjustment to their treatment. 
This supports the suggestion made above that for future research it would be useful to improve 
validity of the VERITAS-Pro and that analysis should be carried out separately on the forgetting and 
skipping subscales in addition to adherence sum scores. 
Clinical information (number of bleeds and hospital visits) was only available for 83% of patients. 
However, there is no reason to believe that cases are missing in a systematic way and so for 
analyses list-wise deletion was employed.  
 
4.4.3 Reliability of scales use 
The internal reliability of the sub-scales used to measure adherence was good as indicated by 
Cronbach’s α in Table 4.1. The internal reliability of the Timing, Remembering and Communicating 
subscales improved (albeit not significantly) after missing data was imputed.  
Of the remainder of the scales, only the Beliefs about Medicines Concerns sub-scale had a 
reliability score that was lower than ideal (α = 0.69), albeit still acceptable.  None of the 5 items in 
this subscale appeared particularly problematic (item-total correlations were all above 0.3).  
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Table 4.1: Internal consistency shown by Cronbach’s α for each questionnaire subscale 
Scale Cronbach's α 
Veritas-Pro Questionnaire   
Timing 0.82 
Planning 0.68 
Remembering 0.83 
Skipping 0.88 
Communicating 0.71 
Self-efficacy 
 Haemophilia-related 0.81 
Prophylaxis-related 0.92 
Beliefs about Medicines Questionnaire 
 Necessity  0.80 
Concerns 0.69 
Positive Affect Negative Affect Scale 
 Positive Affect 0.91 
Negative Affect 0.85 
Social Support 
 Frequency 0.86 
Satisfaction 0.88 
 
 
4.4.4 Adherence in the sample 
Demographics for the sample are presented in table 4.2.  Information about ethnicity was not 
collected. The mean age was 18.99 (SD=4.11). The majority of participants were in school (33%), 
college/university (20.9%) or fulltime work (25.3%).  Many participants still lived at home with their 
parents (78%), and only 19.8% of participants have a sibling who is also affected by haemophilia. 
70% of participants do their prophylactic injections entirely themselves. As described above on page 
50, the sample of 91 participants makes up approx. 19% of the total population of young people with 
haemophilia who follow a prophylactic regimen in England and Wales. Although this is a large 
sample it is difficult to confirm the extent to which this sample is representative of the population, as 
we were not permitted to collect information about patients who decided not to take part or patients 
who were not approached. As the questionnaire was completely anonymous it was not possible to 
compare participants to non-participants.  
Adherence in the sample appeared to be good, as indicated by the total sample mean scores (table 
4.2). However the relatively large standard deviation suggests that scores were dispersed widely. 
When the sample was dichotomised into two adherence groups (adherence sum scores ≥ 51 
indicating non-adherence), just 16% of the sample had scores indicating they were non-adherent. 
Both intentional non-adherence (skipping sub-scale scores ≥ 11) and unintentional non-adherence 
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(Remembering sub-scale scores ≥ 11) were low. Only eight patients (9%) had Skipping scores 
above the cut-off point that indicated intentional non-adherence and only 13 patients (14%) had 
Remembering scores above the cut-off point that indicated unintentional non-adherence.  Of these 
21 patients there were six patients (7%) that were both intentionally and unintentionally non-
adherent.  
The Communicating sub-scale was the only sub-scale on which a majority of patients (59%) had a 
score above the cut-off indicating non-adherence (scores ≥10).  This may be because some of the 
questions in this subscale appear to lack content validity, as described in the data screening section 
above.  
Comparison of adherence levels among young people who live at home and those who live 
independently were not found to be significantly different: F(2, 84) = 1.64, P =0.199, and young 
people who receive help with taking their treatment were not found to be more adherent than those 
who do their injections entirely themselves: F(3, 83) = 2.33, P =0.080.  This may suggest that higher 
levels of adherence among adolescents may not be due to parental involvement and support. 
However, it could also suggest that the self-report measures do not accurately assess parental 
support and levels of adherence. 
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Table 4.2: Demographics for the entire sample and adherence groups 
  Total sample (n=91) Adherent (n=64) Non-adherent (n=14) 
Age Mean (SD) 18.99 (4.11) 19.00 (4.22) 18.94 (3.75) 
min/max  12/25 12/25 13/24 
skewness -0.119 -0.091 -0.32 
kurtosis -1.283 -1.321 -1.169 
 
n (%) n (%) n (%) 
Education/Work    
School 30 (33%) 19 (29.7%) 3 (21.4%) 
College/university 19 (20.9%) 15 (23.4%) 3 (21.4%) 
Other full-time education 1 (1.1%) 0 1 (7.1%) 
Part-time work 8 (8.8%) 7 (10.9%) 0 
Full-time work 23 (25.3%) 16 (25.0%) 5 (35.7%) 
Don't work 6 (6.6%) 4 (6.3%) 2 (14.3%) 
Other 2 (2.2%) 2 (3.1%) 0 
Missing 2 (2.2%) 1 (1.63%) 0 
Living arrangements    
I live with my parents 71 (78%) 49 (76.6%) 11 (78.6%) 
I live independently alone 4 (4.4%) 2 (3.1%) 2 (14.3%) 
I live independently with others 15 (16.5%) 13 (20.3) 1 (7.1%) 
Missing 1 (1.1%)  0  0 
Responsibility for prophylaxis    
Someone else does injections for me 8 (8.8%) 7 (10.9%) 0 
They are done by someone else, and I help 10 (11%) 6 (9.4%) 1 (7.1%) 
They are mostly done by me with help from 
someone else 
8 (8.8%) 
6 (9.4%) 0 
I do them entirely myself 64 (70.3%) 45 (70.3%) 12 (85.8%) 
Missing 1 (1.1%) 0 1 (7.1%) 
Siblings with Haemophilia    
Yes 18 (19.8%) 14 (21.9%) 4 (28.6%) 
No 71 (78%) 50 (78.1%) 10 (71.4%) 
Missing 2 (2.2%) 0 0 
Ethnicity was not collected. There were no significant differences between adherers and non-adherers in relation to any 
of the demographics (highest chi-square F=4.39, lowest p value = 0.11). 
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4.4.5 Differences between adolescents and young adults. 
Table 4.3 presents the differences in adherence and clinical outcomes between adolescents and 
young adults. It was hypothesized that unintentional non-adherence would be higher among young 
adults, and that intentional non-adherence would be higher among adolescents. However, there 
were no significant differences between the age groups in relation to adherence scores and clinical 
outcomes.  
 
Table 4.3: Adherence and clinical outcomes for adolescents and young adults.  
    Adolescents (n=41)     Young adults (n=50) 
  N Mean SD Min Max Skewness Kurtosis   N Mean SD Min Max Skewness Kurtosis 
Age  41 15 1.88 12 18 0 -1.09   50 22.26 1.97 19 25 -0.09 -1.17 
Self-reported adherence (VERITAS-Pro)  
Timing 36 7.53 3.75 4 16 1.03 0.18   47 7.57 2.93 4 17 0.95 1.28 
Log Timing 36 6.75 1.59 4 16 0.39 -1.02   47 7.05 1.47 4 17 0.39 -1.02 
Planning 36 7.16 3.31 4 16 1.04 0.26   48 7.39 3.33 4 16 1.07 0.66 
Log Planning 36 6.54 1.54 4 16 0.44 -0.95   48 6.75 1.53 4 16 0.32 -0.86 
Remembering 34 8.05 3.28 4 14 0.41 -1.04   47 8.4 2.92 4 17 0.76 1.14 
Skipping 34 5.59 2.05 4 12 1.52 1.79   47 5.79 2.64 4 15 1.94 3.82 
Log skipping 34 5.24 1.38 4 12 1.031 -0.004   47 5.37 1.45 4 15 1.17 0.6 
Communicating 37 11.53 4.16 4 20 0.08 -0.9   48 12.95 4.07 4 19 -0.5 -0.31 
Sum 33 40.38 12.26 23 73 0.88 0.44   46 42.35 9.16 20 60 0.21 -0.15 
Clinical information 
Pain severity 37 2.73 5.58 0 6 0.26 -0.99   49 3.08 1.41 0 6 0.31 -0.87 
Impact of pain 39 2.23 1.33 0 5 0.98 -0.2   49 2.12 1.39 0 5 1.02 -0.35 
Spontaneous bleeds 32 2.16 5.31 0 26 3.71 14.45   43 1.21 2.77 0 13 2.93 9.1 
Log spontaneous bleeds 32 2.33 2.91 0 26 1.24 0.68   43 3.01 2.51 0 13 0 -1.22 
Traumatic bleeds 32 1.34 2.39 0 12 3.13 12.42   43 0.72 1.42 0 8 3.56 16.24 
Log Traumatic bleeds 32 1.55 1.84 0 12 0.61 1.84   43 1.55 1.84 0 8 1.44 2.07 
Hospital visits 30 4.73 5.58 0 19 1.39 1.12   44 3.07 3.37 0 17 2.26 6.17 
Log Hospital visits 30 3.38 2.93 0 19 0.19 -1.52   44 2.27 2.28 0 17 0.7 -0.56 
Where transformation has been undertaken the geometric mean and SD are shown. Independent t-tests did not detect any significant differences 
between adolescents and young adults. 
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Table 4.4 presents the differences in psychosocial factor scores between adolescents and young 
adults. It was hypothesized that there would be differences in many of the psychosocial factors.  
Young adults had greater beliefs in the necessity of treatment (mean difference -1.967, BCa 95% CI 
[-3.513, -0.421], t(89) = -2.528, p=0.013), and had greater necessity/concern differential scores 
(mean difference -2.488, BCa 95% CI [-4.550, -0.427], t(89) = -2.398, p=0.019) indicating that their 
belief in the necessity of treatment outweighs their concerns about treatment.  
Young adults perceived themselves to have more personal control over their symptoms (mean 
difference -1.202, BCa 95% CI [-2.209, -.196], t(89) = -2.374, p=0.02), and had greater self-efficacy 
scores in relation to haemophilia in general (mean difference -6.720, BCa 95% CI [-12.602, -.838], 
t(89) = -2.270, p=0.026), and prophylaxis specifically (mean difference -8.431, BCa 95% CI [-
16.363, -.499], t(89) = -2.112, p=0.037). They also had fewer negative outcome expectations (mean 
difference 4.820, BCa 95% CI [1.128, 8.513], t(89) = 2.594, p=0.011).  In relation to social support 
young adults reported to receive significantly less social support than adolescents (mean difference 
9.273, BCa 95% CI [5.225, 13.321], t(89) = 4.551, p=0.0001), although their satisfaction with the 
social support they receive was not significantly different (mean difference 3.059, BCa 95% CI 
[0.031, 6.088], t(89) = 2.007, p=0.048). 
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Table 4.4: Psychosocial scores for adolescents and young adults. 
  Adolescents (n=41)   Young adults (n=50) 
  Mean SD Min Max Skewness Kurtosis   Mean SD Min Max Skewness Kurtosis 
Beliefs about medicines 
Concern 11.06 3.23 5 18 0.25 -0.56   10.54 3.98 5 18 0.11 -1.29 
Necessity 18.74 4.25 8 24 -0.73 0.04   20.71 3.17 13 25 -0.60 -0.24 
Differential 7.69 5.00 -7 15 -0.77 0.67   10.18 4.86 -1 20 -0.13 -0.14 
Self-regulatory Model (Brief IPQ) 
Consequences 6.14 2.95 0 10 -0.56 -0.49   5.68 3.20 0 10 -0.21 -1.15 
Timeline 9.48 1.04 5 10 -2.66 8.14   9.70 0.84 6 10 -3.04 9.21 
Squared Timeline 9.54 4.14 5 10 -2.22 5.04   9.74 3.77 6 10 -2.835 7.519 
Personal Control 6.02 2.63 0 9 -1.29 0.72   7.22 2.21 0 10 -1.07 1.25 
Squared Personal 
Control 6.55 4.90 0 9 -0.42 -0.55   7.54 5.26 0 10 -0.18 -0.64 
Treatment Control 8.87 1.35 5 10 -1.30 1.46   8.84 1.57 3 10 -1.70 3.29 
Squared Treatment 
Control 8.97 4.66 5 10 -0.92 0.13   8.98 4.90 3 10 -1.12 0.60 
Identity 5.75 2.45 0 10 -0.53 0.00   5.20 2.54 0 10 -0.93 -0.80 
Concerns 4.71 2.89 0 10 0.21 -0.90   4.63 3.12 0 10 0.09 -1.01 
Coherence 8.53 1.45 5 10 -0.82 -0.32   8.56 1.53 5 10 -0.82 -0.45 
Emotional 
Representations 4.60 2.91 0 10 0.07 -0.69 
  3.70 3.09 0 10 0.26 -1.20 
Self-efficacy and Outcome expectations 
Haemophilia-related  
Self-efficacy 100.00 14.03 73 118 -0.48 -0.86 
  106.72 14.06 54 120 -1.76 3.63 
Squared Haemophilia-
related Self-efficacy 
100.96 52.18 73 118 -0.29 -1.07   107.62 51.79 54 120 -1.30 1.53 
Prophylaxis-related 
Self-efficacy 76.38 21.00 27 100 -0.84 -0.34 
  84.81 17.10 35 100 -1.33 1.25 
Squared Prophylaxis-
related Self-efficacy 79.15 53.70 27 100 -0.44 -1.01 
  86.49 50.48 35 100 -0.90 -0.17 
Positive Outcome 
expectations 
38.22 11.23 6 60 -0.54 0.24   35.91 10.45 8 60 -0.09 0.97 
Negative Outcome 
expectations 18.33 9.62 4 40 0.28 -0.93 
  13.51 8.11 4 29 0.43 -1.06 
Mood (PANAS) 
Positive affect 30.96 9.76 11 49 -0.51 -0.19   31.69 10.15 10 50 -0.51 -0.25 
Negative affect 10.65 4.29 7 23 1.44 1.32   12.56 5.44 7 32 1.36 2.26 
Log Negative affect 9.97 1.42 7 23 0.90 -0.14   11.59 1.49 7 32 0.41 -0.50 
Social Support                           
Frequency 24.03 8.71 10 40 0.18 -1.16   14.75 10.39 0 40 0.78 -0.24 
Satisfaction 12.14 7.19 -2 24 -0.10 -0.78   9.08 7.27 -7 24 0.12 -0.46 
Frequency*Satisfaction┬ 38.69 27.79 -3 96 0.82 -0.27   26.75 29.76 -7 120 1.74 3.05 
Where transformation has been undertaken the geometric mean and SD are shown. ┬ Log transformation of social support 
frequency*satisfaction did not improve skew, therefore this variable was only included in non-parametric analyses and original values are 
shown above . 
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4.4.6 Adherence and clinical outcomes 
Correlation analyses (table 4.5) did not show any significant associations between clinical outcomes 
(bleeds and hospital visits) and adherence sum scores. However, the planning subscale showed a 
significant correlation with pain severity and the impact of this pain over the previous 4 weeks. This 
suggests that pain (or potential anxiety caused by pain) may act as a prompt for patients to plan 
around their treatment.  
Table 4.5: Pearson's correlation between adherence and clinical outcomes.  
  VERITAS-Pro adherence subscales   
  Log Timing Log Planning Remembering Log Skipper Communicating 
Adherence 
Sum 
Pain severity┬ .017 .239* .124 .147 -.110 .103 
Pain impact┬ -.101 .263* .008 .155 -.127 .054 
Spontaneous bleeds┬ .335 -.314 .186 -.011 -.299 -.124 
Traumatic bleeds┬ .050 .121 -.026 -.070 -.109 .019 
Log Total bleeds┬ -.035 -.037 .023 .065 -.126 -.110 
Hospital visits┬ -.383 .463 -.338 .029 -.122 -.107 
* p<0.05, ** p<0.001, ┬ during previous 4 weeks, ┬┬ during previous 6 months. 
Listwise N=79 
 
Despite the lack of significant correlations between adherence sum and clinical outcomes, when the 
sample was dichotomised into adherent/non-adherent (Table 4.6), there were significant differences 
in the number of total bleeds (mean difference -2.71, BCa 95% CI [-4.226, -1.209], t(74) = -3.593, 
p=0.001), and hospital visits (mean difference -0.507, BCa 95% CI [-0.972, -0.041], t(64) = -2.235, 
p=0.034).  
Interestingly, adherent patients experienced more bleeds and visited the haemophilia centre more 
frequently than non-adherent patients. This contradicts the hypothesis that predicted that adherent 
patients would experience less bleeds and would visit the haemophilia centre less frequently. It was 
also hypothesized that higher perceptions of pain and impact of pain would be associated with 
better adherence; however adherers did not appear to experience significantly less severe pain or 
impact of pain.   
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N Mean SD Min Skewness N SD Min Skewness
Age 65 19.34 4.01 12 -0.15 14 3.44 14 -0.27
Timing 65 6.51 2.25 4 0.54 14 3.22 7 -0.23
Log Timing 65 6.14 1.41 4 0.06 14 1.32 7 -0.61
Planning 65 6.75 2.92 4 1.19 14 3.4 6 0.31
Log Planning 65 6.22 1.49 4 0.47 14 1.39 6 -0.14
Remembering 65 7.28 2.27 4 0.01 14 2.59 8 -0.05
Skipping 65 5.27 1.96 4 2.48 14 3.31 4 0.49
Log Skipping 65 5.01 1.35 4 -0.08 14 1.56 4 -0.08
Communicating 65 12.07 4.14 4 -0.13 14 2.65 9 -1.17
Sum 65 37.87 7.24 20 -0.17 14 5.6 53 1.8
Pain severity 62 2.94 1.41 0 0.3 13 1.73 0 0.07
Impact of pain 64 2.16 1.25 0 1.05 13 1.71 0 0.66
Spontaneous 
bleeds
53 2.23 4.69 0 3.43 14 0.27 0 3.74
Traumatic bleeds 53 0.96 1.58 0 2.28 14 0.93 0 1.53
Log Traumatic 
bleeds
53 1.87 1.92 0 1.27 14 1.62 0 1.27
Total bleeds 60 3.37 5.41 0 2.42 14 1.14 0 2.11
Log Total bleeds 60 3.34 2.69 0 0.35 14 1.79 0 1.53
Hospital visits 54 4.09 4.7 0 1.77 12 2.09 0 2.1
Log Hospital 
visits
49 2.82 2.62 0 0.46 11 1.95 0 0.85
Table 4.6: Clinical outcomes of adherent and non-adherent patients.  
Max Kurtosis
19 -1.12 1.95 8 0.47
Where transformation has been undertaken the geometric mean and SD are shown. Difference between adherent and non-
adherent (*p<0.05, **P<0.001) as measured by independent t-test.
26 -0.876 1.41 4 1.43
19 2.83 2.25 8 5.29
8 -0.11 1.35 3 -0.11
26 6.21 0.71 4 4.99
26 13.58 0.07 1 14
8 6.59 0.64 3 2.03
6 -0.87 3.15 6 -1.42
5 0.08 2.46 6 -1.14
51 -0.35 58.5 73 2.88
Clinical information 
12 -1.31 7.06 14 -1.31
20 -0.67 15.26 18 1.02
11 -1.15 12.38 17 -0.37
15 8.53 7.71 14 -0.78
16 1.12 10.67 16 -1.13
16 -0.79 10.16 16 -0.95
12 -0.48 12.48 17 -1.12
12 -1.23 12.06 17 -0.61
25 -1.27 19.5 24 -1.07
Self-reported adherence (VERITAS-Pro) 
Adherent (n=65) Non-adherent (n=14)
Max Kurtosis Mean
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4.4.7 Psychosocial factors and adherence 
Table 4.7 shows the Pearson’s correlations between the adherence subscales and psychosocial 
factors.  
Better adherence sum scores were significantly associated with greater beliefs in the necessity of 
prophylaxis, fewer concerns about prophylaxis, and therefore a greater necessity/concern 
differential, which indicates that the necessity of prophylaxis outweighs concerns about this 
treatment.  
In relation to illness perceptions, greater emotional representations (negative feelings such as fear, 
anger or distress) were associated with better adherence, indicating that haemophilia-related fear or 
anxiety may encourage better adherence.  
Better adherence was also associated with greater positive outcome expectations and social 
support (frequency and satisfaction). This suggests that patients who believe that taking their 
treatment will result in more positive outcomes, and patients with better social support are more 
likely to adhere to their treatment. 
Drilling down into the results deeper shows some significant associations between the different 
adherence subscales and psychosocial factors. Greater concerns about prophylaxis treatment were 
associated with worse scores on the timing, remembering and skipping subscales, whereas greater 
beliefs in the necessity of treatment were associated with better scores on the timing subscale.  
In relation to illness perceptions, the results suggest that patients who have greater concerns, better 
coherence and more emotional representations in relation to their haemophilia are more likely to 
contact the haemophilia centre. Patients with greater coherence are also more likely to plan better 
in relation to their treatment (e.g. ensuring they do not run out of factor treatment and supplies). 
Positive outcome expectations were shown to be associated with better planning and less 
forgetting, whereas negative outcome expectations were associated with more skipping. 
Haemophilia-related self-efficacy was not associated with any of the adherence subscales. 
However, prophylaxis-related self-efficacy was significantly associated to better adherence in 
relation to timing of treatment. 
More frequent social support was associated with better scores on the communicating subscale and 
better adherence sum scores. Greater satisfaction with social support was associated with better 
adherence in relation to remembering treatments and communicating with the haemophilia team.  
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Table 4.7: Pearson's correlation between adherence subscales and psychosocial factors 
  
Log 
Timing 
Log 
Planning Remembering 
Log 
Skipping Communicating 
Adherence 
Sum 
Beliefs about Medicines (BMQ) 
BMQ Concern .248* .124 .290** .359** -.033 .262* 
BMQ necessity -.325** -.124 -.090 -.057 -.148 -.249* 
Differential -.414** -.178 -.265* -.286* -.090 -.366** 
Self-regulatory model (IPQ) 
Consequences -.081 .125 -.038 .046 -.092 -.019 
Squared Timeline -.021 .083 .196 -.082 .015 .086 
Squared Personal Control .017 .119 .132 .085 .146 .161 
Squared Treatment Control .120 .029 .190 -.087 -.084 .057 
Identity -.016 .208 .005 .053 -.096 .047 
Concerns .023 -.070 .025 .081 -.244* -.098 
Coherence -.125 -.229* -.058 .181 -.320** -.206 
Emotional representations -.112 -.126 -.061 .025 -.348** -.223* 
Outcome expectations and Self-efficacy 
Positive outcome expectations -.145 -.456** -.285* -.183 -.124 -.363** 
Negative outcome expectations .148 -.008 .157 .293** -.181 .087 
Squared Haemophilia-related Self efficacy -.092 -.147 .008 -.147 .018 -.107 
Squared Prophylaxis-related Self efficacy -.254* -.199 -.154 -.198 .093 -.188 
Mood (PANAS) 
Positive affect -.075 -.159 -.090 -.025 -.045 -.128 
Log Negative affect -.057 -.004 .028 .191 -.061 .007 
Social support 
Frequency -.123 -.160 -.191 -.048 -.400** -.297** 
Satisfaction -.153 -.105 -.232* -.165 -.334** -.301** 
* p<0.05, ** p<0.001, ┬ during previous 4 weeks, ┬┬ during previous 6 months. Listwise N=79 
  
 
Table 4.8 compares the psychosocial factor scores of adherent and non-adherent participants. Non-adherent 
participants had significantly lower BMQ Necessity scores (mean difference -2.494, BCa 95% CI [-4.4423, -
0.564], t(89) = -2.568, p=0.12), BMQ Necessity/Concern Differentials (mean difference -4.219, BCa 95% CI [-
6.723, -1.715], t(89) = -3.348, p=0.001), Prophylaxis-related self-efficacy scores (mean difference -1865.226, 
BCa 95% CI [-3260.590, -469.860], t(89) = -2.656, p=0.009), and Social support scores 
(frequency*satisfaction; mean difference -118.248, BCa 95% CI [-201.770, -34.726], t(89) = -2.824, p=0.006) 
than adherent participants. 
Non-adherent participants also had higher IPQ Timeline scores than adherent participants (mean difference 
6.144, BCa 95% CI [0.528, 11.760], t(89) = 2.194, p=0.033). 
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N Mean SD Min Max Skewness Kurtosis N Mean SD Min Max Skewness Kurtosis
Concern 64 10.12 3.65 5 18 0.23 -1.05 14 11.71 2.70 7 16 -0.08 -1.07
Necessity 64 20.26 3.68 8 25 -1.09 1.29 14 17.36 4.40 9 25 -0.03 -0.53
Necessity/Concern differential 64 10.14 5.08 -7 20 -0.65 1.01 14 5.64 4.27 -3 11 -0.54 -0.35
Consequences 63 6.05 3.07 0 10 -0.40 -0.84 14 5.36 3.57 0 10 -0.47 -1.15
Timeline 63 9.56 1.03 5 10 -2.68 7.51 14 9.86 0.54 8 10 -3.74 14.00
Squared Timeline 63 9.61 4.12 5 10 -2.34 5.06 14 9.87 3.10 8 10 -3.74 14.00
Personal Control 62 6.61 2.64 0 10 -1.10 0.69 14 7.43 1.56 5 10 -0.42 -0.47
Squared Personal Control 63 7.11 5.35 0 10 -0.12 -0.67 14 7.58 4.73 5 10 0.01 -0.30
Treatment Control 63 8.81 1.55 3 10 -1.59 2.67 14 9.07 1.21 7 10 -0.76 -1.14
Squared Treatment Control 63 8.94 4.89 3 10 -1.06 0.37 14 9.15 4.58 7 10 -0.69 -1.36
Identity 63 5.25 2.67 0 10 -0.03 -0.84 14 5.43 2.31 0 8 -1.05 1.11
Concerns 63 4.35 3.00 0 10 0.50 -0.87 14 4.14 3.13 0 10 0.09 -0.83
Coherence 63 8.59 1.50 5 10 -0.92 -0.15 14 8.36 1.55 6 10 -0.56 -1.17
Emotional Representations 62 4.10 3.14 0 10 0.21 -1.08 14 3.64 2.59 0 7 -0.32 -1.38
Haemophilia-related Self-efficacy 65 105.48 14.01 54 120 -1.37 1.92 14 105.14 9.62 90 118 -0.23 -1.21
Squared Haemophilia-related Self-efficacy 65 106.39 52.04 54 120 -0.12 -1.25 14 105.55 44.80 90 118 -0.12 -1.25
Prophylaxis-related Self-efficacy 65 84.06 18.27 27 100 -1.46 1.53 14 73.94 19.85 31 100 -0.71 0.52
Squared Prophylaxis-related Self-efficacy 65 85.99 52.28 27 100 -0.99 0.04 14 76.38 52.28 31 100 -0.09 -0.70
Positive Outcome expectations 65 37.49 11.45 6 60 -0.30 0.21 14 32.50 10.54 10 53 0.08 1.21
Negative Outcome expectations 64 14.34 9.24 4 40 0.69 -0.30 14 16.93 8.52 5 33 0.46 -0.88
Positive affect 63 32.90 9.84 10 50 -0.72 0.20 14 28.73 7.73 12 38 -0.72 -0.05
Negative affect 63 11.72 5.23 7 32 1.64 3.07 14 12.14 4.94 7 21 0.64 -0.92
Log Negative affect 63 10.83 1.47 7 32 0.72 -0.13 14 11.26 1.49 7 21 0.21 -1.33
Frequency 64 18.36 11.21 0 40 0.35 -0.99 14 15.50 8.37 2 30 0.25 -1.08
Satisfaction 59 10.59 7.68 -7 24 -0.11 -0.85 13 8.65 5.89 -1 19 -0.14 -0.62
Frequency*Satisfaction 54 30.74 29.47 -7 120 0.89 0.19 11 27.91 21.58 -3 64 0.71 -0.65
Table 4.8: Psychosocial factors scores of adherent and non-adherent patients.
Social Support
Adherent (n=65) Non-adherent (n=14)
Adherence scores were available for 79 partic ipants. Where transformation has been undertaken the geometric mean and SD are shown. 
Difference between adherent and non-adherent (*p<0.05, **P<0.001) as measured by independent t-test.
Beliefs about medicines (BMQ)
Self-regulatory Model (Brief IPQ)
Self-efficacy and Outcome expectations
Mood (PANAS)
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4.4.8 Ability of psychosocial factors to predict adherence 
To further test the association between overall adherence (adherence sum scores) and 
psychosocial factors multiple linear regression analyses were carried out (Table 4.9). It was 
hypothesized that higher perceptions of necessity of prophylaxis (BMQ Necessity) would be 
predictive of better adherence and that concerns about prophylaxis (BMQ Concerns) would not be 
predictive of adherence. In relation to the Self-regulation model of chronic illness, it was anticipated 
that higher perceptions of chronicity, consequences and treatment control would be predictive of 
higher adherence. 
To start with all psychosocial factors were entered using the fixed enter method, which resulted in a 
model that accounted for 48.8% of the variation in adherence (df=19, p=.001). In the model better 
adherence was associated with fewer concerns about treatment, greater belief in the necessity of 
treatment, greater emotional responses to haemophilia and greater social support. As the majority 
of factors were not significantly associated with adherence a second model was run in which the 
factors were entered using the forward stepwise method. In this model (table 4.9), which accounted 
for 37.5% of variation, greater necessity/concern differential, greater social support, greater 
emotional responses to haemophilia and more positive outcome expectations were associated with 
better adherence. 
 
Table 4.9: Linear regression model of predictors of adherence sum  
  
Predicting variables b SE B β P ΔR2 
Step 1 
    
.134** 
BMQ Necessity/Concern differential -.744 .216 -.366 .001 
 Step 2 
    .107* 
BMQ Necessity/Concern differential -.785 .204 -.386 .000 
 Social support frequency*satisfaction -.136 .041 -.328 .002 
 Step 3 
    .084* 
BMQ Necessity/Concern differential -.883 .196 -.434 .000 
 Social support frequency*satisfaction -.137 .039 -.331 .001 
 IPQ Emotional responses -1.041 .341 -.294 .003 
 Step 4     .049* 
BMQ Necessity/Concern differential -.757 .197 -.372 .000  
Social support frequency*satisfaction -.125 .038 -.302 .002  
IPQ Emotional responses -.988 .331 -.279 .004  
Positive outcome expectations -.213 .089 -.231 .019   
* p<0.05, ** p<0.001 
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Because the VERITAS-Pro assesses intentional and unintentional adherence separately, and 
because there were some questions about the validity of the communicating subscale (possibly 
affecting the adherence sum scores), separate regression analyses were carried out for the 
remembering and skipping subscales.  
Table 4.10 presents the results of linear regression analyses of the skipping sub-scale and 
psychosocial predictors. As previously, the variables were entered into the model using the forward 
stepwise method, and accounted for 41.5% of the variance (p=0.008). In this model fewer concerns, 
lower coherence, and better social support were associated with less skipping. 
Table 4.10 Linear regression model of predictors of adherence Skipping 
Predicting variables b SE B β P ΔR2 
Step 1 
    
0.103* 
BMQ Concern 0.031 0.010 0.321 0.003 
 Step 2 
    0.096* 
BMQ Concern 0.042 0.010 0.428 0.000 
 IPQ Coherence 0.077 0.025 0.327 0.003 
 Step 3 
    0.043* 
BMQ Concern 0.042 0.010 0.436 0.000 
 IPQ Coherence 0.085 0.025 0.361 0.001 
 Social support frequency*satisfaction -0.003 0.001 -0.209 0.041   
* p<0.05 
      
 
Table 4.11 presents the results of linear regression analyses of the remembering sub-scale and 
psychosocial predictors. The variables were entered into the model using the forward stepwise 
method, and accounted for 44.5% of the variance (p=0.003). Fewer concerns about treatment, 
lower perception of treatment control (the extent to which a patient beliefs their treatment can help 
their condition), and greater satisfaction with social support showing a significant association with 
better remembering.  
  
70 
 
Table 4.11: Linear regression model of predictors of adherence Remembering 
Predicting variables b SE B β P ΔR2 
Step 1 
    
0.1* 
BMQ Concern 0.274 0.092 0.316 0.000 
 Step 2 
    0.119* 
BMQ Concern 0.392 0.093 0.453 0.000 
 Square Treatment control 0.050 0.014 0.371 0.001 
 Step 3 
    0.069* 
BMQ Concern 0.368 0.090 0.425 0.000 
 Square Treatment control 0.056 0.014 0.413 0.000 
 Social support satisfaction -0.117 0.043 -0.270 0.008 
 Step 4 
    0.042* 
BMQ Concern 0.339 0.089 0.391 0.000 
 Square Treatment control 0.057 0.014 0.426 0.000 
 Social support satisfaction -0.101 0.042 -0.234 0.019 
 Positive outcome expectations -0.058 0.027 -0.212 0.033   
* p<0.05, ** p<0.001 
    
  
 
4.5 Discussion 
This study aimed to assess levels of adherence to prophylaxis among young people with 
haemophilia in the UK, and to identify the key correlates of adherence in this patient group.  
 
4.5.1 Findings 
The findings of this study suggest that overall adherence among YPH in the UK is good, and 
appears to be better than adherence to treatment for other chronic illness. This may be because, 
due to the relatively few patients, haemophilia teams are able to keep in regular contact with 
patients, with a particular focus on patients they are concerned about or who need some extra 
encouragement to keep to their treatment regimen.  
The good overall adherence found in this study is in line with some previous studies that looked at 
adherence to prophylaxis (De Moerloose et al., 2008), but exceeds adherence levels reported by a 
previous UK study (Llewellyn et al., 2003) and several other studies conducted in Europe and the 
US (du Treil, Rice, & Leissinger, 2010; Geraghty et al., 2006; Hacker et al., 2001; Lindvall et al., 
2006). Differences in adherence levels reported by different studies may be due to the diverse 
methods used to assess adherence, and variations in the way haemophilia is treated in different 
countries, or even within countries. Differences within countries are often due to costs, and 
therefore the way that haemophilia care is funded for individual patients plays an important role (e.g. 
insurance, state funded, or privately funded).  Indeed, several studies from the U.S highlight cost of 
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treatment as one of the main barriers to adherence (Hacker et al., 2001; P. Petrini, 2007). Because 
of the unique healthcare system in the UK, which funds all haemophilia treatment for all patients, 
levels of adherence in the UK are unlikely to be associated with concerns about costs.  
 
Unintentional and intentional non-adherence 
When non-adherence was split into intentional (skipping) and unintentional (mostly forgetting) it 
appeared that non-adherence was more likely to be due to forgetting than skipping. With the busy 
lifestyles that most YPH live it is quite understandable that they sometimes forget to take treatment. 
However, this finding may also indicate that patients find it easier to admit to forgetting than 
skipping, as they are more likely to be ‘told off’ by the haemophilia team and loved ones if they 
admit to intentionally skipping treatments whereas they tend to get a more understanding response 
when they admit to sometimes forgetting.  
 
Differences between adolescents and young adults 
It was anticipated that young adults would be worse at remembering treatment (hypothesis 1), and 
that adolescents would skip treatments more frequently (hypothesis 2). However, there were no 
significant differences between adolescents and young adults in relation to adherence.  
As anticipated (hypothesis 3) there were significant differences in the psychosocial factors that may 
influence adherence between adolescents and young adults.   
The findings suggest that young adults had greater beliefs in the necessity of treatment and greater 
necessity/concern differential scores, indicating that their belief in the necessity of treatment 
outweighs their concerns about treatment.  
Young adults perceived themselves to have more personal control over their symptoms, and had 
greater self-efficacy scores in relation to haemophilia in general and prophylaxis specifically. They 
also had fewer negative outcome expectations, suggesting that they have less negative 
associations with taking their treatment. In relation to social support young adults reported to 
receive significantly less social support than adolescents, although their satisfaction with the social 
support they receive was not significantly different. As a result adolescents and young adults did not 
have statistically significant  different social support total scores (social support 
frequency*satisfaction). 
It is interesting that despite the significant differences in psychosocial factors described above there 
was no significant difference in adherence between young adults and adolescents. This is likely 
because the of psychosocial factors that significantly contributed to the variation in adherence in the 
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regression analyses only the necessity/concern differential showed to be significantly different 
between the age groups.  
 
Association between adherence and clinical outcomes 
It was anticipated that non-adherence to prophylaxis would be related to higher numbers of bleeds 
and hospital visits (hypothesis 8). However, there was no significant association between 
adherence as a continuous measure and clinical outcomes (the number of bleeds and hospital 
visits). However, when the sample was dichotomised into adherers and non-adherers there were 
significant differences in the number of bleeds and hospital visits.  Interestingly, this was not in the 
anticipated direction, with adherers experiencing more bleeds and visiting the hospital more 
frequently than non-adherers.  
There are several potential explanations for this:  
- We collated the number of bleeds and hospital visits that patients had during the last 6 months, 
whereas we assessed patients’ adherence during the last month. Therefore it could be that 
patients who experienced frequent and/or severe bleeds more than one month ago were 
motivated to improve their adherence in order to reduce the risk of bleeding, resulting in better 
adherence scores. 
- Adherent patients may be more attentive to bleeding episodes and symptoms of bleeds, 
whereas less adherent patients may be more relaxed and less likely to interpret symptoms as 
bleeds. Non-adherent patients may also be less likely to report bleeds to the haemophilia team 
(through Haemtrack or by contacting the haemophilia centre), resulting in underreporting of 
their number of bleeds. 
- More adherent patients may be more confident in the protection afforded by their prophylaxis, 
and therefore more likely to engage in physical activity. This in turn may increase their risk of 
bleeding (due to activity-related injury or increased pressure on joints and muscles), compared 
to non-adherent people. 
- 10-15% of patients with severe haemophilia have a mild bleeding phenotype (Santagostino et 
al., 2010) which means that they are less likely to suffer bleeds and may therefore ‘get away’ 
with suboptimal adherence to prophylaxis. 
The findings did not support the expectation that higher perceptions of pain and impact of pain 
would be associated with better adherence (hypothesis 4). Indeed, pain was not correlated or 
predictive of adherence and non-adherers did not report more pain or greater impact of pain. 
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Psychosocial factors of adherence 
According to the Necessity-Concerns Framework (Horne et al., 1999) adherence is influenced by 
implicit judgements that patients make in relation to their personal need for the treatment (necessity 
beliefs) and their concerns about the potential negative consequences of taking it. Hypothesis 6 was 
based on the findings of a recent study in a single haemophilia centre in the UK (Llewellyn et al., 
2003), which suggest that better adherence to clotting factor is associated with stronger perceptions 
of necessity of treatment,  but not fewer concerns about treatment. However, the findings of the 
current study indicate that better adherence to prophylaxis among young people with haemophilia is 
correlated with stronger perceptions of necessity of treatment, as well as fewer concerns about 
treatment. However, when comparing adherers and non-adherers only beliefs about the necessity 
of treatment were significantly different (with adherers having greater belief in the necessity of 
prophylaxis). In the regression analyses only a greater necessity/concern differential (and not 
greater believe in necessity or fewer concerns in relation to prophylaxis) was predictive of better 
overall adherence. However, fewer concerns about prophylaxis did predict greater remembering 
and less skipping.  
According to Bandura (Bandura, 2006; Albert Bandura, 1977) better adherence is associated with 
greater self-efficacy and positive outcome expectations, and fewer negative outcome expectations. 
This has been supported by findings of studies that have investigated adherence among young 
people with various chronic illnesses (e.g.Holden, Moncher, Schinke, & Barker, 1990; Iannotti et al., 
2006).  The findings of the current study suggest that greater positive outcome expectations are 
correlated with better adherence, and predictive of better overall adherence and better 
remembering. Although self-efficacy was not significantly correlation to or predictive of adherence, 
adherers did have greater prophylaxis-related self-efficacy than non-adherers. 
In relation to illness perceptions, the findings suggest greater emotional representations (negative 
feelings such as fear, anxiety or anger about haemophilia) are correlated with and predictive of 
better overall adherence. This suggests that negative feelings, most likely fear or anxiety about the 
impact of haemophilia, may act as a motivator to stay on track with treatment. In addition, lower 
perceptions of treatment control were predictive of better remembering, and lower perceptions of 
coherence were predictive of less skipping. However, when comparing adherers to non-adherers 
only illness perceptions in relation to the timeline of haemophilia were significantly different, with 
non-adherers perceiving their haemophilia to last longer. These findings do not support the 
anticipation that higher perceptions of chronicity, consequences and treatment control would be 
predictive of higher adherence (hypothesis 5).  
Social support has been highlighted as an important facilitator of adherence among young people 
with chronic illness (M. R. DiMatteo, 2004; Annette M La Greca & Bearman, 2002; Williams & Bond, 
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2002). The findings of the current study support this suggestion, with greater social support both 
correlated to and predictive of better overall adherence, better remembering and less skipping.  In 
addition, adherers reported to have greater social support than non-adherers. 
The anticipated association between greater negative mood and lower adherence (hypothesis 7) 
was not supported by the findings of this study. Indeed, no significant associations were found 
between mood (neither positive nor negative) and adherence in the sample. 
In summary, the findings of this study suggest that psychosocial factors that are widely quoted as 
important factors in relation to adherence to long-term treatment for a range of chronic illness also 
appear to play an important role in adherence to prophylaxis among young people with haemophilia. 
In particular social support, beliefs about the necessity of prophylaxis, emotional responses to 
haemophilia, and self-efficacy in relation to prophylaxis may play a valuable role in identifying 
patients who may be least likely to adhere to their prophylactic treatment, any may also form a 
useful basis for the design of interventions aimed at improving adherence. 
 
4.5.2 Strengths and Limitations 
As highlighted in the literature review, the existing literature in this area is very limited in terms of the 
number as well as the quality of studies published.  The strength of this study is that it is a 
nationwide study (recruiting participants from 13 hospitals across England and Wales, including 
paediatric, adult and mixed haemophilia centres); has a large sample (nearly 20% of the total 
population of patients who meet the study criteria in England and Wales); and has a specific focus 
on young people rather than including patients of all age groups, as there are age specific issues 
that may influence adherence. Thanks to the large number of participants recruited from different 
types of haemophilia centres across a wide geographic area the study sample is more likely to be 
representative of the total population, and the findings less likely to be biased towards individual 
patients’ experiences. Lastly, rather than asking parents or HP to estimate levels of adherence and 
reasons for non-adherence, this study asked young people to complete the questionnaire 
themselves.  
The main outcome measure of this study, the VERITAS-Pro, is a relatively new scale and no 
literature exists using this scale in the UK. Therefore the original plan was to triangulate this self-
report data with information from treatment logs (self-reported frequency and dosage of treatments 
taken), and pharmacological data (amount of treatment prescribed and delivered to patients).  
However, due to technical issues and limited resource haemophilia centres were unable to provide 
this information. Therefore this study relies solely on the self-report measure of adherence as 
assessed by the VERITAS-Pro questionnaire, which may be considered a limitation. The results of 
this study suggest that there may be some issues around validity of the VERITAS-Pro, as the 
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majority of missing data for this scale was due patients answering ‘not applicable’. This appeared to 
be particularly the case for questions that assume that patients take treatment according to a pre-
agreed schedule that does not allow for flexibility. This reflects the fact that the VERITAS-Pro was 
constructed and validated in the US, and perhaps does not reflect the more flexible and 
personalised way in which many YPH in the UK manage their haemophilia treatment. For instance, 
one of the questions asks patients if they make decisions about their treatment themselves, without 
calling the Haemophilia Centre. According to the VERITAS-Pro scale this behaviour would be 
classed as non-adherent. However, patients in the UK are increasingly encouraged to tailor their 
treatment around their lifestyle based a number of principles that have been pre-agreed with their 
haemophilia doctor.  In reality this means that patients make day-to-day decisions about changes in 
the dose and/or frequency of their injections without contacting the haemophilia team. Therefore, 
some patients who would be considered non-adherent according to the VERITAS-Pro 
communicating sub- scale would not be considered non-adherent by clinicians.  
A strength of this study is that it assessed a wide range of psychosocial factors that have been 
found to be associated with, or predict adherence. However, to keep the questionnaire to an 
acceptable length illness perceptions, mood and social support were assessed using short form 
scales. These scales are not as comprehensive as the longer versions, which may have influences 
the findings to some extent.  However during the design of the questionnaire it was decided that the 
benefit of assessing a wide range of factors would outweigh the downside of using some shorter 
scales in the questionnaire. Another limitation that should be highlighted is the fact that clinical 
outcome data (bleeds and hospital visits) were collated by nurses from individual patient medical 
files. This method is prone to inaccuracies and missing data as medical files are often incomplete 
and difficult to read. Therefore, the unexpected association between adherence and more frequent 
bleeds and hospital visits could be due to errors and missing data.  
In order to provide a comprehensive analysis of adherence in the sample, the questionnaire 
assessed a number of psychosocial factors that have been shown to be associated with adherence 
among young people with other chronic illnesses (including beliefs about medicines, illness 
perceptions, outcome expectations, haemophilia- and prophylaxis-related self-efficacy, feelings, and 
social support). To keep the questionnaire to an acceptable length, a number of these factors were 
assessed using a short-form scale (such as the Brief Illness Perceptions Questionnaire), rather than 
more comprehensive or full-length scale (such as the Illness Perceptions Questionnaire).  Although 
it is unlikely that the use of these shorter version questionnaires has significantly biased the 
findings, it may have influenced the size or strength of associations reported. 
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4.5.3 Implications 
Notwithstanding the limitations discussed above, the findings of this study have a number of 
implications. The findings of this study suggest that adherence to prophylaxis among YPH is 
generally good, and much better in comparison to adherence in other chronic illnesses.   
As described above, the findings of this study suggest that the VERITAS-Pro scale may require 
some revisions, to improve validity for research in the UK. It appears that the skipping and 
remembering subscales tap into distinctly different types of                    (non-)adherence, and it may 
therefore be useful to carry out analysis on each of these subscales separately in addition to 
adherence sum scales.  
As collating clinical data from medical files is resource-intensive, and likely to result in missing and 
inaccurate data, it would be advisable to include self-report measures of bleeds and hospital visits in 
any future studies. This would allow researchers to validate information from medical files against 
self-report data, and may give some valuable insight into the extent to which self-report information 
agrees with information from medical files. 
 
4.5.4 Conclusion 
It appears that adherence among YPH is relatively good, which indicates that patients are 
knowledgeable and motivated enough to look after their haemophilia well, and that the haemophilia 
care and support they receive is generally working well.  
The findings of this study suggest that social support, beliefs about the necessity of prophylaxis, 
emotional responses to haemophilia, and self-efficacy in relation to prophylaxis may play a valuable 
role in identifying patients who may be least likely to adhere to their prophylactic treatment, any may 
also form a useful basis for the design of interventions aimed at improving adherence. 
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Chapter 5: Approach and methodology for three qualitative 
interview studies  
5.1 Introduction 
The qualitative research included in this thesis consists of three separate interview studies which all 
employ the same approach and methodology. The aim of the qualitative studies was to examine 
participants’ personal experiences in relation to prophylaxis, and how they make sense of these 
experiences.  Participants for the first study were young people with haemophilia (YPH) who follow 
a prophylactic treatment regimen.  Participants for the second study were parents of YPH who 
follow a prophylactic regimen, and participants for the third study were haemophilia healthcare 
professionals (HP). This Chapter will start with a brief summary of the qualitative approach that was 
utilised for the studies, after which a description of the methodology will follow. 
 
5.2 Interpretative Phenomenological Analysis (IPA) 
IPA was the chosen methodology because it aims to offer insights into how a given person, in a 
given context, makes sense of a given phenomenon (Jonathan A Smith, 2010). As part of the 
”double hermeneutic‟ employed by IPA the researcher tries to make sense of the participant trying 
to make sense of their experiences (Smith and colleagues, 2003; 2009) . Therefore IPA was found 
to be the ideal methodology to examine participants’ experiences and perceptions in relation to 
prophylaxis. IPA studies usually draw on the accounts of a small number of people who have 
certain experiences in common (Reid et al., 2005). Data were collected through face-to-face semi-
structured interviews which were audio-recorded. To try and encourage participants to tell their story 
in their own words and time, the researcher used as few prompts as possible. The interviews were 
transcribed verbatim, and then analysed following IPA principles and guidelines (Jonathan A. Smith, 
2003; J. A. Smith, & Osborn, M. , 2008). The transcription process, seen as the first stage of IPA, is 
described below, followed by a detailed description of each of the four Hermeneutic Cycles (HCs).   
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5.3 Rigour, validity and credibility 
Various guidelines (Elliott, Fischer, & Rennie, 1999; Snape & Spencer, 2003; Yardley, 2008) have 
been developed to facilitate the assessment of quality and rigour in qualitative research. Yardley’s 
(2000, 2008) ‘Characteristics of good qualitative research’ were used as the guiding principles to 
ensure that the research would meet standards in relation to rigour, validity and credibility. Key 
considerations in the research process that will be demonstrated in the following chapters are 
transparency of data presentation, reflexivity around the researchers own assumptions and 
consideration of alternative perspectives. 
 
5.4 Data collection 
Smith & Osborn (2008) recommend the use of semi-structured interviews to collect data for IPA 
studies. This facilitates a more informal and free-flow interview, which enables the researcher to 
follow cues from participants and probe areas of interest that appear particularly relevant to each 
individual’s experiences.  
Semi structured interview schedules (Appendix 5.1) were developed based on relevant literature 
and guidance from Smith & Osborn (2008). These were then circulated to the research supervisory 
team and a number of patients and haemophilia doctors and nurses for validation. Some revisions 
were made in response to their comments. 
The schedules were used as interview guides only, allowing participants to tell their own story in 
their own words. Every effort was made to deliver questions in an open-ended and non-directive 
style, to create an atmosphere in which participants felt comfortable to share their story without 
being led too much by the interviewer’s questions.  After each interview the researcher made 
detailed notes about the interview experience. This included the researchers’ thoughts, feelings and 
impressions as well as anything that might have affected the interview, such as salient points about 
the interview environment or interruptions that occurred during the interview.  
Participants were given a choice about whether they would prefer to be interviewed at home or at 
the hospital. Eight out of eleven YPH and all four parents were interviewed at the hospital and three 
patients were interviewed at home. All six HP were interviewed in a private room at their place of 
work. Interviews lasted between 35 to 95 minutes and were audio recorded and then transcribed 
and analysed. The transcription and analysis was completed for one study at the time to ensure 
there was no confusion between the different studies.  The patient study was completed before the 
parent study and the HP study was completed last.   
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5.5 The transcription process 
Transcription was conducted partly by the researcher and partly by a transcription service in three 
stages:  
• First transcription - the ‘everything audible’ version  
• Second transcription – the ‘pre-validation, cleaned and confidentialised’ version  
• Third transcription – IPA format  
 
5.5.1 First transcription 
The recordings of the interviews were firstly transcribed on the basis of ‘everything audible’ meaning 
that in addition to basic conversation, additional noises and events (such as stuttering, interjections, 
repetitions, hesitations, part words and background noises and events) were also transcribed. This 
was to ensure that future transcriptions stemmed from the maximum possible transcribed content. 
No audible material was overlooked and punctuation was kept to an absolute minimum, as any 
additions or changes as a result of the transcription process itself may inadvertently alter meanings. 
Instead of punctuation, a system of identifying pauses in the conversation of different lengths was 
used to reflect the natural way in which the conversation flowed. This convention is shown in Table 
5.1.  As regards other punctuation, commas were used sparingly, and question marks were only 
used when it was clear that a question was being asked.  If a portion of interview was inaudible 
then: ‘[inaudible]’ was used.  
 
Table 5.1: Convention employed to indicate the flow of conversation in the first transcription 
‘   ’ (3 spaces) are used to indicate a short pause  
‘…’ (3 dots) is used to indicate a definite break  
‘[hesitation]’  is used to indicate a break in the flow where a participant hesitates before they 
answer 
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5.5.2 Second and third transcription 
After the first transcription, a second ‘cleaned and confidentialised’ transcription was made in which:  
1. Background noise, stuttering, interjections, repetitions and ‘part words’ were removed. 
Indication of emphasised words that had been underlined in the first transcript was retained.  
2. Punctuation was inserted carefully so that the transcription read as a narrative. However, the 
author was mindful of the potential for punctuation to subtly alter intended meanings; adding 
punctuation only at the absolute minimum level. Commas were only used sparingly. 
3. Then any names and locations were confidentialised.  Great care was taken to ensure that 
none of the interview participants could be identified by anyone, in particular their 
haemophilia healthcare team.  
 
As haemophilia is such a rare disorder, it is relatively easy for HP to identify their patients based on 
very limited information. Therefore in some instances names of cities, towns or villages were 
changed and references to the number of (un)affected siblings mentioned by participants were 
removed. 
Although the second transcription was ‘cleaned’, no attempt was made to correct grammatical 
errors, primarily because the transcript was intended to accurately represent the spoken word, not 
merely a ‘correct’ and ‘easy-to-read’ version of the spoken word. The first eight participants were 
given the opportunity to review their interview transcript for validation; however none of these 
participants took up the opportunity to do so. Due to time restrictions, and none of the previous 
participants taking the opportunity to review their interview transcript it was decided that transcripts 
of the final 6 participants would not be sent out for validation. 
As part of the third transcription each interview transcript was re-read again to ensure that each of 
the three steps described above had been completed and that the transcripts were ready for 
analysis. They were then imported into NVivo, the software that was used to complete the first stage 
of analysis. 
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5.6 Analysis 
5.6.1 The ‘IPA-ready’ transcripts 
IPA is inherently a dynamic process (Smith 1996). Although the principles set down by Smith and 
colleagues (Jonathan A. Smith, 2003; Jonathan A Smith, 2010; J. A. Smith, & Osborn, M. , 2008) 
were closely followed throughout, the result of the practical application of those principles was an 
idiosyncratic data analysis. The initial analysis was carried out using NVivo software, and therefore 
does not follow the typical IPA format of left-hand and right-hand columns (or left- and right-
hermeneutic). Instead each transcript went thought the following process: 
 While reading and re-reading the transcript comments and annotations were made (in NVivo). 
This stage is often referred to as the ‘left-heuristic’ as these comments are made in the column to 
the left of the transcript. 
 While re-reading the transcript and annotations the text was coded (in Nvivo). This is often 
referred to as the ‘right-heuristic’ referring to the column on the right. 
 The coded transcript was then reviewed, and the coding was refined where needed (see 
appendix 5.2 for an example page).This completed the first hermeneutic cycle. To illustrate how 
the dynamic processes evolved appendix 5.3 shows the full list of themes after the first 
hermeneutic cycle for study one (YPH). 
 The NVivo coded transcript was then exported, creating an Excel spreadsheet  containing one 
line for each code and the following columns: 
o Name of the code (node in NVivo) 
o Number of coding references (frequency it was used to code a section of the transcript) 
o Example of a coded piece of text for each code 
o Notes/reflections on what the coded text indicates about participant experiences and the way 
they make meaning of this  
o Researcher’s reflections (bracketing off personal interpretation that may interfere with 
analysis) 
o Themes (identifying themes within the codes). This completed the second hermeneutic cycle. 
 The themes were then reviewed with the aim of identifying overarching themes, which were 
reported in an additional column. This completed the third hermeneutic cycle. 
 Finally, the overarching themes were refined and presented in a table together with each of their 
subordinate themes. This completed the fourth and last hermeneutic cycle. 
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5.6.2 The first hermeneutic cycle (HC) 
The ‘left-hermeneutic’ 
Before commencing analysis the author read and reread the example of IPA provided by Smith & 
Osborn (2003) particularly the chapter covering data analysis (pages 64-79), which suggest that 
‘left-hermeneutic’ is achieved by:  
• Summarising and paraphrasing  
• Associations that come to mind  
• Connections that come to mind  
• Preliminary interpretations  
• Commenting on the use of language  
• Sense of the participants themselves  
• Similarities and differences between and within transcripts  
• Echoes, amplifications and contradictions  
 
The ‘right-hermeneutic’ 
According to guidelines by Smith & Osborn (2010) the right-hermeneutic is achieved by:  
• Concise phrases which aim to capture the essential quality of the left-hand hermeneutic  
• Phrases at a slightly higher level of abstraction  
• Might use psychological terminology  
• Phrases that allow theoretical connections but are firmly grounded in the spoken words of the 
transcript  
 
The next stage was to read and re-read the transcript to get a feel for the overall nature of the 
participant’s personal story, and to clarify and engage with the narrative before moving on to the 
‘left-hermeneutic’ process described above. The reflections, comments, notes, questions and 
reiterations that resulted from this process were added to the transcripts in NVivo using the 
Annotations function. 
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Particularly at the start of the ‘right-hermeneutic’ coding process it was sometimes difficult to find 
‘concise phrases’ that adequately captured the essential quality of the left-hermeneutic, without 
being too detailed or too abstract. In some cases it was therefore decided to include more than one 
code. This was usually because: 
- The left-hermeneutic being analysed did not fit a single theme  
- There wasn’t a clear focus within the left-hermeneutic 
- There was more than one dimension to the left-hermeneutic (such as a figurative and literal 
expression being made simultaneously)  
The coding was carried out in NVivo using the Node function.  
During the analysis it was clear that, despite detailed bracketing in the reflective journal, the author 
was ‘seeing’ the text in ways that were likely to be influenced by personal interpretations and 
therefore biased in some way. Therefore a column was added to the analysis sheet that provided a 
place for the author to record personal interpretations, to try to stay with the participant’s individual 
experience and the way in which they made meaning of their experience. 
As recommended by Smith & Osborn (2003), it was decided to firstly conduct IPA on a single 
interview in its entirety.  The remainder of the transcripts were taken through each of the 
hermeneutic cycles together, producing a list of themes for the entire study at the end of each HC.  
 
5.6.3 The Second HC 
At the end of the first HC the coded transcript was exported from NVivo into Excel to allow a more 
free-flow analysis with the aim to identify overarching themes. This sheet included one line for each 
code, and columns to record the name of the code, the number of times it had been used in the 
transcript for each participant, and an example of a piece of text that had been allocated this code. 
Columns were then added to record the results of the second cycle of analysis. During this cycle the 
researcher aimed to identify what each code meant to participants, and identify emerging themes to 
organise the codes thematically.  This involved moving to more interpretative level of abstraction to 
allow theoretical connections within and across cases, whilst remaining grounded in each 
participant’s individual account. During this process the researcher was mindful of any personal 
interpretations that may bias the analysis, recording these in a separate column on the sheet 
(bracketing off). 
Appendix 5.4 shows an example of a transcript page at the completion of the second HC. At the end 
of the second stage any themes not directly relating to adherence were separated out and not taken 
further to the next stage of analysis.  However, these themes were retained as they were useful in 
setting the scene and developing a deeper understanding of what it is like to be a YPH in the UK.  
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5.6.4 The Third and Fourth HC 
During the third cycle, the themes were refined and re-organised underneath superordinate themes. 
This was done by re-reading the specific texts related to the emerging themes, but also by re-
reading the context of entire coded transcriptions.  The emergent themes were listed in order of 
appearance and attempts were made to look for and make sense of connections between them, 
creating theme clusters and ultimately superordinate themes. Smith & Osborn (2008) suggest 
imagining a magnet, “with some themes pulling others in, helping to make sense of them”. 
Throughout this process it was essential to continually return to the transcripts to ensure that the 
superordinate themes still reflected what participants had actually said. Appendix 5.5 shows an 
example of a transcript page at the end of the third HC. 
During the fourth cycle these main (superordinate) themes were refined and reorganised and 
presented in a table together with the subordinate themes underneath each main theme.   
 
5.6.5 Writing up the results 
The list of superordinate themes and corresponding subordinate themes was translated into a 
narrative account that expanded the analysis and explained the themes, illustrated with verbatim 
extracts. During the process the researcher continued to bracket off any personal reflexions or 
interpretations to stay true to the participants stories.  
Chapter six presents the analysis of patients’ accounts of adherence to their prophylactic treatment. 
Chapter seven presents the analysis of parents’ accounts of managing their sons’ haemophilia, 
including adherence to his prophylactic treatment. Chapter eight presents the analysis of haemophilia HP 
accounts in relation to adherence to prophylactic treatment. Although the three studies are similar in that they 
address the same issue, because they reflect different perspectives they are subtly different. To retain these 
differences the specific methodology for each of the studies, including recruitment and data collection, will be 
presented at the start of each chapter. Although the following chapters will each end with a summary of the 
findings, an overall discussion relating to the results of the three qualitative studies combined will follow in 
chapter 9. 
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Chapter 6: Interpretative Phenomenological Analysis of 
patients’ accounts of adherence to their prophylactic treatment 
6.1 Introduction 
This section presents the results of the Interpretative Phenomenological Analysis (IPA) of 
participants’ accounts of managing their prophylactic treatment regimen. The aim of this study is to 
examine the complexities surrounding prophylaxis and adherence to this treatment among young 
people with haemophilia (YPH). This will provide context to the quantitative findings described in 
chapter 4, and contribute to a better understanding of what drives (non-)adherence in this patient 
group. 
 
6.2 Methods 
6.2.1 Recruitment 
Participants were recruited in five haemophilia centres across England and Wales. Eligible patients 
were approached while they were in the haemophilia centre for a routine check-up appointment.  All 
participants who met the inclusion criteria (aged 12-25, diagnosed with severe haemophilia and 
following a prophylactic treatment regimen) were invited to take part, and all participants who 
agreed to take part were interviewed.  
 
6.2.2 Participants 
Participants were 11 males with a mean age of 18.82 years (SD=4.99) who follow a prophylactic 
treatment regimen for their severe haemophilia (see Table 6.1 for details).  
Five participants lived with their parents, three lived independently with friends or housemates, and 
the remaining three lived with a partner or wife. 
 
 
  
86 
 
Table 6.1: Young people with haemophilia interview study participant characteristics  
Participant code Ethnicity Age Treatment regimen 
1 White British 17 Three times per week 
2 White British 24 Activity based 
3 White British 21 Twice per week Long-acting 
4 White British 12 Three times per week 
5 White British 25 Three times per week 
6 Asian Pakistani 22 Alternate days 
7 White other European 13 Twice per week Long-acting 
8 White British 12 Alternate days 
9 White British 16 Daily 
10 White British 21 Three times per week 
11 White British 24 Three times per week 
 
 
6.2.3 Data collection 
Each participant was interviewed face-to-face at their home or in a private room at the haemophilia 
centre.  The interviews were semi-structured using a topic guide (appendix 5.1), although 
participants were encouraged to tell their own story in their own words with as little interruption from 
the interviewer as possible. At the start of their interview participants were invited to describe their 
experiences in relation to their haemophilia, starting with what it was like when they were a child.  
The main aim of these questions was to ease participants into the interview and gain a sense of 
how they felt about their haemophilia and the extent to which it influences their life. To gain insight 
into their experiences and perceptions in relation to prophylaxis, participants were then invited to 
describe their treatment regimen, their feelings about their treatment and potential barriers and 
facilitators to their adherence.  Lastly participants were asked about the social support they receive 
in relation to their haemophilia and treatment. The order in which the above subjects were 
discussed was flexible, and very much driven by participants themselves. In some of the interviews 
very few prompts were needed, as  
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participants were very keen to share their story.  In other interviews the prompts were used to 
encourage participants to ‘open up’ and share their story, or to bring the discussion back to 
experiences and perceptions in relation to prophylaxis. Interviews were recorded and then 
transcribed verbatim before being analysed following the IPA methodology. 
 
6.2.4 Analysis 
IPA emphasises that the process of discovering themes is based on the researcher being engaged 
in a double hermeneutic (Smith, Flowers & Larkin, 2009), with the aim to make sense of the 
participant attempting to make sense of their experiences.  These themes, therefore, form one 
possible account of how YPH experience their prophylactic treatment regimen. This analysis is 
partial and subjective and may have reached different conclusions and highlighted different aspects 
in comparison to what other researchers may have found. After examining themes, and 
convergence and divergence of themes, and after immersion in the data, it was decided to report 
those that emerged most strongly from the interview data and that were relevant to the research 
questions. In this chapter these themes will be explored and illustrated with verbatim extracts that 
were selected from across all participants’ transcripts, to ensure they were representative of the 
sample. In instances where different participants had different opinions or experiences, all views are 
illustrated. In cases where participant responses were similar, only those quotes that illustrate the 
theme most clearly have been included. This approach was true to the aims of the study, 
participants’ accounts and the richness of the data.  
 
6.3 Results 
6.3.1 Superordinate and subordinate themes 
Participants’ accounts clustered around four superordinate themes, which are shown in table 6.2 
together with their related subordinate themes. The table also shows for which participants each of 
the subordinate themes was relevant.  
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6.3.2 Theme 1: Difficult balance between good self-management and not letting 
haemophilia stop you from living the life you want to live. 
This theme encapsulates the impact haemophilia has on day-to-day life of YPH. Often diagnosed at 
a very young age, haemophilia is not only a lifelong health condition, it is part of who they are and 
the way they live their lives. Participants described how they were often in and out of hospital as 
children, resulting in school absence which for some had a negative effect on academic and 
professional opportunities.  They also described how they had missed out on social occasions and 
opportunities to make friends because they were often excluded from activities that were deemed 
too risky. The young people involved in this study vocalised a strong desire to live a ‘normal’ life, 
however for most of them managing risk is an important part of their daily routine. This includes 
taking their prophylactic treatment and taking top up treatments to provide extra protection for 
physical activities.  
 
Subtheme 1: Haemophilia, bleeds and pain are part of life and who I am 
As haemophilia is usually diagnosed in the first few years of life, patients have always lived with the 
condition and it is therefore part of their identity. 
It’s something obviously I was born with it so I don’t know any different. So me for me it’s 
uhm it it’s just part of my lifestyle (P.2, 24 years old) 
I just kind of accept it as a part of who I am and what I’ve got. (P.1, 17 years old).  
 
Some of the participants felt that having haemophilia had not only shaped their life, but also their 
personality. Having haemophilia clearly had a big impact on them when they were growing up, and 
particularly those with non-affected siblings were aware that they were ‘different’ and were treated 
differently by parents, teachers and peers. Missing school regularly affected their qualifications, and 
consequently their job prospects. 
It changes who you are because I, never going through it, I probably would have been a 
completely different person. Of course you would because you will have the additional things 
going on. Wouldn’t have missed so much time off school, like when my brother had a couple 
of weeks off because he was ill, they had a letter sent because he missed so much time, 
now I could miss time and it wouldn’t, because I’ve got like a, not so much an excuse, just 
different circumstances -- It's like when I broke my leg some of my friends …I went into the 
ambulance that night and then I had to go back into the school to do my GCSEs. I only did a 
couple because of the amount of time I missed and I didn’t see some of them again which 
didn’t bother me because it was just oh they weren’t great people (P.8, 12 years old).   
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Whereas for others it meant they had more time to focus on academic activities and achievements, 
particularly in the run up to GCSE and A-level exams. 
It’s easy. Just make notes because that’s something that I’ve gotten used to now after not 
being able to do much sport, I just sit and learn things. (P.9, 16 years old) 
 
Striking a balance between living a normal life, while avoiding situations that increase the risk of 
bleeding is challenging for most young people who were interviewed for this study.  However, it 
seems that there are many different interpretations of what ‘avoiding risk’ is, and how this influences 
the way you live your life.  Some participants are more or less able to live the life they want, as long 
as they take their treatment to protect themselves.  This included two young adults who live very 
active lifestyles and take part in sports at a competitive level. Whereas other participants felt that 
they have to miss out on many things they would like to do, because of their haemophilia. 
 But knowing my limitations is definitely, ah, a very important part of having haemophilia, cos 
if you go past what you’re limited to be able to do,  then you are gonna cause more damage. 
(P.1, 17 years old) 
 
Participant 1 appeared to have quite ambivalent feelings about the way haemophilia affects him.  
He felt quite strongly that he would not let his haemophilia hold him back, but avoiding risk 
appeared to be quite central to his life.  This ambivalence was not unique to this participant, 
although it was not quite as strong in others. The majority of participants mentioned some limitations 
to what they are able to do, either because they want to avoid risk, or because they have already 
suffered joint damage as a result of recurring bleeds. 
Many people with haemophilia develop target joints (recurrent bleeding in a particular joint) by the 
time they reach young adulthood. Recurrent bleeding in these target joints can lead to joint damage 
resulting in mobility issues or disability. Most people interviewed for this study appeared to accept 
haemophilia-related issues (e.g.  bleeds, pain, and joint damage) as part of their life. They tend to 
take a ‘you just have to get on with it’ approach, and do not dwell on these issues. Some recognised 
that their joint problems were probably caused by recurring activity-related bleeds during their 
childhood. Some voiced regret as they now realise that these recurring bleeds were caused by risky 
activities, such as playing contact sports or rough play with friends. 
Whereas before I had all this ankle problem I’d just do what I want really. Ehm, all the things 
what they’d say they didn’t want me to do, I would just go and do it, not to be a pain, but cos 
I wanted to. But I’m a bit more calmed down now. So I don’t need to go do all that stuff (P.3, 
21 years old). 
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For many patients their joint damage results in significant and frequent pain. However, it appears 
that pain does not stop them from ‘getting on with it’ as they are so used to pain and have found a 
way to cope with it.   
It’s something I --my body’s got used to so much that it kind of just ignores it now. If I-- If for 
example I knock against something you-- you do notice it’s there quite heavily--because the 
pain comes flooding back very quickly. But that settles down, but it’s always there. And I’ve 
kind of accepted the fact that it’s always gonna be there. But it’s just easier because my 
body ignores it now (P.1, 17 years old). 
 
Subtheme 2: Avoiding risk is key 
Many patients are diagnosed when they first start moving around as small children. The small 
bumps and falls that happen to all us when we learn to crawl or walk can cause severe bruising in 
children with severe haemophilia. This is often a traumatic experience for parents, as they learn that 
even low-risk day-to-day activities can cause harm to their child. Almost all participants explained 
that while they were growing up they were not able to join in with all activities at school, or with 
friends.  For some this meant that they were also excluded from playing outside at break times at 
school, on advice from the haemophilia team or because school or parents felt it was too risky. 
Some felt that not being able to join is when they were at school held them back, and made it 
difficult for them to make friends and develop social skills.  
As I said I try not to let the Haemophilia hold me back, but the fact that we’d been told that I 
shouldn’t-- to protect me, that I shouldn’t go out at break or lunch was what held me back. 
(P.1, 17 years old) 
Sometimes at school I do try and do football and things like that but I mean I’ve been taught 
to like stay away from it but it’s hard. Because I just want to do the same as everyone else 
and be active and do sports and stuff but like because my illness it kind of stops me a little 
bit. (P.8, 12 years old) 
 
It became clear that different families and individuals deal with haemophilia in different ways, and 
perceive the potential risks associated with activities differently. However, it appears that managing 
risk is an important part of life for all young people involved in this study. For some this means that 
they keep to their treatment regimen religiously, so that they feel protected while they get on with 
the life they want to live. 
Like If I am doing anything active obviously I would have always had my medication uhm. I 
don’t really leave anything to chance. Uhm so as long as I’ve had that then there is not a 
huge panic uhm but obviously if I have broken a bone then you’re gonna have to go to 
hospital either way uhm (P.2, 24 years old) 
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For others managing risk has a more central role in their lives, where each activity is risk assessed, 
and where limitations to what they are able to do are an important consideration in everyday life. 
But knowing my limitations is definitely, ah, a very important part of having haemophilia, cos 
if you go past what you’re limited to be able to do, then you are gonna cause more 
damage.(P.1, 17 years old). 
 
Particularly participants who live an active lifestyle feel their treatment is crucial in reducing the risk 
of activity-related bleeds and preventing problems. This is clearly also an incentive to adhere to their 
treatment regimen, and sometimes take additional top-ups to be prepared and ensure they are 
covered for their activities. 
Recently I’ve done a 10k run and I knew that the week before I’m training for it, make sure 
you’ve given yourself plenty of factor, maybe increase the dosage a little because you’ve got 
a big run coming ahead and if something were to happen or generally you’re going to ache 
after the run anyway so it would be good to have that factor in your system and a good 
healthy amount in that week before to get you prepared. So if I did miss something, which I 
didn’t, I would have been worried just in case something happens or I get a cut or something 
or I bang my head or something and you keep on bleeding and bleeding, whereas if you 
were prepared then you wouldn’t bleed as much (P.10, 21 years old).              
 
It is interesting that patients’ perceptions of the advice they receive from their haemophilia centre 
differs widely, with some suggesting that they feel that they are not allowed to get involved with 
sports, whereas others feel that their haemophilia centre encourages them to be active and fit. This 
could be because different haemophilia centres give different advice, but could also be due to 
different interpretations of the same advice. This may indicate that HP need to consider more 
carefully how the advice they give is understood and implemented. Particularly as individual 
circumstances, family dynamics and personalities will influence the way in which patients and their 
families take on advice. 
I think there’s a couple of haemophilia centres who aren’t handing out, just aren’t really 
handing out treatment. They’re just saying don’t do sport, if you continue to do it we don’t 
give you the treatment. Which is a shame to hear because I know all the centres <in this 
area> encourage sport and encourage an active lifestyle.  And you know I’ve learned since I 
was swimming at a high level that’s when all my problems stopped. That coupled with the 
medication.  It’s been super fit, super healthy, treating the haemophilia with a bit of respect. 
(P.2, 24 years old) 
 
As illustrated by the above quote, feedback from several participants in this study suggests that 
being fit, healthy and strong helps to manage haemophilia and reduces bleeding. Many haemophilia 
93 
 
centres advise their patients to take up swimming, as it is a non-weight bearing activity that can help 
patients to stay fit and strong without risk of injury. This advice seems to be taken on by many 
patients, and several participants in this study mentioned that they swim regularly, or are intending 
to take up swimming in the near future. 
I’ve always liked swimming but my mum says that we’re going to try and   do   get into doing 
more things like swimming, activities that I can do. (P.8, 12 years old) 
They’ve opened a new baths by me so hopefully I’m gonna start going there soon. If I could 
play football like you run around for like ninety minutes, that could affect me like the next day 
because I could have sore ankles, because swimming’s not weight-bearing it’s ideal (P.11, 
24 years old) 
 
The theme of reducing risk does not only apply to physical activity, participants also suggested that 
they do not like to take any chances in relation to other elements of their haemophilia management. 
For instance, several participants mentioned that they would not trust a digital device to remind 
them to take their treatment, instead relying on several ways to remind themselves. One participant 
described how he checks each box individually before signing for a new treatment delivery. 
I don’t think we’ve ever had the wrong medication delivered--but it-- we have to check just-- 
Just in case /just to -- for peace of mind--  (P.1, 17 years old). 
 
Another described how he travelled back from abroad to have his injury treated in his usual NHS 
haemophilia centre rather than relying on treatment in a foreign hospital. 
To make sure I was treated in England cos I trust yeah I trust the NHS with my life basically 
(P.2, 24 years old). 
 
Subtheme 3: Patient is haemophilia expert 
In particular participants aged 18 and older described how they feel that they are experts in 
haemophilia. They have learned how to recognise the symptoms of a bleed, they know what kind of 
activities increase the risk of bleeding and they know how to treat themselves if a bleed does occur.   
I think, I’m also haematologist [laughs] because I had so much experience of these things 
but obviously I feel I had to teach myself, I’ve improved myself a lot and I’ve gained enough 
confidence too (P.11, 24 years old) 
 
As haemophilia is a rare condition, several participants described situations in which (non-
haemophilia) HP did not know how to deal with their condition, or gave them incorrect advice (e.g. 
some were prescribed nonsteroidal anti-inflammatory drugs, which can worsen bleeding problems). 
For some participants these experiences encouraged them to become more self-sufficient, and 
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potentially increased their reluctance to allow others to do their treatment or even their blood tests. 
Although in some cases this may also be related to some anxiety around needles and injections. 
When I’ve been in hospital in the past I have still done all my own injections. At one time I 
even had a doctor come and ask me, cos they needed help to mix it up. Yeah, like I don’t let 
anyone do blood tests, I just do it all myself.  I don’t like people putting needles in me; I’d 
rather do it myself (P.3, 21 years old) 
 
Even those participants who did not describe themselves as experts appeared very confident about 
their abilities to manage their haemophilia, and were mostly quite knowledgeable about the way 
factor replacement treatment works.  
Cos there’s nothing high-risk about sleeping. The only time I’ll take it in the evening is if I’ve 
had like 2000 on a Monday and then I am doing something active on the Tuesday evening 
then I’ll maybe have a top-up of a 1000 that evening (P.2, 24 years old) 
 
Subtheme 4: I tailor my treatment around my lifestyle 
In recent years the focus in haemophilia care has been moving towards a more individualised 
approach, where patients are encouraged to tailor their treatment around their lifestyle.  So instead 
of the standard 3 injections per week (usually on Monday, Wednesday and Friday in the morning), 
patients may tailor the treatment frequency and dosing around their activities and lifestyle. Many 
patients also take additional treatments (top-ups) to cover themselves for ad-hoc activities on days 
that fall outside of their usual prophylactic regimen. The majority of participants in this study tend to 
tailor their treatment using top-ups. However two participants described more flexible regimens that 
they tailor on a daily basis around their very active lifestyles. 
I can have some pretty intense weeks. Where I maybe go over, uhm not my quota because 
there is not really a quota for it, but kind of if I’ve taken it every day and I’ve had couple of 
days where I’ve gone 1000 and 2000. If I have a day or a few days where I am not really 
active then I sort of try and knock it back quite a bit.  (P.2, 24 years old) 
 
This personalised approach to prophylactic treatment raises some interesting questions in relation 
to adherence, as in some instances behaviour that would have been considered non-adherent just a 
few years ago (e.g. reducing number of injections during a ‘quiet’ week), may now be seen as an 
acceptable adjustment. Equally, the definition of ‘over-treating’ may also need to be revised, as 
patients who increase the dose or frequency of their injections to accommodate a more active 
lifestyle are not necessarily over-treating.  This has some important implications for patient 
education and information; adherence assessment and research; and haemophilia care. Patient 
education about treatment is likely to become more complicated, as tailored treatment regimens are 
more difficult to explain and require patients to have a better understanding of how the treatment 
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works. Assessing adherence will also become more complicated, as standard questionnaires may 
not accommodate a more flexible treatment approach. This will have implications for adherence 
research but also for routine care, as HP are likely to find it more difficult to ascertain if their patients 
are adhering to their treatment.  
 
6.3.3 Theme 2: Grappling with barriers that make it harder to adhere to prophylaxis 
This theme encapsulates barriers to adherence to prophylaxis as described by the participants in 
this study, and may therefore not include all possible barriers to adherence that a young person 
may experience.  
 
Subtheme 1: Barriers to adherence 
Most young people involved in this study have a busy lifestyle, which at times can make it hard to fit 
treatment in.  Many leave home early in the morning to get to school or work, and fit in social and 
physical activities before they return home in the evening.  
Most participants mentioned that they have to get up a little earlier to take their treatment and that 
when they are particularly busy they do sometimes forget. 
I was going to be at work so I really didn’t find enough time to do it and when I come back I 
was really tired, I went to sleep (P. 6, 22 years old).     
 In the morning I’m normally in a rush. So that’s when I normally tend to have it, so that’s why 
I tend to forget. I struggle to keep track of the days as well. So, I remember  I started to just 
feel a bit - - just a bit funny like in the joints. And a bit achy. And then I realized I’ve gone four 
days without it. So that made me realise that’s why I was aching. (P.3, 21 years old) 
 
Next to forgetting, one of the main barriers for the participants in this study is the intravenous 
injection. It is not very pleasant to have to inject yourself several times each week, and several 
participants mentioned that they would much prefer to take their treatment through oral tablets, or 
subcutaneous injections like insulin-dependent diabetics. Although most participants did not 
describe any issues around needle phobia, it appears quite common for patients to experience 
some issues around venepuncture or venous access. In particular for younger patients, who 
perhaps have not had as much practice. Not being able to find or access a vein can be frustrating, 
painful and sometimes can cause anxiety.  
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Some patients described how they tend to give up on their injection if it doesn’t work the first or 
second time, and come back to it later in the day or even the following day.  
…sometimes when you put the needle in, sometimes it can be quite difficult. Cos you can’t 
always you don’t always find the eh find the ehm the vein. You don’t always find it. But it 
doesn’t --it can -- cos I got used to it you normally find them now. (P.4, 12 years old) 
 I have, I do have -- I sometimes have trouble with them, the veins. But it is not - - recently it’s 
not been too much of a problem. Like if it’s not gone in the first time, then you can just get 
another needle whatever and just try again. (P.3, 21 years old) 
 
Once they have found one or two injection sites that work well, most patients tend to stick to those 
sites for all their injections. This makes it easier and less painful, particularly as the sites become 
less sensitive due to the scar tissue that results from frequent injections. 
 I could obviously just go into another vein. But that would just be going into tender skin then 
(P.3, 21 years old). 
 
Sometimes there are practical reasons why patients struggle to take their treatment. They may not 
be able to find an appropriate or private place, or may not be able to do the injection themselves 
because of an injury. For instance, if a right-handed person has an injury to their right arm, it would 
be very challenging for them to take their treatment themselves.  
 I broke my elbow so I couldn’t actually treat myself so I had to direct my sister to do it (P.2, 
24 years old).     
 
In emergencies patients may not always be able to mix up and take treatment themselves. Two 
participants mentioned that the design of the treatment, and the way it is mixed up in preparation for 
the injection, makes it quite challenging for inexperienced people to help. This makes emergencies 
more stressful, and may increase general anxiety about managing life with haemophilia. One 
participant described an experience during a ‘lads holiday’ which has made him more anxious and 
risk averse about going away with friends or  attending parties that involve alcohol and young 
people having fun.   
 “I’m going to have to go back to the room to treat myself, can one of you come and help me?” 
my mates offered and we went back. It was hard for me to do it because it was bleeding, so I 
had to describe to my friend how to make the bottle up to get the injection ready. Obviously I 
don’t expect my friend to inject me. But I thought if you make it up for me I could put this extra 
pressure on and give myself a bit more time to make it stop. So when I come to inject and go 
like that then the blood will be minimal compared to if I just make it and the blood flow is going 
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down. So I was telling him but it was slightly complicated. For me it’s second nature, but 
obviously for him I was just …trying to take it on board what I was giving to him. But if it was just 
maybe an easier way of making it or less compartments. Sort of readymade so all you have to 
do is inject then it would be like simpler. I could have just got on with it. (P.10, 21 years old)  
 
One participant also mentioned that changes in the design or packaging of existing treatment, or 
changing to a different treatment, can be challenging. The frustration of having to buy materials that 
used to come with the treatment for free (such as antiseptic wipes), became a barrier to adherence 
for this individual. 
…it takes long because in that little package, they don’t have the dry things for your hand 
and the wiping and the plaster because we used to have that in the other box. (P.7, 13 years 
old) 
 
Because prophylactic treatment involves an intravenous injection, it is important for patients to find a 
private and clean place to do their treatment.  When at home, or in a familiar location this is often 
not a problem. For instance, several participants described how they are able to take treatment at 
work or school if they need to. However it can be challenging to find an appropriate place when on 
holiday, or out and about.  
I’ve never had factor on a plane before, and then we get in the airport and it’s hustle and 
bustle, you can’t really pull the lads to one side say “I’ve got to go to the toilet and do it”, so 
‘‘I’m not really going to have treatment here until I get home’’. So it was just the fact that I 
couldn’t have any, that was more the worry. It made me feel a bit not organised, not good 
about myself (P.10, 21 years old)   
 
Subtheme 2: Haemophilia- and treatment related anxiety 
As described above, anxiety can make the intravenous injections more challenging, particularly for 
patients who have venous access or venepuncture issues. 
What makes treatment difficult is if I’m in-- If I’m stressed. If I had a stressful day and I’m 
doing it in the evening it’s difficult to locate veins. Because they tend to shy [laughs] away 
from you. If I’m in a bad mood they shy away. I--it’s always very mood specific. If I’m quite 
relaxed and n a good mood then I can easily see them on the surface and it’s easy to get in 
there. (P.1, 17 years old) 
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Most of the participants were not particularly anxious or stressed about their injections, although two 
of the younger participants who were not doing their own injections yet appeared a little anxious 
about the idea of taking over their own injections.  
I have to one day obviously do it but it’s a bit scary, but I do have to eventually (P.8, 12 years 
old). 
 
The majority of participants explained that having to do their injections themselves was difficult to 
start with, but became easier with time and experience. None of the participants developed needle 
phobia, or anxiety about injections, although there was some indication that some of them may not 
have been completely at ease with their treatment. Several participants explained that they would 
never take their treatment in front of someone else, or would only do it in front of people they are 
familiar with.  
Generally I’ll always do it before I go out or a place or work is okay because you’re familiar 
with work so, I don’t like doing it in front of like, I don’t mind doing it in front of but, you know, 
people that don’t know about it and don’t know what it is, that’s, so generally I always make 
sure I have it in a safe place at home, have it at work, have it at a friend’s house…  (P.10, 21 
years old) 
 
Not wanting to take treatment in front of others perhaps indicates that there is some anxiety about 
how others respond to the injection, and possibly some concern about stigma. Some participants 
described how reactions from work colleagues and potential partners can sometimes be upsetting 
or cause insecurity.  
Whereas some girls maybe I’ve seen in the past they’re like “what is it? What is it? You have 
to inject yourself, you know, I don’t understand why” and makes you look a bit like, you 
know, it shows you up, makes you feel like, you know, I’m not good enough because I’ve got 
to inject myself or because it looks bad and as soon, normally generally the girls, I explained 
to them and said “look this is what it is, this is what I have to do” and they’re fine. (P. 10, 21 
years old). 
 
It is clear that even for patients who have supportive families and friends around them, haemophilia 
can cause anxiety at times. Bleeding episodes can be painful and can cause stress or anxiety for 
patients and their loved ones. Particularly in cases where the bleeding causes them to miss school, 
work or social occasions because they cannot move around or have to take rest to recover.  
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Patients interviewed for this study generally took a ‘You have to get on with it’ approach to life with 
haemophilia, indicating a certain level of pragmatism and not wanting to dwell on issues. However, 
it became clear that for some of them haemophilia-related issues can become overwhelming at 
times. 
Like if I have a bleed and I’m resting, I sometimes go on the Xbox and just like play and kind 
of forget about like the bleed. (P.8, 12 years old) 
 
Some described how they would ‘flee’ from their haemophilia for a while by becoming absorbed in a 
film or computer game, others engaged in more active coping mechanisms like speaking to friends 
or seeking psychological support to help them deal with issues related to their haemophilia. 
It’s great; it’s good to relieve stress that way because she understands me.  It’s a lot easier if 
someone else knows all about (P.9, 16 years old) 
I do have counselling as well. And it all must stem back to when it all started or whenever. 
That’s just another problem I think. Just for someone to talk to, it is helpful. But I don’t like to 
--- I don’t like to talk about a lot of things. I keep a lot to myself, so that’s why I go there. So 
yeah, haemophilia does cause a few problems in that way. Yes, it’s all about that, obviously 
growing up with it (P.3, 21 years old). 
 
Some participants were able to access psychological support through their haemophilia centre 
directly, or through a referral from their haemophilia consultant to a psychological support service 
provided by the hospital or local NHS trust. However, long waiting lists or difficulty in accessing 
psychological support meant that some participants decided to find a private counsellor or therapist, 
whom they have to pay themselves. Regardless of how they accessed the support, participants felt 
it was very helpful to discuss their haemophilia-related issues with someone outside of their family, 
social circle or HP. Without prompting from the interviewer several participants suggested that it 
would be helpful if psychological support was easier to access. They felt that in an ideal world 
psychological support would be available through haemophilia centres, so that patients could 
receive support without delay and without incurring costs.  Support from family, peers, friends and 
the haemophilia theme will be addressed in more detail below under theme 4 (page 99). 
 
Subtheme 3: Transition of responsibility for treatment  
As patients tend to be diagnosed at an early age, their parents or caregivers are usually responsible 
for their treatment to start with.  Initially they come to the haemophilia centre for every treatment, or 
in some cases a nurse may visit the family at home to help with the injections.  Once parents are 
confident and skilled enough to do the injections themselves, patients move onto home treatment.  
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This can be a very positive step forward, as it dramatically reduces the number of required hospital 
visits. However, it can also cause some difficulties, as parents have to inject their son several times 
per week without support from a HP. This study did not interview parents and children from the 
same family, so we are not able to check if there are any links between parental anxiety and the 
way patients take over responsibility for their treatment.  However, it is likely that in families with 
high parental anxiety around haemophilia and prophylaxis, patients may find it more challenging to 
start doing their own injections. 
Although there did not seem to be much anxiety about treatment among the older participants in this 
study, the younger participants who had not taken over full responsibility for their treatment were 
clearly anxious about having to start doing the injection themselves. Participants were unable to 
verbalise how they felt in detail, other than saying that they were worried or found the idea of 
injecting themselves a bit scary. However, despite feeling apprehensive, they also recognised that 
they had to take over responsibility eventually, adopting a ‘You have to get on with it’ approach. 
 It’s okay, the only thing I’m really worried about is when I have to inject myself but then I 
think that everyone with haemophilia has to do it (P.8, 12 years old) 
 
The age at which patients take over treatment responsibility from their parents appears to vary 
widely, with some patients being able to inject themselves from age four, while others still rely on 
help at the age of 20.   
I think from like 6/7 I’ve been doing it myself and it’s just, you just get used to it, it becomes a 
part of what you have to do. (P.11, 24 years old) 
Yeah. I think about 15, 16 years old I went to the hospital there and they said, you know “you 
need to learn” and practiced doing it there for a couple of hours and then I walked away 
thinking “yeah, I know how to do it now” so mixing it, making it and really got myself involved 
with it, so yeah. (P.10, 21 years old) 
 
It appears that there is not a set age or time to train patients to do their own injections, although in 
many haemophilia teams appear keen for young people to become independent by the time they go 
to secondary school.  In reality, the time at which patients start doing their own injections is often 
dictated by practicalities.  For instance, several participants explained that they had to learn to do it 
themselves because they wanted to go on a school trip. In other families it may be because mum 
has to look after younger siblings and doesn’t have time to help with treatment, or she may need to 
leave home early for work. However, in most families parents stay involved with their son’s 
treatment in some capacity right up to when he leaves home.  
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Subtheme 4: Inhibitors have a significant impact on my treatment and health outcomes 
Two participants in this study suffered with the added complication of inhibitors, which has made 
managing their haemophilia significantly more challenging. Inhibitors occur when the immune 
system starts to create antibodies to block the effects of the clotting factor. The inhibitors can make 
treatment less effective, making it more difficult to prevent and control bleeding. For one of the 
participants, who has had inhibitors since he was a small child, it has had quite a negative impact 
on his quality of life.  He is on an intensive treatment regimen that involves daily injections of large 
volumes of treatment, and relies on a wheelchair and crutches to get around due to the severe joint 
damage that he has suffered due to frequent bleeding issues. Because of the large treatment 
volume he uses a Hickman line, which is a central venous catheter. As the risk for infection using a 
Hickman line is much greater, it is very important that the environment is aseptic. This can make 
administering the treatment very challenging and time consuming, which at times may negatively 
impact on adherence. 
I just wish it was more concentrated because at the moment it’s really, there’s a lot of 
syringes and stuff involved with doing it and that’s what stopped me having a, not having 
another Hickman line because it would just be too much to put through a needle every day. 
(P.9, 16 years old). 
 
6.3.4 Theme 3: I don’t like taking treatment but hardly ever miss an injection 
Although needle phobia or venous access did not appear to be an issue for the majority of 
participants, almost all mentioned that they did not like taking their treatment and would much prefer 
to take a tablet or subcutaneous injections similar to insulin-dependent diabetics. The key issue for 
most patients appeared to be the fact that the treatment consists for an intravenous injection that is 
not very pleasant, and can be time consuming.  
 
Subtheme 1: Reported adherence is high 
Despite the treatment being quite unpleasant for patients, self-reported adherence among 
participants in this study was high. Very few participants admitted to deliberately skipping 
treatments, and those participants who did would usually only skip a treatment if they were 
expecting to have a very inactive day. As described above, these circumstances are not necessarily 
considered as non-adherent for those participants who have agreed a more tailored treatment 
regimen with their consultant.  
We do sometimes just not bother with the treatment, if I’m not going to be doing anything 
that day (P.9, 16 years old) 
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None of the participants felt that adherence was an issue for them, and most were very motivated to 
keep to their treatment regimen. Some participants admitted to sometimes forgetting treatments, 
due to their busy lifestyle or being distracted by other priorities.   
over really important stuff it’s no I don’t miss it. But I’ve had the odd uhm kind of day where 
I’ve gone uhm. Where I’ve had an active day and I’ve got halfway through it and bugger it I 
didn’t take my medication. So uhm I’ll either go home and take it or if I just be super careful 
then… Uhm So  I think you know maybe we’re talking twice a year I make a mistake with 
it.(P.2, 24 years old). 
Yeah, I occasionally do forget it… if I have forgotten during the day mum would say have 
you done it? If not, right, you do it tomorrow morning then ---(P.4,12 years old)  
 
Most participants take their treatment as soon as they realise they have forgotten it, others wait to 
the next morning to make up for it. There were two participants who, despite reporting high 
adherence, described situations where they may miss two, three or even four injections in a row. It 
was not clear what the actual level of adherence of these participants was, and the language they 
used indicated that perhaps they were a little confused about this themselves. For instance, 
participant 1 initially reported a very high level of adherence, and that any missed treatments were 
due to forgetting rather than skipping. However, the language he used suggested that perhaps he 
does skip injections occasionally.   
No I-- I won’t deliberately miss two three or four in a row, and if-- if-- the problem is if I forget 
one--the little dull aches a bit, yeah ok, if I miss two then they  get worse, then it-- then that’s 
it.  Because you realise, yeah I’ve missed two, I need to get it done.  And even if it’s a day 
when I’m not treating, I’ll treat myself for it.  Because I can’t get these bruises (P.1, 17 years 
old) 
 
Some participants described being quite anxious or worried about the risk, when they realise they 
have forgotten their treatment. They clearly feel that their treatment protects them, and feel 
vulnerable when they realise they are not covered by treatment. For these participants this anxiety 
could also act as an extra motivator to adhere, as it appeared that these participants forget very 
rarely, perhaps less than those who did not voice anxiety about forgetting. 
But I mean it’s such a for me it’s a really horrible feeling to be doing something active having 
not had my medication because then you know you’re you’re vulnerable. Uhm So  I think you 
know maybe we’re talking twice a year I make a mistake with it.(P.2, 24 years old). 
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One participant in particular described how forgetting treatment affects his mood, and makes him 
feel disappointed in himself.  He feels happy when he has had his treatment, as he knows he is 
protected. But when he has forgotten his treatment he feels exposed and anxious. 
A bit like exposed, feel a bit like, you know, a bit disappointed in myself in a way, sort of a bit 
like I should have had some before and I feel a bit like anxious to get it done really and I go 
in a bit of a bad mood or I go a bit, you know, feel a bit uncomfortable and not as happy as 
usually would be. (P.10, 21 years old) 
 
Subtheme 2: Taking treatment is inconvenient and no fun 
It is very clear that none of the participants enjoy taking their treatment, and would much prefer not 
to have to take it.  Although needle phobia does not seem to be much of an issue for any of the 
young people that were interviewed for this study, many of them did mention that they do not like 
having to inject themselves intravenously.   
No, not at all.  For preference, if I’m being really picky I’d like to do it a little bit less. Just 
because like everyone. I’d like to not do it all. (P.5, 25 years old) 
 
A number of the interview participants explained that they would much prefer to take a tablet, or 
subcutaneous injection like insulin-dependent diabetics.   
maybe just that instead of having treatment, different things like a bit of medicine or 
something to do with it. Like instead of doing the injection you just gotta  take a tablet. I know 
that you can’t do that but … (P.4, 12 years old).     
The other thing at times, like I wish it could be like a diabetic who gets it in a pen? (P.11, 24 
years old) 
 
Most participants explained that they tend to inject in the same place, as this is much easier for 
them and less painful (as the injection site becomes scarred and numb to the pain of injections). 
Um, it’s alright, I’ve got used to it now because I’ve had so many needles, I’ve been-- Like 
my veins are quite scarred so I don’t feel it anymore and I just have to live with it (P.8, 12 
years old) 
 
One of the most frequently mentioned issues around the treatment was that it can be quite time 
consuming. As most patients take their treatment in the morning it can be difficult to fit it in, and 
some participants admitted to sometimes having to miss breakfast when treatment takes a bit longer 
than usual, or when they do not have time for both treatment and breakfast. 
the prophylaxis only really takes about 20 minutes but I don’t really have time for breakfast 
afterwards so it’s quite irritating before school but most of the time it’s not really too bad (P.9, 
16 years old) 
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However, most participants appeared to realise how important treatment is for them. They feel that 
prophylaxis allows them to live the life they want, and reduces the number of bleeds they suffer. 
Therefore, although they do not like their treatment, they take it as religiously as they can. Being on 
a home treatment plan means that patients do not need to come to the hospital for treatment, which 
allows them to get on with their normal day-to-day life. 
Obviously sometimes it does frustrate you a little bit but it’s more better to treat yourself at 
home and being in a comfort than coming along to the hospital every day (P.6, 22 years old) 
 
Interestingly, there was one participant who really disliked having to mix the treatment.  He was not 
concerned about the injection itself, but felt mixing up treatment is boring and tedious and resented 
having to do it before every injection. He explained that his parents would often mix his treatment for 
him when he was growing up, which made life a little easier for him. 
and that’s something just at times, especially when you’re growing up sometimes, like once 
a week for someone to mix it for you so you ain’t got to worry about it, it’s just “here you are, 
I’ve done it”, ain’t giving it, it’s just mixing it, especially when there was a lot of it, it was really 
tedious. (P.11, 24 years old) 
 
Only one participant mentioned that when he gets frustrated with his treatment, he gives up and 
leaves it to the next day. However, it is important to note that this participant has some specific 
challenges due to his inhibitors, which requires him to take a much larger volume of treatment on a 
daily basis. 
I get frustrated with it pretty easily if I’m doing it myself and if I get too frustrated I just stop 
doing it altogether and I won’t bother for that day. (P.9, 16 years old)  
 
Subtheme 3: Taking treatment is part of my routine 
Although many participants admitted that they dislike their treatment, they also appeared to have 
accepted it as part of their life and have fitted it in their routine. For most it has become just another 
thing they need to do before they leave home in the morning. 
it’s become second nature. It’s an easy thing to do now. I get up early in the morning and I 
sit-- sat at the breakfast bar in there and I just sit and do it. I don’t even give it a second 
thought, you put it together and inject (P.1, 17 years old).       
It’s uhm it’s just something that’s gotta be done. It’s like  it’s like having a shower in the 
morning. That’s pretty much the long and short of it. (P.2, 24 years old)  
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Participants described how the prophylactic injections were often difficult and painful when they 
were younger, particularly when they were learning how to do the injection themselves. But by the 
time people with haemophilia reach young adulthood they tend to be very skilled, and able to inject 
themselves without any issues.   
Yeah, I can do it with my eyes closed I reckon [both laugh] if I had to I think I could. (P.5, 25 
years old) 
Not really no, I really find it quite easy. I don’t really need much help with it to be honest. You 
get used to it. It’s quite easy now to sort it out (P.4, 12 years old). 
 
In recent years factor replacement treatment has improved significantly, which has made it much 
easier for patients to keep to their regimen.  Key improvements include the reduction in volume 
(making it easier to mix up and requiring much smaller syringes); easier to store and transport (it 
does not require refrigeration and the boxes are much smaller) and the improved instructions on the 
packaging (particularly helpful in emergencies when other people may need to mix up the 
treatment).  
None of the participants suggested that these improvements have had a direct positive influence on 
their adherence, particularly as their adherence was generally already quite high.  However, they 
felt that taking their treatment has become a lot easier and less time-consuming, which in turn may 
reduce negative associations with treatment and therefore reduce the risk of patients skipping 
treatments. 
It’s a lot smaller now, so it’s a lot easier. You haven’t got to take these massive bottles which 
takes hours to mix up. It’s all very easy, you squirt in, you squirt out, and it’s all very quick 
these days  (P.5, 25 years old). 
It used to   it had to be kept like fridge cold. But now it’s more just under more like room 
temperature which is fine. Which makes life quite easy  (P.2, 24 years old). 
 
As described above, non-adherence in this patient group tends to be due to forgetting. Many 
participants described easy and practical solutions that help them to remember to take their 
treatment, such as visual reminders (e.g. putting the bright yellow sharps bin on the breakfast bar); 
linking treatment to particular activities (such as having breakfast); and digital reminders (alerts on a 
mobile phone, tablet or computer). 
It appeared that they were keen to find their own solutions, and were therefore not always keen to 
discuss different strategies with the haemophilia team. Participants appeared to feel that people 
need to find their own way of managing their treatment, as everyone is different and has their own 
challenges to overcome. For instance some were keen to use their smartphone for reminders, 
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whereas another participant explained that he would never trust a digital device alone without a 
back-up reminder. 
 So it would make a noise or whatever, so you’d know it was that day. But that’s just then 
trusting a device to tell you when to do it without thinking… (P.3, 21 years old). 
 
Despite the various reminders, and the motivation to keep to their regimen, some participants 
admitted that they do occasionally forget their treatment. This is often because they live busy lives, 
and are sometimes distracted by other priorities. However, they tend to have some treatment stored 
at work or school so that they can take their treatment there in case they have forgotten to do it at 
home. Having some treatment stored at work or school provides an extra safety net, which seemed 
particularly important for those participants who do not like to take any risks with their health.  
but I’ve also got some at work. You know, just in case I need it. Like in an emergency, which 
I’ve had to before. Or just in case I forgot to take some with me, so there’s always some 
there (P.3, 21 years old). 
 
Subtheme 4: Treatment protects me so I can live a normal life 
Many participants explained that they feel their prophylactic treatment protects them, and allows 
them to live a normal life.  For some that means that they feel protected in everyday activities, such 
as going to school or work. Others feel that prophylaxis supports them in living a very active 
lifestyle, including competing in top-level sports.  
It’s helping me lead a normal life. (P.2, 24 years old) 
The treatment works quite well, it stops most bleeds. It’s only the serious ones that get 
through now. We do a big dose before and after the activity … I’ll still get a small bleed but 
nothing like as bad as I would get if we didn’t (P.9, 16 years old) 
 
Many of the young people explained that they top-up to cover themselves for sport and physical 
activities.  Most seemed to recognise that in addition to reducing the risk of bleeds, prophylactic 
treatment helps to prevent long-term issues such as joint damage.  
If I don’t take my medication I’ll start getting internal bleeds that’s going to affect me later in 
life with joint damage and what not. (P.2, 24 years old) 
You do get a better treatment, you develop more chances to progress yourself with the time. 
(P.6, 22 years old) 
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6.3.5 Theme 4: Support from family, friends and the haemophilia centre keeps me on track. 
For the young people involved in this study looking after their health includes a number of self-
management behaviours, some of which can be quite challenging. The majority of participants felt 
that they would not be able to look after themselves without support from their parents and the staff 
at the haemophilia centre. This theme covers all the forms of support that were described by 
participants. 
 
Subtheme 1: Support from mum and dad is key 
During the course of this research it became clear that parental support is particularly important in 
relation to adherence. As described above, in the majority of families parents are responsible for 
their son’s treatment for the first decade or so.  This means that they have to inject their son several 
times each week, log each treatment on the log, arrange for treatment to be delivered, arrange 
regular hospital check-up appointments, and be on stand-by just in case their son experiences a 
bleed at school. 
I think they was always worried and mum would come into school every now and then to 
give me treatment and things if I needed, if I fell over in the playground or, you know, when I 
was younger they’d come in and they’d say, you know “I’m here, we need to do this, we 
need to do that”. (P.10, 21 years old) 
 
Parental support appears particularly important in encouraging adherence, as parents tend to 
remind their son to take his treatment every time it is due.  Some parents continue to remind their 
son to take his injections even after he has left home, this appears to be a habit of a lifetime that is 
difficult to break. Many parents also continue to do the actual injection every now and then, just to 
share the burden or make life a little easier for their son.  
and that’s something just at times, especially when you’re growing up sometimes, like once 
a week for someone to mix it for you so you ain’t got to worry about it, it’s just “here you are, 
I’ve done it”, ain’t giving it, it’s just mixing it, especially when there was a lot of it, it was really 
tedious (P.11, 24 years old). 
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Two participants, both living independently, described how their mother still telephones them most 
days to remind them when their injection is due. Parents often also stay involved with arranging the 
deliveries of treatment, and continue to help when bleeds or other health issues occur.   
now that I am a bit older I am quite self-sufficient with it, but uhm cos I travel a fair bit so my 
mum looks after, the treatment gets delivered to my mums house rather than mine, cos uhm 
mum is in a lot more often than I am. She’ll keep an eye on my stock I’ve got. Uhm so, yeah 
they are still. Yeah everyone supports me really nicely (P.2, 24 years old). 
 
In addition to caring for their son, some parents become involved with organisations or charities that 
support people with haemophilia, such as the Haemophilia Society (a nationwide charity that 
supports patients and families that are affected by bleeding disorders).  These organisations are 
involved in a range of activities, including fundraising, lobbying and peer support, and become an 
important part of a family’s support network. 
Yeah. She’s still doing events and things, you know, she’s helped me raise money for the 
run just gone, she helped me get the shirts for me, sponsor forms so, you know, she’s still 
very much involved in that kind of thing and she likes to raise money just as much as me 
so—(P.10, 21 years old). 
 
Subtheme 2: Social and peer support 
In addition to support from parents and siblings, many patients described a supportive social 
network they could rely on for practical and emotional support. 
And especially with the friends who I’ve been on holiday with they understand it a lot better 
because I understand their problems they understand my problem, we know what our 
limitations are--and we can just stick together make sure each one of us completes it (P.1, 
17 years old). 
 
Whereas some others felt that they did not need any support or help from friends, possibly because 
they are very keen to be independent, or find it hard to accept help as this could be perceived as a 
sign of weakness. 
Not really, to be honest because I feel, I don’t normally like to rely on other people, I like to 
keep it to myself and just do it on my own basis so that behaviour may be just I don’t rely on-
- I don’t normally just ask them, oh can you do this thing for me, do that thing for me, I 
normally keep it to myself (P.6, 22 years old). 
 
As described above, some participants felt that they had missed out on social development due to 
their haemophilia. This appears to be particularly relevant for participant 1, who felt that it took him a 
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lot longer to develop his social skills, and therefore found it difficult to make friends and form 
relationships. This participant appeared to have quite ambivalent feelings about the way his 
haemophilia affects him.  He felt quite strongly that he would not let his haemophilia hold him back, 
but also described how he felt that there are many limitations to what he can do due to his condition.   
I try not to let the Haemophilia hold me back, but the fact that we’d been told that I shouldn’t-
- to kind of protect me, that  I shouldn’t really go out at break or lunch-- that was what held 
me back  (P.1, 17 years old).                                      
 
Advice about what activities children with haemophilia should avoid has changed in recent years, 
and many boys are now allowed to take part in physical education lessons at school as long as they 
avoid contact sports such as rugby and hockey. Any activities that may cause head injury need to 
be avoided at all costs, as intracranial bleeding represents one of the biggest risks.  However, it is 
unlikely that young boys who are growing up with haemophilia today are excluded from playing 
outside at break time at school. Hopefully this means that this new generation is able to take part in 
most activities at school, and does not miss out socially.  This in turn may help them develop social 
skills and form supportive friendships. This certainly appeared to be the case for the younger 
participants in this study, who described very supportive friendships. 
It doesn’t really bother me that much now because most of my friends at school help me. It 
feels alright because most of my friends know about it and they to talk to me about it (P.8, 12 
years old). 
Sometimes when I’m at school I do talk about it or like if I say I’m in pain they normally help 
me and take me to a teacher (P.4, 12 years old). 
 
One form of social support that may be particularly helpful is peer support from other young people 
who are affected by haemophilia.  As it is such a rare disease, patients do not often meet other 
people who are affected. Participant 3 joked that he always felt that he was the only person with 
haemophilia, even though he knew from the hospital that there were other boys. Now that he is in 
his early twenties he receives psychological support from a counsellor to help him talk about his 
haemophilia and the way it has affected him.  It may have been quite helpful for him to meet with 
other boys like him when he was younger, and may have helped him feel less alone with it all.  
Some of the hospitals that were involved in this study have peer support groups, and organise 
social outings to give YPH the opportunity to meet each other.  Pressure on budgets and resources 
make it hard to keep these activities going, and in some of the hospitals they have now stopped.  
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Interview participants indicated that they had benefitted from opportunities to interact with other 
YPH outside the hospital setting. 
It’s really good spirited, everyone’s in a good mood, they do swimming and things and it’s for 
charity and there’s bike rides and things, haemophilia so, I think mum puts her effort in and 
so do all the other society people, they put their effort in and get kids involved and get their 
husbands involved and their mums involved so it’s fun. I enjoy it, yeah. (P.10, 21 years old) 
 
Subtheme 3: Haemophilia care in the UK is second to none 
People with haemophilia in the UK receive their treatment from the NHS free of charge. 
Haemophilia can affect patients in many different ways, and different treatments can impact on each 
other (e.g. dental work can cause severe bleeds, and so needs to be planned in conjunction with 
the haematology team). For this reason haemophilia care is often centralised through 
comprehensive care centres (haemophilia centres). These centres are able to deliver different care 
needs directly, or through collaboration with other local centres (including musculoskeletal care, 
dentistry, physiotherapy, etc.). The experiences of patients who have come to the UK from other 
countries illustrates that haemophilia care in the UK is amongst the best in the world. 
since I came here I was trained myself to give the treatment, coming up, look this is on three 
months, every three months, getting communication whenever I need them, trust me, it’s the 
best support I can get ever so I think I wouldn’t give any more suggestions to getting things 
from the right places because to me, it’s organised..(P.6, 22 years old) 
 
Although having haemophilia has had a negative impact on many of the participants in this study, 
several described how they felt lucky to have been born in the UK, as they realised that they would 
not receive such excellent healthcare in some other countries. 
I know, I’ve read, I’ve seen stories from other countries where there isn’t the support there 
isn’t the treatment and it’s you know, it’s killing kids basically. It’s uh they’re just leading just 
horrible lifestyles, it’s yeah it makes me feel lucky that we’ve got the system in place we 
have. (P.2, 24 years old) 
 
Participants were particularly positive about the support they receive from the team at the 
haemophilia centre, recognising that this support helped them keep on track with their treatment 
and helping them through difficult situations. 
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Subtheme 4: The staff at the haemophilia centre is very supportive and they encourage me to 
keep to my treatment regimen 
The majority of patients appear to have a good relationship and regular contact with the team at the 
haemophilia centre. Sometimes this is just informal contact to check how patients are doing, and 
other times it may be specifically aimed at providing support or solutions for specific issues.  Many 
of the HP I came across have worked in the same haemophilia centre for a number of years, and 
have seen patients grow up from babies to adolescents and young adults. As a result they know 
most of their patients well, and appear to have a sixth sense on when particular individuals needs 
additional support.   
Yeah, it’s nice to know, they ring up and ask and they’re concerned and, you can, obviously 
it was a mistake on my behalf so I said like no, and they told me how to do it properly and 
generally it was, the nurses are good I think, yeah, they’re okay. They help out as much as 
they can and it was good that they’re keeping an eye on me really. (P.10, 21 years old) 
 
In all of the haemophilia centres that were involved in this research nurses appear to keep a close 
eye on their patients, particularly those who suffer from regular bleeds.  They tend to do this by 
logging onto the online treatment log (Haemtrack) to check if patients have logged any bleeds and 
also to monitor prophylactic injections.  
Haemophilia centres encourage patients to contact the centre whenever they have a serious bleed, 
so that they can assess if the patient needs to come to hospital or if they can treat the bleed 
themselves at home. In many cases where a review of Haemtrack reveals that a patient may not be 
adhering to their agreed treatment regimen, or has had a serious bleed without contacting the 
centre, nurses contact the patient to discuss potential issues.  This appears to encourage patients 
to adhere to their prophylaxis, and stay on top of managing any bleeds. 
Generally the nurse will ring up and say “you’ve had a lot of factor, we’re looking on your 
Haemtrack, you’ve had a lot”, I think one time they’d mistaken, I had this ankle injury but I 
kept putting it was a follow-up bleed, because it was the same sort of bleed reoccurring 
again, but in fact I should have done new bleed every times, so it looked like I’d had this 
bleed for like nine hundred hours or something. So then they rang up and was like “look, is 
this bleed this bad or is it because it’s, you know, it’s reoccurring but is it because it’s a new 
bleed? (P.10, 21 years old) 
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It appears that many haemophilia centres use the carrot and stick approach, where they combine 
regular encouragement and support with a telling off when patients are not adhering to their 
treatment. 
I know definitely you do get the same motivation when every time I go for the clinic 
appointments, trust me, I do get a big lecture! (P.6, 22 years old). 
 
Regardless of how the different haemophilia centres approach different patients, all participants in 
this study were very positive about the healthcare and support they receive. It is clear that patients 
receive more than just medical attention from their haemophilia team, and that nurses, 
haematologists, psychologists, physiotherapists and other allied health professionals often go out of 
their way to support their patients. 
Support from the centre makes me feel less alone (P.3, 21 years old) 
The nice thing for me is I know they’re there if I need them (P.2, 24 years old) 
 
One example that illustrates the faith and trust that patients have in their NHS haemophilia centre is 
of a patient who experienced a medical emergency abroad. He was in great pain, but chose to 
travel back to England to make sure that his injury was treated in the haemophilia centre he has 
been attending since he was a baby. He believes that the care he receives through the NHS is 
unrivalled, and trusts the NHS with his life. 
I phoned the doctor at 1 o’clock in the morning cos I needed surgery and he he was there. 
And I mean you don’t   that sort of service is unrivalled I think by anywhere…I had my car 
and I drove drove back to England to make sure I was treated in England cos I trust yeah I 
trust the NHS with my life basically. So it was so  uh  see that’s the extent  that I yeah trust 
the NHS. (P.2, 24 years old) 
 
6.4 Discussion 
The findings of this study suggest that haemophilia can have a significant impact on young patients’ 
lives, even for those with few symptoms or haemophilia-related issues. Often diagnosed at a very 
young age, haemophilia becomes part of who patients are and the way they live their lives. 
Participants appeared very keen to live a ‘normal’ life, however for most of them managing risk is an 
important part of their daily routine. For many participants there appeared to be a tension between 
their desire to be normal and successful self-management.   
Self-reported adherence in the sample appeared to be good, with few participants admitting to 
intentionally skipping injections.  However, due to the increasingly personalised and flexible 
approach to prophylaxis adherence is not straightforward to define. Several participants appeared 
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slightly confused when describing their own levels of adherence, particularly when they were asked 
to distinguish between forgetting and skipping. 
The main barriers to adherence suggested by participants were the time and effort needed to take 
treatment (fitting this in an already busy lifestyle) which at times causes them to forget; dislike of the 
intravenous injection; venous access issues; anxiety or stress (both related and unrelated to 
haemophilia); and being out of the normal routine (e.g. on holiday). 
The majority of participants described how support from their family, friends and haemophilia team 
helped them to keep on track with their treatment.  In particular parents appear to be very involved 
with their sons’ haemophilia management, even after they leave home. Almost all participants 
agreed that they have a good relationship with their haemophilia team and that the help and support 
they receive from them helps them to keep on track with their treatment.  
There is significant overlap between the results of the three qualitative studies included in this thesis 
(investigating experiences and perceptions of patients, their parents and HP respectively). And 
because the findings also appear to complement each other, it was decided to include one 
comprehensive discussion chapter (chapter 9) that will describe the findings, implications, strengths, 
weaknesses and conclusions of all three qualitative studies.  
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Chapter 7: Interpretative Phenomenological Analysis of 
parents’ accounts of prophylaxis and their sons’ adherence to 
this treatment 
 
7.1 Introduction  
This chapter presents the results of the Interpretative Phenomenological Analysis (IPA) of 
participants’ accounts in relation to their son’s haemophilia, and his prophylactic treatment. The aim 
of the study is to examine parents’ experiences and perceptions in relation to prophylaxis, and 
adherence to this treatment, and the way they make sense of these experiences and perceptions. 
Together with the findings of the IPA studies described in chapter 6 (young people with 
haemophilia, YPH), and chapter 8 (haemophilia healthcare professionals, HP), this study is 
anticipated to contribute to a better understanding of facilitators and barriers to adherence to 
prophylaxis among YPH.  
 
7.2 Methods 
7.2.1 Recruitment 
Participants were recruited in five haemophilia centres across England and Wales. Potential 
participants were approached while they accompanied their son while he attended a routine check-
up appointment in the haemophilia centre.  All participants who met the inclusion criteria (parent of a 
young person aged 12-25 inclusive, who has been diagnosed with severe haemophilia and follows 
a prophylactic treatment regimen) were approached by a nurse or doctor to invite them to 
participate in the study. All participants who agreed to take part were interviewed.  
 
7.2.2 Participants 
Participants were two males and two females who were all parents to a young male with 
haemophilia (see Table 7.1 for details).  To protect confidentiality and anonymity, the parents 
interviewed were not related to participants interviewed for the study described in the previous 
chapter. 
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7.2.3 Data collection 
Each participant was interviewed face-to-face in a private room at the haemophilia centre. The 
interviews were semi-structured using a topic guide (appendix 5.1), however participants were 
encouraged to tell their own story in their own words and time with few interruptions from the 
interviewer. At the start of their interview participants were invited to describe their experiences in 
relation to their son’s haemophilia, starting with what it was like when he was born and diagnosed. 
The main aim of these introductory questions was to build a report with participants and to gain a 
sense of how they felt about their son’s haemophilia. To gain a good insight into their experiences 
and perceptions in relation to their son’s prophylaxis, they were then invited to describe their son’s 
treatment regimen, their feelings about prophylaxis, and potential barriers and facilitators to their 
son’s adherence. Lastly participants were asked about the social support they receive in relation 
their son’s haemophilia, and what support they offer to their son in relation to his haemophilia and 
treatment. The order in which the above subjects were discussed was flexible and driven by the way 
in which the conversation with participants developed. Several of the participants explained that 
they had not been asked to share their experiences in relation to haemophilia before. These 
individuals were grateful for the opportunity to share their experiences and keen to share their story 
about their entire haemophilia journey. In these circumstance prompts were used to bring the 
discussion back to experiences and perceptions in relation to prophylaxis.  
Interviews were recorded and then transcribed verbatim before being analysed following the IPA. 
 
 
 
 
Table 7.1: Parent interview study participant characteristics 
 
Participant 
code 
Ethnicity Sex 
Age of        
son with 
haemophilia 
Other 
children 
Other 
children 
affected 
Living arrangements 
Parent 1 
White 
British 
Male 24 Yes No 
Son lives with his 
wife/partner  and child(ren) 
Parent 2 
White 
British 
Female 24 No - 
Son lives with his 
wife/partner  and child(ren) 
Parent 3 
White 
British 
Female 14 Yes No Son lives with parent 
Parent 4 
Black 
African 
Male 15 Yes No Son lives with parent 
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7.2.4 Analysis 
As described in chapter five, IPA emphasises that through the process of discovering themes the 
researcher aims to make sense of the participant attempting to make sense of their experiences. 
Therefore these themes form only one possible account, and the researcher may have reached 
different conclusions and highlighted different aspects in comparison to what other researchers may 
have found if they had analysed the same data.  
After immersion in the data, and examining themes and the convergence and divergence of themes, 
it was decided to report those themes that emerged most strongly from the interview data and that 
were relevant to the research questions. In this chapter these themes will be explored and 
illustrated with verbatim extracts that were selected from across all participants’ transcripts. In 
instances where different participants had different opinions or experiences, all views are illustrated. 
In cases where participant responses were similar, only those quotes that illustrate the theme most 
clearly have been included. This approach was true to the aims of the study, participants’ accounts 
and the richness of the data.  
 
7.3 Results 
7.3.1 Superordinate and subordinate themes 
At the start of their interview parents were invited to describe their experiences in relation to their 
son’s haemophilia, starting with what it was like when he was a child. They were then asked about 
their perceptions in relation to their son’s prophylactic treatment and barriers and facilitators to his 
adherence. Participants’ accounts clustered around four superordinate themes, which are shown in 
in table 7.2 together with their related subordinate themes. The table also shows for which 
participants each of the subordinate themes were relevant.  
After examining themes and the way in which they were embedded and linked, and after immersion 
in the data, it was decided to report the master themes which emerged from the transcripts and that 
were relevant to the research questions. In this chapter these themes will be explored and 
illustrated with verbatim extracts from the interview transcripts. The illustrated quotes were taken 
from across the transcripts of all the participants, to ensure they were representative of the sample.  
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Table 7.2: Parent interview study superordinate and subordinate themes for each participant 
Superordinate 
themes 
Subordinate themes 
Participants 
Parent 
1 
Parent 
2 
Parent 
3 
Parent 
4 
Self-management 
Logging treatment on Haemtrack x 
  
x 
Avoiding risk x x x x 
Treating bleeds x 
 
x 
 
Drivers of 
adherence 
Barriers x x x x 
Facilitators x x x x 
Skipping or Forgetting? 
 
x x x 
Impact of 
haemophilia 
Social impact x x x 
 Impact on academic and career 
prospects x x x x 
Impact on parents and siblings x x x 
 
Haemophilia care 
Support from haemophilia centre x x x x 
His haemophilia has become part 
of our lives x x x x 
Haemophilia awareness needs to 
improve 
 
x x 
  
 
7.3.2 Theme 1: Self-management 
In addition to adhering to their agreed treatment regimen, YPH are expected to engage in a number 
of other self-management behaviours. This theme encompasses all of the behaviours that were 
described by parents that were interviewed for this study, including logging treatment, avoiding risk 
and treating bleeds. 
 
Subtheme 1: Logging treatment on Haemtrack 
Patients who receive home delivery of their prophylactic treatment are required to log each 
treatment they take. Treatment logs enable the clinical team to monitor their patients, check if they 
adhere to their treatment, treat bleeds appropriately, and do not waste treatment. Treatment logs 
can also be useful starting points for discussions between clinicians and patients about treatment, 
and help decide if a patient is on the right regimen. Haemtrack is a UKHCDO (United Kingdom 
Haemophilia Centre Doctors' Organisation) system that allows patients to log their treatment online 
or via a smartphone app. It works like a diary, where patients can add their treatment and other 
details including date and time, the product used and the reason for treatment.  Haemtrack data is 
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saved in the National Haemophilia Database and helps the UKHCDO to plan haemophilia services, 
inform purchasing decisions and to learn more about the treatment and complications of bleeding 
conditions. Haemtrack is now part of standard care, and most haemophilia centres require their 
patients to use it. However, in some cases patients continue to complete paper treatment logs, 
which are then transferred to Haemtrack by the haemophilia centre. 
Most patients, parents and clinicians who were involved in this study recognised Haemtrack as a 
useful tool. However not all patients appear to complete Haemtrack as required. Parents appeared 
to be keen for their son to log each treatment on Haemtrack directly after taking it, but recognised 
that this was probably not realistic.  Completing Haemtrack is just another thing to do, which 
competes with the many other activities that keep young people busy.   
In terms of keeping the records up to date, that is still a work in progress. Because if he has 
an injection in the morning with a view to entering it on the system later in the day, the 
likelihood that it will get forgotten is fairly high. I’ll probably search the App Store and see if 
there’s anything on Haemtrack that will be more convenient for him because he’s always on 
the phone anyway [laughs] so as soon as he’s had his injection that would be quite easy to 
upload details on the phone. (Parent 4) 
 
Interestingly, there does not necessarily seem to be a relationship between adherence to treatment 
and adherence to completing Haemtrack logs. It appears that even young people who take their 
treatment religiously do not always complete their logs. 
I think it probably would if, um, especially in terms of recording [laughs] his details on the, on 
the Haemtrack because that’s the one area that is still hit and miss because he will have his, 
um, treatment but may not record it on Haemtrack so-- (Parent 4) 
 
Subtheme 2: Avoiding risk 
Parents of children with haemophilia learn early on that even low-risk day-to-day activities can 
cause harm to their child. Diagnosis is often preceded by severe unexplained bruising, caused by 
small bumps and falls as babies learn to crawl and walk.  As children grow up and become more 
physically active there are often frequent visits to the hospital to receive treatment for activity-related 
bleeds, and a significant percentage of patients develop joint damage caused by repeated bleeding.  
All the parents who were interviewed for this study explained that they worried about the potential 
risks of physical activity, and that they were always conscious of ways in which they could reduce or 
manage the risk for their son.   
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Parents described how they had limited the physical activities that their son could take part in, 
usually on advice of the haemophilia team.  For most this meant that their son was able to take part 
in Physical Education (PE) at school, but only in sessions that did not involve high risk sports (such 
as rugby and hockey). However, two parents described how their son was not able to participate in 
PE lessons at all. In both cases this was because the combination of haemophilia with other 
medical issues, such as loose ligaments, significantly increased the risk of bleeding.   
No, he hasn't been able to do PE for a couple of years now, because he got to the risk, the 
risk factor was there. Like, if he joined in, because his ligaments were so loose, he'd go over, 
then there'd be a bleed, so it was a case of, you know, what can, what can he do that wouldn't 
cause bleeds.  (Parent 3) 
 
Reducing risk can also have negative consequences.  Being involved in sports and other physical 
activities has been shown to positively influence physical and mental health, which some YPH may 
miss out on. One of the parents expressed concern about his son limiting his participation too much 
for fear of injury, and was worried that he would miss out on things that he loves doing as a result. 
but I sort of worry as well as to whether he’s maybe sort of limiting his activities in fear of 
whether or not he’s going to have a bleed because he does play football, he does participate 
in school activities but as you say he is a teenager now and sometimes it’s not very easy to 
know exactly what he’s doing or why he’s doing it. He says he plays football in school, he 
plays basketball in school but I sometimes worry whether he’s sort of limited his participation 
in those for fear of either injuring himself or aggravating an injury. (Parent 4) 
 
All parents recognised that it was important for their son to be physically active, and it appears that 
most would organise alternative activities, such as swimming, to ensure that their son would get 
sufficient exercise. 
so he's had his legs in splints and all sorts, so we just came to the decision that, you know, no 
PE, but what we've had to do with him is like do a lot of taking him swimming, like after school, 
and things that aren't so harsh on his body, just to keep him sort of with some exercise. 
(Parent 3) 
 
The interviews with parents supported the findings of the patient interviews, highlighting that 
managing risk is an important consideration in daily life. In addition to taking treatment and reducing 
risky activities, this also includes avoiding potentially dangerous situations.  This influences 
academic and professional choices, as certain career choices would not be appropriate for 
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someone with haemophilia.  It also impacts on social life, particularly for young people who want to 
enjoy the nightlife with friends.  This is not just because consuming alcohol increases the risk of 
accidents, such as falling or bumping into things.  It is also because people in groups sometimes get 
involved in physical confrontation, whether that is ‘play fighting’ or brawling.  
For parents this means additional worry when their son wants to go out independently with friends, 
and often means they are ‘on-call’ to pick him up at any time during the night.   
If they’re going off and they’re getting into trouble, just ring me and I’ll come and get you, it 
doesn’t matter if it’s two, three, four o’clock in the morning,” and very often I’d have a phone 
call, “Oh mam, the boys are messing about, can you come and get me,” so yeah fine   
(Parent 2) 
 
Although parents described how they would worry about their son going out with friends, they also 
recognised that that he was probably more sensible and responsible that any of his friends. Several 
of the parents felt that their son was probably more sensible because of this haemophilia. 
because he’s haemophiliac he don’t back down, he knows he’s got to be careful, it’s like if he 
sees a gang of lads, a confrontation, he’ll say no, I can’t get involved and walk away.  
(Parent 1) 
 
Subtheme 3: Treating bleeds 
Very few patients do not experience any bleeds, even those who regligiously adhere to their 
prophylactic treatment may experience occasional bleeds. For some patients this may only be once 
a year, whereas others suffer from more regular bleeds that have a significant impact on their lives. 
Treating bleeds quickly and appropriately is very important to prevent longer term problems.  Most 
haemophilia centres encourage patients to contact the centre when they are experiencing a bleed, 
so that they can assess (over the telephone) if the patient can treat the bleed themselves or if they 
need to come to the hospital. 
That was good like that, you could phone the hospital at any time of day, I mean even if it was 
out-of-hours, the doctor would come on the phone or phone you back. They’d say, give him 
2000 units or whatever they wanted you to give him, if there’s no improvement tomorrow bring 
him over or they’d say, bring him over and they’d give him treatment there at the hospital and 
then they’d say, treat him every day with so many units and if by Friday he’s no better, I mean 
I phoned back every day (Parent 1) 
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Parents appeared to be aware of the importance of treating bleeds appropirately, and felt this was 
just as important for their son as him adhering to his prophylactic regimen. In particular one of the 
parents voiced concern about bleeds, as he feels that perhaps his son does not take them seriously 
enough.   
That’s what I keep saying to him, all of them are the same because to them it’s just life, it’s a 
bleed, you know what I mean, they don’t think. ‘Oh well, Dad I’m used to it, I’ve grown up with 
it’. Yeah, but you still need to put it on your computer, I’ve had a bleed in the left leg, right leg, 
arm, just so they know, I say so they know what’s going on with you and they’re all the same 
because they’ve grown up with it, some of the kids, they don’t put it down and it’s just another 
day in their life. (Parent 1) 
 
It became clear that each of the parents interviewed are very involved with their son’s treatment, 
even parents of young adults who no longer live at home.  In particular at times when their son is 
suffering with a bleed they tend to be there to offer practical help (such as driving him to the 
hospital), but also to support him in treating the bleed and deal with the hospital if needed. 
 
7.3.3 Theme 2: Drivers of adherence 
This theme encapsulates all barriers and facilitators that influence adherence among YPH, as 
perceived by their parents.  As discussed in the previous chapter, each individual is different and is 
therefore likely to have different experiences in relation to their haemophilia and prophylactic 
treatment.  However, during the interviews it became clear that there were commonalities in relation 
to the barriers and facilitators to adherence that different participants described, and reasons why 
they believe their son may forget or skip some of his treatments.  
 
Subtheme 1: Barriers 
Lifestyle 
One of the main barriers mentioned by parents was that their son’s busy lifestyle sometimes 
interferes with treatment. Patients who have to get up early to go to school or work may find it 
difficult to take their treatment in the morning. Particularly when they get up too late, or have other 
important things to do.  
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Others may be preoccupied with other things they have to do, which can lead to them 
procrastinating their treatment. 
But when he was younger, me and his mum, we made sure we done it, he got it done but 
when he left home, I think it was just the hustle and bustle of daily life, I’ll do it in a minute, 
that’s younguns for ya, everything’s in a minute and in a minute never seems to come 
(Parent 1) 
 
Routine 
Being out of your normal routine can also make it difficult to take treatment.  For instance, when you 
are on holiday you may forget what day it is, or be distracted by holiday activities.  It is also likely 
that a different sleep pattern on holiday influences the time treatment is taken. Most parents 
explained that forgetting one treatment usually is not an issue, as they just compensate for it by 
moving the treatment days for the rest of the week.  However, these ad-hoc changes to the regimen 
can lead to confusion and more missed treatments 
I think there was when I was on holiday, because I forgot my days, because when you're 
relaxing, you've gone two weeks, but it was only a case of,  I'll just give him the treatment 
today and then move it on another couple of days. So you just have to remember they've still 
got to have it, but just move your next lot on another couple of days and then your week just 
sort of sorts itself out (Parent 3) 
 
Not wanting to be ‘different’ 
During the interviews it became clear that parents felt that not all missed treatments are due to 
forgetting. All parents described periods, mainly during adolescence, during which their son was 
reluctant to take his treatment or would miss treatments because he did not feel like taking it.   
I think between the ages of 13 and 15 there’s a time there when things were not really 
working properly and you check whether or not he’s had his treatment and sometimes he 
wouldn’t have had or he would say he had his treatment but when you try to harmonise the 
quantities available as compared to what he said he had used then they were not actually 
matching up but I mean we sat down, we had a discussion with him about the importance of 
continuing with the treatment, of course with the nurse upstairs, just to totally emphasise that  
(Parent 4) 
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Parents felt that this was probably because their son did not want to be different to his peers, and 
resented having to inject himself with treatment so frequently. 
Oh what’s the point, you know, oh why?” he’s gone through moments like that and like when 
he was younger growing up he refused to have his treatment, “I don’t want my treatment, I 
want to be normal, I want to be like everybody else, I don’t see why I should have to have 
these all the time,”  (Parent 2) 
 
Venous access and needle phobia 
Other reasons why young people may not want to take their treatment are issues around venous 
access and needle phobia. Patients who have difficulty in accessing their veins often require help 
with their injections, and may come to the hospital to receive treatment. However, this is not feasible 
for patients who are on regular prophylaxis because of the number of injections they require.  In 
many cases this means that a parent or other caregiver continues to do the treatment until the 
patient is able to inject himself.   
Yes, sometimes his veins are really bad and that’s when his wife will ring me, “Oh can you 
come up?” ‘cos sometimes we’ve been down here and depending sometimes on who does 
it, if he’s having a bad day and I’m down here and they’ve tried a couple of times I’ll do it, 
and but yeah sometimes his veins are absolutely horrendous, especially if he’s not well as 
well, if he’s got something else going on, you know, like if he’s got a cold or tonsillitis or 
something, then his veins are (Parent 2) 
 
During the interviews it was not always easy to distinguish between venous access issues and 
needle phobia, as the two can be related. It appeared that for patients who have difficulty in finding 
good veins taking treatment can cause anxiety, which in turn can lead to needle phobia. Resolving 
needle phobia can be a complex situation, which not only requires a patient to overcome their 
anxiety and fear, but also requires their parent to let go and allow their son to become independent. 
One of the parents explained that for the time being it was just easier to continue doing the 
treatment for their son, not only because he has some issues around venous access, but also 
because he appears to suffer from needle phobia. 
I still do it for him because he can't do it himself. Just the idea of sticking it into himself, he's 
all caggy hands, because he's only got one arm which is good with the veins, and you can 
guarantee, usually that's the arm he's hurt [laughs]. So it's not, I keep asking him to do it. 
And probably, if he stays on it in adult life, that maybe he'll start doing it himself then 
 (Parent 3). 
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Other psychological issues 
In contrast to needle phobia, some of the other psychological issues that were reported by parents 
are not necessarily as clearly associated with prophylactic treatment.  However, parents felt quite 
strongly that their son’s issues (such as OCD, and general anxiety and stress) were directly related 
to haemophilia and the treatment. 
My son’s got OCD and I’m convinced it’s from, I don’t know whether it’s from spending so 
much time in the hospitals, and with the haemophilia and having to do everything a certain 
way but he’s got terribly OCD (Parent 2). 
 
Although it would be difficult to confirm whether haemophilia directly causes psychological issues 
such as anxiety, it is clear that parents felt that haemophilia plays an important role.  They also felt 
that anxiety or external stresses (such as bereavement) interfere with haemophilia treatment and 
sometimes directly cause physical symptoms such as bleeds. 
Since we found out about my mum having cancer, they told us the end of January that there 
was nothing they could do for her, and she went in the hospice for some respite, on then 
they told us that she only had a couple of days to a week and… obviously then we told him 
and since then he had a bleed then a couple of days later, so I do think stress plays a part in 
it (Parent 2). 
 
Although it would be hard to prove a direct causal relationship between haemophilia and the 
psychological issues that parents described, it is clear that those patients who suffer from stress or 
anxiety find it harder to manage their haemophilia, and may suffer physical symptoms such as 
bleeds as a result of their missed injections.  In turn, these physical symptoms are likely to cause 
more anxiety or stress. Equally, it is likely that patients who have experienced frequent and/or 
severe bleeds are more likely to suffer from psychological issues due to the pain, stress and 
lifestyle-limiting physical symptoms caused by bleeds. It became clear from the parent interviews 
that young people who suffer with treatment-related issues (such as venous access or needle 
phobia) also suffer from other anxiety or stress-related issues (such as stress-related migraines). 
he said his head feels like it's exploding, like they're sitting him down and they're asking him 
questions and everything, and yet the neurologist has said, "He knows how to try and de-
stress himself", take yourself away, quiet room, you know, and everything (Parent 3). 
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Subtheme 2: Facilitators 
Routine 
As time passes many patients and their families find their own solutions to make remembering and 
taking treatment easier. These solutions tend to be very specific to each family, depending on their 
individual circumstances.  However, one key thing that they all agreed on was that it is important to 
establish a good routine, which helps you to remember when treatment is due. The regular time 
also allows patients to set reminders or alarms for themselves, or for others to send them reminder 
messages. 
Well obviously doing it at a regular time, that’s got to be most important because they-- 
generally with the prophylaxis it’s normally say like a Monday Wednesday and a Friday 
anyway, or Tuesday, Thursday, Saturday. So I think that would be quite easy generally to 
implement. Just send reminder texts or emails, but yeah I think a reminder text would 
probably be the easiest. (Parent 2) 
 
Building the treatment into the routine also means that the extra time that is needed to take 
treatment is planned for. So in most families this means getting up a bit earlier, getting breakfast 
ready the evening before, or finding a quicker way to get to work or school to compensate for the 
time spent on treatment.   
 
Maturity and independence 
In addition to establishing a good routine, parents felt that it is important to talk to your son about his 
haemophilia and treatment. This may help them understand why taking treatment is so important, 
and help them develop the maturity and self-management behaviours that are required. 
I think we had that discussion just explaining the importance of continuing to take the 
treatment in order to prevent something from happening rather than trying to address it once 
it had happened. I think as you imply sort of it’s part of the maturing process. I think he can 
see that correlation quite clearly now and he  appreciates that it’s no good lying in hospital 
while you could be out doing other things. If just by complying with his treatment he can 
prevent himself from having to, to come into hospital and all that then everything works out 
alright (Parent 4). 
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However, most parents also agreed that it is important to give young people some leeway and give 
them the room to find out for themselves why their treatment is so important. For instance, if they 
miss out on activities or opportunities to have fun because of a bleed, they may come to accept that 
they need to take their treatment in order to prevent bleeds. 
Um, I remember a few years ago when there was, um, the tall ships thing and we had all 
planned to, [laughs] to go and attend and see but he couldn’t because he was in hospital, I 
think he didn’t really like that (Parent 4). 
 
Parents agreed that it is likely to be much more powerful if young people find out for themselves 
why their treatment is so crucial, and that nagging them to take their treatment all the time can have 
a negative impact. 
You can’t make them. And it doesn’t matter how much you tell them they need it. Whether 
he’s got a bleed at the time it doesn’t matter, because if they dig their heels in there’s no 
point. So it’s, fine, whatever, just go and do what you want to do. Go on your computer for an 
hour, go chill out, go de-stress and I’ll come up and we’ll have a chat in a little bit and that’s 
the only way you can do it and that’s the way that I’ve learnt over the years to counteract, 
you know, he's saying no I don’t want my treatment, I want to be normal and that’s the only 
thing you can do. It’s just patience really, just learning as well about your child because you 
know, with him, that you leave him be for a little bit instead of-- you know, just calm down 
and get over his rant then he’s fine, and that’s all you can do, yeah.  (Parent 2) 
 
Social support 
For the majority of parents interviewed their son was the first person diagnosed with haemophilia in 
the family. However one of the parents explained that she and her sisters all have sons who are 
affected by haemophilia. Although this has caused much upset and difficulty for the family, it has 
also meant they were able to support each other much better as they all understood the specific 
issues associated with haemophilia. 
Yeah, it probably has because there is quite a few boys, so it’s almost like haemophilia’s 
normal, I think (Parent 3). 
 
In addition to social support from family, parents felt that support from the Haemophilia Society had 
been important. They described a range of different ways in which the society had supported them, 
including help with accessing financial support, giving advice, and providing a support network. The 
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haemophilia society organises peer support groups and activity breaks for YPH, which allow them to 
socialise with other young people affected by haemophilia. Parents felt that their son had benefited 
from attending these activity breaks, as they had provided informal opportunities for him to learn 
and talk about haemophilia outside of the hospital or home environment. They also felt that it had 
probably helped them to step back and allow their son to become more independent. 
When he was a kid, he’s gone on holiday with them because they have a nurse with them 
and it’s made a difference. The first time he went away his mum was worried. He only went 
for seven days. I said don’t worry. Phone him every day, because there’s a nurse there. And 
he had a fabulous time. So some things he might have missed out on, but he made up in 
other ways (Parent 1).  
 
Some haemophilia centres provide peer support groups for YPH, or even organise social outings.  It 
appears that some hospitals have stopped or reduced these activities, mainly due to pressures on 
funding.  However, parents were keen for the hospitals to continue to provide these activities locally, 
and would encourage their son to attend. 
He quite enjoyed that but there hasn’t been anything like that as far as we’re aware since. 
But activities like that when they’re available I think would be useful in sort of getting them 
together, exchanging ideas with other children with haemophili. I know there’s the 
Haemophilia Society but the activities here at the hospital probably something that we need 
to encourage him to participate a bit more, yeah (Parent 4). 
 
One parent also suggested that it would be a good idea to put parents of children with haemophilia 
in touch with each other, to encourage informal support between parents. 
You’ve got the option to say, “Oh hi, I’m such and such, I come down to the Haemophilia 
Centre as well and I understand you’ve get a little boy who goes there,” and yeah it would 
help. Be nice to have a chat and go for a coffee, or even just have somebody at the end of 
either the telephone. You could say, “Oh hi, how’s your day been, how’s your little one, have 
you been down the centre lately, has he had any bleeds? ”Ooh mine-- we’ve had three 
bleeds in the last month, how’s your little one doing?” Just something like that (Parent 2). 
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Psychological support 
In addition to clinical care, some haemophilia centres also provide psychological services to their 
patients. Some centres have their own team of psychologists embedded in the haemophilia centre, 
whereas others have close links with psychologists who are attached to the hospital or are able to 
refer patients to a local psychological support service.  Only one of the centres involved in this study 
has direct access to a psychologist, who sits in on many of the routine check-up consultations. The 
psychologist is therefore known to most patients, and the barrier to access psychological support is 
therefore low.   
Interestingly, the parent who was interviewed at this particular centre was very positive about the 
psychological support that her son receives, whereas the parents in the other centres were perhaps 
not aware that these services may be available to their sons, or that their sons may benefit from this 
kind of support. 
I think it would save a lot of problems for a lot of boys with haemophilia when they get to 
their teens, I do, to have somebody to talk to as they’re growing up and the way that 
haemophilia impacts on their life, their everyday life in school, yeah, definitely  (Parent 2). 
 
Of course not all individuals will need psychological support, as experiences in relation to 
haemophilia, and life generally, differ widely between individuals.  
So, I suppose, everyone’s different. I mean, I have seen the kids here where they’re literally 
crying and screaming and I suppose that’s when you feel really guilty trying to stab them with 
a needle. So, I suppose, every family, you know, depends on the child that’s having it and 
the parents giving it and whatever, so I’ve been lucky, he just gives me his hand and that’s it 
[laughs].  (Parent 3) 
 
However, as described in the next chapter, many haemophilia HP feel that many of their patients 
would benefit from psychological support at least at some point in their life. 
 
Subtheme 3: Skipping or forgetting? 
This sub-theme describes parents’ experiences and perceptions in relation to non-adherence.  
When describing non-adherence, it is important to distinguish between intentional (skipping) and 
unintentional (forgetting) non-adherence.  
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From the interviews it became clear that parents felt that all YPH skip their treatment once in a 
while. Most parents described situations where they have to remind (or nag) their son to take his 
treatment.  
Sometimes you’ve got to nag, yeah, sometimes you’ve got to give a bit of a nag and say, 
“Right, come on, have you done your treatment?” “No, not yet,” “Right, come on then, 
treatment now,”  (Parent 2) 
 
However, most also felt that it is quite understandable that their son wants to skip his treatment 
every once in a while and try to give him some leeway. 
We sort of try to give him a bit of the leeway, you don’t want to be on his case all the time 
(Parent 4). 
 
All parents agreed that the key thing is that he takes his treatment before he does anything active, 
and there are no long gaps between injections. They appeared to understand how treatment works, 
and had worked out a way of compensating for any missed injections. 
As long as he has it when he's doing something active, then it does all sort of fit into place. 
So, if I miss it on the-- because it's a big gap, I can't really miss it, can I? I mean, when it's 
three times a week, we have more chance of missing it, especially if you've done a needle 
wrong and you were dreading that Wednesday. And you're thinking, oh, I'll do it tomorrow. 
But that's probably when you could mess up more, than being on twice a week. You've got 
more days to play with. Yeah, it's fine  (Parent 3). 
 
Although all of the parents agreed that their son sometimes skips an injection deliberately, they also 
felt that the majority of missed injections are due to forgetting.  
usually he’ll be having his injections on the morning and sometimes you find he’s ready to 
leave for school and ask him. Hey, I haven’t seen you have your injection this morning. And 
he realises he’s probably forgotten that it was Thursday. But I think-- Well without being 
paranoid keep an eye on Mondays and Thursdays if he does forget either his mum or myself 
surely would remind him (Parent 4). 
 
As explained previously, establishing a good routine can help patients to keep to their regimen. If 
they are out of their normal routine (e.g. on holiday) they are more likely to forget. 
The only time is when he's on holiday (Parent 3). 
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Parents understood the clear distinction between skipping and forgetting, however it was not always 
clear which one they were referring to when they described their son’s non-adherence.  Perhaps 
they are not entirely sure why their son misses his treatment every now and then, or it could be that 
they feel it is easier to justify forgetting an injection, rather than deliberately skipping one.  
 
7.3.4 Theme 3: Impact of haemophilia  
This theme describes the ways in which parents feel that haemophilia has impacted their son’s life 
and the rest of the family.  Although this does not relate directly to adherence, it is important to 
report as indirectly many of these factors are associated to adherence. 
  
Subtheme 1: Social impact 
Three different parents described how they felt that their son’s social life and emotional health had 
been negatively impacted by haemophilia.  Sometimes in quite emotional language, they 
remembered their son being upset about being different, or not being able to take part in certain 
activities. 
“I feel different, I don’t feel normal, I don’t feel normal, I know I’m different, I can’t do the 
same as my friend,” you know, “he’s going on his skateboard up the skate park and my 
mother doesn’t want me to do it because she thinks that I’m going to fall and bang my head, 
and I can have a bleed,” (Parent 2) 
 
This can have a positive influence on adherence for patients who believe that the protection 
afforded by prophylaxis makes them almost the same as others, and allows them to take part in 
many activities.  However, it can also have a negative impact on adherence as young people may 
feel anxious or upset about having to inject themselves, and feel that it sets them apart from their 
peers. 
if he’s really down he just says, “Oh what’s the point?” when he was younger growing up he 
refused to have his treatment, “I don’t want my treatment, I want to be normal, I want to be 
like everybody else, I don’t see why I should have to have these all the time” (Parent 2). 
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Some YPH may feel inadequate and worry about the way their haemophilia could impact their 
relationship with a (potential) partner. One mother described how her son worries that he may lose 
his wife because of haemophilia-related stress and complications.  This particular individual is 
wheelchair-bound and suffers with chronic pain and disability which appears to have been caused 
by haemophilia-related complications.   
He’s worrying because he thinks that because he can’t do all the things and he’s on bed rest 
he’s stressing ‘cos he’s convinced that his wife’s going to leave him because he can’t do 
anything, and he just thinks that she’s just going to get up and say, “Oh, you know, I can’t do 
the stress anymore,”   (Parent 2) 
 
Another parent explained that her son attends a school where there is a lot boisterous behaviour 
between the boys, such as play fighting and thumping each other. In this context being different can 
also mean that a boy may get singled out or bullied. This could be because he cannot take part in 
this behaviour, or is disproportionately affected by it (e.g. more severe bruising or bleeding). It 
appears that this boy is able to stand up for himself, and does not appear to be worried about it. 
However, boisterous behaviour and potential physical bullying at school represents an extra risk for 
YPH.  
He said to me a couple of weeks ago that someone came up to him and said, “Oh, you 
bleed. If I hit you, you’re going to bleed” and he went, “No”, you can hit me and I won’t bleed. 
But I’ll hit you hard twice back” and he will [laughs]. So he was just like, “Oh, okay mate, it’s 
alright”. I mean, he’s got a big bruise on his arm at the moment from school, it’s been there 
for about two weeks. It’s a big yellow one on his muscle. Obviously takes longer to clear up, 
doesn’t it, but it wasn’t a bleed, it was a bruise. And he’s not bothered, he’s like, well, you 
should see his arm [laughs]. So, he’s been fine (Parent 3). 
 
YPH are likely to miss school quite regularly, because of bleeding-related issues or regular hospital 
check-ups. This means that they miss out socially, as they are sometimes unable to take part in 
activities, attend birthday parties or take advantage or other opportunities to build friendships.  
And it probably has affected his social circle, because he's had to have a lot of time off 
school and he's had to have a home tutor and that kind of thing, so he's missed a big gap in 
his grow-- between twelve and fifteen. Where his friends that he had had gone on and made 
their groups of friends and they do the skateboarding and all that kind of thing, so he's sort of 
missed out on that     (Parent 3) 
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Instead of socialising with friends, YPH have to find other ways to occupy themselves while they are 
on bedrest, or admitted into the hospital.  This can shape the way they look at life or even their 
personality. This is not necessarily a bad thing, as one of the parents explained when he described 
his son’s ability to concentrate and entertain himself. 
has been a loner as well, I actually do think it’s because of his haemophilia, he's always liked 
his own company, he can-- The thing with him he can, he can sit down and do summit, me 
other son, he ain’t got the concentration like he does and I think that is through his 
haemophilia, not on his own, he’s like, he’ll be on his own but like not other kids round him 
because he’s been in hospital, confined to bedroom, a bed, complete bed rest, been at 
home, bed rest, he’s had his telly, he’s had his game and that as much as you can give him 
like but they have to have rest, I mean he’s hurt his thumb and a young lad who’s hurt his 
thumb and he’s got his PlayStation to play, oh my Lord! (Parent 1) 
 
Subtheme 2: Impact on academic and career prospects 
In addition to missing out socially, parents felt that their son had missed out on academic or career 
opportunities because of regular school absence and haemophilia-related issues.  Three parents 
described how the situation was quite good when their son was in primary school, but that things 
got a lot worse when he moved to secondary school. One major issue that they described was that 
schools were not adapted and did not have a lift, which meant that children using crutches or a 
wheelchair could not attend all their classes.  
it’s always one thing that’s bugged me, he missed a lot of school. When he went to high 
school that was terrible, every time he got a bleed they’d send him home, wouldn’t have him 
in school, if he was in his wheelchair ‘health and safety’, which I think is rubbish! I mean, 
through his life at high school he was never there for his illness and he spent a lot of time in 
hospital, they used to have teacher in the hospital but it weren’t the same and I had to try 
and explain to my other son, he missed out on a lot of stuff, not like, definitely he got stuff the 
same as other teens at Christmas and that but I think it’s the lifestyle.  (Parent 1) 
 
Most of the parents interviewed also felt that teachers and managers at school had been rather 
unhelpful, and far too focused on academic and attendance targets, which their son was unlikely to 
meet due to his haemophilia.  One parent described the struggles with her son’s school, and felt 
that school set him up to fail. 
They weren’t helpful at all, in the end I had to get him statemented so that we could get the 
help that he needed and they basically brushed him off and they said -- this is form one we 
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went in and parents’ evening -- “Oh judging by the results of his exams now, when he gets to 
form five--” I think it’s year ten now,  they said, “oh that his predicted grades are going to be 
like basically all fail,” I said, “Well how can you predict that, that’s four years away?” and so 
because of that they like basically weren’t interested. And I had him statemented then and 
he came out of school, he sat his English GCSE a year early, they fast-tracked him, a B in 
maths, a B in his chemistry, biology, all his sciences, he came out with mostly Bs (Parent 2) 
 
Two other parents described how they felt that their son had been labelled a ‘problem child’ 
because he missed school regularly (affecting the school’s attendance statistics), or was unable to 
take part in PE lessons or classes in upstairs classrooms. 
I think it still comes down to school targets. I don’t really think it’s actually the child that 
they’re that worried about, I think it’s their targets, and that’s a pressure, obviously, they’re 
getting from the government and whatever. That’s the biggest struggle, and most parents 
would say school (Parent 3). 
Or, and the one school, when he went to one, they used to put him, the one room they used 
to put him which was one for kids who played up and he used to go, why should I go in there 
because I’m a haemophiliac, I ain’t played up but I’m in the same room as them (Parent 1). 
 
However, it is important to highlight that not all YPH have negative experiences at school.  Perhaps 
the situation has improved over the last decade, as parents of younger patients appeared to have 
more positive experiences in relation to school.  This is probably also because their sons did not 
suffer many bleeds, and therefore did not have significant mobility-related issues.  They did 
however also appear concerned about their son missing school because of frequent hospital visits. 
so about an hour here, an hour for the appointment and an hour back so he misses a couple 
of hours of school but he’s able to go back and continue with his studies so if that’s 
happening just once in three months it’s not too much of a concern but when it used to be 
every six weeks, with the schools having their targets as well on absence, whether or not it’s 
authorised absence, it was a bit of a concern but not anymore (Parent 4). 
 
Even young people who successfully pass their GCSE and A-level exams can find it difficult to 
progress their education or career. One of the parents explained that her son was not able to take 
up the university place he was offered, because he would not be able to get to lectures in his 
wheelchair.  
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He had a massive bleed in his leg, he was cast. And at the University it’s all on a hill, not 
suitable for wheelchairs. And then he wasn’t allowed to go in the lecture rooms and labs on 
crutches. And I said, “Well I can’t see that, I thought you were supposed to accommodate 
people,” “Oh yeah, but there’s certain ones,” and so he couldn’t do it and he hasn’t gone 
back, (Parent 2). 
 
Another parent’s story illustrates that even young people who obtain a qualification may struggle to 
find work, as potential employers worry about the impact that haemophilia may have on 
performance or attendance.   
Because he’s a haemophiliac no-one would give him a chance to work because of 
insurance… I know you’re well aware but with haemophilia some people won’t give him a 
chance plus him being severe haemophilia you can have a spontaneous bleed (Parent 1). 
 
From the interviews it became clear that all parents felt that haemophilia had in some way affected 
their son’s schooling. This ranged from missing school occasionally to attend hospital check-ups, to 
missing significant periods of school which in turn had a negative impact on academic achievement. 
Three of the four interviewees felt that the lack of support and understanding from school was a key 
issue, as it often lead to a battle between parents and school management.  
 
Subtheme 3: Impact on parents and siblings 
Haemophilia usually has a clear impact on parents, siblings and sometimes other family members.  
One mother explained that she felt very guilty after her son’s diagnosis. This was not helped by the 
haematologist encouraging her to get sterilised within a year of her son’s birth, as they felt that she 
should not risk having another child with haemophilia.  This had a huge fall-out for the family, and 
caused friction between the parents. This mother’s experience may not be representative of all 
mothers, but it did highlight that haemophilia, and the way HP approach parents, can have a 
devastating impact on emotional well-being and family dynamics. 
I felt guilty because when he was first diagnosed, even though I knew it was in the family I 
used to think well perhaps if I’d ate this or perhaps if I’d done that, would it have been 
different. And my husband when my son got older and we’ve sat talking and I said something 
about getting sterilised and he said to me, “Well I’m not getting sterilised, you’re the one with 
the problem, I can have normal kids.” So he said, “If I have more kids, they’ll be fine, so I'm 
not doing it, I’m not the one with the problem, it’s you.” And we split up not long after that mind 
we did, but yeah so there was always guilt and even now I still feel guilty (Parent 2). 
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Another parent became quite emotional when he described the period before his son was 
diagnosed, as he and his wife were accused of abusing their son, because he had such severe 
bruising.  He described how frightening it was when his son was finally diagnosed, as the family did 
not know anything about haemophilia. However, his story was also quite positive, as he described 
how the whole family learned about the condition and how to manage it.  Many parents were quite 
philosophical about life as a parent of a child with haemophilia; the first few years are hard but 
haemophilia becomes part of your life and then you just get on with it. 
Social Services was called because they thought we was hitting him and I think everybody 
who has haemophilia, they’ve all gone through that. They saw us when he’d been in hospital 
for five days and they couldn’t diagnose him. They moved us to the haemophilia centre and 
they diagnosed him, severe haemophilia. It was frightening because we’d never heard of it 
but now because I’ve grown with it, he’s grown up with it. It was frightening at the time, me 
mum used to try and wrap him in cotton wool. But you’ve got to let them get on with it; you’ve 
got to let them enjoy life (Parent 1). 
 
Situations such as the two described above are perhaps less likely  to happen today, as 
haemophilia teams are very active in raising awareness and knowledge of haemophilia in patients’ 
direct social environment (such as family), as well as the wider environment (such as childcare 
settings, school, sports clubs, GPs, etc.).  The assumption is that this better knowledge and 
awareness of haemophilia will prevent issues and support parents in managing their child’s 
haemophilia. 
The advances in medical treatment also mean that today many YPH can live a fairly normal live, 
with relatively few bleeds.  However, particularly for patients affected by the consequences of 
regular bleeding episodes (ie mobility issues or disability), haemophilia can still have a significant 
impact on day to day life.  This in turn can also affect their relationships with their partner and family, 
as haemophilia is likely to impact all of them.  
It just causes so many problems with just everything, everyday life. Even with the school 
holidays, we know that to take my granddaughter out we’ve got to think about where we’re 
going. We’ve got to make sure that you’ve got enough pain relief for him. We can’t really go 
too far because he will sit in the car, it’s painful for him and so it’s not just an impact on his life, 
it’s everybody’s. I worry because he’s married, that him and-- I don’t want to interfere, but then 
sometimes I-- like sometimes he’ll come and stay down with us to give his wife a break 
(Parent 2) 
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Two of the interviewed parents appeared to worry about their son constantly, even now that they 
are becoming older and independent.  It is difficult to confirm the extent to which haemophilia 
contributed to this based on the interviews, but it is likely that it played a role. 
I find it hard like when he was younger and he was in the hospital I was there constantly with 
him, didn’t go home, just stayed in hospital constantly, but of course now obviously now he’s 
grown up, I can’t do it, even though I want to, but you can’t. But it is hard and when he was 
younger the support chain wasn’t as good as it is now, when you listen and you talk to him 
and obviously they talk to other parents, that I think the support network is different now than 
what it was like 25. I mean as long as it was in the day the support network was there, but it’s 
the out-of-hours one was always the issue.   (Parent 2) 
 
In addition to the emotional impact of haemophilia, there are also many practical implications in day-
to-day life. Something that many people would not think about twice, such as going on holiday, can 
be tricky and expensive to organise.  For instance, popular holiday destinations such as Turkey are 
ruled out because adequate haemophilia care is not available. One mother explained that she has 
had to cancel several holidays because her son could not travel due to a bleeding episode, so now 
she books holidays at the last minute. 
But, yeah, it’d be nice, I suppose, to book a holiday a year before like some people do and 
then you’ve got something to look forward to the whole year. But I think, it just becomes part 
of your life so you just don’t, you never think about it. (Parent 3) 
 
Several of the parents explained that they try hard to find activities that the whole family can do 
together, to encourage their son to get exercise without risk of bleeding.  This means that family 
outings and activities have to be tailored to the child with haemophilia, which does not always go 
down well with other sibling and can be expensive and time consuming to organise. 
So we just came to the decision: no PE. But what we've had to do with him is like do a lot of 
taking him swimming, like after school. And things that aren't so harsh on his body, just to 
keep him sort of with some exercise. So I suppose that's the way it has affected, like our lives. 
That's what I say, we do more to help with the other things that he needs that he can't get 
from school. So, as I say, he's missed a lot of time off school, ever since he started school, 
you know, with nose bleeds and legs and head bumps and arms and fingers and [laughs]  
(Parent 3). 
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It became clear that in many families the main focus is on the son with haemophilia, which can also 
lead to tension between siblings.  One father explained that his other (unaffected) son told him that 
he wanted to have haemophilia too, so that he would get as much attention and would not have to 
go to school every day. 
him and his brother they fight like cat and dog when they was little and I’ve even had 
because like he was in hospital, the littlun said to me, ‘’I wish I’d got haemophilia’’. ‘’What did 
you say that for?’’ ‘’Because he has stuff’’ (Parent 1) 
 
Another important consideration is the impact on parents’ work or career. Two of the parents that I 
interviewed gave up work, as they found it impossible to combine their work with looking after a 
child with haemophilia. A third parent found alternative employment working in the family business, 
which allowed her the flexibility she needed to look after her son. 
So I think now with all this new rules and regulations they have to be more flexible with you, 
whereas when he was born they weren’t, you know, it was like well basically tough like, you 
know, whereas again it’s time isn’t it and again it’s understanding isn’t it with employers, and 
you know, and I-- you know, with all the disability rights and everything, you know, I think that, 
I think that’s made a lot of difference because people are-- they’re more flexible, you know, 
they have to be. (Parent 2) 
 
But of course haemophilia can also have a positive influence in different ways.  Some parents 
described a very close relationship with their son, and others explained that looking after their son 
and overcoming their apprehension to do the injections, had given them confidence in their own 
abilities.   
One mother explained how she had suffered with needle phobia initially, but eventually became a 
phlebotomist after her son left home. 
when he moved out and I thought what do I do now and then I thought well, I’ll go back to 
work. I said, oh what do I do, so I thought oh I’ll apply for a job as phlebotomist and anyway 
that’s why I thought well I’d basically been doing it for the last like 20 odd years so-- and so I 
applied for it.  (Parent 2) 
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7.3.5 Theme 4: Haemophilia care 
This theme encapsulates how parents experience and feel about the haemophilia care that their son 
(and their family) receives through the NHS.  This includes parents’ descriptions of support from the 
Haemophilia centre, treatment, and haemophilia awareness among the wider healthcare 
community. 
 
Subtheme 1: Support from haemophilia centre  
All parents felt that the support from the haemophilia centre is great.   
The support off the hospitals is big, couldn’t knock it, they’ve been golden, so the hospital 
side of it has been good  (Parent 1). 
 
It appears that staff turnover is low in most haemophilia centres, which means that families tend to 
deal with the same consultants and nurses for years.  This allows the haemophilia team get to know 
the patients and their families, and vice versa. This also means that the team are able to identify 
potential issues, such as non-adherence, early and work with families to address these. 
Oh, it’s excellent. I definitely do not have any complaints. The consultant who’s seen him 
today, she’s been seeing him for quite some time, um, started with Dr A and Dr B were here, 
I haven’t seen them much of late, I don’t know whether [laughs] they’re still on there but she 
has been seeing him regularly so, um, I think they’re quite familiar with [laughs] his case, 
yeah. (Parent 4) 
 
Parents feel that if they have any issues they can always call the haemophilia centre for advice, or 
in some instances just a bit of moral support.  
Probably got good support from here when he was a baby, we was always here. And then 
as soon as I could do the treatment at home, that was all set up. And if I’ve got any 
problems, I’ll give the unit a ring. When there’s tablets he’s been given but I’m not sure 
about, then I’ll call and check.  (Parent 3) 
It was good ‘cos then if there was any issue then we used to come down and sit and have a 
chat and they-- it does make a difference. If you’ve got somebody that you can ring up and 
say, “I’m feeling a bit stressed,” and I think it goes a long way to help, to helping you.   
(Parent 2) 
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In addition to the excellent medical care, parents also felt supported by the haemophilia team in 
other ways.  For instance, when a child with haemophilia starts at a new school a nurse will visit the 
school to give information, and check what facilities are available in case of emergencies. Some 
centres also have a social worker or welfare officer, who is able to support families in many different 
ways. However, in some centres these functions have disappeared due to reductions in funding. 
I think so, yeah, because when we first were down the Hospital we got a welfare officer who 
used to look after us, he was brilliant and they helped us sort out when he was old enough to 
have mobility, sort that side out but then he disappeared, like his job role must have gone 
and it was hard then to get help with everybody else, they’d try and help you out, the nurse 
and that, they’d give you letters who you could get in touch with and you’d/  (Parent 1) 
 
Subtheme 2: His treatment has become part of our lives 
Parents agreed that prophylaxis has made life better, and reduces the risk of bleeds and associated 
issues. 
Prophylaxis, it has made life easier. Don’t get me wrong he still has to go to the hospital and 
there’s still times he needs to come over the hospital. But if he has a bump, he knows 
himself. He’ll go. ‘’I need to treat that now’’. The next day he’ll phone me to say ‘’Dad, I need 
to go over the hospital’. He’ll phone the nurses, he’ll ask their advice and they’ll say ‘have 
this treatment, no problem’. Or ‘No, better come in’.  The nurses have been brilliant. So it 
does, it has made life a lot, a lot easier. (Parent 1) 
 
In particular in families where previous generations were affected by haemophilia they appreciate 
the positive changes prophylaxis has made. 
Whereas in my dad's day, he'd by lying in bed for six months, you know, constantly bleeding 
and everything. So it's sort of, yeah, it's not too bad, it's manageable.  (Parent 3) 
 
As described in previous chapters, many YPH and their families suggest that treatment becomes 
part of life.  It is just another thing you have to do, which becomes part of your routine. 
It’s sort of now been built into the routine, during the earlier days it was quite hectic but at the 
moment we’ve sort of settled into a routine and know what to expect when so it’s just one of 
the things you get on with really. (Parent 4) 
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In the early days after diagnosis it is often difficult and stressful for parents to manage their son’s 
haemophilia. Parents described how slowly and gradually haemophilia became part of their lives, 
and that stress and constant worry reduced.  However, all the interviewed parents appear to worry 
about their son considerably and continue to be involved in managing their haemophilia, even after 
they have left home. 
Cos it’s a learning experience, you don’t know whether that little tiny bruise was a bleed and 
so it was just worry, just all the time. But as he gets bigger you learn, you adapt, you know 
what to worry about and what not to worry about, but  he’s left home now and I still worry, 
just all the time.  I still ring him every night, check how he’s doing and, to say about anything 
you need, how are you doing, have you had your treatment and that, so yeah, it’s just worry 
[laughs].  (Parent 2) 
 
While recognising the impact that haemophilia has had on their son and the rest of the family, three 
out of four parents were quite positive about the future and felt well-equipped to help their son 
manage his haemophilia. They agreed that as long he takes his treatment he should be ok, and be 
able to enjoy his life.   
Yeah, it has, but it sort of becomes part of your life.  I think, probably, say you were 
somebody just coming into it and you explained to them, they'd probably think really has 
messed his life up and stuff, but he's not really ever complained about, he looks to the 
future. He's had his needles, he actually just thinks, he just gets on with it, like I say, it is part 
of his life.  (Parent 3) 
 
Subtheme 3: Haemophilia awareness needs to improve 
Although they agreed that haemophilia care in this country is very good, several parents described 
situations in which they felt HP were not aware or knowledgeable enough about haemophilia. This 
included situations where they prescribed medication that is contraindicated for people with 
haemophilia, or where they would withhold treatment because they were not confident in treating a 
patient with haemophilia. 
And in that time this joint is weaker anyway, you’re protecting it a lot, and you want to know 
what’s going on with it. And when you do get to see the consultant a hundred percent of the 
time he’ll say, “Well, not really much we can do because of the haemophilia” and it drives me 
crazy because I’m thinking, “Well, why have--?”. They can whatever needs to be doing, do it. 
Because the treatment's there, but they’re scared, I think, a lot of the time, to do anything. 
(Parent 3) 
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This seems to be a particular issue in situations where a person requires emergency (non-
haemophilia related) treatment following an accident, or dental treatment. 
They’d rather leave a child with haemophilia alone. Even simple things like their teeth. I can 
see the difference because I’ve got a child without and a child with. Now, with my daughter if 
she needs a tooth out, it’s a tooth out. If my son needs a tooth out, it’s a big process. You’re 
at the dental hospital, you’ve got to-- can’t get through to the dental hospital, they don’t 
answer the phones, you leave messages, it takes months to deal with the fuss. (Parent 3) 
 
The parents interviewed for this study did not appear to have much confidence in out-of-hours care, 
and try to avoid it if they can.  
I dodge out of hours. So occasionally if he’s done something on a Saturday, I’ll treat him. 
And if it’s okay on the Sunday, I’ll leave it and then bring him on the Monday. As for night 
times, say he’s come home from school and he’s hurt himself or if he hurt himself after 
school, say it’s five o’clock, then I’ll treat him and bring him the next day. So I’m actually 
dodging out of hours [laughs]. (Parent 3) 
He will try not to come down out-of-hours or on a weekend because you tend to see the 
haematologists rather than the doctors from the Haemophilia Centre, it tends to be the on-
call haematologists and I think sometimes you’re lucky, you get one of the doctors who know 
you, but generally on a weekend it’s hit and miss so   (Parent 2) 
 
Haemophilia care is centralised through regional haemophilia centres. This means that not all 
hospitals offer haemophilia treatment, and that in some hospitals emergency doctors or nurses are 
unable (or unwilling) to treat people with haemophilia because they lack knowledge and experience 
in this area.  This can cause issues when a patient is brought in by ambulance after an accident.  
One parent explained how he had to pick up treatment at home when his son was driven to the 
wrong hospital by ambulance, and then had to help his son to administer the treatment himself 
because the hospital did not have factor replacement treatment in stock and staff could not 
administer treatment that was brought in by patients themselves.  
they seem to want to take you to another hospital where they can’t treat him so the last time 
I took him there he’s sixteen, of a night, I had to fetch his treatment from home, I had to mix 
his treatment, I had to phone the haemophilia centre, they told me how much treatment to 
give him there and then, I mixed it up meself, went to give it him, they wouldn’t let me 
because they don’t know it was mixed up so I had to make him sit up and give it him to give 
himself because they couldn’t stop him. (Parent 1) 
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It is difficult to ascertain if the issues described above are still relevant today, as some of the 
situations occurred years ago and healthcare provisions may have changed since. However, it 
appears that due to its rarity many doctors and nurses in other specialties are not knowledgeable 
enough about haemophilia.  Many parents appear to deal with this by becoming ‘experts’ 
themselves and seeking advice from the haemophilia centre to provide guidance to other HP.   
 
7.4 Discussion 
From the interviews it became clear that parents felt that most YPH skip their treatment 
occasionally. They agreed that the key thing is that he takes his treatment before he does anything 
active, and that the gaps between injections are not too long. They appeared to understand how 
treatment works, and had worked out a way of compensating for any missed injections. All parents 
appeared concerned about the potential risks associated with physical activity and going out with 
friends (particularly going out to enjoy the nightlife, including consuming alcohol). 
Parents understood the distinction between skipping and forgetting, however it was not always clear 
which one they were referring to when they described their son’s non-adherence. Perhaps they are 
not entirely sure why their son misses injections, or perhaps they find it is easier to justify forgetting 
an injection, rather than deliberately skipping one.  
The most important barriers to adherence described by parents include lifestyle (fitting treatment in 
with other priorities such as school); being out of the normal routine (e.g. on holiday); not wanting to 
be ‘different’;  issues around venous access and needle phobia; and psychological issues (such as 
stress and anxiety). The most important facilitators described by parents include establishing a good 
routine which includes treatment; setting reminders or alarms; parental and peer support; 
psychological support; helping patients to develop the maturity and self-management that are 
required to manage haemophilia; and giving young people some leeway and give them the room to 
find out for themselves why prophylaxis is so important. 
Parents appeared to be aware of the importance of treating bleeds appropriately, and felt this was 
just as important for their son as him adhering to his prophylaxis. It became clear that parents are 
very involved with their son’s treatment, even parents of young adults who no longer live at home.  
All parents felt that the support from the haemophilia centre is great.  It appears that staff turnover is 
low in most haemophilia centres, which means that families tend to deal with the same consultants 
and nurses for years. This allows the haemophilia team get to know the patients and their families, 
and vice versa. This also means that the team are able to identify potential issues, such as non-
adherence, early and work with families to address these. Parents felt that if they have any issues 
they can always call the haemophilia centre for advice, or in some instances just a bit of moral 
support.  
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As explained in the last chapter, a comprehensive discussion of all the qualitative studies will be 
provided in chapter nine. 
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Chapter 8: Interpretative Phenomenological Analysis of 
haemophilia healthcare professionals’ accounts of adherence 
to prophylactic treatment 
8.1 Introduction 
This chapter presents the results of the Interpretative Phenomenological Analysis (IPA) of 
healthcare professionals’ (HP) accounts in relation to prophylaxis and adherence to this treatment 
among young people with haemophilia (YPH). The aim of this study is to examine participants’ 
perceptions and experiences and the way they make sense of these. Together with the findings of 
the qualitative studies described in the previous two chapters (which represent the views of YPH 
and their parents) the findings of this study are anticipated to contribute towards a better 
understanding of the complexities around prophylaxis and adherence to this treatment among YPH.  
 
8.2 Methods 
8.2.1 Recruitment 
Participants were recruited in five haemophilia centres across England and Wales. All HP involved 
in the care for YPH were eligible to take part. To ensure that the findings would represent the views 
of different members of haemophilia teams, nurses and doctors with different levels of experience 
and seniority were approached to take part. All potential participants who agreed to take part were 
interviewed. 
 
8.2.2 Participants 
Participants were two haematologists (one Registrar and one Consultant) and four nurses with 
different levels of seniority (see Table 8.1 for details). To protect anonymity and confidentiality 
details of which hospital participants work in are not included. 
 
Table 8.1: Healthcare professional interview study participant characteristics 
Participant code Role Sex 
HP 1 Nurse Female 
HP 2 Nurse Female 
HP3 Nurse male 
HP4 Haematologist Female 
HP5 Haematologist male 
HP6 Nurse Female 
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8.2.3 Data collection 
Each participant was interviewed face-to-face in a private room (or their office) at the haemophilia 
centre. The interviews were semi-structured using a topic guide (appendix 5.1), although 
participants were encouraged to tell their own story in their own words with little interruption from the 
interviewer. At the start of the interview participants were invited to describe an ‘average day’ in the 
haemophilia centre to get a sense of what it is like to work in a haemophilia centre. Participants 
were invited to highlight any changes in haemophilia care that occurred during the last decade, and 
potential improvements to haemophilia care that they would like to see introduced. They were also 
invited to describe their experiences and perceptions in relation to prophylaxis, and potential 
barriers and facilitators to adherence to prophylaxis among YPH. As described in the previous 
chapters, the order in which the different subjects were discussed was flexible. This allowed 
participants to tell their own story, and highlight those topics they felt were most relevant. Interviews 
were recorded and then transcribed verbatim before being analysed following the IPA methodology 
 
8.2.4 Analysis 
As described in chapter five, IPA emphasises that the process of discovering themes involves the 
researcher being engaged in a double hermeneutic (Smith, Flowers & Larkin, 2009), with the aim to 
make sense of the participant attempting to make sense of their experiences. Therefore this 
analysis is partial and subjective and may have reached different conclusions than other 
researchers may have done if they had carried out this analysis. This chapter will explore those 
themes that emerged most strongly from the interview data and that were most relevant to the 
research questions. These themes will be illustrated with verbatim extracts that were selected from 
across all participants’ transcripts, to ensure they were representative of the sample. In some 
instances, where different participants had different opinions or experiences, all views are 
illustrated. Where participant responses were similar, only those quotes that illustrate the theme 
most clearly have been included. This approach was true to the aims of the study, participants’ 
accounts and the richness of the data.  
 
8.3 Results 
8.3.1 Superordinate and subordinate themes 
At the start of their interview HP were invited to describe their day-to-day responsibilities and 
experiences in relation to haemophilia patients.  They were then asked about their perceptions and 
experiences in relation to prophylactic treatment and barriers and facilitators to adherence to this 
treatment among their patients. Participants’ accounts clustered around four superordinate themes, 
which are shown in table 8.2 together with their related subordinate themes. The table also shows 
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for which participants each of the subordinate themes was relevant. These themes were identified, 
analysed and reported following the same process that was described in previous chapters, 
ensuring that themes emerged from the data and were relevant to the research questions. The 
approach used was true to the aims of the study, the experiences described by participants and the 
richness of the accounts in the data.  
 
Table 8.2: Healthcare professional interview study superordinate and subordinate themes for each participant 
Superordinate themes Subordinate themes 
Participants 
1 2 3 4 5 6 
Healthcare professionals’ 
estimates of adherence 
Adherence fluctuates x   x x x x 
Timing of injections x 
 
x x x x 
Variability of symptoms (bleeds) x 
 
x x x x 
Haemtrack and adherence x  x x x x 
Drivers of non-adherence? 
Lifestyle/time management x x x x x x 
Venepuncture issues 
 
x x x 
 
x 
Not wanting to be different x x 
 
x x x 
Absence of symptoms 
  
x x x x 
Family and social issues  x   x x x 
Improving adherence  
Education x x x x x x 
Psychological support x x x x x x 
Peer support x x x x x x 
Support for parents     x   x x 
How can healthcare 
professionals help to 
improve adherence? 
Being sensitive to individual needs x x x x x x 
Regular contact and continuity of staff x 
 
x x x x 
Collaboration with schools and community x 
 
x 
 
x x 
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8.3.2 Theme 1: Healthcare professionals’ estimates of adherence 
During the interviews HP were invited to comment on levels of adherence among their patients, and 
reasons why they feel YPH do not keep to their treatment regimen.  They were encouraged to 
comment in any way that reflected their own personal experiences and perceptions. 
 
Subtheme 1: Adherence fluctuates 
HP found it difficult to estimate adherence levels in terms of percentages, but agreed that 
adherence is generally good. Four participants estimated that at least 90% of patients adhere to 
their treatment, one participant estimated that at least 75% adhere, and one participant was not 
sure.  
Gosh, quite hard to think of [laughs] I don’t know if I could put a percentage. But I would say 
that the vast majority [pause] are actually quite adherent. I’d say the vast -- I don’t know, it’s 
kind of [pause] 75%. I don’t know, it’s kind of a random number, but I’d say -- or even maybe 
more.  I think, the bulk are more or less [hesitantly] fairly adherent. (HP1) 
About 5-10% are people who might not take their treatment as prescribed. (HP4) 
 
However, participants also felt that adherence levels are likely to fluctuate.  They explained that 
even patients who tend to be very adherent can go through short periods of non-adherence, often 
caused by circumstances. 
So some people are really good for a while and they have blips as well but they don’t adhere 
all the time it’s just circumstance. (HP1) 
 
Participants also explained that it is not always straightforward to ascertain if someone is adherent 
or not. In recent years haemophilia centres have increasingly encouraged patients to tailor their 
treatment around their lifestyle.  Particularly patients who live an active lifestyle may change the 
dosage and frequency around their activities. Therefore in some cases you may argue that 
someone who follows a rigid three times per week regimen is non-adherent because they do not 
top-up in advance of activities. 
Hmm, so even though they are adhering to their regimen, actually they are sort of non-
adherent because they are not managing around their activity. Or treating at the wrong time 
(HP3.) 
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It is also important to consider all the other self-care behaviours that patients are expected to follow 
in addition to taking their treatment.  
I suppose my perception would be that adherence is quite good in terms of prophylaxis. It’s 
the other things, so if they’re attending clinic, treating their bleeds appropriately, taking it at 
the right time. I suppose we’re expecting quite a high standard on a lot of things. Completing 
treatment records, they’re the things that are really poor adherence rather than the actual 
sticking to prophylaxis (HP6) 
 
Subtheme 2: Timing of injections 
HP agreed that the majority of non-adherence is about timing of treatment. Indeed three participants 
estimated that although nearly all (90 to 100%) of their patients take their prophylaxis, significantly 
fewer patients (50%; 70% and 80% respectively) take it at the agreed time. 
Well ‘as directed’ would probably mean before they go to school, and I would think roughly 
about 70, 80% of them will do that and they will find it easier to do as well because parents 
have got to go to work as well so everyone comes home at different times. There are some 
families that just can’t do in the morning, they might have three or four children and it’s just 
impossible. That’s something that you have to accept and they will do it when the boy gets 
home from school (HP5) 
 
The haemophilia professionals interviewed for this study appear to take quite a pragmatic approach, 
and accept that not all patients will be able to follow their recommended regimen. In most cases 
they work with the patient and/or family to find a compromise with a focus on reducing the treatment 
burden while still making sure that the patient is protected, particularly during times that they are at 
higher risk of bleeding. 
So although there’s lots of positives of daily treatment and that would be ideal in terms of 
levels. The practicality of that for some families is that it’s not going to work. I suppose the 
compromise then is alternate days or we say “Monday, Wednesday and Friday and once at 
the weekend’’. If that’s what’s prescribed, I would say 90 to 100% of people are doing that. I 
would say particularly in children that less than 50% of them would be doing it in the 
morning. I think it’s after school, in the evening. I suppose it should be like brushing your 
teeth that you shouldn’t do something without it, but that’s not how it works for the families. 
(HP6) 
149 
 
In some cases a compromise between the ideal regimen clinically, and a regimen that 
accommodates patients’ lifestyles can ensure that the patient is at least able to take some 
treatment, rather than none at all. 
 “Okay, well why are you missing it? Is there things we can do to help, is it the time of day?” 
Cos some patients will do things like, they’ll get in their head it has to be done at this time of 
day. And then things change in their life, or something happens and they can’t do it easily at 
that time of day. But they don’t necessarily think, actually you could just do a different day 
[both laugh] so that helps. (HP4) 
 
However, it can be challenging to strike the balance between accommodating patients’ lifestyles 
and ensuring treatment efficacy is not affected.   
We had one who was treating at night, because they had to wake up early to go to work and 
they didn’t want to take the treatment at work, because of what people would say. So the 
only time he would treat would be when he comes back home. After which - - after he comes 
home he’s gonna go to sleep, so all that factor is just being wasted. (HP1) 
 
Participants explained that it is important to take personal circumstances and clinical variables into 
consideration when agreeing a treatment plan.  An important variable is the bleeding phenotype, 
which indicates an individual’s tendency to bleed.  The variability in bleeding phenotype between 
patients means that non-adherence does not have the same repercussions for all.   
Some of our boys do get away with that. A boy who’s 17 has always struggled to do 
prophylaxis, dad’s always done it a bit and dad will be away with work so sometimes he 
wouldn’t have it. A really sporty boy, as a family they go off on skiing holidays, never had any 
problems. What we would prescribe as prophylaxis would not be what they can manage, so 
when they come to clinic they openly say “We don’t do that, we might manage twice a week” 
but that’s okay he doesn’t bleed in between, he comes to clinic, his joints are checked and 
he’s managing that because his bleeding phenotype is very different. (HP6) 
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Subtheme 3: Variability of symptoms (bleeds) 
During the interviews participants were asked whether they felt that bleeds are the best indicator of 
non-adherence, and the responses were mixed. Some felt that patients who suffer frequent bleeds 
and those who stop attending clinic appointments are more likely to be non-adherent. 
Yes I think so, probably bleeds. Well bleeds and not attending clinic, I think when they’re not 
turning up that’s a clue of this is all going a bit wrong, but we tend to chase those so yes 
bleeds… (HP4) 
 
However, others pointed out that there are patients who keep to their regimen religiously but still 
suffer frequent bleeds.  This could be because the dosage or frequency of their treatment is not 
sufficient, due to existing joint damage, or other clinical factors that may cause bleeding. 
I know one guy who kind of adheres, but he’s always getting bleeds. So you keep on 
adjusting their treatment as soon as they recover. Some of which you can put down to 
having joints which were already knackered from before. But you adjust the treatment. (HP3) 
 
Of course treatment cannot prevent bleeds that are caused by trauma (a fall, cut, sports injury, etc.). 
However, prophylaxis is likely to make trauma bleeds less severe and helps patients to heal more 
quickly. 
All children are going to get bleeds, there’s no such thing as a haemophiliac who doesn’t get 
bleeds, what they’re not getting is breakthrough bleeds on prophylaxis, but they will get 
trauma related things and that’s on occasion going to make them miss school, less so than if 
they’re not on prophylaxis because I think being on prophylaxis itself ameliorates the bleed if 
you like. (HP5) 
 
Some patients are encouraged to contact the haemophilia centre when they have a bleed, so that 
they can assess whether the bleed can be treated at home or requires hospital treatment. Most 
patients are required to log bleeds on Haemtrack (including additional treatment they have taken to 
treat the bleed). However, it appears that not all patients treat bleeds appropriately. Some do take 
extra treatment, but do not log it on Haemtrack. Others keep to their normal treatment regimen 
without taking additional treatment, which often causes the bleed to last longer and cause more 
damage. 
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All of a sudden they find themselves with a bleed, some will then just try ‘Ok, I’ve got my 
treatment tomorrow anyway, so do I wait and do a treatment tomorrow? Whereas they are 
supposed to treat there and then. But you find someone waiting until tomorrow, cos it wasn’t 
their treatment day. When they call it hasn’t resolved. Usually we do regular checks on 
Haemtrack.  If you see several bleeds you give them a call and find out ‘are you ok’ I see 
you recorded this’ and they will start telling us ‘oh, this is the case’ so the log is really good. 
Cos you can see how the bleeding pattern of some people, then you are able to give them 
advice (HP3). 
 
One of the participants suggested that patients who present late with bleeds are often also those 
who struggle to keep to their normal treatment regimen, or those who do not attend clinic 
appointments. So in some cases recurrent bleeding can be an indication that someone is 
disengaged with their treatment, or is struggling with it. 
Some are obvious because they stop coming to clinic, that happens quite a lot, or they miss 
a lot of appointments and they will show up for one and they’re a bit sporadic, so they’re just 
not very engaged with it, things like they’ll present late with a bleed, you can also notice 
they’re not picking up their treatment and that kind of thing, and that kind of thing can 
happen. (HP4) 
 
Subtheme 4: Haemtrack and adherence 
As described in previous chapters, the majority of patients who follow a prophylactic treatment 
regimen are required to log their treatments on Haemtrack, an online treatment log.  Haemtrack 
allows haemophilia centres to monitor patients remotely, to check whether they are taking their 
treatment as agreed and whether they are experiencing any bleeds.  HP were generally very 
positive about Haemtrack, because they felt that in addition to helping to monitor patients it also 
helps to engage patients and give them some autonomy. 
And I think anything where things like Haemtrack where the patient’s much more involved 
and much more in control, I think that’s a really good thing and I think we’re trying to go 
there, or trying to increase the autonomy is really good. (HP4) 
 
Information logged on Haemtrack can be a good conversation starter with patients, and can help to 
illustrate the link between missed treatments and bleeds. Nurses tend to regularly use Haemtrack to 
check how patients are doing. They then telephone patients who have logged a bleed, or patients 
who have not logged treatments for a while. Haemtrack data can help to start a conversation about 
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adherence, and how the centre may be able to support the patient to keep to his treatment. 
Haemtrack data are automatically uploaded onto the UKHCDO database, analysed and then 
presented annually in a summary report.  The data are also shared with Specialist Health 
Commissioners to help justify the significant cost of prophylactic treatment. 
We have had to write letters and say “We get this amount of money; if you don’t give back 
treatment returns we get less money, so less treatment available and so more people will 
bleed. If you reduce it to that level, I think most people will accept that and understand there 
is a responsibility and contract of care (HP5). 
 
However, it is important to note that Haemtrack is 100% reliant on the accuracy of information 
entered by patients.  One participant felt that some patients may log trauma bleeds as breakthrough 
(spontaneous) bleeds, as they do not want to admit that the bleed was caused by an activity they 
should not have been doing.  They felt that Haemtrack could potentially be used by commissioners 
to prove that prophylaxis (one of the most expensive treatments available through the NHS) does 
not work, as patients should not be having spontaneous bleeds while on prophylaxis.  In a time of 
austerity this is a real concern for haemophilia treaters.   
But if a boy’s been playing football and you’ve told him the week before he shouldn’t be 
playing football and he gets a bleed, he’s not going to put down on Haemtrack that he’s had 
a bleed whilst playing football.  He’s going to say he had a breakthrough bleed and that’s 
where Haemtrack is very poor. Haemtrack is okay but it’s very reliant on what the parent or 
the boy fills in. So Haemtrack is going to provide a lot of data for the UKHCDO, but it’s also 
going to prove that prophylaxis doesn’t work. That’s going to be the bottom line and that’s so 
utterly stupid because all commissioners will do is watch the results on 
Haemtrack,‘Goodness me, look at all those breakthrough [spontaneous] bleeds that these 
people are having on prophylaxis, prophylaxis doesn’t work’. Not going to give you this 
money. It is so badly thought out (HP5). 
 
HP were unable to estimate how many patients complete Haemtrack as directed, but it became 
clear that they put a lot of effort in to encourage patients to complete Haemtrack. 
You get times, months where people are just too lazy to bring their treatment logs. And we 
have to chase them up. So at times they are really good, you’re not chasing anyone up. 
Then there are times where you are chasing up about a quarter of them. If they don’t return 
for more than 3 months we tell them that they have to come and collect their treatment from 
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the centre, rather than having home delivery. But as soon as you tell them that, they start 
filling it in. (HP3) 
 
Participants explained that many of their patients appear to complete Haemtrack periodically rather 
than after each treatment as prescribed.  This means that Haemtrack may not be as useful to 
monitor patients’ bleeds.   
We try to go through it thoroughly monthly to update our own spreadsheet as to who’s 
compliant with returns. So there are those who put it in right away and there are those who 
leave it months [laughs]. Or there are those who just default random things in I think [laugh]. 
So when you go through it you can see who’s treating. Some are really easy; it’s all exactly 
what you expect. No bleeds, no qualms. Others, there’s a random odd bleed. Sometimes 
they give you insufficient information. And if there is any issues then I phone them and say, 
‘look I noticed you have such and such’ (HP1). 
 
Haemtrack completion rates, and the data entered on Haemtrack are not necessarily indicative of 
how well patients adhere to their treatment, as even patients who generally adhere to their 
treatment do not always log their treatment as directed. However, it is probably fair to assume that 
those patients who complete Haemtrack religiously are likely to be adherent, whereas those who 
are not engaged with Haemtrack are probably also less engaged with their treatment and 
haemophilia generally.  
I think it’s self-selecting thing, I think the people that engage and do it generally are more 
engaged in their treatment and the condition. (HP4) 
 
8.3.3  Theme 2: Drivers of non-adherence 
This theme describes all the factors that HP highlighted as drivers of non-adherence.  It is possible 
that not all potential drivers of adherence that a patient may experience are included in this theme, 
as only the factors that were described by the HP who were interviewed are included. 
 
Subtheme 1: Lifestyle and time management 
When discussing reasons why patients do not adhere to their treatment HP suggested that for many 
patients it is a question of time and lifestyle. During a busy time, or during a significant life event or 
change it is much more likely that someone forgets to take their treatment or finds it harder to fit in.  
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I think the occasional ones, I think some will have a busy period and will genuinely forget 
and I think that’s fine and, that’s human error [laughs] and I think -- I don’t really see that as 
a problem. (HP3) 
It’s usually been a change of circumstance. So a new job, a pregnancy or they’ve got 
married. Something that’s completely changed their lifestyle. Especially because it’s 
something that tends to be tied to a particular day and a particular time. Anything that alters 
that and it takes a while for it to settle down again into a new pattern. (HP4) 
 
HP agreed that one of the most challenging aspects of prophylaxis is the timing of the injections. 
For many patients it would be best to take treatment in the morning, before leaving home.  
However, HP agreed that this is simply not achievable for all their patients. 
You say to somebody to have prophylaxis in the morning before school, as it’s wasted in the 
evening. The prophylaxis then gets done in the evening because life is too busy in the 
morning. I think that that’s also why it’s really important that we visit families at home 
because that gives you a much better reality of what family life is like for them. Families 
maybe where there’s single parents, there’s multiple children, that in the mornings before 
school is a rubbish time. As the health professional and the expert we’re saying “This is what 
you should be doing” but the reality of that happening is really, really difficult in terms of 
practical. (HP6) 
 
Although non-adherence appears to occur across the board, HP suggested that many YPH go 
through a period during which adherence is significantly reduced.  This often coincides with them 
becoming more independent, and taking over responsibility for their own treatment from their 
parents. For some this may be when they leave home, and are forced to look after themselves.  
If they’re at home they’ve got the parents there making sure they do the treatment. When 
you get more to later teens and early 20’s that’s where I think it probably falls apart more. 
Once they gain more independence, and they haven’t got the parent breathing over them 
saying “You must take this treatment and do such and such”. I think that is where it tends to 
sort of fall off easier. (HP1) 
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Gaining more independence does not only affect treatment adherence, it is also likely to impact on 
other self-care behaviours, such as avoiding risk and managing delivery of treatment. 
A lot of these boys are starting to go to university and are leaving their family, and if they’ve 
not been properly prepared for that. All of a sudden they’ve not only got to deal with doing 
prophylaxis and looking after themselves, like any other boy leaving home. But with the 
added complication of going out and getting completely trollied [drunk] on a Friday, Saturday 
and whatever other nights. But making sure they’re safe to do that, because they haven’t got 
mum sitting there going “oh if you’re going out you need to go and do such and such.” 
They’ve also got home therapy, making sure that it’s recorded somewhere, and then also 
making sure they’ve enough treatment to see them through to the next delivery (HP2). 
 
In some cases lifestyle is such an important consideration that patients decide to stop prophylaxis, 
because they feel treatment is too much of a burden, or stops them from living the life they want to 
live. 
There’s one gentleman I spoke to and he had-- he just said, “Well I know what you’re saying 
and I can see why you’re saying it and you’re right, but actually what would be worse for me 
right now is having to take prophylaxis, so I’d rather live with the fact that I might have a bit 
of arthritis in one joint in the future than actually spend my 20s doing this,” right, okay 
[laughs], I thought well you can’t really argue with it. So I have seen it for that reason as well, 
where they’ve made a definite decision (HP4). 
 
Subtheme 2: Venepuncture issues 
Needle phobia or issues in relation to venous access can have a dramatic impact on adherence.  
HP suggested that needle phobia only affects a small number of patients, but that it is an issue that 
can consume a lot of time. This is because patients require a lot of support, and in some cases 
come to the centre for all of their injections.  
Children are often taught about their treatment slowly and gradually, starting out with helping to mix 
treatment, leading to helping with the injection and finally doing it themselves.  During this process 
the haemophilia team have a range of tools available to help, including anaesthetic creams, 
distraction techniques, and help from play therapists. As a result most children learn to do their 
injections without developing needle phobia.  However, if parents struggle with needles it is more 
likely that their children will struggle too. 
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Sometimes I think it’s affected by how the parents react to it and how they’re feeling about it. 
We do have play specialists, distraction and we have local anaesthetic creams. If all of those 
things are in place in the beginning, what you see then in the centre is that we have boys 
that are three or four that will come in and accept it and it all happens really smoothly. Now 
that didn’t happen without some other things happening before it. But I think it’s more 
perhaps the parents struggle with a bit of needle phobia. And is that needle phobia or the 
thought of doing something so invasive to your child? (HP6) 
 
One HP noted that issues related to contaminated blood may also cause anxiety or phobia in 
relation to injections, particularly for patients with family members who were infected with HIV or 
Hepatitis C during the 1970s and 1980s. 
Most probably their family got affected either with HIV or Hep C, or both. So, it’s really hard 
to break through those barriers. That’s where I am not so sure whether after that period how 
much information was given to them about the recombinant factor but we try our best just to 
tell them ‘there’s no, it’s not from any human’. No matter how you try and explain, it’s a bit 
hard. (HP3) 
 
Several HP highlighted that venous access is an issue that can also affect adherence. For some 
patients it is very hard to find a vein to inject into, and in some cases it can even be challenging for 
doctors and nurses to inject these patients. 
I think also whether they’ve got decent veins or not. Again if they’re left-handed and all their 
veins are in their left arm it can be quite tricky. It might not cause a problem, they might 
adapt quite well to using their right arm but, or right hand but it doesn’t always follow. (HP2) 
 
If a patient has an injury in one arm or hand, this can also make it difficult or painful for them to 
inject themselves. Participants explained that for some patients issues in relation to venous access 
can make treatment very stressful, and cause anxiety that in turn can lead to needle phobia. 
Venous access can often be a massive battle and for some of our families, perhaps where 
they’re not doing so much or children are overweight then it’s a real battle with trying to find 
veins to be able to treat. And that puts stress on the families and on the child; it can lead into 
some needle phobia. (HP6) 
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Three participants explained that patients are taught to rotate their injection sites, to prevent any 
scarring or damage to veins. However, they suggested that many patients use only one or two sites 
because the skin scars after some time, numbing the skin making the injections less painful.   
So the people who use the same injection site/ it’s just numb. When you train them you try 
and get- - if they’ve got multiple veins, to rotate round so that each one can heal and not 
scar. But some of the guys who have quite bad scarring if they’re just using the same 
injection site do that because it becomes less sensitive and easier for them to do (HP1). 
 
Subtheme 3: Not wanting to be different 
Most interviewees agreed with the suggestion in the existing literature that adherence may be a 
particular issue during adolescence because of the developmental issues that characterise this 
period. The main focus for many adolescents is on their social life and asserting independence from 
parents.  They tend to live in the here and now and find it  
difficult to understand that not taking their treatment may have repercussions for their future health. 
They also struggle with the idea that their haemophilia makes them different from their peers. 
For any adolescent the emphasis to be the same and liked and popular and to be all these 
things is quite strong isn’t it? And they want to do what everybody else is doing and for some 
I imagine that haemophilia and having to treat themselves may be something that’s setting 
them apart (HP2). 
Don’t like to be different, don’t like to be seen different. Don’t want to do it, had enough of it, 
don’t want to stick needles in themselves, no one else to stick needles in them, feel well in 
themselves, a desire to conform with peers (HP5). 
 
All participants agreed that most adolescent patients go through a stage of suboptimal adherence, 
ranging from occasional skipping to complete disengagement with treatment. This period appears to 
occur mostly between the ages of 12 and 15, and is characterised by patients becoming more 
independent and assertive.    
Hmm. 12 to 15 year olds [laughs] just everything’s an issue for that age group I think. I used 
to work in schools with some of that age group and they’re just challenging most of the time. 
I’m going to do the opposite” kind of thing (HP1). 
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During this period it can be challenging for the haemophilia team to engage with patients, as 
patients rebel against the haemophilia team as well as their parents.  During the interviews it 
became clear that particularly nurses spend a lot of time working with each patient, and tend to be 
very sensitive to each individual’s needs. 
And with some patients ‘I don’t really want to come to the unit, I don’t want to be having 
treatment, I don’t want all this fuss, I don’t want all these appointments’, and that’s a bit more 
difficult. I can think of a patient that comes and he has a bleed and you’ve to judge the timing 
because if you push too much for him to get to clinic and getting prophylaxis they completely 
back off, because they obviously have a reason that they’re choosing not to and it is their 
body and if they feel like you’re really pushing them then they’re just going to turn up even 
later after the next bleed. So sometimes I’ll bring it up and other times I won’t and I try and 
do it in little bits, and try and encourage them back. (HP4)  
 
Subtheme 4: Absence of symptoms 
The introduction of prophylactic treatment has revolutionised haemophilia care, and improved 
patients’ quality of life significantly.  Some patients even manage to get to adolescence without 
having experienced any severe bleeds. Some of these patients stop taking their treatment because 
they find it difficult to understand why they need it, as they have no idea what it is like to suffer a 
bleed.  
Because they’ve had a little bleed and they’ve never experienced pain like it. People forget 
that haemothrosis is exquisitely painful. Some boys won’t and they’ll just say “Okay, I’ll 
accept that and I’ll just give treatment when I bleed. But most of them if they do experience a 
bleed will want to stay on prophylaxis. It’s quite difficult to argue if they’ve not experienced it 
and it’s sort of a predictable outcome of prophylaxis that some boys will forget they’ve got 
haemophilia, and can’t rationalise why they shouldn’t do things like skateboarding, like 
signing up for soccer clubs. And that’s when it becomes difficult because they’ve lived their 
life really with prophylaxis and kids have been on regular prophylaxis since the 90’s. So 
they’ve got no experience of acute bleeds, unless they do something really daft. (HP5) 
 
Once they experience their first serious bleed due to skipping prophylaxis, many non-adherent 
patients start taking their treatment again. However, once they have had a period without bleeds 
they sometimes stop taking their treatment again with more bleeds as a result.  This can become a 
vicious circle for some. 
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We try and encourage them, I mean - - we have managed to encourage them to a certain 
extent that they’ll go on the prophylaxis. When they know that they are not getting any 
bleeds they fall back again. And say ‘no, no, I don’t need it’. But when they got a really bad 
bleed, that’s when reality hits them and says ‘ no I need to be on prophylaxis’. (HP3) 
 
A minority of patients decide to stop their prophylaxis completely. Interviewees explained that they 
do what they can to re-engage these patients, but have to accept that this is not possible in all 
cases.  Some patients make the conscious decision to stop their treatment because they feel that 
reducing the long-term risks to their health does not weigh up against having to take regular 
prophylaxis. 
he just said, “Well I know what you’re saying and I can see why you’re saying it and you’re 
right, but actually what would be worse for me right now is having to take prophylaxis, so I’d 
rather live with the fact that I might have a bit of arthritis in one joint in the future than 
actually spend my 20s doing this,” right, okay [laughs], I thought well you can’t really argue 
with it (HP4). 
 
Some HP use case studies of patients who have bleeding-related joint damage to show younger 
non-adherent patients why taking prophylaxis is so important. Sometimes this ‘shocks’ a young 
person into adhering to their treatment regimen again. 
You see the older patients that haven’t had it and the difference in their joints and their 
general health. It’s like having two cohorts of patients it’s really stark. I guess as the older 
cohort get smaller it’s going to be harder and harder to convince the younger one that 
actually this is a really good plan [laughs]  (HP4). 
 
Subtheme 5: Family and social issues 
Each family is different and has its own challenges. The impact that haemophilia has on the patient 
and his family seems to range widely between families, and the interview data does not clarify the 
exact reasons why some families appear to cope better than others. However, it does suggest that 
the family set-up and relationship between patients and their parents and siblings appears to be one 
key factor. 
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I think all parents try and do their best and they live in a huge spectrum of social 
environments. I think it’s a huge spectrum where people are coming from and people that 
live in the most poor circumstances and the most chaotic circumstances have done 
fantastically well persuading their children to take home treatment. And some parents are 
just pretty rubbish parents. And that’s when I think life becomes difficult because there are 
other priorities in your life because it has to be said that coming in for their treatment 
overrides lots of other things and sometimes that is quite a negative thing but other times it’s 
a low priority for parents. Luckily we don’t have very many families like that (HP5) 
 
Haemophilia teams appear to spend a significant proportion of their time and resource on helping 
patients who struggle with their treatment due to social issues or chaotic lifestyle.  
And we’ve got another family where we have to do supervised prophylaxis for different 
reasons ‘cos their lives are crazy chaotic and they have huge dogs, like really big dogs in the 
house and there’s nowhere safe to actually…These dogs are quite aggressive so there’s no 
way you’d want anyone using a needle near a child with all this going on. So they come to 
the unit and get to the prophylaxis and I have to say they do come and they are engaged 
and things. The first family I was talking about it’s quite interesting how it’s changed… as the 
children are getting older it’s just adding to the complexity because they’re refusing to do it to 
make their parents look bad with social services and it’s very complicated. (HP4) 
 
HP appear to be sensitive to individual circumstances, and appreciate that looking after a child with 
haemophilia can be stressful. However, it can also be challenging for HP themselves to work with 
these families. It is not always clear whether haemophilia itself is the cause of stress or anxiety, or 
whether stress or anxiety caused by outside factors make it harder to manage haemophilia. 
I don’t think it’s a particular type of person but I think it’s. Would some of the families be like 
they were if haemophilia was there or it wasn’t there, is it that haemophilia has created some 
of these stresses or is it actually just as a family and as a unit they would have functioned 
like this, say throwing haemophilia in just kind of makes that even worse, it kind of 
exacerbates that (HP6) 
 
8.3.4   Theme 3: Improving adherence 
This theme describes all the suggestions that were made by the HP of ways in which adherence 
may be improved. This includes education of parents and patients, psychological support, peer 
support and support for parents. 
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Subtheme 1: Education  
HP agreed that knowledge and understanding about haemophilia and how prophylaxis works are 
crucial, and that education may help to improve adherence.    
You hope that by promoting and improving their knowledge that that’s going to improve their 
adherence. (HP6) 
When a child is first diagnosed parents are educated about haemophilia and then trained to 
administer treatment when prophylaxis is initiated. Several interviewees emphasized that it is 
important to involve patients from an early age, so that they can learn to do their treatment 
themselves gradually before they start secondary school.  Several participants suggested that the 
key reason to start educating and training patients early is that younger children tend to be easier to 
engage, and curious to learn.   
The norm would be persuasion I think and gradual involvement of the child and we do make 
it quite clear to the boys when they start on prophylaxis, when they’re going through 
prophylaxis in primary school, that the aim is that by the time they go to secondary school 
they’ll be giving their own treatment under pain of death if they don’t! And most of them will 
accept that so then it’s a question of really reinforcing when they do come up or if we’re 
seeing them in clinic, particularly the multidisciplinary clinics, to emphasise that and to try 
and make it more firm so that we encourage boys to start helping the parents at home, 
mixing up treatment, cleaning the skin, take needles out after finishing treatment, you know 
doing everything other than venipuncture. And then school holidays we try and get them to 
come to the unit so I guess depending on how they’re doing but certainly from the age of 
nine they’d be coming to the unit to try and learn some venipuncture (HP5) 
 
Participants agreed that starting early also ensures that patients are used to doing their own 
treatment before they hit adolescence, which is a period during which it is generally harder to 
engage patients. 
They need to learn before secondary school because if they don’t, they’re not interested, 
they go to secondary school and mum’s doing it, it’s easier, it’s always been that way. 
Whereas if around seven or eight, although they might not be able to take it on completely 
independently, they’re interested, they want to do it, you can reward them, they’re young 
enough that they can have incentives to want to do it. And I think if we get them then that 
then, we’ve got two boys that are eight and they’re doing it completely independently. They 
say it’s like eating their dinner, it’s just part of what life has become for them. (HP6) 
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It is important to consider that haemophilia HP are not necessarily trained to be educators and do 
not always have sufficient time or resources to work with families who are struggling. Several 
participants suggested that in some cases it can be challenging to ascertain what the exact issues 
are, and what the haemophilia team can do to help improve adherence. 
I mean there’s an element to kind of their family, their understanding so a lack of knowledge 
does go a long way to not helping with any kind of compliance. But that, whether that’s 
because they’re not interested in learning or they don’t have the capabilities to understand it 
or they just don’t, don’t want it to be part of their life and they’d rather forget about it, I think 
that has a big influence in whether or not they are compliant. (HP2) 
 
Subtheme 2: Psychological support 
HP suggested that support from a psychologist, play therapist or social worker can be helpful when 
working with a patient or family who are struggling with prophylaxis. However, the way in which 
support from these specialists is accessed differs from centre to centre. In two of the centres that 
were involved in this study the haemophilia team includes at least one psychologist and/or social 
worker, who can identify psychosocial issues as they arise and work with patients before problems 
escalate.  In the other centres patients have to be referred to psychological services that are 
provided by a separate team within the hospital, an associated hospital or in the community.  It 
appears that in many cases it is very difficult to access external support services for patients, due to 
a lack of funding and resources.  
You would try and refer for psychological support but we don’t actually have anything within 
the unit and we don’t have anything to access. We’ve had a real difficulty with a gentleman 
who really does need some long-term therapy, and we don’t have that. We have it for 
patients with HIV or hepatitis and trying to get that in the community is very difficult and very 
challenging, they don’t have the resources and it’s so frustrating ‘cos you can see that he 
needs it and he wants it [laughs]. (HP4) 
 
In contrast, in the centres where psychosocial services are embedded the multidisciplinary team 
appear to work together to try and meet as many of their patients’ needs without the need for 
referral.   
I think it helps me sometimes because they’re looking from the outside, I’m involved in the 
moment, they’re just kind of observing what’s happening and then they can offer some 
different advice. We’ve done lots since we had psychology embedded in our service, so 
there’s families with children that are new to haemophilia so a new diagnosis, we do some 
joint work (HP6) 
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Most of the HP who were interviewed felt that a multidisciplinary team that includes a psychologist is 
the ideal set-up, as patients would see the psychologist as part of the team and the threshold to 
access support would be low.   
But it would make it more acceptable if it was part of a team, ‘cos I’m sure the reason our 
social worker works for us as a social worker is there is an element of, “Oh I’m not really 
seeing a social worker, I’m just seeing…” and so that works [laughs], definitely (HP4) 
 
Interviewees agreed that, rather than having to see a psychologist separately once potential issues 
arise, an in-house psychologist may be able to identify issues early and support patients and their 
families through challenging periods without the need for significant psychological interventions.  
Whereas I think if we had access to someone most of the time or a lot of the time so this 
person’s not a complete alien to these patients, you or they see things different to the way 
we would see things. They will ask questions differently to the way that we, we would and, 
you know, you might, I can’t help but think that some of the problems that you do see these 
patients going through could be nipped in the bud. You wouldn’t get so bad that you’re 
having to refer them to a counsellor, it’s something that might have been able to have been 
dealt with before it became a big problem. (HP2) 
 
Several HP described how they sometimes feel unsure about how to deal with mental health issues 
that are interfering with adherence. In particular nurses described how they try and support patients 
as best as they can with psychological or social issues, but feel ill-equipped to do so. 
if they were in-house it maybe they would be able to build it as part of the relationship with 
the centre in a more holistic sort of way --- but I think there is a lot of psychosocial bits that 
as nurses we try to do our best but it would be nice if we had somebody who was a 
professional who knew how to deal, especially with, because some of them have some 
pretty major issues that, that, you know, sometimes I think we feel a bit lost with how to 
really deal with properly and support, because then you end up getting involved in all these 
sorts of things like I say, that aren’t really the haemophilia nursing side of things, you’re 
dealing with a lot of other, sorting out other issues and trying to help. (HP1)  
 
During the interviews it also became clear that HP felt that play specialists are very helpful when 
working with younger patients and their parents. They can play with a child to distract them while a 
doctor or nurse examines or treat them, they help prepare children for surgery, and work with them 
164 
 
pro-actively to ensure that children do not develop a negative association with the haemophilia 
centre. 
She’ll do play therapy with some of our little ones, so they’ll come to the centre when we’re 
not really doing anything but they’re just going to have a nice time with her. I think that’s also 
really important that it’s not that every time they come here there’s a massive traumatic 
event. So they’ll be doing things with her, she’ll have them in regularly then she’ll also do 
some things around distraction when we’re doing something. If she’s been working with a 
child I think then it’s really important. There’s been a little boy she’s been working with here 
before he was going to theatre  [for surgery] so the little boy didn’t have regular treatment so 
then she came and went with him to theatre to keep that continuity to play some of the things 
that she’d been doing with him and I think that that helps, I think that’s why we’re fortunate 
that we have our own, if we had to tap into somebody else’s service all the time then you 
don’t get that same continuity. (HP6) 
 
Subtheme 3: Peer support 
Health professionals suggested that some YPH can feel quite alone with it, as they have never 
come across another boy with haemophilia due to the rarity of the condition.    
When you’ve got spontaneous mutations or split-up families that haven’t necessarily kept in 
contact. I had one little one in clinic, he was convinced he was the only boy with 
haemophilia. I don’t think that’s uncommon these days. They go to big clinics, there’s lots of 
people, they’re not all necessarily coming to a haemophilia clinic. So a lot of them don’t see 
other boys with haemophilia. Being able to compare themselves with like-for-like is quite 
difficult for them (HP2). 
 
Most participants felt that bringing YPH together at peer support groups, or through activities and 
trips, can be beneficial in many different ways.  It gives young people the opportunity to socialise 
with others who are like them, and compare notes on how they deal with certain issues.  Meeting 
others that are affected by the same condition may make them feel less alone or isolated. 
We used to do residential trips which were fantastic and we haven’t done in a while. But I 
think that’s good if you’ve got a group of boys together, they’re all giving themselves 
treatment, it’s fairly normal, that’s the way it goes. I think it really helps, especially if you’ve 
got someone that doesn’t know other patients. If you can actually get them together that’s 
really good. And then do activities, not limit them that way, that helps. I think that would be a 
good idea. (HP4) 
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In some centres nurses facilitate peer support meetings between young patients to try and address 
specific issues.  For instance, two HP explained that they occasionally bring together non-adherent 
patients with patients who do keep to their treatment to try and encourage non-adherent patients to 
get back on track with their treatment.  
And we got the two boys together and I think it went very well because the one who didn’t 
treat was able to see someone of the same age, and see how he managed to do it himself. 
And he showed him -- and the other boy who didn’t treat himself was able to actually do it 
himself and it’s given him confidence because he didn’t seem like the most -- one child was 
quite a confident child and the other one was not such a confident personality and I think it 
was good for them and I believe they even exchanged numbers. It just gives them a chance 
to meet someone else with the same condition. (HP3) 
 
Peer support groups or activities can also help to educate patients. For instance, the Haemophilia 
Society used the London Olympics as an opportunity to engage young people and illustrate that 
despite having haemophilia some are able to participate in sport at a high level. 
In the Olympic team we’ve got a few haemophiliacs so they organized some swimming team 
where they invited the haemophiliacs to see what kind of sports you could do which are with 
minimal contact. Which may be advantageous (HP1). 
 
However, participants explained that the current pressures on budgets and resources have made it 
harder and sometimes impossible to organise regular groups or activities locally. As a result patients 
have to travel to other parts of the country to attend national or even international events organised 
by the haemophilia society. In addition to the challenges associated with travel to attend these 
events, staying in contact with other attendees after the event can be difficult as they may live on 
the other side of the country. 
Particularly when we had Social Workers and Psychologists attached to the unit, we had 
groups for teenage boys. So they had days out bowling and just group activities and a 
chance to meet others to chat. And I suppose it was easier to do when we did have the 
resource of having a Social Worker attached to the unit, Psychologists attached to the unit 
and those resources have long dried up. (HP5) 
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Subtheme 4: Support for parents 
In many cases parents needs support to help them look after their child. During the interviews it 
became clear that haemophilia centres are the driving force in educating and training parents, but 
also in addressing issues that may interfere with haemophilia management (e.g. parents with 
needle phobia).  
It was clear that in centres where psychosocial services are embedded this is often easier. This is 
because multidisciplinary teams are more likely to have all skills and expertise required to support 
families, and are able to work pro-actively with families to identify potential issues before they 
escalate. 
I had some clinics with the Psychologist and both of us worked with families to reflect on 
what had happened in the year just gone that was good, what are the challenges of the year 
ahead? What do we need to be working on together to try and do some proactive things and 
I think that will be the difference for the new families against the old. I think some of our older 
families even with children of 10 that have maybe had a really rough ride with haemophilia to 
get them to accept psychology is a huge challenge. Because almost to just accept it is 
admitting there’s a problem and that makes people feel vulnerable. I think it’s how we 
change that or, as nurses that’s, frustrating is the wrong word I think but quite, you kind of 
feel quite disempowered, you feel that these are your families you work with, you want to 
help them, you can see something that would be good for them and when they won’t accept 
it, it’s quite frustrating I suppose. (HP6) 
 
In many centres the teams use a range of ways to improve the communication with families, with 
the ultimate aim is to build better relationships, provide better support and address practical issues.  
It is assumed that a better informed patient, who has a good relationship with the team, will have 
better health outcomes as they are more likely to adhere to treatment and contact the centre pro-
actively to resolve potential issues. 
And we’re going to try and develop Skype as a means of enhancing that message, that 
communication, so if there’s any doubt about whether treatment or not than maybe for us to 
use Skype and actually have a look at a child who got a bleed, that might help reinforce or 
sort out that ambivalence maybe. But I don’t know, we’re just having a think about it. (HP5) 
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8.3.5 Theme 4: How can healthcare professionals help to improve adherence? 
HP described a range of ways in which they felt they could help patients to improve their adherence. 
They all felt that it is important to be sensitive to individual patients’ needs in everything they do. 
 
Subtheme 1: Being sensitive to individual needs 
Personalising, or individualising, haemophilia care appears to be a key focus that is reflected in 
many different ways, from designing treatment regimens around patients’ lifestyles to adjusting 
communication to individual needs and being sensitive to patients’ circumstances. 
So I suppose what we try to do as well is to look at our, look at people in the context of their 
situation because it can’t be the same for everybody, it’s not, it’s doesn’t work the same for 
everybody. (HP6) 
 
In the past patients would follow a standard treatment regimen on set days (Monday, Wednesday, 
and Friday). However, in recent years regimens have become increasingly personalised and take 
individual differences and lifestyles into account.   
Well it would be true to say that it’s not prescriptive or didactic and that people’s prophylactic 
regimens may differ from patient to patient and that depends on the patient, it depends on 
their bleeding phenotype and it depends on the parents, it depends on the geography, etc. 
(HP5) 
 
All interviewees emphasized that personalising care is not just about treatment, but also about the 
way you approach a patient and communicate with them. This can be about providing telephone 
appointments to accommodate people who work long hours or considering patient’s contact 
preferences (e.g. email, text or telephone), but also about the tone and language one uses and 
being mindful of any personal issues. 
I just think it’s very different for different people but, you know, you’ve kind of got to get to 
know them and try and build your strategy around that if you can. (HP2) 
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Haemtrack can be a useful tool to start a conversation with a patient about how and when they are 
taking their treatment, and in some cases it can help highlight issues that patients may not discuss 
with the team without being prompted. In that sense it contributes to the individualised approach, as 
the team log into Haemtrack during a consultation so that they can look at it with the patient, and 
work on a solution together. 
Haemtrack is really good because for some reason people will happily lie to my face [both 
laugh], then when I get up Haemtrack and they’ll say, “Oh, actually I am missing the odd 
one’’. It’s really odd because they’ve been really honest and then we look at it. I think 
sometimes they find it difficult to say to the doctor, actually I’m not doing it all the time or I 
have missed the odd one. I think Haemtrack is quite good because it’s quite nice, not to 
check up on people but because it starts the conversation and it makes them actually talk 
about it and you can say, “Okay, well why are you missing it, is there things we can do to 
help?”. Cos some patients will do things like they’ll get in their head it has to be done at this 
time of day, and then things change in their life or something happens and that they can’t do 
it easily at that time of day but they don’t necessarily think actually you could just do a 
different day [both laugh] so that helps. (HP4) 
 
Although prophylaxis is the treatment of choice, HP appreciate that for some patients it is simply not 
possible to follow a prophylactic regimen.  During the interviews they explained that they often try a 
range of different strategies that take the individual patient’s circumstances into account, but that in 
some cases they have to accept that a patient does not want to take prophylaxis.  In those cases 
the focus shifts to making sure that the patient does not disengage completely, and adheres to an 
on-demand regimen to treat bleeds if and when they occur. 
Other times they’ve deliberately chosen that actually I don’t want to be doing this now and 
with some patients that I don’t really want to come to the unit, I don’t want to be having 
treatment, I don’t want all this fuss and all these appointments. And that’s a bit more difficult. 
And you try and I can think of a patient that comes and he has a bleed and you’ve to judge 
the timing because if you push too much for him to get to clinic and getting prophylaxis they 
completely back off, because they obviously have a reason that they’re choosing not to and 
it is their body and if they feel like you’re really pushing them they’re just going to turn up 
even later after the next bleed. So sometimes I’ll bring it up and other times I won’t and I try 
and do it in little bits, and try and encourage them back. (HP4) 
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In other cases haemophilia teams reach a compromise with a patient or family that reduces the 
treatment burden while still providing some prophylactic cover for the patient. 
No, I think it’s persuasion and education and if they understand why you’re saying what 
you’re saying and most of them will go along with that, it makes life harder for families who 
are rushing around first thing in the morning and that in itself can influence when you’re 
teaching the boys prophylaxis because it’s much easier for a parent to spend five minutes to 
do treatment than to go through this whole thing of letting the boy do everything on a 
weekday but it’s reasonable to start thinking about changing the days and doing prophylaxis 
at the weekend because then that gives them a bit more time and flexibility. (HP5) 
 
From the interviews it became clear that HP are passionate about supporting their patients, and 
believe that a good relationship between patients and the haemophilia team can be crucial in 
keeping patients on track. 
There’s a lot of things that contribute to compliance and I think not least how well we support 
them from here and how early that starts I think is fairly fundamental. If we’re supportive from 
the outset and we’re available and if they find that the information that’s coming back from 
here is useful. I think ringing in out-of-hours and having a doctor that doesn’t really know 
anything, is probably not very helpful. And it would then “oh what the hell, I’m not going to 
bother, I’ll wait till Monday”, potentially that’s three days gone if they’ve done something 
Friday evening. And it starts quite early I think, and if they’ve got rubbish veins, if we’re crap, 
excuse the language, but at getting their veins then again if we can’t get it how do we teach 
them how to do it? And it doesn’t reflect very well on us and it doesn’t build them any 
confidence in us either so they’re not necessarily going to engage particularly well. And, as 
much as I hate to say it, sometimes I think you really do have to give the extra mile in order 
to actually get it back from them but you’ve got to be willing before they’re going to be. 
[Laughs] (HP2) 
 
Maintaining a good relationship with patients used to be more straightforward, as patients had to 
come to the haemophilia centre frequently to receive treatment, or to pick up their home treatment. 
These visits offered an opportunity to catch patients for an informal chat, and enabled the team to 
quickly identify potential issues. Several participants felt that, now that many patients get their 
treatment delivered to their home, contact has become less frequent with some patients only 
coming to the centre once or twice a year.  
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No, I think the main reasons for that lack of contact are not necessarily home treatment 
because people have been on home treatment for a long time, home delivery I think because 
when treatment was picked up from the hospital that was always an opportunity to have a chat 
to the parents, I think the parents found it very helpful that they could come in and have a cup 
of coffee and talk about what had been happening. Whereas now it’s quite a lot different, so 
the treatment will get delivered, if prophylaxis is going very well then there’s no contact at all 
with the hospital. (HP5) 
 
Subtheme 2: Regular contact and continuity of staff 
HP identified the lack of regular contact with some of their patients as a potential issue that may be 
associated with low adherence.  Participants explained that when contact with a patient breaks 
down (i.e. when they do not attend clinic appointments, or do not answer telephone calls or letters 
from the hospital) it can be an indication that the patient is not keeping to their treatment regimen 
and not treating bleeds appropriately. These patients tend to be aware that they are not looking 
after their haemophilia adequately, but do not want to engage with the haemophilia team. 
The severes [patients with severe haemophilia] are meant to be seen at least six-monthly 
minimum. But there’s been a recent case that people have fallen through the loop --- Weather 
they’ve DNA’ed [did not attend], and then they got discharged somehow. Or a patient can 
walk out without making their appointment. And therefore then they don’t have one. You really 
need to get them in, but getting in contact with them can be difficult. And getting them to 
come… (HP1) 
 
It can be very challenging to re-engage these patients, and convince them to attend a clinic 
appointment.  
People are less inclined to come because they think they’re going to get told off so they think 
actually I didn’t manage this right and it’s how we get that quite right as well (HP6). 
 
Interviewees explained that they tend to spend a lot of time and effort trying to contact and chase 
patients that they are concerned about. They agreed that this tends to be a small group of patients 
who take up a disproportionate amount of time.  
A fairly small group of patients who take up a significant amount of time and worry if you like 
because they don’t adhere (HP4). 
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During interviews it became clear that HP care about their patients very much and are genuinely 
worried when a patient goes ‘off radar’. In particular nurses felt that they support patients in many 
more ways than described in their job description. They appear to go above and beyond to help 
patients, usually with the ultimate aim to get them back on track with their haemophilia treatment. 
We kind of joke with each other that you’re the Nurse, you’re the Social Worker, you’re the 
Psychologist, you’re the Teacher, you’re kind of everything because you’re involved in 
somebody’s life often at a really kind of tricky or sticky time. And that kind of happens 
throughout with our families. We don’t have a huge number of children in our centre but what 
tends to happen is that for each of our families at some point there’s a little kind of blip and the 
intensity of what they need goes up and then fortunately somebody else, they kind of need a 
little bit less and it’s kind of like that’s a kind of up and down for all of the families. (HP6) 
 
Staff turnover appears to be very low in many haemophilia centres, with many staff members 
working in the centre for many years. As a result HP and patients get to know each other well, and 
often develop a close relationship.  
Well there’s been a paediatric nurse and she’s been here for, has she been doing it? Ten year 
or maybe, eight years, eight years maybe but you know, you think of younger children so she 
will have seen them from quite young/ yeah, you do sort of get to know and you get to know 
more about their wider circumstances over time as well, you know. (HP1) 
 
Visiting families at home can help with establishing a good relationship, and identifying potential 
issues that would be difficult to ascertain in clinic. 
But I think once you start actually going and seeing them outside the hospital it gives you a 
completely different dynamic on things and them you, and sometimes it becomes a lot more 
personal and you are more involved in their lives, you’re more involved because you’re 
watching them grow-up and they know you, which is nice and it helps to some extent because 
they’ve got a better trust and a better bond with you and they’ll let you do, you know, that 
sounds awful but, you know, with their treatment, they’ve got used to mum and dad doing it, 
for a lot of them they will let me do it but not necessarily other nurses that, you know, are just 
as capable but because they don’t know them and it’s never been done on them and they’ve 
not seen them do it, they’re not going to do it (HP2). 
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Although the close relationship between the haemophilia team and their patients was generally 
seen as positive by interviewees, it was also recognised that it can lead to over-dependency on a 
specific nurse or doctor. One nurse explained that she regularly gets contacted on her personal 
mobile phone by patients, another joked that nurses do not need to say their name when they 
answer the phone as patients tend to recognise their voices.  
when I go and see them at home everything, all the contact then once I leave the hospital is 
on my mobile so they automatically get my mobile number so out-of-hours on occasions I’ll 
get calls and things that are happening over the weekend. I had this argument with my 
husband the other day actually because I kept getting a few texts from one of them this 
weekend and it’s like “you’re not at work, why are you, you know, why are they still bothering 
you?” I was like “well their treatment doesn’t stop just because it’s not 9 to 5 Monday to 
Friday, you know, they’re still treating at the weekend and if they’re worried about something”, 
you know, (HP2) 
 
Subtheme 3: Collaboration with schools and community 
In addition to working with patients and their families directly, haemophilia teams try to engage and 
collaborate with schools and community teams as much as possible.   
I also do go in to see them at home and go to schools, to visit schools for education 
particularly, often for our boys when they’re changing from junior school up to secondary 
school, that’s quite a change, in terms of dependence and the number of staff that are going 
to be involved with them, it’s very different from what it’s like in a primary school setting. 
Sometimes because of our geographical location do quite a bit of supporting other community 
teams so the thing that sometimes we struggle with, kind of outsourcing it is, is that as a 
Paediatric Nurse the skill of venepuncture is not something that Paediatric Nurses take on 
often in a hospital setting, it’s the doctors that are doing it. So in the community we have a few 
teams that have got involved in doing it with some of our children and then if we have other 
children in that area that really helps but then we have other teams that we’re trying to find 
something more local for our families and we can’t find things and that’s quite challenging 
(HP6). 
 
Collaboration with schools is an important priority for haemophilia teams, as young patients spend a 
significant amount of time at school and may take part in potentially risky activities, such as PE 
lessons and playing outside at break time. Interviewees explained that they also try to educate 
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schools about what haemophilia is, and what it means for the patient and their family, to encourage 
schools to focus on supporting the patient rather than just managing risk.  
Schools, um, the Haemophilia Nurses will visit all schools anyway when a child with a 
bleeding disorder starts, just really to talk generally about the haemophilia and what to do in 
terms of what happens if they bump their head or they fall over and get a graze on their knee, 
it’s really just to educate and sort of calm people down a bit about you know, this child is not 
going to bleed to death in the playground and really just to get a sense of perspective about it 
as well. But they won’t be teaching the School Nurses how to give treatments, absolutely not. 
(HP5) 
 
Haemophilia Comprehensive Care Centres tend to cover a wide geographic area, which means that 
patients may live quite some distance from the centre.  To make life easier for those patients who 
are not able to come to the centre because of the distance, the haemophilia teams often engage 
community teams to provide additional support. 
Yeah, but they’re taking on, so they’re doing some of his treatment for the older boy because 
mum hasn’t been able to take that on and they’ll be doing that for the younger boy as well and 
I think the bonus for this family is that the same team of nurses work across the school and 
the community whereas if they were somewhere else that wouldn’t happen, you’d have two or 
three teams of nurses so that would kind of make it a bit more complex but they’ve got 
masses of support. (HP6) 
 
There is also a significant amount of collaboration with HP in other specialties. This can be 
challenging, as haemophilia is not necessarily well understood by all due to its rarity. One 
interviewee felt quite strongly that patients need help and support to ensure they receive adequate 
treatment for non-haemophilia related health issues. 
I think we struggle with some of the other specialities and their poor knowledge, not 
understanding, not wanting to actually get involved in something that’s not their thing, which is 
kind of fair enough but at the same time well if we didn’t act the same, if we acted the same 
way god knows what would happen to some of these people. [Laughs] But, you know, 
someone’s got to advocate for them haven’t they? And I think that’s where we come in, 
whatever it is and obviously you draw a line somewhere but at that point you need to find the 
right person to fill in where you can’t. I think that’s what it is all about isn’t it? It’s arming them 
with the right tools to get from A to B safely and happily so that they’re prepared to do what 
they need to do with those tools in order to get there I think. (HP2) 
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8.4 Discussion 
HP interviewed for this study felt that adherence among YPH is generally good, although they 
explained that levels of adherence are likely to fluctuate with even very adherent patients 
experiencing short periods of non-adherence.  As prophylactic regimens are increasingly 
personalised and flexible it is much harder to ascertain if a patient is adherent. In many cases 
haemophilia teams only intervene if a patient is presenting with bleeds or not attending check-up 
appointments, as they are often an indication that someone is not engaged with their treatment, and 
may be struggling with managing their haemophilia.  
Interviewees expressed concern about patients who do not treat bleeds appropriately, as these 
bleeds often last longer and cause more damage. It was suggested that patients who present late 
with bleeds, or do not treat bleeds adequately are often also those who struggle to keep to their 
normal treatment regimen. 
Time management and lifestyle-related issues were suggested to be key reasons why their patients 
do not adhere to their treatment. During a busy time, or during a significant life event or change, 
someone is much more likely to forget their treatment or find it harder to fit treatment in.  Most 
interviewees agreed with the existing literature that adherence may be a particular issue during 
adolescence, as a result of the specific developmental issues that characterise this period.  It can 
be challenging for haemophilia teams to engage with adolescent patients, particularly if they rebel 
against the haemophilia team and parents.  Other reasons for non-adherence that were mentioned 
were issues related to venous access (difficulty in accessing veins or injection-related anxiety); 
absence of symptoms (patients who have not experienced any serious bleeds thanks to prophylaxis 
can find it difficult to understand why they need it); family dynamics (relationship with and support 
from parents and siblings); psychosocial issues (stress and anxiety, chaotic lifestyle, social issues); 
and a lack of knowledge about haemophilia and treatment. 
HP felt that a multidisciplinary team that includes a psychologist, play specialist and social worker 
would be the ideal set-up to support patients (and families) who are struggling with prophylaxis.  
However, in most haemophilia centres psychological or social support have to be accessed via 
referral which is often difficult due to a lack of funding and resources. Participants also felt that YPH 
together through peer support groups or activities is beneficial, as it gives them the opportunity to 
socialise  and compare notes with others who are in the same position, and may make them feel 
less alone or isolated. However, they explained that the current pressures on budgets and 
resources have made it harder and sometimes impossible to organise support groups or activities 
locally. 
From the interviews it became clear that HP are passionate about supporting their patients, and 
believe that a good relationship between patients and the haemophilia team can be crucial in 
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keeping patients on track. They explained that they tend to spend a lot of time and effort trying to 
contact and chase patients that they are concerned about, and agreed that this tends to be a small 
group of patients who take up a disproportionate amount of time.  
As young patients spend a significant amount of time at school and may take part in potentially risky 
activities, (such as PE lessons) increasing knowledge and awareness of haemophilia at schools 
attended by patients appears to be an important priority for haemophilia teams. They explained that 
they also prioritise collaboration with HP in other specialties who are treating one of their patients for 
a health issue that is not related to haemophilia. This is key because haemophilia is not necessarily 
well understood by all due to its rarity.  
The interviews conducted with HP made it clear that they are passionate about supporting patients 
in as many ways they can.  The underlying motivation appears to be to keep patients on track with 
their treatment, to ensure optimal health outcomes. Their work is made challenging by pressures on 
resources, patients’ social and psychological issues, and limited understanding of haemophilia 
within and outside of the medical profession. However, it appears that they manage to maintain their 
motivation to do their best, which is so very clearly appreciated by patients and their families.  
The next chapter will provide a discussion of the findings, implications and conclusions of all three 
qualitative studies described above. 
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Chapter 9 - Discussion of qualitative interview studies 
The aim of the qualitative studies was to gain a comprehensive view of experiences and 
perceptions in relation to prophylactic treatment among young people with haemophilia (YPH), their 
parents and healthcare professionals (HP) in order to better understand what drives (non-
)adherence among adolescents and young adults with haemophilia. 
 
9.1 Findings 
Table 9.1 presents the superordinate themes of the three studies, and a short discussion of 
commonalities and differences between the three studies. 
There were many commonalities between the barriers and facilitators/motivators of adherence that 
were described by patients, parents and healthcare professionals (HP). However, there were some 
differences in the emphasis that was put on different factors. Patients felt that non-adherence was 
mainly due to treatment being inconvenient, time-consuming and unpleasant. They recognised an 
association between their mental state and adherence, where stress and anxiety can have a 
negative impact on adherence, but also in the other direction where treatment can cause some 
anxiety and stress. Parents felt that psychosocial factors (such as not wanting to be different from 
peers and prioritising social life) are key barriers to adherence. HP agreed with the barriers that 
were suggested by patients and parents, but also mentioned social and family issues (such as 
chaotic lifestyle and lack of parental support).  
The analysis suggests that barriers and facilitators/motivators of adherence can be roughly grouped 
in four areas; the patient themselves, the treatment, the social environment and the haemophilia 
team. Barriers are mostly related to the patient’s lifestyle, negative experiences and perceptions in 
relation haemophilia and treatment, psychological issues (such as anxiety), and prophylactic 
treatment itself (venous access, treatment being unpleasant, needle phobia, etc.). Facilitators 
and/or motivators to adherence are mostly related to the social environment (e.g. support from 
parents and friends) and care and support received from the haemophilia team. 
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Superordinate themes
Patient interviews
Difficult balance between avoiding risk, 
managing haemophilia and living a normal 
life
Patients explained that haemophilia, bleeds and in some cases pain are part of 
their life and identity. By young adulthood patients feel that they are experts in 
haemophilia, and have found a way to tailor their treatment around their lifestyle.
I don’t like taking treatment but hardly 
ever miss an injection
Most patients dislike taking treatment because it is inconvenient and at times 
painful. However, they realise prophylaxis will protect them against bleeds and 
allow them to live a normal life, which encourages them to keep to their regimen. 
Most patients have found a way to incorporate prophylaxis into their routine, 
which helps them to remember it.
Support from parents and the haemophilia 
centre keeps me on track
Patients tend to be very happy with the support they receive from their parents 
and the haemophilia team. This support appears to be a key facilitator to their 
adherence. Many patients also receive support from friends/peers and siblings.
Parent interviews
Self-management
Parents felt that their son's adherence was generally good in relation to taking 
his treatment, but that he tends to be less adherent in relation to completing his 
treatment log, avoiding risky activities and treating bleeds in a timely and 
appropriate manner.
Drivers of adherence
Parents described similar barriers as patients, but emphasised the psychosocial 
impact of haemophilia. Parents agreed that social support is a key facilitator and 
that better access to psychological support would help improve adherence. 
Parents understood the distinction between skipping and forgetting, but when 
describing their son’s non-adherence it was not always clear which one they 
were referring to.
Impact of haemophilia
Patients were keen to emphasize that they do not let haemophilia impact their 
life. However, parents spoke extensively about the negative impact on family life 
and school, which in turn had a negative impact on their son’s academic and 
career prospects.  
Haemophilia care
As patients, parents felt that after the initial period of adjustment haemophilia 
had become part of their reality and routine. They were very positive about the 
care/support their son (and family) received from the haemophilia team. Parents 
felt that awareness among the wider medical profession needs to improve.
Healthcare professionals interviews
Healthcare professionals’ estimates of 
adherence
Healthcare professionals agreed with parents that overall adherence is generally 
good, and suggested that non-adherence is mostly about timing of treatment. They 
also agreed that it is challening to persuade young people to complete their 
treatment logs, and treat bleeds immediately and appropriately.
What drives non-adherence?
Healthcare professionals described similar barriers to those mentioned by patients 
and parents. However, they felt that social and/or family issues, and absence of 
significant symptoms (ie bleeds) are also common causes of non-adherence.
Ways in which adherence can be improved
Healthcare professionals agreed with patients and parents that social support (for 
patients and parents) is the most important facilitator to adherence, and that 
psychological support can be hugely helpful and is likely to facilitate better 
adherence.
What do healthcare professionals think 
they can do themselves to improve 
adherence?
Haemophilia healthcare professionals appear motivated and dedicated to support 
patients and their families. They are often sensitive to individual needs, and go 
above and beyond to support patients. This includes staying in regular contact 
with patients who are struggling, and visiting schools and sport clubs to raise 
awareness and educate care givers in how to look after a boy with haemophilia. 
Table 9.1: Discussion of superordinate themes of patient, parent and healthcare professional interviews
Discussion of commonalities and differences between patients, parents and 
healthcare professionals
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The patient 
The findings of the three interview studies suggest that haemophilia can have a significant impact 
on young patients and their families. Patients are keen to live a ‘normal’ life, and parents and HPs 
do what they can to support this.  Managing risk appears to be an important part of daily life, and 
many patients experience a tension between their desire to be normal on the one hand and 
managing their haemophilia successfully on the other.   
Patients, parents and HPs described that it can be challenging to fit treatment in with other priorities 
such as school, work and social life. This is particularly because treatment often has to be taken 
before a patient leaves the house in the morning, which means that they have to get up earlier to 
allow enough time to take treatment. Most patients and parents described how prophylaxis has 
become part of their routine, and that they find it challenging to remember treatment when they are 
out of the normal routine (e.g. on holiday, or away from home). 
Parents and HPs felt that adherence is a particular issue during adolescence, as a result of the 
specific developmental issues that characterise this period.  They explained that it can be 
challenging to engage with adolescent patients, particularly if they rebel against the haemophilia 
team and their parents. During this stage young people often strongly identify with their friends and 
resent being different due to their haemophilia.  In some cases this leads to non-adherence and 
disengagement with haemophilia and treatment more generally. 
Several patients and parents described psychological issues (such as stress and anxiety) that they 
felt had had a negative impact on adherence. But also that treatment can cause anxiety and stress 
in situations where there are issues in relation to venous access or needle phobia. This in turn can 
lead to worse adherence. 
HPs mentioned that a lack of knowledge about haemophilia and treatment and in particular an 
absence of symptoms can lead to non-adherence. This is because patients who have not 
experienced any serious bleeds thanks to prophylaxis can find it difficult to make the connection 
(between prophylaxis and absence of bleeds) and to understand why they need to take prophylaxis.  
 
Social environment 
Patients explained that support from parents, friends, and the haemophilia team is the most 
important thing that helps them keep on track with their treatment. In particular parents tend to be 
very involved with their sons’ haemophilia management, and often continue to support with 
treatment after he leaves home. 
HPs agreed that social support is an important facilitator to adherence, but also felt that issues in 
relation to a patient’s social environment can be a barrier to adherence. Examples of situations that 
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can have a negative impact on adherence that they described include a lack of family support, a 
chaotic lifestyle, and issues related to relationships within and outside of the family.  
 
The treatment 
YPH, parents and HPs agreed that adherence tends to be good. However, due to the increasingly 
personalised and flexible approach to prophylaxis, adherence is not straightforward to define and 
assess. Some patients and parents appeared slightly confused when describing adherence, 
particularly when they were trying to distinguish between forgetting and skipping. This could be due 
to confusion, or because they find it is easier to justify forgetting an injection rather than deliberately 
skipping one.  
Both patients and parents felt that it is ok to miss occasional injections, as long as the gaps between 
injections are not too long. They also felt that it is important that treatment is always taken in 
advance of physical activities, to reduce the risk of activity-related bleeding. HP agreed with this to a 
certain extent, particularly because they conceded that it is very difficult to convince a patient who 
does not bleed to improve their adherence. They also explained that at times they find it challenging 
to ascertain whether their patients are adherent or not. In practice they therefore tend to direct their 
focus towards patients who are presenting with bleeds or those who have clearly become 
disengaged with their treatment (e.g. not attending clinical appointments, not responding to letter or 
telephone messages, not completing treatment logs, etc.). 
One key barrier to adherence is the fact that treatment can be time-consuming and unpleasant; 
particularly if there are issues in relation to venous access or needle phobia.  
Facilitators mentioned by both patients and parents included establishing a good routine; setting 
reminders or alarms;; and psychological support (from psychologists, counsellors, social workers, or 
other support workers). In addition, parents felt that it is important to give young people some 
leeway, and allow them the space to develop the maturity and self-management skills that are 
required to manage haemophilia, and find out for themselves why prophylaxis is so important. 
Parents appeared to be aware of the importance of treating bleeds appropriately, and felt this was 
just as important for their son as him adhering to his prophylactic regimen. HP expressed concern 
about patients who do not treat bleeds appropriately and suggested that these patients are often 
also those who struggle to keep to their prophylactic regimen. 
 
 
 
180 
 
The haemophilia team 
Both parents and patients felt that the support from the haemophilia centre is excellent. They felt 
that they can always call the haemophilia centre for advice, or in some instances just a bit of moral 
support. In particular nurses, who have often worked in the centre for a number of years, appear to 
play an important role in supporting patients and their families. Because of their often pro-active 
approach they are able to identify potential issues (such as non-adherence) early, and then work 
with patients to try and find a solution. It appears that nurses often become involved with a range of 
issues that may affect patients, which are not necessarily always limited to medical problems.  
HPs felt that a multidisciplinary team that includes a psychologist, play specialist and social worker 
would be the ideal set-up to support patients (and families), particularly those who are struggling 
with prophylaxis. They also felt that bringing YPH together through peer support groups or activities 
is beneficial, as it gives them the opportunity to socialise and compare notes with others who are in 
the same position. HPs described how patients who are managing their haemophilia successfully 
(and adhere to their prophylaxis) can become role models for patients who are struggling with their 
treatment. They described examples of situations in their own haemophilia centre where these peer 
support relationships had resulted in improved adherence among young people who had previously 
struggled. 
Increasing knowledge and awareness of haemophilia at schools attended by patients appears to be 
an important priority for haemophilia teams. Another important part of their role is collaboration with 
HP in other specialties, particularly those who are treating one of their patients for a health issue 
that is not related to haemophilia. This is key because haemophilia is not necessarily well 
understood by all due to its rarity. 
 
9.2 Strengths and Limitations 
As highlighted in the literature review, the existing literature in this area is very limited in terms of the 
number as well as the quality of studies published.  The strength of these qualitative studies is that 
they are nationwide (recruiting participants from five haemophilia comprehensive care centres 
across England and Wales, including paediatric, adult and mixed centres).  Additionally, the focus in 
the studies is specifically on young people, rather than including patients of all age groups. This is 
particularly important because there are age specific issues that may influence adherence. 
Participants include YPH, parents of YPH, and HP, who were recruited from five very different 
centres (in terms of their geographic location as well as their organizational structure). As a result 
the findings represent views of a range of individuals, who are likely to have different experiences 
and perceptions in relation to haemophilia and prophylaxis. Another key strength is that these 
studies are part of a larger mixed method research project, in which quantitative and qualitative 
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findings complement each other to present a comprehensive study of adherence to prophylaxis 
among young people in the UK.  
The most important limitation that needs to be highlighted is the fact that all the interviews were 
conducted by a PhD student with limited previous experience in qualitative research. This potentially 
may have influenced or biased the discussions with participants, particularly during the first few 
interviews. The interview data represent the lived experience of individual participants, which are 
not necessarily representative of the whole population. It is possible that those YPH who agreed to 
be interviewed are more motivated and engaged in relation to their treatment, and that YPH who are 
non-adherent or disengaged with their treatment would have been less likely to take part in research 
about adherence. Particularly because disengaged patients often do not attend their clinical 
appointments, and would therefore not have been approached to take part. It is impossible to know 
whether the lived experiences represented in the interview data are still true today, as individual 
circumstances, experiences and perceptions may have changed since the interviews took place, or 
indeed may fluctuate over time. However, as the findings from the YPH, parent and HP studies were 
broadly in line it is reasonable to assume that the findings are representative of the wider 
haemophilia community. Another potential limitation is that the majority of interviews took place 
within hospitals. The interviews were always conducted in a private room, and participants were 
reassured that everything they said would be confidential. However, patients’ responses during the 
interview may have been biased or influences by their previous (potentially stressful or traumatic) 
experiences in the hospital. 
 
9.3 Implications 
Notwithstanding the limitations discussed above, the findings of this study have a number of 
implications. The findings from interviews with patients, parents and HP indicate that adherence is 
generally good among YPH. Support from parents and the haemophilia team appear to be the most 
important facilitators to their adherence. Haemophilia teams tend to have good relationships with 
many of their patients. These relationships are often maintained by regular contact, particularly with 
those patients who are struggling. In the current economic climate, and context of reorganisation 
and rationalisation of the NHS, this model of care may come under increased scrutiny and may not 
be able continue if resources are cut.  However, the findings from this study provide evidence for 
the benefits of the current approach in managing patients with severe haemophilia, and may 
therefore help haemophilia centres to build a case to retain their current level of resource.  
Many patients require, and indeed access, additional support from a psychologist to help them with 
the psychological and social impact of haemophilia. YPH, parents and HP agreed that psychological 
support is an important element of the comprehensive care that many haemophilia patients require. 
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They felt that this support should ideally be provided within the haemophilia centre setting, so that 
the threshold to access this support is low and psychologists are able to work with patients pro-
actively to address issues before they escalate. HP felt strongly that regular psychological input 
would contribute towards better patient outcomes, particularly for patients who struggle or are 
disengaged with their treatment. However, several of the centres involved in this research no longer 
have (or never had) a psychologist embedded in their team.  The findings of this research may help 
centres to put forward an argument to improve access to psychological support, or indeed appoint a 
psychologist in their centre. 
The findings also indicate that, due to the increasingly flexible approach to haemophilia treatment in 
the UK, adherence to prophylaxis is difficult to define and assess. HP agreed that they often 
prioritise working with patients who are clearly struggling, as indicated by bleeding episodes or other 
haemophilia-related issues they present with.  This is partially because they have to prioritise due to 
limited resource and time, but also because patients who are not bleeding are often assumed to be 
doing well, even if they are not adhering to their treatment.  
Patients’ tendency to bleed is not only determined by the severity of their haemophilia and extent to 
which they adhere to their treatment. But also by their bleeding phenotype, which can be relatively 
mild even for patients with severe haemophilia.  Therefore it could be that a patient with severe 
haemophilia ‘gets away’ with non-adherence to a certain extent, and may not necessarily need to 
improve their adherence. The findings of this research suggest that it may be useful to shift the 
focus of future research away from looking for ways to improve adherence generally, but rather to 
focus on improving adherence among those patients who are likely to have worse outcomes due to 
sub-optimal adherence.  It would be useful for the haemophilia HP community to discuss adherence 
in this wider perspective, to come to a nationwide agreement of what good adherence looks like in 
the context of improving outcomes in this patients group. 
 
9.4 Conclusion 
Adherence to prophylaxis among YPH tends to be good, and support from parents and the 
haemophilia team appear to be crucial to maintain good levels of adherence. The findings from the 
qualitative studies indicate that there is a need for the haemophilia healthcare community to 
consider ways in which to assess adherence that reflect the increasingly flexible and personalised 
approach to prophylaxis. With increased pressure on resources haemophilia teams may not be able 
to maintain regular contact with all patients. They may therefore need to focus their attention on 
those patients who are struggling (e.g. presenting with bleeds), or are clearly disengaged with their 
treatment (e.g. not attending regular check-ups, difficult to contact or not completing treatment logs). 
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Chapter 10 - General discussion 
The aims of this mixed methods research project were to assess levels of adherence among 
adolescents and young adults with haemophilia, and learn what drives their    adherence. 
 
10.1 Findings 
The quantitative findings of this study suggest that overall adherence among young people with 
haemophilia (YPH) is generally good.  The qualitative findings confirm this, and suggest the support 
provided by haemophilia centres is likely to contribute to these high levels of adherence. The good 
relationship and regular contact between the clinical team and their patients appears to enable 
healthcare professionals to identify and address potential issues (such as non-adherence) early.  
 
Unintentional and intentional non-adherence 
The quantitative study found that non-adherence was more likely to be due to forgetting than 
skipping. It is likely that young peoples’ busy lifestyles are partially responsible for this. However, 
findings from the qualitative studies also indicate that patients may find it easier to admit to 
forgetting than skipping. This may be because they are more likely to be ‘told off’ if they admit to 
intentionally skipping injections, whereas they get a more understanding response when they admit 
to sometimes forgetting injections.  The increasingly flexible approach to prophylaxis can at times 
make it confusing for patients to work out when their next injection is due, leading to unintentional 
non-adherence. It can also make it more challenging for the haemophilia team to ascertain the 
extent to which individual patients adhere to their treatment regimen, and identify the reason why 
they miss injections.  
 
Differences between adolescents and young adults 
Interestingly, the quantitative findings suggest that despite the fact that there were some significant 
differences between adolescents and young adults in terms of psychosocial factors that may be 
associated with adherence, there was no significant difference in their level of adherence. This is 
most likely because the psychosocial factors that were significantly different may not significantly 
contribute to the variation in overall adherence. 
However, that does not necessarily mean that it has no merit to assess differences in psychosocial 
factors between age groups, as they may provide further insight and help identify potential areas for 
intervention or improvement. For instance, young adults had greater beliefs in the necessity of 
treatment and greater necessity/concern differential scores, indicating that their belief in the 
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necessity of prophylaxis outweighs their concerns about this treatment. This suggests that potential 
interventions to change patients’ beliefs in relation to necessity of and concerns about prophylaxis 
may be better targeted towards younger patients. 
In relation to social support the findings suggest that although young adults receive less support, 
they are not less satisfied with the support they receive. This indicates that adolescents are likely to 
require more/more frequent support with their treatment. The interview findings confirm this, and 
suggest quite strongly that support by parents and the haemophilia team are key facilitators that 
help in particular young patients keep on track with their treatment. 
. 
Association between adherence and clinical outcomes 
In the quantitative analyses there was no significant association between adherence as a 
continuous measure and clinical outcomes (the number of bleeds and hospital visits). However, 
when the sample was dichotomised into adherers and non-adherers there were significant 
differences in the number of bleeds and hospital visits. Both of these findings are in line with a 
recent single centre study in the US (Duncan, Kronenberger, Krishnan, & Shapiro, 2014).  However, 
the direction of the relationship between adherence and bleeds was not in the direction suggested 
by Duncan and colleagues (2014). Interestingly, the findings of our study suggest that adherers 
experience more bleeds and visit the hospital more frequently than non-adherers. As described in 
chapter five, there are several possible explanations for this:  
- Clinical data were collated retrospectively for a six month period (i.e. the number of bleeds and 
hospital visits that patients had during the last six months), whereas patients were asked to 
report their adherence during the last month. It could therefore be that patients who 
experienced frequent and/or severe bleeds more than one month ago were motivated to 
improve their adherence during the last month in order to prevent further bleeds. 
- It may be that more adherent patients are more attentive to bleeding episodes and symptoms of 
bleeds (and more likely to report bleeds through Haemtrack or by calling the haemophilia 
centre), whereas less adherent patients may be more relaxed or less likely to interpret 
symptoms as bleeds (and less likely to report bleeds). It may therefore be that the number of 
bleeds for non-adherent patients are under-reported in their clinical notes. 
- Patients with good adherence may be more confident in the protection afforded by their 
prophylaxis, and therefore more likely to engage in physical activity compared to non-adherent 
patients. This in turn may increase their risk of bleeding (due to activity-related injury or 
increased pressure on joints and muscles). 
- Patients with a mild bleeding phenotype are less likely to suffer bleeds and may therefore ‘get 
away’ with suboptimal adherence to prophylaxis. 
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The current literature suggests that indications for and the efficacy of prophylaxis in adults with 
haemophilia remain controversial. It appears uncertain whether prophylaxis should stop or continue 
once adulthood is reached (Hay, 2007). Currently, many patients (particularly those with an active 
lifestyle) with severe haemophilia in the UK continue their prophylactic treatment into adulthood. 
However, there are also patients who choose to follow a less intensive regimen (usually by reducing 
the frequency of injections), or even switch to on-demand treatment without any prophylactic 
injections. The current more flexible approach to prophylaxis allows haemophilia teams to work with 
each individual patient to find a regimen that works for them in terms of lifestyle but also affords 
them the protection required to minimise bleeds 
In future research studies it would be useful to validate clinical outcome data collated from medical 
files against self-reported data, so that the analysis can provide more insight into the association 
between adherence and clinical outcomes. The addition of a haemophilia-related quality of life 
measure would allow for analysis of the wider implication of non-adherence, rather than just 
focussing on clinical outcomes such as bleeding episodes. 
 
Psychosocial factors of adherence 
Social support has been widely reported as an important facilitator of adherence (DiMatteo, 2004; 
La Greca & Bearman, 2002; Williams & Bond, 2002). The quantitative findings provide further 
evidence for this suggestion, with greater social support both correlated with and predictive of better 
overall adherence and better remembering and less skipping. The qualitative findings indicate that 
patients, parents and HP all feel that social support (from parents, family and friends) is a key 
motivator that helps patients to keep on track with their prophylaxis. The close relationship with the 
haemophilia team, and the support that patients and their families receive from them, were also 
highlighted as  important facilitators to adherence. HPs explained that they do what they can to 
support patients and their families, as they feel this directly contributes to patients’ adherence. 
Findings from a previous UK study which recruited participants aged 12 years and older in a single 
centre in London (Llewellyn et al., 2003) suggest that better adherence to clotting factor is 
associated with greater perceptions of symptomatology (Illness identity) consequences of 
haemophilia, and necessity of prophylaxis, but not fewer concerns about this treatment. However, 
the findings of the current study indicate that both greater perception of necessity of prophylaxis and 
fewer concerns about this treatment (and therefore the necessity/concern differential) are 
associated with better adherence. Only a greater differential (and not greater belief in necessity of 
prophylaxis or fewer concerns about this treatment) was predictive of better overall adherence.  
However, fewer concerns were predictive of both better remembering and less skipping. The 
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interview findings also highlight that patients feel that the reason they keep to their regimen is that 
they believe they need prophylaxis to prevent bleeds, and live a ‘normal’ life. 
In relation to illness perceptions only perception of greater emotional responses (negative feelings 
such as fear, anxiety and anger) was associated with better adherence. This suggests that these 
negative feelings, most likely anxiety or fear about haemophilia, may act as a motivator to stay on 
track with treatment. However, when comparing adherers and non-adherers only illness perceptions 
in relation to the timeline of haemophilia were significantly different, with non-adherers perceiving 
their haemophilia to last longer. It is interesting that only negative feelings in relation to haemophilia, 
and not negative mood in general, was associated with adherence. Indeed, there was no 
association between positive or negative mood and adherence.  
The findings suggest that greater positive outcome expectations (perception that taking treatment 
will have positive outcome) are correlated with better overall adherence, and also predictive of 
overall adherence and better remembering. Although self-efficacy was not significantly correlated to 
or predictive of adherence, adherers did have greater self-efficacy scores in relation to taking their 
prophylaxis. This suggests that talking to patients about the efficacy of prophylaxis (providing 
protections against bleeds), and helping them to develop the skills and confidence to take their 
treatment, may help patients keep to their regimen. 
In summary, it appears that better social support, greater belief in the necessity and efficacy of 
prophylaxis, fewer concerns about this treatment and more negative feelings about haemophilia are 
the most important factors associated with better adherence among young people with haemophilia. 
 
Facilitators and barriers of adherence 
There were many commonalities between the barriers and facilitators/motivators of adherence that 
were described in interviews with patients, parents and healthcare professionals (HP). However, 
there were some differences in the relation to the order of importance that participants put on 
different barriers. Patients felt that non-adherence was mainly due to treatment being inconvenient, 
time-consuming and unpleasant. They recognised an association between their mental state and 
adherence, where stress and anxiety can have a negative impact on adherence, but also in the 
other direction where treatment can cause some anxiety and stress. Parents felt that psychosocial 
factors (such as not wanting to be different from peers and prioritising social life) are key barriers to 
adherence. HP agreed with the barriers that were suggested by patients and parents, but also 
mentioned social and family issues (such as chaotic lifestyle and lack of parental support). The 
qualitative analysis suggests that barriers and facilitators/motivators of adherence can be roughly 
grouped in four areas; the patient themselves, the treatment, the social environment and the 
haemophilia team. Barriers are mostly related to the patient’s lifestyle, negative experiences and 
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perceptions in relation haemophilia and treatment, psychological issues (such as anxiety), and 
prophylactic treatment itself (venous access, treatment being unpleasant, needle phobia, etc.). 
Facilitators and/or motivators to adherence are mostly related to the social environment (e.g. 
support from parents and friends) , care and support received from the haemophilia team, and 
positive treatment beliefs. 
Combining the qualitative and quantitative findings suggests that key facilitators to adherence are: 
greater belief in the necessity of prophylaxis, fewer concerns about prophylaxis, greater positive 
outcome expectations, greater negative emotions (such as fear and anxiety) in relation to 
haemophilia, more frequent social support and greater satisfaction with this support, positive 
experiences and perceptions in relation to treatment, and the support and guidance received from 
the haemophilia team, 
In relation to barriers, the quantitative and qualitative findings suggest key factors relate to the 
patient’s lifestyle (e.g. chaotic lifestyle, or finding it hard to fit treatment into a busy schedule), 
negative experiences and perceptions in relation haemophilia and treatment (including concerns 
about treatment), not believing in the necessity of treatment, psychological issues (such as anxiety 
or mental health issues), lack of social support, and prophylactic treatment itself (e.g. venous 
access, treatment being unpleasant, and needle phobia).  
A recent systematic review in relation to adherence to prophylactic treatment (Schrijvers et al., 
2013) suggests that key motivators of adherence include experience of symptoms, a positive belief 
of necessity of treatment and a good relationship with the healthcare provider. And that the key 
barriers to adherence are infrequent or absence of symptoms and increasing age. The same review 
suggests that the key determinants of adherence to prophylaxis are age, symptoms, beliefs, and the 
relationship with the health care provider. The findings of the current study confirm that beliefs in 
relation to prophylaxis and the relationship with the haemophilia team are key determinants. 
However, the findings suggest that in addition, social support, lifestyle, more positive (and fewer 
negative) experiences and perceptions in relation to treatment and its efficacy, and negative 
emotions about haemophilia also play an important role. 
 
10.2 Strengths and Limitations 
The existing literature is limited, as very few studies have been published in relation to adherence in 
this patient group. As yet no studies have been published that have applied a mixed methods 
approach.  Other limitations of the current literature are that most of the studies were conducted 
outside of the UK in countries where haemophilia healthcare is organised in a different way. The 
increasing flexibility and personalisation of prophylactic regimen in this country have thus far not 
received much attention in the literature. 
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The strength of this study is that it is a nationwide mixed method study with a large sample. It has a 
specific focus on YPH, who are likely to have had a very different experience in relation to their 
treatment in comparison to older patients (who most probably did not have prophylaxis available to 
them when they were young). The advantage of the mixed methods approach adopted in this 
research is that it allowed rigorous assessment of adherence and its correlates, and in-depth 
analysis of experiences and perceptions of YPH, parents and HP. In combination these quantitative 
and qualitative findings contribute to a deeper and more comprehensive understanding of 
adherence to prophylaxis among YPH, and the key drivers (barriers and facilitators) of adherence in 
this patient group.     
Detailed descriptions of the strengths and limitations of the individual studies included in this 
research are reported in each individual study chapter.  However a short summary of the key 
limitations follows below. 
A key limitation of the quantitative study is its cross-sectional design, which means that the findings 
are based on a 'snapshot' of the outcome and the characteristics associated with it at a specific 
point in time.  As a result the findings may have been different if the data were collected at a 
different point in time. Cross-sectional data also makes it difficult to make causal inference. 
The main outcome (self-reported adherence) was assessed by a relatively new scale, the 
VERITAS-Pro, which has not been validated for use in the UK. The findings suggest that the 
VERITAS-Pro may lack some content validity, as the majority of missing data was due to 
participants indicating that certain questions were not applicable. This reflects the fact that the scale 
was constructed and validated in the US, and does not consider the increasingly flexible and 
personalised approach to prophylaxis in the UK. Another limitation relates to the clinical data, which 
was collated from individual medical files. Because this process is resource intensive haemophilia 
centres were unable to provide clinical information for all participants. In addition to missing data it 
appears that the clinical data also included some inaccuracies, possibly because it can be 
challenging to ‘decipher’ information in medical files. Lastly, to keep the questionnaire to an 
acceptable length some of the psychosocial factors were assessed using short form scales. These 
scales are not as comprehensive as the longer versions, which may have influenced the findings to 
some extent. 
The most important limitation of the qualitative studies that needs to be highlighted is the fact that all 
the interviews were conducted and analysed by a PhD student with limited previous experience in 
qualitative research. This potentially may have influenced or biased the discussions with 
participants (particularly during the first few interviews) and analyses and conclusions drawn from 
this analysis. To reduce the risk of bias the qualitative analysis was supervised by an experienced 
qualitative research supervisor, who validated the themes identified by the researcher.  
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The interview data represent the lived experience of individual participants, which are not 
necessarily representative of the whole population. It is possible that those YPH who agreed to be 
interviewed are more motivated and engaged in relation to their treatment, and that YPH who are 
non-adherent or disengaged with their treatment would have been less likely to take part in research 
about adherence. Particularly because disengaged patients often do not attend their clinical 
appointments, and would therefore not have been approached to take part. It is impossible to know 
whether the lived experiences represented in the interview data are still true today, as individual 
circumstances, experiences and perceptions may have changed since the interviews took place, or 
indeed may fluctuate over time. However, as the findings from the YPH, parent and HP studies were 
broadly in line it is reasonable to assume that the findings are representative of the wider 
haemophilia community. 
 
10.3  Implications 
Notwithstanding the limitations discussed above, the findings of this study have a number of 
implications. The qualitative and quantitative findings were broadly in line in terms of estimated 
levels of adherence, and the key facilitators and barriers of adherence. 
 
Framework to understand Adherence  
One key finding of the current study indicates that in the context of the increasingly flexible and 
personalised approach to haemophilia treatment, a focus on improving adherence to prophylaxis 
alone may not improve outcomes for all patients. Patients, parents and healthcare professionals all 
suggested that the increasingly flexible approach means that adherence is more difficult to define 
and assess, and that what was historically seen as ‘good adherence’ is no longer relevant. For 
instance, many patients now have an agreement with the haemophilia team that allows them to 
tailor their treatment on a day-to-day and week-by-week basis, to ensure that they are adequately 
protected against bleeds when they need to be, and that they do not need to ‘waste’ treatment on 
days that they do not require such comprehensive protection.  This means that they would not be 
seen as non-adherent if they skip a treatment, as long as it is within the boundaries agreed with the 
haemophilia team. Clinicians appear to focus their efforts more and more on patients who 
experience bleeds or those who are clearly disengaged with their treatment and health situation. 
Patients who are not presenting with bleeds or other issues (e.g. pain, reduced mobility, concerns or 
anxiety about haemophilia and treatment), are usually only seen at their regular six-monthly check-
up and not contacted unless the haemophilia team have a specific reason to speak to them. 
Therefore it appears that the way in which adherence to prophylaxis among people with 
haemophilia is looked at requires updating to reflect the more flexible approach described above. 
The below framework proposes that adherence should be considered in relation to the key clinical 
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outcome (bleeds), and health-related quality of life (which includes physical, mental, emotional, and 
social functioning). Together bleeds (often reported as Annualised Bleeding Rate, ABR) and quality 
of life (QoL) provide a good indication of both physical and mental wellbeing. If one would focus 
solely on ABR, it would be difficult to ascertain how well a patient is doing generally, as the number 
of bleeds a patient suffers may not be directly related to their QoL. Equally, if one would solely focus 
on QoL there would be a risk that one would not consider (preventable) bleeds of patients who have 
a good QoL score. 
 
 
 
 
 
 
The framework suggests that both bleeds and QoL have a bidirectional relationship with adherence.  
For instance, in many cases non-adherence may cause a bleeding episode which in turn is likely to 
have a negative impact on a patient’s QoL. Particularly if the bleeding becomes recurrent and leads 
to long-term damage and potentially disability.  In reverse the absence of bleeds is likely to improve 
quality of life for many patients. However, according to the existing literature and findings from the 
Figure 10.1: Framework for understanding adherence among young people with haemophilia 
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healthcare professional interviews absence of bleeds can also decrease adherence (as patients do 
not consider treatment necessary), which in turn can then lead to bleeding.   
It is important to emphasize that not all bleeding episodes are caused by non-adherence. In some 
instances an injury caused by physical activity or an accident may cause a bleed. In other 
circumstances physical activity without apparent injury may still cause a bleed due to the pressure 
that exercise may put on joints or muscles.   
In particular the qualitative findings of this study suggest that some of the factors that are associated 
with adherence are also associated directly with bleeds and QoL  For instance a treatment 
approach that is sensitive to an individual patient’s circumstances is likely to improve adherence, 
but is also likely to improve several dimensions of QoL, such as mental well-being (being less 
anxious about treatment and feeling understood and supported) and physical activity (a 
personalised or tailored prophylactic regimen allows patients sufficient protection for physical 
activity). However, it may also reduce bleeds directly (e.g. a regimen that is tailored around a 
patient’s lifestyle is likely to prevent activity-related bleeds). Considering adherence together with 
QoL and bleeds is likely to improve HP and researchers’ understanding of this patient group, and 
enable them to put in place interventions aimed at improving patient outcomes that go beyond 
solely improving adherence or clinical outcomes. 
Based on the qualitative and quantitative findings presented in this thesis, the framework proposes 
that factors that influence adherence, QoL, and bleeds can be broadly categorised in four groups: 
the patient themselves; their social environment; their treatment; and the haemophilia team. 
However, the framework is not prescriptive about where each factor sits exactly in terms of which 
category they belong to and which of the three outcomes they are associated with. This flexibility in 
the framework recognises that key drivers of adherence are likely to vary between individual 
patients and circumstances, depending on patients’ symptomatology, treatment-related 
experiences, social circumstances and clinical variables (such as bleeding phenotype and joint 
health). As haemophilia teams care for patients in an increasingly personalised manner, it follows 
that any approach aimed at improving outcomes or QoL should follow the same personalised 
approach. This is something that many haemophilia HP already recognise, and in many cases have 
implemented in their daily practice.  Good examples of this are the way in which many nurses 
approach patients who are struggling with their treatment, or who have disengaged with treatment 
and/or the haemophilia team.  Nurses in particular appear very sensitive to individual needs in 
considering the best way to approach and work with each individual patient.  
In their systematic review Schrijvers and colleagues (Schrijvers et al., 2013) present a model of the 
factors that influence adherence among patients with haemophilia who use prophylaxis. Their 
review includes studies of haemophilia patients of all ages, so it does not look specifically at young 
people. Motivators included in their model are: a good relationship with the health care provider, 
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experience of symptoms. Barriers included in the model are: Absence of or infrequent symptoms, 
and increasing age. 
Figure 10.2 below is an updated version of this model, which presents the barriers and facilitators to 
prophylaxis among young people with haemophilia specifically, which were identified by the 
quantitative and qualitative studies. Motivators to adherence among YPH are highlighted in green 
whereas barriers are highlighted in red. The centre of the model includes Quality of Life, Bleeds and 
Adherence, rather than just adherence. This reflects the finding that, due to the increasingly flexible 
and personalised approach to prophylaxis in the UK, it is no longer relevant to look at just 
adherence as described above.  
 
 
 
Figure 10.2: Factors influencing adherence to prophylaxis among young people with  haemophilia 
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Assessing adherence, clinical outcomes  
Adherence was assessed using the VERITAS-Pro scale (N. Duncan et al., 2010), which measures 
self-reported adherence to prophylaxis. The findings from the study suggest that it appears a 
reasonable measure of adherence in this patient group. But that its validity could potentially be 
improved with some revisions to reflect the increasingly flexible and personalised approach to 
prophylaxis in this country. Ideally triangulation of data collected (using a revised version of the 
VERITAS-Pro, Haemtrack treatment logs and pharmacy data) should be carried out to test the 
validity of the revised scale, as the research included in this thesis had originally intended to do. 
Any future studies should address the issues that prevented the current study to collate Haemtrack 
and pharmacy data, to ensure that triangulation of data can be carried out. In terms of clinical 
outcomes (number of bleeds and hospital visits), it would be useful to include self-report measures 
in future studies to validate clinical information collated from medical files. It would also be useful to 
assess participants’ physical activity as during this study it became clear that physical activity is 
likely to increase patients’ risk of bleeding.  
 
Potential interventions 
As knowledge and believe in the efficacy of prophylaxis (positive outcome expectations) was found 
to be the only significant predictor of overall adherence in the quantitative study, it may be useful to 
test an intervention aimed at increasing positive outcome expectations. This may be a simple 
educational intervention that informs and educates patients (or parents of young patients) about 
how prophylaxis works, and how it improves outcomes. 
The quantitative study found that non-adherence was more likely to be due to forgetting than 
skipping. Although it is likely that young people’s busy lifestyles are partially responsible for this, 
findings from the qualitative studies also indicate that patients may find it easier to admit to 
forgetting than skipping. This may be because they are more likely to be ‘told off’ if they admit to 
intentionally skipping treatments, whereas they tend to get a more understanding response when 
they admit to sometimes forgetting.   
The increasingly flexible approach to prophylaxis can at times make it confusing for patients to work 
out when their next injection is due, leading to unintentional non-adherence that is not ‘forgetting’. It 
can also make it more challenging for the haemophilia team to ascertain the extent to which 
individual patients adhere to their treatment regimen and the reason why they miss injections. 
Therefore, dichotomising non-adherent patients into ‘forgetters’ and ‘skippers’ may not very useful 
when designing interventions aimed at improving adherence. As treatment regimen are now often 
tailor-made for individual patients, it follows that approaches aimed at improving adherence may 
also need to be tailored around individual circumstances. It appears that in many circumstances this 
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is already the case, as haemophilia teams appear to make an effort to work with individual patients 
in a way that suits their personal situation. 
 
10.4 Future research 
The findings of the studies described in this thesis have informed the design of a new study which is 
currently being undertaken in the NHS, recruiting participants in haemophilia comprehensive care 
centres across England and Wales.  The primary aim of the new study is to test a new device that 
helps clinicians to personalize treatment regimens by calculating what happens to factor treatment 
once a patient has injected it (a process called pharmacokinetics).  
The study consists of several blood tests (to determine a patient’s individual pharmacokinetic level) 
and an educational session that explains what pharmacokinetics (PK) is, and what the implications 
of a PK-guided regimen may be for individual patients. At the end of the (one-to-one) educational 
session the clinical team and patient will together agree a PK-guided treatment regimen which also 
takes a the patient’s lifestyle and bleeding history into consideration.  
Participants will be invited to complete several questionnaires (before and just after the educational 
session and then 6 and 12 months later). This questionnaire will assess participants’ self-reported 
Health-related Quality of Life, Annualized Bleeding Rate, Adherence, and Patient Activation (a 
measure which assesses the underlying knowledge, skills and confidence integral to managing 
one’s own health and healthcare). This study is not a randomised controlled trial, but a naturalistic 
evaluation of the impact of the educational session (and PK-guided treatment decisions). The study 
follows the framework developed during the course of this PhD.  
The findings of the research reported in this thesis suggest that the educational session may 
improve adherence, as it is likely to improve patients’ knowledge and believe in the efficacy of 
prophylaxis (increasing positive outcome expectations). This improvement in adherence may 
improve patient outcomes (as it may decrease the number of bleeds). The more personalised 
treatment regimen is also likely to decrease the number of bleeds directly, as it will provide 
protection at times that patients need it most (e.g. when they are physically active), and will be 
personalised based on individual PK levels. It is anticipated that health-related QoL will improve 
indirectly thanks to better adherence and a reduction in bleeds. It is also likely that QoL will improve 
directly thanks to the personalised treatment regimen. This is because patients may feel less 
anxious about treatment as they understand it better and are reassured that their regimen is 
personalised based on their individual circumstances and lifestyle. 
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10.5 Conclusion 
This study has provided evidence that shows that the current approach that haemophilia teams 
follow to support patients in managing their haemophilia treatment is working well.  The increasingly 
flexible and personalized approach allows patients to tailor their treatment around their lifestyle and 
personal circumstances. This often means that patients can live the life they want to live, and suffer 
few bleeds. This in turn motivates them to keep on track with their treatment, which in turn results in 
reduced bleeding episodes and its associated costs for patients, the NHS, and the wider society. 
However, it also appears that this more flexible approach can lead to some confusion around 
treatment frequency, dosing and may lead to accidental non-adherence. Some additional training 
and education of patients and their families to increase their knowledge and skills around 
prophylaxis may help to improve adherence among those patients who currently miss occasional 
treatments due to confusion.  
In a time of austerity, with management in the NHS looking to reduce costs, the evidence provided 
by this study may help haemophilia teams to build their case to continue with their current way of 
working with patients. Although it may be seen as a very resource intensive and costly approach, it 
is clear that the current approach keeps the majority of patients on track and as a result reduces 
bleeding episodes. It therefore reduces bleeding-related costs in the short-term (additional 
treatment and hospitalization), and the long-term (treatment of joint damage and joint 
replacements). 
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Appendix 4.1: Assessing adherence to prophylaxis among 
young people with haemophilia questionnaire 
 
About you  
Before you start, please write the participant number you were given by the researcher in the box.  
 
 
Please circle one answer for each of the below questions. 
1. Where do you live? 
With parents/carers   Independently alone   Independently with other(s)     Other 
 
2. Do you have brothers or sisters?  
No        Yes, they live in same house as me        Yes, they do not live in the same house 
 
3. Do you have any brothers or sisters who have a bleeding disorder? 
Yes         No 
 
4. Do you? 
I go to school     I go to college/university     I’m in other full-time education      
I’m in part-time education    I work part-time     I work full-time    I  don’t work    Other 
 
5. Please describe your current prophylactic treatment regime in the below box. Please describe the 
days of the week and time of day that you take prophylaxis, and the dosage that you take. 
 
 
 
 
 
 
 
 
6. What is the name of the prophylaxis you take?  
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Please circle one answer for each of the below questions. 
 
7. Do you think your treatment is…       
Cheap            Moderate in cost             Expensive             Very expensive            I don’t know 
 
8. Pain in your body 
a. How much pain that you feel is caused by your haemophilia, have you had in your body during the past 
4 weeks? (this can be new pain or chronic pain you have had for a while) 
None Very mild Mild Moderate Severe Very severe 
 
b. During the past 4 weeks, how much did this haemophilia related pain interfere with your activities? 
(school, work, hobbies, etc.)  
 
 
9. At what age (roughly) did you start helping with your injections? (for instance helping with making up 
factor or with the actual injection).  
                                 
 
 
If you can’t remember tick this box    
 
 
10. At what age did you start doing your injections by yourself?  
 
  
 
 
If you can’t remember tick this box   
 
 
11. Who usually does your prophylactic injections?   (please tick one answer) 
 Someone else does injections for me    
 They are done by someone else, and I help 
 They are mostly done by me, with help from someone else  
 I do them entirely myself 
Not at all  A little bit  Moderately  Quite a bit Extremely 
Write the age you started helping in the box on  
the right. 
Put an X if someone else doe s your injections. 
 
Write the age you started doing your injections 
yourself in the box on the right. 
Put an X if you receive help with your injections. 
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About managing your haemophilia and treatment  
Managing haemophilia is a challenging task. The questions below ask about how you manage your 
haemophilia and prophylaxis. We’d like to get an idea of how often you have done each of these things in 
the past three months.  
 
Please answer each question using the following scale: 
Always – all of the time, 100% of the time.    Rarely – not often, 25% of the time.    
Often – most of the time, at least 75% of the time.  
 
Never – not at all, 0% of the time 
 
Sometimes – occasionally, at least 50% of the time.    
 
N/A – tick if the question is not relevant to you 
 
Please tick one box next to each of the below statements. Please tick the Not applicable box if a 
statement doesn’t make sense to you or if it isn’t relevant to you. 
  
1. Timing Always Often Sometimes Rarely Never N/A 
I do prophylactic injections on the days 
recommended by my doctor or nurse 
      
I inject the recommended number of times per 
week 
      
I do prophylactic injections at the time of day 
that was  recommended by my doctor or nurse  
      
I do injections according to the schedule that 
was given to me by my doctor or nurse  
      
2. Planning Always Often Sometimes Rarely Never N/A 
I plan ahead so I have enough factor at home       
I keep close track of how much factor and how 
many supplies I have at home 
      
I run out of factor and supplies before I order 
more 
      
I have a system for keeping track of factor and 
supplies at home 
      
3. Remembering Always Often Sometimes Rarely Never N/A 
I forget to do prophylaxis injections       
Remembering to do prophylaxis injections is 
difficult 
      
I remember to inject on the schedule agreed 
with my doctor  
      
I miss recommended injections because I forget 
about them 
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4. Skipping Always Often Sometimes Rarely Never N/A 
I deliberately miss (skip) prophylaxis injections       
I choose to inject less often than prescribed       
If it is inconvenient to inject, I skip the injection 
that day 
      
I miss recommended injections because I skip 
them 
      
5. Communicating Always Often Sometimes Rarely Never N/A 
I call the Haemophilia Centre when I have 
questions about  haemophilia or my treatment 
      
I call the Haemophilia Centre when I have 
concerns about my health or when things 
change 
      
I make decisions about my treatment myself, 
without calling the Haemophilia Centre 
      
I call the Haemophilia Centre before I have 
medical interventions (for instance dentist 
treatment, or when you have to visit A&E) 
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Outcome expectations 
Below are 16 statements that finish the sentence:  If I always did everything I am supposed to do to manage 
my haemophilia, it would......     
Please circle ONE number next to each statement to show how much you agree with it, using the following 
scale: 
Don’t agree at all 1 2 3 4 5 6 7 8 9 10 Agree a lot 
 
If I always did everything I am supposed to do to manage my haemophilia, it would......   
…reduce the number of bleeds I experience 
Don’t 
agree 
at all 
1 2 3 4 5 6 7 8 9 10 
Agree 
a lot 
…be too much to think about 1 2 3 4 5 6 7 8 9 10 
…keep me healthy 1 2 3 4 5 6 7 8 9 10 
…help me do better at my studies/work 1 2 3 4 5 6 7 8 9 10 
…be too time-consuming 1 2 3 4 5 6 7 8 9 10 
…make me be admired by my friends 1 2 3 4 5 6 7 8 9 10 
…be difficult to live my life the way I want to 1 2 3 4 5 6 7 8 9 10 
…make me feel good about myself 1 2 3 4 5 6 7 8 9 10 
…be too much responsibility 1 2 3 4 5 6 7 8 9 10 
…make my family proud of me 1 2 3 4 5 6 7 8 9 10 
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How confident are you that you can do each of the below things in the future?   
Below are 12 statements about things that you may do to manage your haemophilia. Please circle ONE 
number next to each statement to show how confident you are that you can do this.   
Not confident at all 
that I can do this 
1 2 3 4 5 6 7 8 9 10 Totally confident 
that I can do this 
 
Communication             
Talk to doctor/nurse about my 
treatment  
Not 
confident 
at all 
1 2 3 4 5 6 7 8 9 10 
Totally 
confide
nt 
Talk to friends about my haemophilia 1 2 3 4 5 6 7 8 9 10 
Explain my haemophilia to other 
people 
1 2 3 4 5 6 7 8 9 10 
Taking prophylaxis 
 
          
 
Take my prophylaxis myself without 
help 
Not 
confident 
at all 
1 2 3 4 5 6 7 8 9 10 
Totally 
confide
nt 
Get out the equipment I need for 
taking prophylaxis 
1 2 3 4 5 6 7 8 9 10 
Put the needle into the vein 1 2 3 4 5 6 7 8 9 10 
Take the needle out 1 2 3 4 5 6 7 8 9 10 
Apply pressure to the puncture wound 
to stop bleeding 
1 2 3 4 5 6 7 8 9 10 
Dispose of sharps and other materials 
safely  
1 2 3 4 5 6 7 8 9 10 
Record the injection on my treatment 
record 
1 2 3 4 5 6 7 8 9 10 
Your health             
Tell when I need to get medical care 
and when I can handle a health 
problem myself 
Not 
confident 
at all 
1 2 3 4 5 6 7 8 9 10 
Totally 
confide
nt 
Take actions that will prevent or 
minimize some symptoms or problems 
that are associated with my 
haemophilia 
1 2 3 4 5 6 7 8 9 10 
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About your prophylaxis 
In some situations it may be difficult for you to take your prophylaxis. Below are 10 situations, please circle 
ONE number next to each situation to indicate how confident you are that you can take your prophylaxis in 
that situation, using the following scale. 
 
 
Please describe things that make it difficult for you to take your prophylaxis? (situations, things people do 
or say, equipment, activities, etc.). If you need more space please use the back of this sheet. 
 
 
 
 
 
Not confident at all  1 2 3 4 5 6 7 8 9 10 Totally confident  
I am confident I can take my prophylaxis…  
1. … when I am tired 
Not 
confident 
at all 
1 2 3 4 5 6 7 8 9 10 
Totally 
confident 
2. … when I am busy with other things 1 2 3 4 5 6 7 8 9 10 
3. … when I am on holiday, or away from home 1 2 3 4 5 6 7 8 9 10 
4. … when I skipped or forgot the last injection 1 2 3 4 5 6 7 8 9 10 
5. … when I am stressed 1 2 3 4 5 6 7 8 9 10 
6. …when there are guests in the house 1 2 3 4 5 6 7 8 9 10 
7. … when last injection was difficult or painful 1 2 3 4 5 6 7 8 9 10 
8. … when I am experiencing personal problems 1 2 3 4 5 6 7 8 9 10 
9. … when I can’t find a quiet/private place to 
take it  
1 2 3 4 5 6 7 8 9 10 
10…when I am worried about my haemophilia 1 2 3 4 5 6 7 8 9 10 
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Please describe things that would make it easier for you to take your prophylaxis? (situations, things 
people do or say, equipment, activities, etc.). If you need more space please use the back of this sheet. 
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Beliefs about your prophylaxis 
Below are 10 statements that other people have made about their medicines. Please tick one of the boxes 
next to each statement to show us how much you agree/disagree with it. 
 
Strongly 
Disagree 
Disagree 
Neither 
agree nor  
disagree 
Agree   
Agree 
Strongly 
My health, at the moment, depends on my 
prophylaxis 
     
Having to take prophylaxis worries me      
My life would be impossible without 
prophylaxis 
     
Without my prophylaxis I would be very ill      
I sometimes worry about long-term effects of 
prophylaxis 
     
My prophylaxis is a mystery to me      
My health in the future will depend on my 
prophylaxis 
     
Prophylaxis disrupts my life      
I sometimes worry about becoming too 
dependent on my prophylaxis 
     
Prophylaxis protects me from becoming worse      
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Your views about your haemophilia 
The questions below ask about your views about your haemophilia. Please circle ONE number from 0 to 10 
under each statement to describe your view.  There are no right or wrong answers; we are just interested in 
what you think. We will not show your answers to your doctor or nurse. 
 
1. How much does your haemophilia affect your life? 
Haemophilia does not 
affect my life at all 
0 1 2 3 4 5 6 7 8 9 10 Haemophilia severely 
affects my life 
 
 
2. How long do you think your haemophilia will continue? 
My haemophilia will 
last a very short time 
0 1 2 3 4 5 6 7 8 9 10 My haemophilia will 
last forever 
 
 
3. How much control do you feel you have over haemophilia related symptoms? 
I have absolutely no 
control over my 
symptoms 
0 1 2 3 4 5 6 7 8 9 10 I have an extreme 
amount of control 
over my symptoms 
 
 
4. How much do you think your treatment can help haemophilia related symptoms? 
Treatment can’t help 
with my symptoms   
at all 
0 1 2 3 4 5 6 7 8 9 10 Treatment can be 
extremely helpful 
 
 
5. How much do you experience symptoms to do with your haemophilia? 
I have no symptoms 
at all 
0 1 2 3 4 5 6 7 8 9 10 I have many severe 
symptoms 
 
 
6. How concerned are you about your haemophilia? 
I am not concerned at 
all about my 
haemophilia 
0 1 2 3 4 5 6 7 8 9 10 I am extremely 
concerned about my 
haemophilia 
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7. How well do you understand your haemophilia? 
I don’t understand my 
haemophilia at all 
0 1 2 3 4 5 6 7 8 9 10 I understand my 
haemophilia very 
clearly 
 
 
8. How much does your haemophilia affect your feelings (either good or bad)? 
My haemophilia does 
not affect me 
emotionally l 
0 1 2 3 4 5 6 7 8 9 10 My haemophilia 
affects my emotions 
extremely 
 
 
9. Please write in the box below the most important factor(s) that you believe causes haemophilia.  
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Your feelings  
The words below describe different feelings and emotions. Please tick one box next to each word to show us 
how much you have felt like this THIS WEEK.   
 
 Very slightly 
or not at all 
A little Moderately Quite a bit Very much 
1 Enthusiastic      
2 Scared      
3 Interested      
4 Afraid      
5 Determined      
6 Upset      
7 Excited      
8 Distressed      
9 Inspired      
10 Jittery      
11 Alert      
12 Nervous      
13 Active      
14 Strong      
15 Proud      
16 Irritable      
17 Attentive      
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Social Support  
We want to know how often you are offered help or support with your haemophilia. Under each statement 
below, circle the number that indicates how often you receive help or support with this. However, everyone 
has different ideas about what is helpful and supportive. We want to know what is helpful and supportive 
for you.  So please also circle the number that shows how supportive each behaviour is for YOU. 
These are the scales to use in answering the questions: 
 
How often does this happen?  
0 1 2 3 4 5 
Never Less than 
2x a month 
Twice a 
month 
Once a 
week 
Several times 
a week 
At least 
once a day 
 
 
When this happens, how do you feel about it? 
-1 0 1 2 3 
Unhelpful or NOT 
supportive 
Neutral A little helpful 
or supportive 
Helpful/ 
supportive 
Very 
supportive 
 
Note: if a behaviour never happens, click ‘0’ for never. Please try to rate how you would feel if this did 
happen. 
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How often does anyone…  How does this make you feel?... 
Or How would you feel? 
1. Remind you to take you prophylaxis 
How often  0    1    2    3    4    5  It feels:   -1    0    1    2    3 
2. Let you  know they appreciate how hard it is to take prophylaxis 
How often  0    1    2    3    4    5  It feels:   -1    0    1    2    3 
3. Give you a hard time when you have skipped or forgotten a prophylaxis injection 
How often  0    1    2    3    4    5  It feels:   -1    0    1    2    3 
4. Praise you for giving yourself injections correctly or on time 
How often  0    1    2    3    4    5  It feels:   -1    0    1    2    3 
5. Help when you might be having a bleed  
How often  0    1    2    3    4    5  It feels:   -1    0    1    2    3 
6. Listen to you when you want to talk about worries or concerns you have about your 
haemophilia 
How often  0    1    2    3    4    5  It feels:   -1    0    1    2    3 
7. Encourage you to do a good job in taking care of your haemophilia 
How often  0    1    2    3    4    5  It feels:   -1    0    1    2    3 
8. Understand when you sometimes make mistakes in taking care of your haemophilia 
How often  0    1    2    3    4    5  It feels:   -1    0    1    2    3 
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Appendix 4.2: revisions to VERITAS-Pro questionnaire 
About managing your haemophilia and treatment  
Managing haemophilia is a challenging task. The questions below ask about how you manage your 
haemophilia and prophylaxis. We’d like to get an idea of how often you have done each of these things in 
the past three months. Please answer each question using the following scale: 
 
Always – all of the time, 100% of the time.    
Often – most of the time, at least 75% of the time.  
Sometimes – occasionally, at least 50% of the time.    
Rarely – not often, 25% of the time.    
Never – not at all, 0% of the time 
Not applicable – tick if the question is not relevant to you 
Please tick one box next to each of the below statements. Please tick the Not applicable box if a statement 
doesn’t make sense to you or if it isn’t relevant to you. 
  
Timing Always Often Sometimes Rarely Never 
Not 
applicable 
I do prophylactic infusions on the scheduled days 
injections on the days recommended by my doctor 
or nurse 
      
I infuse inject the recommended number of times 
per week 
      
I do prophylactic infusions in the morning as 
recommended injections at the time of day that was  
recommended by my doctor or nurse  
      
I do infusions injections according to the schedule 
that was given to me by my doctor or nurse  
      
Dosing Always Often Sometimes Rarely Never 
Not 
applicable 
I use the doctor-recommended dose for infusions       
I infuse at a lower dose than prescribed       
In increase or decrease the dose without calling the 
treatment center 
      
I use the correct number of factor boxes to total my 
recommended dose 
      
Planning Always Often Sometimes Rarely Never 
Not 
applicable 
I plan ahead so I have enough factor at home       
I keep close track of how much factor and how 
many supplies I have at home 
      
I run out of factor and supplies before I order more       
I have a system for keeping track of factor and 
supplies at home 
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Remembering Always Often Sometimes Rarely Never 
Not 
applicable 
I forget to do prophylaxis infusions injections       
Remembering to do prophylaxis injections is difficult       
I remember to infuse inject on the schedule 
prescribed by the treatment center agreed with my 
doctor  
      
I miss recommended infusions injections because I 
forget about them 
      
Skipping Always Often Sometimes Rarely Never 
Not 
applicable 
I skip deliberately miss (skip) prophylaxis infusions 
injections 
      
I choose to infuse inject less often than prescribed       
If it is inconvenient to infuse inject, I skip the 
infusion injection that day 
      
I miss recommended infusions injections because I 
skip them 
      
Communicating Always Often Sometimes Rarely Never 
Not 
applicable 
I call the treatment center Haemophilia Centre when 
I have questions about  haemophilia or my 
treatment 
      
I call the treatment center Haemophilia Centre when 
I have haemophilia-related health concerns about 
my health or when changes occur or when things 
change 
      
I make treatment decisions about my treatment 
myself, rather than calling the haemophilia center 
without calling the Haemophilia Centre 
      
I call the treatment center Haemophilia Centre 
before I have medical interventions such as dental 
extractions, colonoscopies, visits to the emergency 
room, or hospital stays (for instance dentist 
treatment, or when you have to visit A&E) 
      
© Indiana Hemophilia and Thrombosis Center, Inc. 2010 
 
  
225 
 
Appendix 4.3: Boxplots for the frequency distribution of the 
VERITAS-Pro adherence subscales and sum scores 
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Appendix 4.4a: Statistical power calculation for analyses testing the 
difference of means (t-test) 
 
 
  
Effect size 2-tailed 1-tailed 2-tailed 1-tailed 2-tailed 1-tailed
20% 620 475 790 620 1060 860
15% 160 120 200 160 270 220
10% 75 55 90 75 120 100
Calculated using Gpower 3.1.9.2 (Faul, Erdfelder, Lang, & Buchner, 2007). 
Appendix 4.4a. Overview of required sample size to achieve statistical power (70%, 80%, 
and 90%) and effect size (20%, 15%, and 10%). 
Based on analyses testing the difference of means (t-test, p<0.05)
Power
70% 80% 90%
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Appendix 4.4b: Statistical power calculation for linear multiple 
regression analyses 
 
 
 
 
  
Effect size 2-tailed 1-tailed 2-tailed 1-tailed 2-tailed 1-tailed
20% 65 50 85 65 110 90
15% 35 26 45 35 55 45
10% 25 20 30 25 40 35
Calculated using Gpower 3.1.9.2 (Faul, Erdfelder, Lang, & Buchner, 2007). 
Based on linear multiple regression analysis with 10 predictors
Appendix 4.4b. Overview of required sample size to achieve statistical power (70%, 80%, 
and 90%) and effect size (20%, 15%, and 10%). 
Power
70% 80% 90%
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Appendix 4.5: Table 4.9A: Linear regression model of predictors 
of adherence sum, fixed enter method  
 
 
  
Table 4.9A: Linear regression model of predictors of adherence sum scores 
  b SE B β P 
Constant 33.370 16.317   .045 
BMQ Concern 1.053 .438 .351 .020 
BMQ Necessity -.782 .315 -.291 .016 
Positive outcome expectations -.152 .104 -.164 .151 
Negative outcome expectations .085 .156 .073 .589 
Squared Haemophilia-related self-efficacy .000 .001 .088 .528 
Squared Prophylaxis-related self-efficacy -.001 .000 -.143 .242 
PANAS positive affect -.139 .130 -.125 .287 
Log PANAS negative affect 4.778 3.997 .173 .237 
IPQ Consequences .035 .455 .010 .938 
IPQ Squared Timeline .107 .076 .160 .166 
IPQ Squared Personal Control .031 .046 .079 .502 
IPQ Squared Treatment Control .092 .055 .200 .100 
IPQ Identity .316 .486 .077 .518 
IPQ Concerns -.008 .491 -.002 .988 
IPQ Coherence -.253 .788 -.035 .750 
IPQ Emotional representations -1.303 .488 -.367 .010 
Social support frequency .030 .183 .031 .868 
Social support satisfaction .071 .246 .047 .775 
Social support frequency*satisfaction -.158 .079 -.381 .050 
R2 = .488, p = .001         
229 
 
Appendix 4.6: Table 4.10A: Linear regression model of 
predictors of Skipping, fixed enter method 
 
Table 410A: Linear regression model of predictors of adherence skipping 
  b SE B β P 
Constant -.056 .573   .923 
BMQ Concern .042 .015 .435 .007 
BMQ Necessity -.006 .011 -.064 .606 
Positive outcome expectations -.003 .004 -.101 .396 
Negative outcome expectations .011 .005 .296 .033 
Squared Haemophilia-related self-efficacy .000 .000 .158 .291 
Squared Prophylaxis-related self-efficacy .000 .000 -.089 .486 
PANAS positive affect -.003 .005 -.094 .442 
Log PANAS negative affect .315 .138 .342 .026 
IPQ Consequences .006 .016 .057 .689 
IPQ Squared Timeline -.001 .003 -.048 .690 
IPQ Squared Personal Control .000 .002 .038 .760 
IPQ Squared Treatment Control .000 .002 .031 .804 
IPQ Identity .008 .017 .062 .622 
IPQ Concerns -.005 .017 -.047 .751 
IPQ Coherence .086 .028 .363 .003 
IPQ Emotional representations -.045 .017 -.383 .010 
Social support frequency .003 .006 .098 .614 
Social support satisfaction .003 .009 .060 .727 
Social support frequency*satisfaction -.004 .003 -.268 .187 
R2 = .415, p = .008         
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Appendix 4.7: Table 4.11A: Linear regression model of 
predictors of Remembering, fixed enter method 
 
Table 4.11A: Linear regression model of predictors of adherence remembering 
  b SE B β P 
Constant -1.819 4.868   .710 
BMQ Concern .448 .126 .517 .001 
BMQ Necessity -.173 .095 -.220 .072 
Positive outcome expectations -.045 .031 -.164 .160 
Negative outcome expectations .008 .044 .025 .851 
Squared Haemophilia-related self-efficacy .000 .000 .274 .060 
Squared Prophylaxis-related self-efficacy .000 .000 -.186 .145 
PANAS positive affect -.030 .039 -.094 .442 
Log PANAS negative affect -.140 1.102 -.017 .899 
IPQ Consequences -.049 .137 -.049 .722 
IPQ Squared Timeline .042 .023 .225 .067 
IPQ Squared Personal Control .004 .013 .039 .748 
IPQ Squared Treatment Control .058 .016 .432 .001 
IPQ Identity -.054 .145 -.044 .713 
IPQ Concerns .156 .148 .149 .297 
IPQ Coherence .174 .236 .083 .463 
IPQ Emotional representations -.044 .143 -.043 .761 
Social support frequency .023 .052 .079 .664 
Social support satisfaction -.048 .074 -.110 .519 
Social support frequency*satisfaction -.024 .023 -.199 .297 
R2 = .445, p = .003         
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Appendix 5.1 a: Interview schedule study one (young people 
with haemophilia) 
Theme 1 Living with haemophilia 
1.  What does having haemophilia mean to you on a day to day basis? 
 Probe differences between 
 at school/work 
 at home with parents/siblings 
 with friends 
2. Do you remember when your parents (carer) first told you about haemophilia? 
 What was that like/ what did they tell you? 
 How did you come to understand what haemophilia means? 
 
3. What kinds of things do you do to make yourself feel better? 
 Probe strategies for both physical and emotional wellbeing. 
 
Theme 2 Treatment 
1. How often do you have to take prophylaxis? 
 Probe regimen (do they keep to regimen advised by clinicians or do they self-manage based 
on their daily needs, e.g. exercise etc). 
 Does your doctor encourage you to follow more bespoke dosing around your lifestyle? 
2. What is the treatment like? 
 Probe to get to feelings around treatment (difficult, painful, etc.) 
3. What kinds of things might interfere with you taking treatment on time? 
 Probe to gauge frequency of missed or not-on-time treatment 
 Probe body image issues (needle marks, impact on body appearance, perceptions of 
weakness) 
 Probe if/what role relationships with friends/family play 
 What about girlfriends/boyfriends? 
 
Theme 3 Transition of care and responsibility 
1. How involved are your parents/carer in your treatment regime? How involved are you? 
 Probe to gauge  
o who takes main responsibility for treatment 
o whether participant thinks he has too much or too little responsibility 
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2. How often do you attend the haemophilia treatment centre?  
 What is it like going there? 
 What are the staff there like? How do they talk to you? 
 Are there are any challenges directly related to the treatment centre? 
 Suggestions for potential improvements? 
 
3. What do you think is the difference between paediatric and adult care centres? 
 Probe to explore 
o Whether current treatment setting is appropriate for participant 
o If has gone through transition from paediatric care, what was transition like? 
 
4. Is there anything about the illness or treatment that you don’t quite understand? 
 
5. Who would you go to with questions about haemophilia? 
 Probe 
o Parents 
o Health care staff 
o Internet 
o Haemophilia society 
o Friends 
o Other people with haemophilia 
o Other 
 
Theme 4 Social support 
1. What support do you get in managing your haemophilia? For instance reminding you to take your 
prophylaxis, listening to you if you want to talk about things, going to the centre with you, etc. 
 Probe to gauge social support from  
o Parents 
o Siblings 
o Friends 
o Girlfriend/boyfriend 
o Other people with haemophilia 
 
2. What effect do you think haemophilia has on your relationship? 
 Probe to gauge impact on relationships with 
o family 
o friends 
o girlfriend/boyfriend 
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Appendix 5.1 b: Interview schedule study two (parents of young 
people with haemophilia) 
Theme 1 Living with haemophilia 
1. Tell us about what an average day is like? 
 Probe 
 What influence does haemophilia have on daily life 
 Influence on relationships in the family 
 Influence on parent’s work/social life 
 Other things (e.g. finances, holidays, etc.) 
 
2. Do you remember when you first told your son about haemophilia? 
 What was that like/ what did you tell him? 
 
3. How have things changed as he has got older? 
 Probe what has become better and also key challenges 
 
4. What kinds of things do you do to make things better for your son and yourself? 
 Probe strategies for both physical and emotional wellbeing. 
o E.g. going to school, going to work, going on holiday, going out 
 
Theme 2 Treatment 
1. How often does your son take prophylaxis? 
 
2. What is the treatment like? 
 Probe to get to feelings around treatment (difficult, painful, etc.) 
 
3. What kinds of things might interfere with him taking treatment? 
 Probe to gauge frequency of missed or not-on-time treatment 
 Probe body image (needle marks, impact on body appearance, perceptions of weakness) 
 Probe technical skills needed to administer treatment (probe needle phobia if it comes up) 
 Probe if/what role relationships with friends/family play 
 What about girlfriends/boyfriends? 
 
4. Who would you go to with questions about haemophilia? 
 Probe 
o Health care staff 
o Internet 
o Haemophilia society 
o Friends 
o Other parents of young people with haemophilia 
o Other  
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Theme 3 Responsibility for care 
1. How involved are you in his treatment regime? How involved is he? 
 
2. If son still lives at home: probe to gauge  
 who takes main responsibility for treatment 
 whether parent thinks their son has too much or too little responsibility 
 
3. How often do you attend the haemophilia treatment centre with your son?  
 What is it like going there? 
 What are the staff there like? How do they talk to you? 
 Are there are any challenges directly related to the treatment centre? 
 Suggestions for potential improvements? 
 What was the transition from paediatric to adult care like? 
 Suggestions for potential improvements to help with transition? 
 
Theme 4 Social support 
1. What support do you get in managing your son’s haemophilia?  
 Probe to gauge support from 
o Husband/wife 
o Family 
o Son with haemophilia 
o Other children 
o Friends 
o Treatment centre 
o Social care 
 
2. What support are you able to offer your son in managing his haemophilia? For instance reminding 
him to take his prophylaxis, going to the treatment centre with him, etc. 
 
 
3. What effect do you think haemophilia has on your relationships? 
 Probe to gauge impact on relationships with 
o Husband/wife 
o Son with haemophilia 
o Other children 
o family 
o friends 
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Appendix 5.1 c: Interview schedule study three (haemophilia 
healthcare professionals) 
 
Theme 1 The treatment centre 
1.  Tell us about what an average day is like in the treatment centre (both in the day unit and on the 
wards)? 
Probe: 
 How many patients do you see? 
 What age range? 
 Collaboration with colleagues 
 Do you deal with many parents of patients 
 Split routine check-ups/ad-hoc treatment 
 
2. In what way have things changed in haemophilia care since you started? 
Treatment and prescription probes: 
 How are prescriptions generated in your centre? 
 How are treatment schedules assessed? 
 Do you ask for treatment sheet returns? 
 Do you use Haemtrack? And if yes, in what way? Do you use it as a clinical tool? 
 Does your department encourage patients to follow more bespoke dosing around their 
lifestyle? 
 If yes, do all the clinicians in your centre do this? 
 Potential conflicting messages for staff and patients if not all clinicians follow the same 
practice? 
 
3. How much time are you able to spend with each patient? 
Probe: 
 Able to meet patients’ needs and expectations? 
 Would you like to spend more or less time with them? 
 Are there any changes you would like to see? 
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Theme 2 Treatment 
1. How well does prophylaxis work for your patients? 
 Probe: main problems and challenges, and what works well 
 
2. How well do you think your patients adhere to their prophylaxis? 
 Probe: how do you find out that someone doesn’t keep to their treatment plan? 
 
3. What kinds of things do you think might interfere with your patients’ adherence? 
 Probe to gauge estimated adherence levels in the treatment centre 
 Probe perceptions of the influence of: 
o body image issues (needle marks, impact on body appearance, perceptions of 
weakness) 
o Technical skills needed for treatment (also needle phobia) 
o family/friends of patients 
o girlfriends/boyfriends? 
o School/work 
o Relationships with doctors and nurses 
 
Theme 3 Improvements to care 
1. What do you think would help patients keep to their treatment plan? 
  
2. Are there any improvements you think are needed? 
 
3. Are there any improvements directly in the treatment centre you think are needed? 
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Appendix 5.2: Example page first hermeneutic cycle (study one, 
young people with haemophilia)
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b
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 m
a
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ra
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c
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b
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 b
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c
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b
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.
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 r
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 c
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c
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 f
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 c
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c
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 D
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a
e
m
tr
a
c
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.
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Appendix 5.3: Full list of themes after first hermeneutic cycle 
(study one, young people with haemophilia) 
Superordinate theme Theme  
Number Of 
Coding 
References 
across all 
participants 
Number of 
participants 
with this 
coding 
reference 
Haemophilia, bleeds and 
pain are part of life 
Bleeds 51 10 
reported adherence is high 
I forget to take treatment 
occasionally 
46 9 
I tailor my treatment around 
my lifestyle 
Regimen 44 7 
Support from mum and dad 
is key 
Support from parents/siblings 
most important 
42 5 
I try to be positive haemophilia is not really an issue 30 8 
Support from the 
haemophilia centre is great 
Haemophilia team are nice 30 9 
Avoiding risk is key Avoiding risk 27 7 
Haemtrack Haemtrack 26 4 
Most take over gradually 
from a young age but 
parents stay involved until 
they leave home 
taking over responsibility for 
treatment from parents 
24 8 
I tailor my treatment around 
my lifestyle 
Tailored treatment regimens 20 6 
venepuncture issues venepuncture issues 17 9 
Social support Social support - friends 17 4 
Patient is haemophilia 
expert 
Understanding of haemophilia and 
treatment 
16 4 
Treatment is no problem 
and part of my routine 
Treatment has improved lots 16 5 
Bleeds and pain are part of 
life 
activity related bleeds 15 7 
Taking treatment is 
inconvenient and no fun 
Wish treatment was like diabetic 
injection or oral medication 
15 4 
Social support 
social contact with other patients 
and their families and staff 
14 4 
Support from mum and dad 
is key 
mum does my treatments 14 2 
Deliberately skipping 
treatment is very rare 
Skipping 13 5 
Haemophilia, bleeds and 
pain are part of life 
haemophilia is part of me and who 
I am 
12 7 
haemophilia-  and treatment 
related anxiety 
It is hard to take treatment when I 
am anxious or stressed 
12 4 
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Superordinate theme Theme  
Number Of 
Coding 
References 
across all 
participants 
Number of 
participants 
with this 
coding 
reference 
practical solutions to 
remember to take treatment 
visual prompts and other things 
that help remember 
12 6 
Taking treatment is no 
problem, it's part of my 
routine 
Treatment is part of my day-to-day 
routine 
12 7 
Treatment protects me so I 
can live a normal life 
Treatment allows me to live the 
life I want 
12 5 
Patient is haemophilia 
expert 
I am an expert in haemophilia and 
treatment 
11 2 
Taking treatment is no 
problem, it's part of my 
routine 
Taking treatment is easy and 
quick 
11 5 
Haemophilia care in the UK 
is second to none 
coming to the UK has improved 
my life immensely 
10 1 
Barriers to adherence Barriers to adherence 9 10 
Support from the 
haemophilia centre is great 
The haemophilia team encourage 
me to take treatment 
9 1 
design of treatment and 
packaging 
new treatment doesn't have all the 
bits I need 
8 2 
Taking treatment is 
inconvenient and no fun 
treatment is annoying 8 1 
Taking treatment is no 
problem, it's part of my 
routine 
You've got to get on with it 8 5 
I tailor my treatment around 
my lifestyle 
Topping up 7 3 
Patient is haemophilia 
expert 
time of day i take treatment is 
important 
6 4 
reported adherence is high I hardly ever miss a treatment 6 4 
Taking treatment is no 
problem, it's part of my 
routine 
It's just one of those things 
(treatment) 
6 3 
Support from the 
haemophilia centre is great 
I am very happy with the support I 
receive 
6 4 
Haemophilia, bleeds and 
pain are part of life 
Pain 5 2 
Taking treatment is no 
problem, it's part of my 
routine 
at first it was difficult but now 
things have settled down 
5 3 
haemophilia-  and treatment 
related anxiety 
I am anxious about having to start 
doing injections myself 
4 2 
Inhibitors have a significant 
impact on my treatment and 
health outcomes 
I use a Hickman line or port 4 1 
School and Work are 
usually not an issue 
Taking treatment at work is no 
problem 
4 2 
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Superordinate theme Theme  
Number Of 
Coding 
References 
across all 
participants 
Number of 
participants 
with this 
coding 
reference 
Taking treatment is no 
problem, it's part of my 
routine 
generally things work really 
well\generally taking my treatment 
goes without issues 
4 2 
Treatment protects me so I 
can live a normal life 
Treatment makes me feel 
protected 
4 2 
Haemophilia care in the UK 
is second to none 
i can't think of anything that needs 
to improve 
4 2 
Support from the 
haemophilia centre is great 
I know the haemophilia team are 
there for me if I need them 
4 3 
haemophilia-  and treatment 
related anxiety 
sometimes i have felt inadequate 
because of the way girls respond 
to my haemophilia 
3 1 
practical solutions to 
remember to take treatment 
a digital reminder (text or diary) 
would help 
3 3 
Taking treatment is 
inconvenient and no fun 
I don't like taking treatment but 
accept I need to do it 
3 1 
Treatment protects me so I 
can live a normal life 
treatment prevents or stops most 
bleeds 
3 2 
Social support 
I prefer to be self-sufficient and 
don't ask for help much 
3 1 
Haemophilia care in the UK 
is second to none 
introduction of prophylaxis has 
resulted much better outcomes 
3 1 
Inhibitors have a significant 
impact on my treatment and 
health outcomes 
inhibitors are a big issue for me 2 2 
School and Work are 
usually not an issue 
advancing my education and 
career are priority 
2 1 
Taking treatment is 
inconvenient and no fun 
treatment is time consuming 2 1 
Taking treatment is no 
problem, it's part of my 
routine 
it used to hurt but is fine now 2 2 
Treatment protects me so I 
can live a normal life 
Treatment prevents long-term 
problems 
2 2 
Support from mum and dad 
is key 
sometimes someone else does 
my treatment for me 
2 2 
Haemophilia care in the UK 
is second to none 
I feel lucky to have been born in 
the UK 
2 2 
I tailor my treatment around 
my lifestyle 
Concern about over-using factor 
treatment 
1 1 
 
  
241 
 
Superordinate theme Theme  
Number Of 
Coding 
References 
across all 
participants 
Number of 
participants 
with this 
coding 
reference 
Patient is haemophilia 
expert 
I am an example for younger 
patients and their family 
1 1 
design of treatment and 
packaging 
I didn't used to like mixing it 1 1 
design of treatment and 
packaging 
In emergencies sometimes you 
can't mix or administer treatment 
yourself 
1 1 
design of treatment and 
packaging 
long-acting trial treatment is less 
convenient to take 
1 1 
haemophilia-  and treatment 
related anxiety 
I generally only take treatment in a 
safe place (home, work or 
somewhere familiar) 
1 1 
haemophilia-  and treatment 
related anxiety 
I won't take treatment in front of 
people 
1 1 
haemophilia-  and treatment 
related anxiety 
psychological support 1 1 
haemophilia-  and treatment 
related anxiety 
when I realise I’ve forgotten i feel 
anxious 
1 1 
I try to be positive 
I try to be positive about my 
haemophilia 
1 1 
Inhibitors have a significant 
impact on my treatment and 
health outcomes 
the quantity of treatment is huge 
because of the inhibitors 
1 1 
School and Work are 
usually not an issue 
I’m lucky that work is very flexible, 
so coming to hospital is no 
problem 
1 1 
Taking treatment is 
inconvenient and no fun 
don't have time for breakfast 
because of prophylaxis 
1 1 
Taking treatment is 
inconvenient and no fun 
I'd prefer to do fewer injections, or 
not do it at all 
1 1 
Taking treatment is 
inconvenient and no fun 
sometimes you get fed-up with 
having to do treatment 
1 1 
Treatment protects me so I 
can live a normal life 
non-adherence usually results in 
bleeds 
1 1 
Treatment protects me so I 
can live a normal life 
treatment makes me feel better 1 1 
Support from mum and dad 
is key 
sometimes you just want someone 
else to do it for you 
1 1 
Support from the 
haemophilia centre is great 
I trust the NHS with my life 1 1 
Support from the 
haemophilia centre is great 
support from the centre makes me 
feel less alone 
1 1 
Support from the 
haemophilia centre is great 
the haemophilia nurses regularly 
contact me 
1 1 
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Appendix 5.4: Example page second hermeneutic cycle (study 
one, young people with haemophilia) 
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b
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w
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Appendix 5.5: Example page third hermeneutic cycle (study 
one, young people with haemophilia) 
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